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Abstract 
 
Background:  Dysphagia and cognitive problems, both common after stoke, may affect 
dietary intake increasing the risk of malnutrition.  Malnutrition has adverse effects on 
body composition especially in conditions that escalate the stress response in the body 
and may be associated with immobility such as stroke.   
 
 
Study objective:  The objective of my study was to understand the prognosis of 
malnutrition on post cardiovascular disease (CV) outcomes, understand body 
composition changes after stroke assessed using multi-frequency bioelectrical 
impedance analysis (MF-BIA) methods, examine the utility of MF-BIA in diagnosing 
dehydration in stroke patients, and validate MF-BIA selected body composition 
estimates against the reference method Dual X-ray absorptiometry (DEXA).     
 
Methodology:  To understand the prognosis of malnutrition on post CVD outcomes I 
carried out a systematic review and meta-analysis examining the association between 
selected markers of malnutrition on outcomes.  The systematic review is presented in 
Chapter 2 of this thesis.   Chapter 3 presents an observational longitudinal study that 
describes body composition changes after ischaemic stroke and their prognosis on 
outcomes.  Ischaemic stroke patients admitted to an acute unit were prospectively 
recruited between January-July 2011.  Body composition variables (BioScan 920-2, 
Maltron International Ltd, Essex, United Kingdom) were measured on admission and 
discharge.   Results were descriptively presented stratified by type of feeding regimen, 
type of stroke and stroke severity.  Validated follow up questionnaire were sent to 
participants by post to understand body composition changes association with their 
health and quality of life.     
 
In chapter 4 the diagnostic accuracy of MF-BIA BioScan 920-2 in diagnosing 
dehydration after stroke was examined for several diagnostic cut offs of current and 
impending dehydration.   In chapter 5 external validation of MF-BIA BioScan 920-2 fat 
free mass and fat mass estimates against reference method DEXA was examined using 
ten participants data.   Bland and Altman analysis for understanding the agreement 
between two methods of clinical measurement was carried out.   
Results:  Undernutrition (assessed using nutrition assessment tools) were associated 
with mortality post cardiovascular event.  Other findings are presented in Chapter 2.   
Fat free mass loss, and fat mass gain, protein mass loss, muscle mass loss, and body cell 
mass loss were observed in patients on modified diet (soft/mashed diet, pureed diet, nil-
by-mouth feeding regimen).  Sample size was small to generalize a conclusion on the 
association between body composition changes in acute stay and outcomes.  MF-BIA 
BioScan 920-2 did not show diagnostic accuracy in diagnosing dehydration in stroke 
patients.  MF-BIA BioScan 920-2 fat free mass and fat mass estimates were in 
agreement with their corresponding estimate from the reference methods DEXA.   
 
 
Conclusion:  My study was novel as it provided new information with regard to body 
composition changes in acute stroke while utilizing new validated equipment in 
estimating body composition component of fat free mass and fat mass.  My study also 
aimed to investigate new non-invasive methods to diagnose dehydration in stroke 
patients.  It contributed new knowledge that can be useful in future research, sample 
size calculation, and can help researchers in the field to determine minimally clinically 
significant differences for similar research and targeted intervention clinical trials.   
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1.1 Introduction 
 
1.1.1 Stroke epidemiology  
 
Globally cardiovascular diseases (CVD) are the leading cause of death (1), with stroke 
being one of the major CVD.  According to 2008 figures, stroke contributes to ~36% of 
total CVD mortality (1). In the United Kingdom there were over 190,000 deaths from 
cardiovascular diseases with stroke contributing 43,142 deaths of which 33,896 were 
over the age of 75 (2).  Despite such statistics, better preventative strategies resulted in a 
reduction in stroke incidence in the first decade of the twenty first century.  Stroke 
incidence in England dropped in 2005-2007 from 193 to 178 (per 100,000) in men and 
from 152 to 139 (per 100,000) in women.  Scotland followed the same trend with a drop 
in stroke incidence between 2000 and 2009 from 277 to 202 in men and from 208 to 
160 in women per 100, 000 population (2).   A recent cohort (n= 32,151) of patients 
with a first stroke confirmed these findings and suggested that stroke incidence 
decreased from 1.48/1000 per person-year in 1999 to 1.04/1000 per person-year in 2008 
(p<0.001); a 30% reduction (3).  The same study reported 12.5% increase in stroke 
prevalence between 1999 (6.40/1000) and 2008 (7.20/1000 ); p<0.001 (3).  The 
decrease in stroke incidents (2, 3) accompanied by reduced stroke mortality (4, 5) 
suggest that more people survive stroke and are left to bear its burden.  
 
1.1.2 Stroke Pathophysiology 
 
There are two main types of stroke namely ischaemic stroke and haemorrhagic stroke.   
In both types of stroke the blood supply to the brain is compromised, but in two 
different manners. In haemorrhagic stroke the blood supply to the brain becomes 
inadequate due to bleeding into the brain and in ischaemic stroke the blood supply to the 
brain becomes interrupted due to a blockage as a result of thrombosis or embolism of an 
artery. Reduced blood supply to the brain damages parts of the brain tissues resulting in 
neurological impairment (6).  In both types of stroke, the loss of cerebral function 
occurs and the symptoms usually last for more than 24 hours (7). 
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Ischaemic stroke (infarct) can be further classified depending on the site and the 
vascular territory of the brain affected, and based on modalities of functional deficit.  
One of the most well known classification is the Oxfordshire Community Stroke Project 
(OCSP) classification by Bamford and colleagues which classified cerebral infarction as  
Lacunar Infarct (LACI), Partial Anterior Circulation Infarct (PACI), Posterior 
Circulation Infarct (POCI), and the Total Anterior Circulation Infarct (TACI) (8).   This 
classification does not provide the underlying pathology albeit LACI are usually due to 
small vessel disease. The underlying pathological process leading to an ischaemic 
stroke varies.  Causes can range from plaques in large arteries known as atherosclerosis 
which embolises to brain (arterio-arterial embolism), or an embolus from the heart 
known as cardio-embolism that could occur as the result of conditions such as arterial 
fibrillation, or a small vessel disease related to old age such as hyaline arteriosclerosis 
of blood vessels supplying blood to the brain, or due to unknown causes (9, 10).    
 
1.1.3 Risk factors of stroke  
 
There are many risk factors for stroke.  Examples of stroke risk factors include but are 
not limited to age, sex, ethnicity, family history, previous or current co-morbid 
conditions, lifestyle, or certain treatments and therapies.   
 
The probability of stroke is directly correlated with age and sex.  The 10 year average 
probability of stroke incidence in men and women, with no previous stroke, is directly 
correlated with increasing age and differ between men and women.  For example the 
probability of stroke for those aged 55-59 years was 5.9% and 3.0% for men and 
women and it increased to 7.8% and 4.7% for men and women aged 60-64 years 
respectively; showing continuous increase with age with respect to sex differences (11).  
Although family history is suggested to increase the risk of stroke, a systematic review 
and meta-analysis suggested that it was difficult to interpret the results due to large 
heterogeneity between studies, potential bias, and insufficient details (12).  Nevertheless 
large scale studies of long term follow up suggest that the risk of stroke maybe 
increased with parental history of stroke (13, 14).  
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Co-morbid conditions such as hypertension, diabetes, atrial fibrillation, and small artery 
disease can increase the risk of stroke.  Extensive review of observational studies 
suggests that hypertension greatly increases the risk of stroke.  An increase in blood 
pressure can be associated with  an at least 30% increases stroke risk (15) with risk 
increasing by 90% and 65% in men and women respectively (11).   Studies examining 
the effect of blood pressure reduction suggested that a reduction in blood pressure may 
reduce the risk of stroke by at least 20-30% (16), (17).  Clinical Trials on anti-
hypertensive therapies also provide an idea on the impact that hypertension can have on 
the risk of stroke.   Lawes and colleagues systematic review and meta-analysis of trials 
examining the risk reduction of stroke in anti-hypertensive drug users compared to 
placebo and no treatment suggested a 30% reduction in stroke risk in anti-hypertensive 
drug users (18).  
 
Condition such as diabetes can increase the risk of stroke.  The incident of stroke was 
62.3 and 32.7 per 1000 for diabetic and non-diabetic men respectively, with a relative 
risk of 2.0 (95% CI: 1.4 to 3.0) in participants with diabetes compared to those with no 
diabetes (19).  These finding were further confirmed by a systematic review and meta-
analysis of 102 prospective observational studies which suggested at least a 50% 
increase in the risk of stroke in participants with diabetes compared to those with no 
diabetes (20).   
 
Risk of stroke can also increase due to other conditions such as atrial fibrillation (AF) 
and small vessel disease.  The calculated probability of stroke from Framingham study 
suggested that the risk of stroke in patients with atrial fibrillation increased by 83% in 
men and by more than three fold in women (11).  Wolf and colleagues reported an 
almost six fold increase in the risk of stroke in men and women with Atrial fibrillation 
compared with those who did not have AF (21).   
 
Earlier review of observational studies suggested that the risk of hormone replacement 
therapies (HRT) on stroke was inconsistent (22) however more recent meta-analysis 
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suggested hormone replacement therapy may increase the risk of stroke by more than 20%  
(23).   
 
Lifestyle in terms of habitual physical activity and dietary preferences can also impact 
the risk of stroke.  Long term longitudinal cohort studies suggested that the risk of 
stroke can increase substantially reaching up to 50% in smoker compared to non-
smokers (24).  Review of previous studies examining the risk of smoking on stroke also 
suggested that smoking can increase the risk of stroke up to 50% when compared to 
non-smokers (25).  Similar to smoking, stroke risk increases with excessive alcohol 
consumption. Systematic review and meta-analysis of observation studies (cohort and 
case-control) suggested that heavy and excessive alcohol consumption (more than 60 
g/day) increased the risk of stroke by 64% compared to non-drinker whilst moderate 
alcohol consumption of <12 g/day was found to reduce the risk of stroke by 17% 
compared to abstainers (26).    
A diet high in sodium and saturated fatty acids, and low in potassium can increase the 
risk of stroke (27).  A meta-analysis examining the risk of stroke in high salt consumers 
(diet high in sodium) compared to low salt consumers, suggested that high salt intake 
increases the risk of stroke by 23% (pooled relative risk 1.23, 95% CI 1.06 to 1.43; 
P=0.007)(28).  In contrary, meta analysis of systematic evidence (1966-2011) suggest 
the opposite with a risk reduction of stroke by 11% for every 1 g increase in dietary 
potassium consumption per day  (29).   
 
Another nutrient that was under investigation was saturated fatty acids.  A meta analysis 
of prospective cohort studies suggested that the risk of stroke did not increase with 
higher consumption of saturated compared to those in the lower quintiles of saturated 
fat consumption (30).  However these finding do not necessarily mean that the potential 
risk of saturated fat such as trans-fatty acids should be ignored.  Saturated and trans 
fatty acids increase the ratio of total: high density lipoprotein (HDL) Cholesterol (31), a 
risk factor for stroke (16).  
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Physically active lifestyle as opposed to sedentary lifestyle can reduce the risk of stroke.    
Physical activity improves blood flow to the brain and contributes endothelium 
relaxation (the inner membrane of blood vessels) resulting in protection from stroke 
(32).  A long term follow up study suggested that a physical activity as simple as 
walking can reduce the risk of stroke (33).  These finding were further confirmed in a 
systematic review and meta-analysis that suggested that in physically active individuals 
stroke risk decreased by at least 20% compared to people with a sedentary lifestyle (34). 
  
Risk factors of stroke are many and efforts were made to understand them resulting in 
reduced incidence of stroke (see introduction).   Equally important is to improve stroke 
outcomes once it occurs.  In the next section I will present the prevalence of 
malnutrition in stroke patient and its prognosis on outcomes.   
 
1.1.4 Stroke outcomes and burden 
 
The majority of those experiencing stroke are older than 65 years (35).  In a 13 years 
follow up study, it was reported that life expectancy and average quality of life (QoL) 
loss after ischaemic stroke in people older than 65 years old regardless of gender was 
8.7 and 8.3 years respectively (36).  Fate of younger people who experience stroke is 
not different. Up to 12% of strokes do occur in 15-45 years old population (37). 
Keppelle et al 1994 documented that in their long term follow up study (mean follow up 
6 years, median 5.6 years, range 2 months to 16 years) of 15-45 years old with stroke 
only 49% were still alive at the end of the follow up period, 42% returned to work, and 
quality of life as evaluated by Short Form-36 (SF-36) survey was reduced (38).  
 
Compared to those with no previous stroke, medcial admission risk increased by more 
than two fold in those with pervious stroke (HR: 2.6; 95% CI 2.2-3.0) (39).  Further, 
rehospitalisation after stroke is not uncommon.  One study reported that 25% (n=129) of 
stroke patients were readmitted with stroke during a 12 month follow up period post 
hospital discharge with a mean length of hospital stay of 23±31 days at rehospitalisation 
(40). A reported 33% rehospitalisation rate within the first year after stroke was 
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observed due to complications such as infections, recurrent stroke, or other 
cardiovascular events in a study of 2,657  stroke patients (41).  Recurrent events after 
stroke are one of the major contributors of rehospitalisation with a reported incidence 
rate of 105.4/1000 and 52/1000 during the first year and after the first year post 
ischaemic stroke (42). Recurrent stroke not only contribute substantially to 
rehospitalisation with a suggested rate >20%, but also to disability with 48% of 
rehospitalised patients who were not disabled by a prior stroke becoming disabled as 
suggested by a decrease in the average Barthel index score (p<0.001) and National 
Institute of Health Stroke Scale (p<0.001) (43).   The risk of death or disability also 
increases with recurrent strokes compared to a first ever stroke; (OR=9.4, 95% CI 3.0-
30)(44).  
 
A huge economic burden is inflicted by stroke in the UK given that 300,000 stroke 
survivors live with disability and require care.  Therefore, the burden of stroke on UK 
economy is considerable.  Annual direct costs of stroke are 2.8 billion in the UK which 
included  diagnostic costs, inpatient and outpatient care costs, and community care (45).  
Informal care costs of stroke are 2.4 billion which are defined as costs of caring for 
stroke survivors whether by patient’s families or care homes. The costs of lost 
productivity and disability due to stroke outcome, indirect costs, are estimated be at 1.8 
billion divided into 600 million incomes lost to post stroke morbidity, 480 million 
incomes lost to stroke mortality, and 690 million as benefits costs to support survivors 
(45).   
 
Research to understand stroke risk factors thus becomes pivotal issue in primary and 
secondary prevention of stroke.  Equally important is to develop an understanding of 
how to improve stroke outcomes by how best to monitor stroke complications and 
manage them appropriately. One of the major complications following stroke is 
malnutrition.  Understanding the nutritional status and its prognosis on stroke outcomes 
is very important if successful intervention strategies are to be integrated in stroke 
management.  In the next section I will briefly discuss the association between stroke 
and malnutrition to introduce you to the focus of this research.   
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1.1.4 Malnutrition and Stroke 
 
Evidence suggests that at the time of stroke, the malnutrition already exists (46, 47).   
The deterioration in nutritional status in people with stroke during hospital stay is also 
common  (48, 49).   Malnutrition prevalence in UK hospitals is not to be underestimated.  
Edington and colleagues estimated the prevalence of malnutrition to be at 20% on 
admission at four UK hospitals as estimated with a body mass index (BMI) <19 kg/m2 
(50).  These finding were further confirmed by Lamb and colleagues who reported 
malnutrition, assessed using Malnutrition Universal Assessment Tool (MUST), 
prevalence at 37% and 24% in women and men patients respectively admitted to a UK 
hospital; 328 patients were included from all in patients medical, surgical, orthopaedic, 
and critical care in an acute hospital in North East England (51).   An earlier study 
suggested that the prevalence of malnutrition in acute setting is a concern that continue 
to persist till today.  The study suggested that of the 500 patients included in the study 
with 100 patient from each of general surgery, orthopaedic surgery, medicine for the 
elderly, general medicine, and respiratory medicine who have their nutritional status 
assessed on admission.   Forty percent (40%) were diagnosed as experiencing 
malnutrition (52).  Assessing malnutrition using “Malnutrition Universal Screening 
Tool” in elderly patients (n=150),  Stratton et al 2005 reported the prevalence of 
malnutrition to be at 58% (53).   
 
In a prospective observational study that included 131 patients with stroke,  under 
nutrition 24 hours post-admission was diagnosed in 12.2% of patients compared to 19.8% 
of patients at one week post admission; p=0.03 (54).  In this study malnutrition was 
diagnosed if one or more of the following criteria were met including a 10% weight loss 
in the past 3 months and/or 6% weight loss one week post admission, weight index 
(actual weight compared to reference weight) less than 80%, serum albumin <3.0g/dL, 
prealbumin <10.0 mg/dL, or transferrin < 150mg/dL (54).   Gariballa et al reported a 
decline in average weight in stroke patients at 2 and 4 weeks post admission to an acute 
stroke unit were 48% (96/201) and 25%(51/201); p=0.002 (55).   
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Another study involving 104 patients with acute stroke reported that malnutrition 
prevalence changed from 16.4% at admission to 26.4% of surviving patients (n=91) and 
35% of patients who remained in hospital (n=43) at one and two weeks post admission 
respectively (see below for implication of malnutrition in this study).   Malnutrition was 
assessed using three measurements of MAC, TSF, and serum albumin (56).   
 
Fluctuations in nutritional status is usually reflected by changes in body composition, 
such as volume and proportion of fat mass and fat free mass (57, 58).  Other body 
composition indices are also affected with changes in nutritional status (57, 59, 60).  
Therefore, body composition measurements may be useful in monitoring nutritional 
status, and evaluating nutrition intervention in management in acute stroke care.  There 
is also existing evidence to suggest that body composition measurements can also be 
used to predict relevant clinical outcomes.  For example, in older people change in body 
composition such as increased fat mass is associated with functional limitation (61).    
 
Assessment of body composition can be done using simple, cheap low technology 
methods as well as, costly and complex, and advanced methods.  Established methods 
that are used to assess body composition include skin fold thickness, underwater 
weighing, dilution method, neutron activation analysis, determination of total body 
potassium, magnetic resonance imaging (MRI), and dual x ray absorptiometry (DEXA); 
Chapter 5 discusses each methods in detail.  Multifrequency Bioelectrical Impedance 
Analysis (MF-BIA) used in this study is a relatively new method that can also be used 
to assess body composition.  
MF-BIA estimates the body components based on the difference in conductivity that 
body tissues imposes on the flow of an electrical current.  This difference in the 
conductivity in different body tissue is due to the impedance imposed by body tissue on 
the flow of that electrical current. The difference in impedance is used to calculate the 
volume of body compartments using validated equations programmed in the MF-BIA 
equipment taking into account of factors such as gender, height, weight, and age (62).  
Changes in body composition measured by MF-BIA such as FFM and FM can provide 
information regarding the nutritional adequacy of stroke patients in acute phase.  
Further body composition components such as total body water may provide 
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information on a patient’s hydration status.  MF-BIA can be a swift method to aid in 
monitoring patients nutritional and hydration status to aid in developing personalized 
nutrition intervention strategies and to improve strictly management in acute phase of 
the stroke.    
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1.2 Study objectives 
 
In depth understanding of the prognosis of malnutrition on cardiovascular diseases is 
important. Therefore the aim of the systematic review and meta-analysis presented in 
Chapter two was to investigate the relationship between nutrition markers of high and 
low energy intake, low protein intake, and low fluid intake on subsequent outcomes 
after a cardiovascular event.  The nutrition markers examined included high and low 
body mass index (BMI), weight loss, skinfold thickness, low serum albumin, high 
serum creatinine, increased serum osmolality, and malnutrition assessed by nutrition 
assessment tools such as the Subjective Global Assessment tool (SGA).  The main 
outcome assessed was mortality with other secondary outcomes such as morbidity (re-
infarction, complications), readmission, disability or functional status, length of hospital 
stay, and discharge destination.   
 
Chapter 3 presents an observational longitudinal study that describes body composition 
after ischaemic stroke and their prognosis on outcomes. The primary objective of the 
longitudinal study was to describe fat free mass and body composition changes during 
acute stroke phase while considering the extent of these changes by type of feeding 
regimen, ischaemic stroke subtype, and the stroke severity.  The study also examined if 
body composition changes were correlated with subjective and objective outcomes in 
both short and longer terms.     
 
Chapter 4 presents the study which examines whether it is possible to diagnose 
dehydration using bioelectrical impedance analysis.  The aim was to assess the levels of 
dehydration after stroke using the reference standard of serum osmolality, and to 
explore whether MF-BIA can be substituted for serum osmolality in diagnosing 
dehydration after stroke.  
 
In the final chapter, Chapter 5 presents the validation studies of MF-BIA.  The objective 
was to validate MF-BIA against reference standard dual x-ray absorptiometry (DEXA) 
in patients with recent stroke/TIA.  The validation of MF-MF-BIA against DEXA can 
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provide information on the level of agreement between major components of interest, 
fat mass and fat free mass, measured using MF-BIA and their corresponding values 
estimated by DEXA for the same study participant.  In addition, the internal consistency 
of MF-BIA measurements, internal validation, was also examined.   
 
I conducted above series of validation studies because MF-BIA method is a relatively 
new method and it is not considered as the gold standard method in estimating body 
composition.  It requires internal validation to examine it reliability in terms of its 
consistency in reproducing results.  It also requires external validation to understand the 
level of variation or agreement in MF-BIA estimates compared to that of a reference 
standard method. I used Dual X-ray Absorptiometry, which is considered a reference 
standard method with a low margin of error, to externally validate the MF-BIA machine 
I used in the observational longitudinal study presented in Chapter 3 (63).  In addition, 
because DEXA does not evaluate fluid components such as total body water I carried 
out a separate study in diagnosing dehydration in stroke patients using reference 
standard of serum osmolality (64).   Upon discharge from hospital I followed up study 
participants to assess their clinical outcomes as well as quality of life and functional 
capacity using self reported validated questionnaires to understand the association 
between body composition changes during acute hospital stay and longer term outcomes 
such as functional health assessed using the Short Form Survey 36 version 2 (SF36v2), 
stroke impact using Stroke Impact Scale (SIS) and activities of daily living using 
Barthel Index.   
 
I hope this study will add new knowledge to the possible utility of MF-BIA in acute 
stroke care, and inspire future research to further build on this knowledge with the 
ultimate goal of improving nutritional care in stroke.   
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Chapter 2: The relationship between nutrition markers and outcomes 
following a cardiovascular event:  A systematic review and meta-
analysis of prospective cohort studies 
 
 
 
 23 
 
Study Summary  
 
Objective:  to systematically investigate the relationship between nutrition markers of 
high and low energy intake, low protein intake, and low fluid intake on outcomes post 
cardiovascular event.  The nutrition markers examined included high and low Body 
Mass Index (BMI), weight loss, triceps skinfold thickness, low serum albumin, high 
serum creatinine, increased serum osmolality, and under nutrition assessed using 
nutrition assessment tools.  Primary outcome was mortality and the secondary outcomes 
included morbidity (recurrent event, complications), readmission, disability or 
functional status, length of hospital stay, and discharge destination. 
 
Data sources:  MEDLINE, EMBASE, and Web of Science were searched from 
inception to October 2010.  
 
Study Selection:  Two investigators assessed the titles, abstracts, and full text of each 
study for inclusion into the systematic review.  The two assessors were independent and 
used an inclusion/exclusion form. 
 
Inclusion Criteria: to be included in this systematic review the following criteria must 
be fulfilled.  1) Prospective cohort studies, 2) People diagnosed with transient ischemic 
attack (TIA), myocardial infarction (MI), or stroke, 3) Assessing the effect of at least 
one of serum albumin, serum osmolality, serum creatinine, BMI, weight loss, or TSF, 
and 4) At least one of these outcomes was reported: primary outcome mortality, 
secondary outcomes including cardiovascular morbidity (reinfarction, complications), 
readmission, disability or functional status, length of hospital stay, and discharge 
destination.   
 
Data Extraction:  A data extraction form was designed to collect variables of interest. 
Two data extractors, the primary author and a clinician, carried out data extraction 
independently.   Data extraction included collecting information on study characteristics, 
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subject characteristics. For each study the nutrition marker cut-offs that defined extreme 
nutritional status were recorded.   Specified review outcomes described in the protocol 
were recorded and outcome estimate (odds ratios, relative risks, or hazard ratios) with 
confidence intervals (or other measure of variance) were recorded for the unadjusted 
and most adjusted model.  Validity of each study was assessed by each data extractor.  
At the end of the data extraction process, data extractors compared their data collection 
outcomes; variations were solved through discussion until a consensus was reached.   
 
Data analysis:  The main analysis was to compare relationship between each nutrition 
marker signifying extreme value to its corresponding normal values on outcomes.  
Meta-analysis for secondary subgrouping was carried out for the nutrition marker with 
the largest data set.  All studies were pooled using an inverse variance method using 
random effects methodology.  Data were primarily sub-grouped by type of risk estimate 
(hazard ratio, risk ratio, or odds ratio).  Secondary subgrouping if possible by age, 
baseline cardiovascular event, and gender was carried out. Secondary outcomes 
morbidity (as defined per study), disability, discharge destination, readmission, and 
length of hospital stay were compared between extreme nutrition marker values and 
their normal values (for example obese BMI vs., normal BMI) and were always sub-
grouped by risk estimate (hazard ratio, risk ratio, or odds ratio) if enough number of 
studies were present to render such subgrouping possible.    
 
Results:  Of the 2000 studies of the search outcome, 23 met the inclusion criteria.  13 
studies examined BMI, one weight loss, four on serum albumin and one of which 
included serum creatinine, one serum osmolality, and four nutrition assessment tools. 
All studies examined the risk of extreme measures of nutrition markers compared to its 
normal measure on the primary outcome mortality and secondary outcome morbidity 
(recurrent event, complications).  The risk of obesity compared to normal weight on 
mortality suggested no association among obese patients RR 1.02 (0.84 to 1.24; p=0.83) 
as opposed to hazard risk of 0.79 (0.48 to 1.32; p=0.37).   No association was also 
observed when examining the risk of overweight compared to normal weight on 
mortality RR 0.90 (95% CI 0.76 to 1.96) and HR 1.09 (0.99 to 1.20; p=0.06).  
Underweight compared to normal weight risk on mortality suggested a 41% increased 
risk RR 1.41 (95% CI 1.17 to 1.70) in the relative risk of underweight compared to 
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normal weight on mortality in CVD patient s (p<0.05) and absence of heterogeneity.  
For the risk of high serum albumin compared to low serum album suggested a reduced 
risk of mortality HR 0.91 (95% CI 0.84 to 0.98; p=0.01), and meta-analysis for the risk 
of under nutrition assessed using nutrition assessment tool compared to normal nutrition 
suggested increased risk of mortality OR 1.88 (95% CI 1.40 to 2.53; p=0.0001).  Of the 
23 studies two had missing data, 22 adjusted for age and one did not adjust for age, 19 
studies adjusted for gender and 4 did not, only two studies adjusted for socioeconomic 
status, six out o the 23 studies did not adjust for comorbidities, nine out of the 23 
included studies did not adjust for smoking, and author/funder affiliation was clear for 
most studies except one study was deemed unclear. 
  
Conclusion:  Undernutrition diagnosed using nutrition assessment tool provide evidence 
that the risk of mortality is higher in undernourished patients compared to well 
nourished patients.   Obesity and overweight were not associated with increased 
mortality.  Underweight, low serum albumin, raised serum osmolality, raised serum 
creatinine all increase risk of mortality.  Prospective observational cohort studies 
confirm these finding and generate a larger systematic review are required.  
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2.1 Background  
 
2.1.1 Effect of Malnutrition on metabolism and body composition integrity 
 
The European Society of Parenteral and Enteral Nutrition (ESPEN) (also known as the 
European Society of Clinical Nutrition and Metabolism) defines malnutrition as “a state 
in which a deficiency or excess (or imbalance) of energy, protein, and other nutrients 
causes measurable adverse effect on tissue/body form (body shape, size, and 
composition) and function, and clinical outcome”(65).   Malnutrition can take two 
dimensions, over nutrition and under nutrition. Over nutrition can be caused by 
excessive macronutrient intake resulting in obesity, and under nutrition can be caused 
by inadequate macronutrient and fluid intake resulting in weight loss and dehydration 
respectively.  There are other types of malnutrition such as fat and water soluble vitamin 
deficiencies and toxicities as well as mineral deficiencies and toxicities, but these are 
beyond the scope of this systematic review.  Over nutrition and under nutrition can be 
assessed by evaluating anthropometric indices, such as weight and body mass index, or 
serum markers such as serum albumin, and serum osmolality.  The next sections present 
the nutrition markers examined in this chapter and summarised in Table 2.1 that may 
reflect a type of malnutrition that may influence body composition changes; the main 
topic of this dissertation.   
  
2.1.2 Anthropometric markers in evaluating over nutrition and under nutrition 
 
2..1.2.1 Body Mass Index, Weight loss, and Upper Arm Anthropometrics 
Over nutrition can cause obesity. Obesity can be influenced by many factors including 
environmental and genetic factors.  Environmental factors include lifestyle and cultural 
values that dictate who we are within our society, and genetic factors that are innate and 
can determine our metabolism and how the body utilises energy (58).  The main 
component of body composition that increases with obesity is fat mass or adipose tissue 
(58).  Increased adiposity is associated with increased risk of co morbidities including 
but not limited to type II diabetes (66) , coronary heart disease (67), hypertension (68) 
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dyslipidaemia (69), and increased risk of mortality (70).  On the other hand, under 
nutrition can affect energy storage.  Redman and colleagues demonstrated in a clinical 
trial that both fat mass and fat free mass loss occurred after six months of 25% calorie 
restriction in healthy volunteers (n=36) of their study (59).  Changes in body 
composition because of over nutrition or under nutrition are measurable.  Energy related 
under and over nutrition can be measured mainly by anthropometric indices including 
body mass index (BMI), weight, triceps skinfold thickness (TSF), and mid arm 
circumference (MAC).    
 
BMI measurement is a swift and non-invasive method to identify both under nutrition 
(<19kg/m2) and over nutrition (overweight 25-29.9 kg/m2; obese ≥30 kg/m2) (71).  
Although a low BMI suggesting underweight secondary to underweight is worrying, a 
single body mass index measurement may not reflect the clinical risk of mortality or 
poor outcomes in people experiencing body mass index reduction but who are still not 
classified as underweight.  Cook and colleagues provided an example to describe how 
BMI may not reflect clinical risk of mortality or poor outcomes.  They provided an 
example suggesting that if a patient height was 1.58 m and weight was 67 kg with a 
BMI of 27 kg/m2 experiencing 10% weight loss, this patient would not be at risk of 
mortality based on BMI as the BMI would then be 24 kg/m2 and within the normal 
range (72).  Nevertheless, a single BMI measure outside the normal range can still 
provide useful information on health risk. In the case of low BMI (BMI <19 kg/m2), it 
may reflect those at risk of negative prognosis outcomes including mortality (73).  In 
the case of over nutrition a high BMI may indicate risk of poor outcomes (74) as body 
mass index mirrors changes in adiposity (58) which is associated with co morbidities as 
well as increased risk of mortality.   
 
Body mass index may mirror changes in body composition mainly adiposity, but is not 
a specific measure unlike triceps skin fold thickness.  Triceps skin fold thickness (TSF) 
is traditionally used to measure adiposity or body fat (75).   It uses percentiles values to 
evaluate the level of adiposity with <5th percentile indicating frailty suggesting severe 
under nutrition due to very low body fat.  When evaluating TSF in patients with liver 
cirrhosis, those with a TSF <5th percentile had lower survival rate compared to those 
with a higher TSF percentiles at six and 12 months post discharge (p<0.001) and at 24 
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months (p<0.002) (76). In-hospital outcomes are also affected by low TSF 
measurements; TSF  was lower in stable patients with chronic obstructive pulmonary 
disease (n=39) requiring rehospitalisation compared to similar patients those who did 
not require rehospitalisation (p<0.05) (77).      
 
Both single measurement of BMI and TSF provide information on the effect of energy 
balance on body composition, but they do not provide information on the deterioration 
of nutritional status over time. Generally, weight loss can provide information on 
nutritional status deterioration in a certain time period providing information on the 
extent of nutritional status change. McWhirter and Pennington 1994 evaluated the 
nutritional status of 500 patients admitted to five different specialties in an acute 
teaching hospital. They evaluated the nutritional status for those patients who had a 
hospital stay greater than 7 days and found that of 112 patients who had their nutritional 
status evaluated on discharge by weight loss, weight loss made two  of the overweight 
patients (n=29)  become moderately undernourished (7%), five (26%) of the mildly 
undernourished patients became moderately undernourished,  and seven (37%) of the 
moderately undernourished patients became severely undernourished (52).  Involuntary 
weight loss can have negative prognostic impact.   Malnutrition assessed by weight loss 
was associated with increased incidence of stomatitis in post cancer chemotherapy 
treatment (p<0.0001) (78).  Wallace carried out a study to understand the consequences 
of weight loss on older patients.  They found that a 4% involuntary weight loss 
increased the risk on mortality by more than two fold compared to non weight losers 
over a period of 2 years with a relative risk ratio of 2.43 (95% CI = 1.34 to 4.41) (79).    
 
 
Lean tissues loss can occur when energy is insufficient.  When fuel is insufficient, the 
body uses its own energy substrates.  Fatty acids, from adipose tissue, and amino acids, 
from body protein (muscles, intestinal lining, etc.), become the main fuel.  This 
metabolic change results in body composition changes that affect lean tissues.  One 
method that can be used to assess change in lean tissue is mid upper arm circumference 
(MAC) measurement. Changes in MAC can be used to evaluate the extent of muscle 
wasting due to energy deficiency.  It provides information on the extent of muscle mass 
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loss, which is an important predictor of negative prognosis in acutely unwell patients.   
Liver cirrhosis patients diagnosed with moderate or severe muscle mass loss with 
muscle mass of <5th percentile (severely malnourished) and <10th percentile (moderately 
malnourished) had a lower survival rate compared to those with a  10th-75th and >75th 
percentile values indicating normal nutrition or over nutrition respectively; evaluated 
using MAC at 6, 12,  and 24 months (p<0.001) (76).   
 
2.1.3 Biochemical Markers in evaluating over nutrition and under nutrition 
 
2.1.3.1 Serum Albumin  
 
Serum albumin has been used as a marker to diagnose protein malnutrition.  Serum 
albumin synthesis appears to rise with an increase in protein intake (80).  Sullivan and 
colleagues examined serum albumin in 102 patients with an average nutrient intake <50% 
of their caloric requirement.  Patients with reduced nutrient intake had lower serum 
albumin levels (mean= 29.1±6.7) g/L ) compared to those with normal nutrient intake 
(n=395; mean=33.2±6.1) g/L) (81).  Mitchell and colleagues compared nutrition 
markers of 150 malnourished hospitalized patients (elderly n=44, age range 62-85 years; 
and young adults n= 65, age range 19-58 years) with 80 healthy control subjects of the 
same age range (40 young adults and 40 elderly); judging malnutrition based on a 10% 
or more weight loss in the past six months.  Serum albumin was clearly affected in 
malnourished patients.   Malnourished elderly males (n=15) had serum albumin level of 
25.0±1.00 g/L compared to 43.0±1.00 g/L in the elderly well nourished males group 
(n=20); p<0.001.  Malnourished elderly females (n=25) serum albumin was 2l.6 ± l1.0 
g/L compared to 4l1.0±l.001 g/L in well nourished (n=20); p<0.01(82).  Low serum 
albumin was significantly associated with increased length of hospital stay (LOS) (p 
<0.001) (83).   
 
 
 
 30 
 
2.1.3.2 Serum Creatinine 
 
It has been suggested that serum creatinine levels may be related to body composition in 
general (84) and lean body mass specifically (85).  Elevated serum creatinine may be 
related to negative energy balance resulting from muscle breakdown to supplement the 
necessary energy in cases of inadequate glucose intake and depleted glycogen stores in 
liver and muscle.  Increased serum creatinine levels may reflect a state of muscle 
metabolism suggesting negative energy balance.     
 
2.1.3.3 Serum Osmolality  
 
Serum osmolality reflects the concentration of solutes, such as minerals and glucose, 
dissolved in the water content of serum; therefore high serum osmolality means that the 
blood is more concentrated (higher proportion of solutes to water). Therefore, serum 
osmolality increases when the fluid intake is inadequate.  A study on healthy elderly 
men documented an increase in serum osmolality after a 24 hour water deprivation (86).  
Increased serum osmolality is associated with poor clinical outcomes.  In critically ill 
patients mean serum osmolality was 297.0±16.7 mOsm/kg for survivors compared to 
312±22.1 mOsm/kg in non-survivors; pcorrelation<0.05 (87).    This retrospective 
observational study compared 16 different laboratory and clinical parameters, acute 
physiologic and chronic health parameters (APACHE), and sequential organ failure 
assessment scores in predicting in-hospital mortality.  The area under the receiver 
operating curve (ROC) value for serum osmolality was 0.732  (95%CI:0.692-0.772) 
second to APACHE in its mortality prediction, but when examined in its predictive 
ability for mortality at > 5days hospital stay suggested it had the best predictive ability 
with ROC value of 0.711 (95%CI: 0.661-0.761) (87).    
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2.1.4 Nutrition assessment tools in evaluating nutritional status  
 
2.1.4.1 Subjective Global Assessment Tool,  Mini Nutrition Assessment Tool, and 
combination of Nutrition Markers 
 
There are several nutrition assessment tools used to evaluate the nutritional status of 
patients.  No method is used universally; nutritional status assessment ranges from 
complex nutrition assessment tools to a combination of individual anthropometric and 
biochemical markers.  The Subjective Global Assessment Tool (SGA) assesses nutrition 
based on weight change, dietary intake change, gastrointestinal symptoms, functional 
capacity changes, and disease in relation to nutrition requirements (88).  The final 
nutritional status is classified as Grade A, B, or C corresponding to well nourished, 
malnourished, and severely malnourished status respectively (89).   
 
As the name implies the SGA allows subjective evaluation of the nutritional status of 
patients based on historically used subjective assessment of physical examination and 
medical history evaluation (89).  A validation study of SGA was performed on 59 
hospitalized patients, who underwent major gastrointestinal surgery, in whom the 
classification of nutritional status by SGA was compared with measurements of body 
composition (subcutaneous fat measured by triceps skinfold and midaxillary line at the 
level of lower ribs, and muscle wasting at quadriceps and deltoid muscle detected by 
palpations), serum hepatic protein concentrations, total lymphocyte count, and delayed 
hypersensitivity skin testing.   The outcomes of the comparison suggested a strong 
correlation between SGA assessment and all measures except total lymphocyte count, 
transferrin and total body nitrogen.  In addition, clinical outcomes correlated to SGA 
assessment classification with 69% categorized as severely malnourished, 43% as 
mild/moderately malnourished, and 16% as well-nourished of the 18 individuals who 
developed infectious complications (90). Few years later a follow up study compared 
SGA classification with six traditional measurements of nutritional status, including 
serum albumin, serum transferrin, delayed cutaneous hypersensitivity, anthropometry, 
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creatinine-height index, and the prognostic nutritional index suggested that the 
sensitivity and specificity of SGA in assessing malnutrition  were 0.82 and 0.72 
respectively (91).  
 
Another tool used is the Mini Nutrition Assessment (MNA) developed specifically for 
older people ≥65 years old to be assessed in various settings including hospital, care 
home, and in the community.  The MNA is an 18 item assessment integrating lifestyle, 
anthropometric, dietary intake, medical, and psychosocial factors (92) and it considered 
three major areas (93).  It consists of three main areas of assessments with each 
containing of sub items.  The first area is anthropometrics evaluating the four sub items 
of weight loss, calf circumference, mid arm circumference, and BMI.  The second area 
consists of the six dietary sub items of recent change in appetite, meal per day, fruit, 
vegetable, protein, fluid intake, and independence in feeding.   The third area is the 
global item consisting of 6 sub items and these include mobility, lifestyle, medication, 
presence of sore or pressure ulcer, neuron psychosocial health and psychological health 
(93).   
 
In a validation study of MNA, 105 frail elderly patients were recruited from a geriatric 
evaluation unit of the University of Toulouse hospital and 50 healthy elderly subjects 
were recruited from the University of the Third Age in Toulouse.  Two physicians 
trained in nutrition carried out participant’s clinical assessment without prior knowledge 
of MNA results.  The physicians also assessed participants comprehensive nutrition 
status which was considered as a gold standard by evaluating subject’s anthropometrics 
(weight, height, knee height, triceps skin fold, mid arm and calf circumference), 
biochemical markers (albumin, prealbumin, Creatinine, ceruloplasmin, C-reactive 
protein, α1-glycoprotein, cholesterol, triglycerides, vitamins A, D, E, B1, B2, B6, B12, 
copper, zinc, haemoglobin, blood cell count and differential, and dietary intake using 3-
day food record and food frequency questionnaire.  When carrying out discriminate 
analysis to compare MNA results with the physician clinical and comprehensive 
analysis,  MNA identified the nutrition status 92% and 98% correctly based on 
physicians’ clinical and comprehensive analysis respectively (93). For each item (global, 
anthropometric, subjective, and dietary) a validation study was carried out in 1993 with 
90 participants recruited from the geriatric evaluation unit at the University of Toulouse 
 33 
 
and 30 from the University of the Third Age.  Participants MNA, biochemical measures 
(albumin, prealbumin, Creatinine, C-reactive protein, α1-glycoprotein) and clinical 
assessment were evaluated.  MNA identified nutrition status in 89% with identical 
clinical status assessment and 88% with identical biochemical markers (93) .   
 
The MNA diagnostic accuracy compared to BMI in assessing malnutrition was 
examined in sub-acute care patients; patients with a known course of treatment 
requiring comprehensive but not intensive care program or procedure designed for 
individuals with an  illness, injury, or deteriorating disease state after an acute event 
(94).  The highest sensitivity for diagnosing malnutrition by the MNA was correlated 
with a BMI <22 kg/m2 (sensitivity 0.70, specificity 0.71) in sub-acute patients (n=837, 
mean age 76.1±12.1 years) (95).   
 
Both SGA and MNA use a combination of anthropometric, biochemical and other 
components to evaluate the state of nutrition.  In some studies malnutrition was assessed 
using a combination of different anthropometric and biochemical indicators but not 
necessarily using validated assessment tool.  For example, Yoo et al (54) diagnosed 
malnutrition if one or more of the following criteria were met including a 10% weight 
loss in the past 3 months and/or 6% weight loss one week post admission, weight index 
(actual weight compared to reference weight) less than 80%, serum albumin <3.0g/dl, 
prealbumin <10.0 mg/dl, or transferrin < 150mg/dl in the evaluation of their study 
participants’ nutritional status (54).    As described above studies evaluating nutritional 
status in clinical care used either validated tools or a combination of nutrition markers 
mainly, but it was also assessed using individual nutrition markers (either 
anthropometric or biochemical). 
  
Studies discussed so far provide some data on the prevalence of malnutrition in hospital 
setting giving an idea of the magnitude of the problem.  It is important to understand 
how malnutrition can impact on outcomes regardless of the method of nutritional status 
assessment to make recommendations on the best method/s that are associated with 
poor outcomes (i.e. best prognostic indicators or nutrition markers) to develop strategies 
in prevention of poor outcomes.  Concrete evidence is in dire need.  This systematic 
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review compile evidence of prospective observational cohort studies to aid clinicians in 
prioritizing nutrition assessment and intervention in patients with CVD.  Table 2.1 
below presents aforementioned nutrition makers in tabular format and provide 
information what their extreme cut offs values indicate.   
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 Measure Indicator  
Anthropometric BMI ≥ 30 kg/m2 Obesity 
 BMI 25-29.9 kg/m2 Overweight 
 BMI<19 kg/m2 Underweight  
 Weight Loss negative energy balance 
 Weight gain positive energy balance 
 Triceps Skin Fold increase/decrease in fat mass 
 Mid Arm Circumference  increase/decrease in lean mass  
Biochemical  High Serum Albumin adequate protein intake 
 Low Serum Albumin inadequate protein intake 
 High Serum creatinine lean tissue breakdown 
 High serum osmolality low fluid intake 
Nutrition Assessment Tools Subjective Global Assessment  under nutrition 
 Mini Nutritional Assessment under nutrition 
 Nutrition Marker Combination under nutrition 
Table 2.1.   The nutrition markers examined in this systematic review by type, their cut offs, and what each measure indicates 
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2.1.5 Malnutrition in hospital 
 
The prevalence of under nutrition in hospital setting has been reported to be >20% 
depending on the measure used and the population studied (50, 96, 97).  In another 
study of patients in German teaching, community, and university hospitals recruited 
from general surgery, rheumatology, gynaecology, oncology, cardiovascular, 
urogenital/renal, neurological/dementia, and trauma/orthopaedics surgery reported that 
27% were malnourished using SGA (96).  The prevalence of malnutrition was reported 
as high as 50% in adult patients older than 18 years old recruited from several hospitals 
and specialities, a multicentre study conducted in south and central American, and 
Caribbean countries using SGA (97).    
 
The prevalence of malnutrition is unsurprisingly high in conditions associated with 
swallowing difficulty such as stroke.  Up to 71% (10/14) of Australian stroke unit 
dysphagic patients were suffering from malnutrition assessed by SGA within 48 hours 
of admission compared to 32% of non-dysphagic patients (19/59), p=0.007 (46).  
Similarly, during the first week of hospitalisation in an acute stroke unit, dysphagic 
patients were more likely to be malnourished (16/24, 67%) compared to non-dysphagic 
patients (15/67, 24%) as diagnosed by SGA; p<0.001(46).   Dehydration assessed by 
serum osmolality was also prevalent in stroke patients as 30% of the patients had raised 
serum osmolality (>296 mOsm/kg) in a study including 167 stroke patients (98).    
 
Although studies documenting the prevalence of malnutrition in coronary heart disease 
are scarce, obesity as a form of malnutrition or more specifically over nutrition is well 
documented to increase the risk of coronary heart disease (CHD) (99).  In the Honolulu 
study (n=7,692 men) participants with the highest tertile of subscapular skinfold 
thickness indicating increased adiposity experienced higher rates of coronary heart 
disease during a 12 year follow up of men  compared to those with lower skinfold tertile 
(100).   CHD risk increased by more than three fold in obese women (BMI ≥30 kg/m2) 
compared to normal weight women 3.44 (95% CI, 2.81 to 4.21) in a 20 year follow up 
of 88, 393 women (age range 34 to 59 years of age) who participated in the Nurses' 
Health Study and did not have previous CVD at baseline (101).   Considering that 
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malnutrition in the form of increased adiposity increases the risk of CHD, it is important 
to understand further if malnutrition in CHD does have an impact on outcomes after a 
CVD event.  Malnutrition diagnosed by serum albumin suggest that 629 acute 
myocardial infarction patients (40%) had serum albumin <35 g/L (102). 
 
The proportion of stroke patients with under nutrition increases during acute hospital 
care (49, 56).  Axelsson and colleagues assessed nutritional status by evaluating 
anthropometric (weight, triceps skinfold thickness and arm muscle circumference) and 
biochemical (albumin, transferrin and prealbumin) nutrition markers to evaluate 
nutrition status (49) and found that under nutrition increased from 16% to 22% between 
admission and discharge.   
 
As can be seen from the literature the prevalence of malnutrition in hospital settings is 
evident.  To understand the impact of malnutrition after a CVD event requires 
systematic approach. As malnutrition can be diagnosed using variable methods, the 
measure of malnutrition that can best predict outcomes after a CVD event is unclear.  In 
this systematic review I tried to address these questions.   
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2.2 Validity of evidence 
 
Given that malnutrition appears to be prevalent after a CVD event, it is important to 
understand its impact on the final outcomes.  A systematic review of the available 
evidence is essential if such evidence is to be accumulated to aid clinicians in decision 
making.  When carrying out a systematic review and meta-analysis there is always the 
risk of accumulating biased evidence leading to a final biased effect estimate.  In other 
words, bias in each study included based on the inclusion criteria may accumulate if not 
controlled for leading to a biased effect estimate outcome concluded from the meta-
analysis. This systematic review gathered evidence and presented its outcomes 
according to the preferred reporting items for systematic reviews and meta-analyses: the 
PRISMA statement (103)  while monitoring closely if each study reported its outcomes 
following STROBE statement; The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational 
Studies  (104). 
 
The Cochrane handbook for systematic reviews and meta-analysis, version 5.1 (105) 
classification of non-randomized controlled trials (NRS) include but is not limited to  
case-control studies, case series, cross sectional, controlled before-and-after study, and 
historically controlled studies (106). Observational studies are not clinical trials. 
However, as in randomized clinical trials the risk of bias must be assessed, but here it is 
important to evaluate factors that may influence the effect size I am reporting.  In order 
to have an effect size that reflect what I examined and in this case the relationship 
between malnutrition assessed by the nutrition marker of interest and health outcomes, I 
must make sure that the effect size I reported is based on adjusted models that 
controlled for confounders. Therefore as in section 13.5.2.2 in the Cochrane handbook 
many factors were considered in assessing validity of studies.  At the stage of writing 
the systematic review protocol, I considered what can be a confounder for the effect I 
am trying to asses in CVD patients.  Considering patients with CVD may have other 
chronic condition that lead to the CVD event I considered factors or conditions such as 
age, diabetes, kidney diseases, hypertension, and socioeconomic status as confounders 
that can also influence the health outcomes examined in this work (discussed details in 
the risk of bias section in methodology section).   
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The other bias considered was attrition bias.  Attrition bias considers completeness of a 
sample follow-up, and data.  In a way this approach tries to understand the sample and 
how many drop outs were there and due to what reasons, if the sample collected at the 
beginning of the study was all included in the final analysis and if not what are the 
reasons (why are there any missing data), and if the follow up was complete (if the 
study was terminated).  This type of bias assessment ensures that the quality of the 
study is considered.   In this systematic review the extent of sample drop out (missing 
data) was also evaluated to shed light on the quality of each study.   
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2.3 Aim 
 
The aim of this systematic review was to investigate the relationship between nutrition 
markers of high and low energy intake, low protein intake, and low fluid intake on 
relevant clinical outcomes after a cardiovascular event.  The nutrition markers examined 
included high and low BMI, weight loss, skinfold thickness, low serum albumin, high 
serum creatinine, increased serum osmolality, and malnutrition assessed by different 
nutrition assessment tools. The primary outcome was all cause mortality and secondary 
outcomes included morbidity (reinfarction, complications), readmission, disability or 
functional status, length of hospital stay, and discharge destination.   
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2.4 Methodology 
 
Protocol and registration:  no published protocol exists for this study.  The protocol was 
formulated to aid the author and investigators in carrying out the steps of this systematic 
review (Appendix I).  
 
2.4.1 Eligibility criteria and study selection 
 
Two investigators assessed the titles, abstracts, and full text of each study for inclusion 
into the systematic review.  The two assessors were independent and used an 
inclusion/exclusion form.  Inclusion criteria included  
 
• Prospective cohort studies  
• People diagnosed with transient ischemic attack (TIA), myocardial infarction 
(MI), or stroke 
• Assessing the effect of at least one of serum albumin, serum osmolality, serum 
creatinine, BMI, weight loss, or TSF  
• At least one of these outcomes was reported: primary outcome mortality, 
secondary outcomes including cardiovascular morbidity (reinfarction, 
complications), readmission, disability or functional status, length of hospital 
stay, and discharge destination.   
 
2.4.2 Information Source 
 
MEDLINE, EMBASE, and Web of Science were searched from inception to October 
2010.  I carried out the search and it was duplicated by another independent investigator 
with clinical knowledge. All selected studies were available as full text in the used 
search engines MEDLINE, EMBASE, and Web of Science.  Search terms included 
cohort studies, nutrition markers including serum albumin, waist circumference, total 
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body water, other measures of hydration, body mass index, body fat, triceps skin fold, 
and serum Creatinine, and terms for the cardiovascular events stroke, myocardial 
infarction and transient ischemic attack.  Appendix II presents the search strategy with 
the indexing terms used on MEDLINE (similar search strategy was used in other search 
engines). 
 
2.4.3 Data items and extraction 
 
A data extraction form (Appendix III) was designed to collect relevant variables of 
interest. Two data extractors, the primary author and a clinician, carried out data 
extraction independently. Data extraction included collecting information on study 
characteristics including study location, period of participant enrolment, and follow up 
duration.  Number of drop outs and the reasons were recorded whenever available. 
Study characteristics were collected and these included total population eligible for each 
study, number of males and females, actual number of the population completed in the 
study (after drop outs), and study inclusion criteria.   Baseline event (myocardial 
infarction, stroke, or transient ischaemic attack) that was examined in each study was 
recorded, exposure as the nutrition marker including anthropometric (body mass index, 
weight loss), biochemical (serum albumin, serum osmolality, serum sodium, serum 
creatinine), or nutrition assessment tools that use a combination of anthropometric and 
biochemical nutrition markers were all recorded.  For each study the nutrition marker 
cut-offs that defined malnutrition were recorded.   
 
Specified review outcomes described were recorded and outcome estimate (odds ratios, 
relative risks, or hazard ratios) with 95% confidence intervals (or other measure of 
variance) were recorded for the unadjusted and most adjusted model.   At the end of the 
data extraction process, data extractors compared their data collection outcomes; 
variations were solved through discussion until a consensus was reached.   
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2.4.4 Risk of bias   
 
Three components were evaluated to assess the risk of bias in each included study.  
These three components were missing data, adjustment for relevant confounders, and 
source of funding/author affiliation if funded by an interested industry.   Information on 
each component was recorded using a validity tool designed by the investigator 
(Appendix III) to assess the risk of bias of non-randomized studies as described in 
Cochrane handbook of systematic reviews and interventions (105).   
 
2.4.4.1 Missing data   
 
To reduce the risk of bias in observational cohort studies, the STROBE statement was 
formulated indicating how data must be reported in observational cohort studies (104).   
When reporting results each observational study must present numbers of total 
population from which sample is drawn, potentially eligible participants for the study, 
participants included in the actual study based on the inclusion criteria and deemed 
eligible, those completed follow-up, and included in the final analysis. A study must 
report the sample size from the beginning to termination of the study during the course 
of the cohort. In addition, studies must report reasons behind changes in the sample size 
throughout the cohort.    
 
I reported the actual number of participants included in the study, initially meeting the 
inclusion criteria, and the actual number that were included in the final analysis using 
data extraction form and validity tool (Appendix III).  If the sample size changed 
between inclusion and final analysis then I recorded reasons behind changes in the 
sample size.  While prospective cohort studies are expected to lose participants through 
death/refusal/moving out of areas, it was important to report changes in the sample size 
as it can contribute to missing data.  In the Cochrane handbook for systematic review 
and meta-analysis (version 5.1), sources of bias presented in chapter 8 (section 4) refer 
to missing data as attrition bias (106).   Missing data suggest that data concerning 
outcome analysis were unavailable or incomplete shedding light and raising concerns on 
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the data collection process, data management, and overall quality of study design.  Data 
collection maybe incomplete, data management may not have been of highest standards, 
and the study design may not have been set to meet realistic objectives.  I recorded YES 
for missing data if a study had >5% of its data missing.   I recorded NO for missing data 
if a study had <5% of its data missing.  I recorded UNCLEAR if a study may have had 
missing data (not clear if a study had >5% missing or not).   If missing data was 
recorded as NO then I considered the study to have a low risk of bias, and if a study 
missing data was recorded as YES or UNCLEAR then the risk of bias was considered 
high.  I recorded unknown if not information on missing data was provided and the risk 
of bias was considered high (Table 2.2).    
 
2.4.4.2 Adjustment for Confounders 
 
Adjustment for confounders is an important component to make sure that the risk 
estimates we extracted reflect the true risk estimate of interest.  Therefore the extent to 
which a model adjusted for confounders was considered.  The main confounders 
considered were age, sex, socioeconomic status, smoking status and co morbidities.  
Although it is impossible to have each study adjusting for the same confounders, 
scientific evidence suggests that these certain factors are common confounder for the 
outcomes of interest in my study.    
 
Age and sex adjustment are both important as differences in their characteristics may 
contribute to variation in the effect size and interpretation.  The probability of stroke is 
directly correlated with age and differs for men and women.  Wolf and colleagues 
examined the 10 year average probability of stroke incidence in men and women of the 
Framingham study. After sub grouping men and women into age categories (55-59, 60 
64, 65-69, 70-74, 75-79, and 80-84 years old) respectively, their findings suggested that 
the probability of stroke increased with each age category and was not similar for men 
and women.  For example the probability of stroke for those aged 55-59 was 5.9% and 
3.0% for men and women respectively, and the probability of stroke for men and 
women aged 70-74 was 13.7% and 10.9% respectively (from 11.0% in men and 7.2% in 
women in the preceding age category of 65-69 years old) (11).  A more recent study 
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examined lifetime risk of CVD for men (n=3564) and women (n=4362) of the 
Framingham study, both at age 50 year old and with no previous CVD event,  up to 95 
year old.  The risk estimate for CVD event for men and women was 51.7% (95% CI, 
49.3 to 54.2) and 39.2% (95% CI, 37.0 to 41.4) respectively.  The median survival time 
for men was 30 (22-27) years while that for women was 36 (28-42) years (107).   
Available evidence suggests that age and gender are confounders for the risk of CVD 
event.  Age and gender can clearly confound the risk estimate and therefore adjusting 
for age and gender (or not) can influence the level of bias in the selected studies.   
 
Another confounder assessed was socioeconomic status defined as annual earning or 
achieved level of education.  Socioeconomic status indicating poverty or low/no 
education may  increase the risk of CVD (108).  Next in assessing risk of bias was co 
morbidities adjustment.  Co morbidities adjustment included adjusting for diabetes, 
hypertension, and kidney diseases. The risk of CVD was three times higher in people 
with diabetes compared to those who do not have diabetes (p<0.0001) (109), doubled in 
the presence of hypertension compared to its absence (110, 111), and   kidney diseases 
increased the risk of CVD between 20%-50% (112, 113).  Smoking status adjustment 
was also examined in the risk of bias assessment. The risk of CVD almost doubled in 
smokers and those with history of smoking compared to those that do not smoke (24, 
114). 
 
Making sure that studies adjusted for age, gender, socioeconomic status, co morbidities 
(diabetes, hypertension, or renal diseases), and smoking status were very important to 
ensuring that the risk estimates extracted from each study reflect the risk of extreme vs. 
normal nutrition marker after a CVD event and not masked by such confounders.  This 
is the rationale why risk estimates of the most adjusted models were extracted whenever 
possible.  In addition, results were sub-grouped by risk estimate type (relative risk, odds, 
and hazard risk ratios) in order to understand the size of the effect per type of risk 
estimate.  If a study adjusted for all confounders then the risk of bias was considered 
low.  If a study adjusted for all but one (for example for age, gender, socioeconomic 
status, and co morbidities I recorded YES but recorded NO for smoking status) then the 
risk of bias was considered medium.  If a study adjusted for three or fewer of five 
confounders (for example, I recorded YES for age, gender, and socioeconomic status, 
 46 
 
but recorded NO for co morbidities and smoking status) then the risk of bias was 
considered high.   
 
2.4.4.3 Funding/author affiliation 
 
Sources of funding and author affiliation were examined.  Funding affiliation may mean 
that the funder might have participated in some form in the study execution or data 
analysis especially for industry funded studies.   For example, if the study funding was 
received from a pharmaceutical company which hired its own researchers to carry out 
the study, not independent researchers, this may suggest that funder may have an innate 
interest in certain outcomes.  Author affiliation may mean that the author may have 
inherent interest in the study giving biased interpretation.  If funding and author 
affiliation with study was recorded as YES or recorded unknown then the risk of bias 
was considered high.  If funding and author affiliation were recorded as NO, then the 
risk of bias was considered low.   
 
2.4.5 Statistical Analysis 
 
2.4.5.1 Risk Estimates    
 
Quantitative measures of the relationship between a nutrition marker and an outcome 
measure as they were provided in the publication (relative risk, hazard ratio, or odds 
ratio) were abstracted.  Most adjusted and unadjusted risk estimates were recorded 
along with any measure of variance reported, and standard errors calculated where 
possible.  Standard errors were calculated from 95% confidence intervals by subtracting 
the lower limit from upper limit divided by 3.92 (105).  The natural log of the effect was 
entered as required by REVMAN 5.1 software (115) and indicated in section 9.4.3.2  in 
the Cochrane handbook for systematic review of interventions titled “The generic 
inverse variance outcome type in RevMan”(105).  Heterogeneity was assessed using I2, 
an I2 of 0%, 25%, 50%, and 75% corresponded to a no, low, moderate, and high level of 
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heterogeneity respectively as suggested by Higgins et al 2003 (116).   The higher the 
heterogeneity the more variation between studies included in the meta-analysis.  It will 
not be of any meaning to take the combined estimate of a meta-analysis if heterogeneity 
was high.  In such circumstance, the combined estimate cannot provide a meaningful 
interpretation.  Heterogeneity indicates that the studies that were included in the meta-
analysis to generate the combined effect differed to give clear cut evidence and cannot 
provide a confident answer for the research question being investigated.   
 
2.4.5.2 Analysis Plan 
 
Main or primary analysis was to compare relationship between each nutrition marker 
signifying extreme value to its corresponding normal values on primary outcome, 
mortality, sub grouped by the type of risk estimate statistics type (hazard ratio, odds 
ratio, or relative risk).  The prevalence of malnutrition was common and not rare in all 
studies examining the prognosis of malnutrition after a CVD.  It is not appropriate to 
pool all risk estimates regardless of type in one meta-analysis.  I cannot consider odds 
ratio and relative risk similar as they can only be considered similar if the prevalence of 
exposure is rare (106).  This is not the case for malnutrition in CVD event as reported 
earlier in the introduction of this chapter.   Secondary analysis was further carried out to 
examine the risk of extreme nutrition marker compared to its normal parameters (for 
example obese BMI vs., normal BMI) on secondary outcomes, morbidity (as defined 
per study), disability, discharge destination, readmission, and length of hospital stay was 
further sub grouped by the type of risk estimate (hazard ratio, risk ratio, or odds ratio).   
Subgrouping by risk estimate type (hazard ratio, odds ratio, or relative risk) was classed 
as primary subgrouping.   
 
In addition to primary subgrouping described above, secondary subgrouping by 
baselines CVD event, age, or sex was carried out to examine the risk of extreme 
nutrition marker compared to its normal parameters on primary outcome mortality and 
only if enough studies were available.  The Cochrane handbook for systematic review 
and meta-analysis, version 5.1, suggests that to carry out subgrouping, at least ten 
studies must be present to render such sub grouping possible and meaningful (106).  
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Obesity had the largest number of studies and I carried out secondary subgrouping for 
obesity only (as I do not have at least 10 studies with the right comparison group for 
each nutrition marker). All studies were pooled using an inverse variance method using 
random effects methodology.   
 
Studies included in the systematic review were categorized into studies that evaluated 
nutritional status using anthropometric, biochemical, and nutrition assessment tools.  
For each nutrition marker category, the specific nutrition markers were identified and if 
possible a meta-analysis was carried out.  For example, studies using BMI as a nutrition 
marker were all identified and the relationship between BMI and each outcome was 
examined in the meta-analysis.  Underweight, overweight, and obese body mass index 
were each compared to normal weight BMI to understand their prognostic value in 
predicting chosen outcomes on post a CVD event.  The same approach was used for all 
studies for the biochemical and variable nutrition assessment tool categories.  For 
biochemical low and high serum albumin were compared to normal serum albumin 
respectively.  Undernutrition diagnosed by nutrition assessment tools such as SGA was 
compared with well nourished patients.   
 49 
 
2.5 Results 
 
2.5.1 Study Selection 
 
The initial search yielded 2000 titles and abstracts.  Of the computer search outcomes, 
sixty eight articles passed the initial screening and full texts were retrieved.  After 
further scouting a total of 24 studies from the 68 full text papers that passed the initial 
screening met the inclusion criteria and were included in the systematic review for data 
extraction (Figure 2.1).     
 
Reasons for exclusion of full text papers included, use of non-human subjects (excluded 
by default), and use of a nutrition marker that does not meet the study inclusion criteria 
(e.g. urinary creatinine), the studies in which the participants with cardiovascular 
disease were analysed but with people with other sorts of illnesses (so the population of 
interest could not be separated out), and/or the outcomes of interest were not assessed. 
   
2.5.2 Study Characteristics 
   
The total number of participant included in this systematic review was 69,919 (women: 
16,201, 23.2%).  The median follow up period ranged from 1 month (117) to 35 years 
(118).  There were 14 studies assessing the risk of extreme anthropometry nutrition 
marker compared to its normal measure on mortality and secondary outcomes with 13 
using BMI and one study using weight loss.   In the Biochemical nutrition marker 
analysis there were five studies evaluating the risk of extreme serum biochemistry 
compared to their corresponding normal range values on mortality and secondary 
outcomes.  Four were on serum albumin, with one of them including serum Creatinine, 
and one on serum osmolality.    
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There were four studies that considered the risk of under nutrition compared to normal 
nutrition on mortality and secondary outcomes using nutrition assessment tools as a 
nutrition marker.   Baseline cardiovascular events included 10 studies on Myocardial 
Infarction (MI), nine studies on stroke, and four on coronary heart diseases (CHD).  
Table 2.2 a-b presents a brief description of the characteristics of included studies.  
Appendix IVa & IVb present detailed description of all studies included in this 
systematic review and meta-analysis.   
 
2.5.3 Validity of studies 
   
Only two studies had missing data as defined in the methodology (i.e. >5% of the 
baselines sample recruited were excluded due to missing data necessary for analysis).  
Of the 24 studies three had missing data (119-121), 23 adjusted for age and one did not 
(54), 19 studies adjusted for gender and 5 did  not (102, 117, 121-123), only two studies 
adjusted for socioeconomic status (118, 124), seven out of the 24 studies did not adjust 
for comorbidities (55, 56, 117, 121, 125-127), 10 out of the 24 included studies did not 
adjust for smoking (55, 56, 98, 102, 117, 120-122, 126-128), and author/funder 
affiliation was clear for most studies except one study was deemed unclear (122).  
Tables 2.3a-b presented the validity (assessment of bias) of each study including 
missing data, adjustment and author/funder affiliation (A/F).   
 
The selected studies mainly examined the risk associated with the extreme nutrition 
marker compared to its normal measure on mortality (primary outcome).  Tables 2.4 a-b 
present the results of the studies that examine the risk of extreme nutrition marker 
compared to its normal value on the primary outcome, mortality.  Table 2.3c presents 
the results of studies that the risk of extreme nutrition marker compared to normal 
nutrition marker on secondary outcomes  
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45 studies were excluded as they 
did not meet inclusion criteria  
1932 excluded after title and 
abstract review after further 
evaluation as they were not 
relevant.  
24 studies included 
Full text of 68 studies were 
retrieved for more detailed 
2000 potentially relevant abstract 
and identified by the search 
Six Biochemical nutrition 
markers: 4 studies for Albumin 
of which 1 study on examines 
serum Creatinine as well, 2 
serum osmolality 
14 Anthropometrics nutrition 
markers: 13 studies for Body 
Mass Index, 1 weight loss 
4 studies on nutrition assessment 
tools, 2 using SGA, 2 using 
variable nutrition marker 
parameters 
Figure 2.1. The process of filtering electronic search outcomes 
until reaching the articles included in the systematic review and 
meta-analysis that met the inclusion criteria.   
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Study  Follow up 
(months) 
Event Females/Males Exposure  Comparison Outcome Assessed 
Anthropometric Nutrition Markers       
Batty 2006 (118) 42 CHD  18403 men* BMI≥30,25-29.9 
kg/m2 
20-25 kg/m2 Mortality, recurrent 
event 
Buettner  2007 (122) 17 Stroke 480/1196 BMI≥30,25-29.9 
kg/m2 
20-25 kg/m2 Mortality, recurrent 
event 
Dagenaise 2005 (129) 54 CHD  2182/6620 BMI≥30 kg/m2 < 25 kg/m2 Mortality, recurrent 
event 
Domanski 2006(130) 57.6 CHD  1171/5693 BMI≥30 kg/m2 < 25 kg/m2 Mortality, recurrent 
event 
Kragelund 2005 (119) 120 MI 2172/4502 BMI≥30, 25-29.9, 
<19 kg/m2 
20-25 kg/m2 Mortality, recurrent 
event 
Lopez-Jimenez 2008 (120) 6.2 MI 1022/1296  BMI≥30, 25-29.9, 
<19 kg/m2 
20-25 kg/m2 Mortality, recurrent 
event 
Mehta 2007 (131) 12 CHD  606/1719 BMI≥30 kg/m2 < 25 kg/m2 Mortality 
Nigam 2006 (132) 12 MI 278/616 BMI≥30 kg/m2 < 25 kg/m2 Mortality, recurrent 
event 
Nikolsky 2006 (123) 12 MI 542/1493 BMI≥30 kg/m2 < 25 kg/m2 Mortality 
Rana 2004 (124) 45 MI 1317/581 BMI≥30, 25-29.9 
kg/m2 
20-25 kg/m2 Mortality 
Table 2.2a.  Characteristics of included studies utilizing anthropometric nutrition markers included in the systematic review continued. 
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Study  Follow up (months) Event Females/Males Exposure  Comparison Outcome Assessed 
Rea 2001 (125) 36 MI 968/1573  BMI≥30 kg/m2 < 25 kg/m2 Recurrent events 
Sierra-Johnsson 2007 (133) 76.8 MI 79/298  weight loss  Mortality, recurrent event 
Wu 2010 (128) 16 MI 1885/4675 BMI≥30, 25-29.9 
kg/m2 
< 25 kg/m2 Mortality 
Zeller 2008 (134) 12 MI 593/1636 BMI≥30, 25-29.9 
kg/m2 
< 25 kg/m2 Mortality 
Table 2.2a. Characteristics of included studies utilizing anthropometric nutrition markers included in the systematic review. Not all studies were 
included in the meta-analysis. 
 
*men only 
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Study Follow up 
(months) 
Event Females/Males Exposure Comparison Outcome Assessed 
Serum biochemical Nutrition 
Markers 
      
Bhalla 2000 (98) 3 Stroke 87/80 >296 mOsm/kg <296 mOsm/kg Mortality, disability 
Carter 2007 (135) 88.8 Stroke 271/274 >38 g/L <38 g/L Mortality 
Gariballa 1998 (126) 3 Stroke 180/81 <35 g/L ≥35 g/L Mortality 
Gariballa 1998  (55) 3 Stroke 129/96 ≥35 g/L <35 g/L Mortality 
Hirakawa 1998 (102) LHS MI 521/1070 <35 g/L ≥35 g/L LHS* 
Kelly 2004 (121) 21 Stroke 55/47 > 297 mOsm/kg <297 mOsm/kg thromboembolism 
Nutrition Assessment Tools*       
Davalos 1996 (56) 3 Stroke 37/67 Undernutrition* Well nourished* Disability 
Davis 2004 (117) 1 Stroke 87/98 Undernutrition~ Well nourished* Disability 
Food Trial 2003 (127) 6 Stroke 1492/1520 Undernutrition^ Well nourished* disability/Mortality 
Yoo 2008 (54) 3 Stroke 47/84 Undernutrition$ Well nourished* Complications** 
Table 2.2b. Characteristics of studies utilizing biochemical nutrition markers and nutrition assessment tools included in the systematic review. 
 
*LHS: Length of Hospital Stay   
*under nourished definition in Davalos 1996: TSF >59.5% and 62.5% and MAMC (mid arm muscle circumference) below 85% and 86.4% and <34 g/l 
serum albumin 
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 ~under nourished by SGA: rate B or C by the SGA for nutritional status 
 ^under nourished by Food Trial Collaboration: by clinician judgement 
 $ Undernourished definition in Yoo 2008: at least two parameter (described in result section for Nutrition Assessment tools) are below normal of the 
one assessed in the study.   
** Complication in Yoo 2008: Pneumonia, Myocardial Infarction (MI), urinary tract infection, pressure sore, deep vein thrombosis, extra cranial 
haemorrhage  
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 Study  Missing data Age Gender SES comorbidities smoking A/F 
Anthropometric Nutrition Markers        
Batty 2006  No Yes Yes Yes Yes Yes No 
Buettner  2007 No Yes No No Yes No unclear 
Dagenaise 2005  No Yes Yes No Yes Yes No 
Domanski 2006  No Yes Yes No Yes Yes No 
Kragelund 2005 Yes Yes Yes No Yes Yes No 
Lopez-Jimenez 2008 Yes Yes Yes No Yes No No 
Mehta 2007 No Yes Yes No Yes Yes No 
Nigam 2006  No Yes Yes No Yes Yes No 
Nikolsky 2006  No Yes No No Yes Yes No 
Rana 2004  No Yes Yes Yes Yes Yes No 
Rea 2001  No Yes Yes No No Yes No 
Sierra-Johnsson  No Yes Yes No Yes Yes No 
Table 2.3a. Validity assessment of studies utilizing anthropometric nutrition markers, continued 
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 Study  Missing data Age Gender SES comorbidities smoking A/F 
Wu 2010 No Yes Yes No Yes No No 
Zeller 2008 No Yes Yes No Yes Yes No 
Table 2.3a. Validity assessment of studies utilizing anthropometric nutrition markers 
*SES: Socioeconomic Status, Hyper: Hypertension, RD: Renal Disease, A/F: Author funder Affiliation 
For Missing Data:  Yes/unclear means high risk of bias, No means low risk of bias, unknown: no information provided  
For Age, Gender, SES, comorbidities, and smoking: Yes means low risk of bias, No/Unclear means high risk of bias, For A/F affiliation:  Yes/unlcear 
means high risk of bias, No means low risk of bias 
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Study  Missing data Age Gender SES comorbidities smoking A/F 
Serum biochemical Nutrition Markers        
Bhalla 2000 No Yes Yes No Yes No No 
Carter 2007 No Yes Yes No Yes Yes No 
Gariballa 1998  No Yes Yes No No No No 
Gariballa 1998  No Yes Yes No No Yes No 
Hirakawa 1998 No Yes No No Yes No No 
Kelly 2004 No Yes No No No No No 
Nutrition Assessment Tools        
Davalos 1996  No Yes Yes No No No No 
Davis 2004 No Yes No No No No No 
Food Trial Collaboration 2003 No Yes Yes No No No No 
Sung-Hee Yoo 2008 No No Yes No Yes Yes No 
Table 2.3b. Validity assessment of studies utilizing biochemical nutrition markers and nutrition assessment tools 
 
For Missing Data:  Yes/unclear means high risk of bias, No means low risk of bias, unknown: no information provided 
For Age, Gender, SES, comorbidities, and smoking: Yes means low risk of bias, No/Unclear means high risk of bias 
For A/F affiliation:  Yes/unlcear means high risk of bias, No means low risk of bias. 
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 Study Effect Unadjusted (95% CI)  p-value Adjusted (95% CI) p-value Extreme  
Group (n) 
Comparison 
Group (n) 
Anthropometric markers        
Obesity and Mortality      BMI≥30 kg/m2 20-25 kg/m2 
     Kragelund 2004  (Men) RR 0.85 (0.76 to 0.96) P<0.01 0.99 (0.85 to 1.16) 0.2 544 1613 
     Kragelund 2004  (Women) RR 0.85 (0.72 to 1.01) P>0.05 0.9 (0.74 to 1.09) 0.3 255 989 
     Batty 2006 HR NA  1.13 (0.91 to 1.40) 0.24 128 1336 
     Buettner 2007 HR 0.37 (0.17 to 0.77) 0.012 0.27 (0.08 to 0.92) 0.036 292 551 
     Lopez -Jimenez 2008 HR NA  0.74 (0.51 to 1.08) 0.1 700 528 
     Rana 2004 RR 2.57 (1.87 to 3.51) p<0.05 1.46 (0.99 to 2.16) 0.8 459 607 
Overweight and Mortality      BMI 25-30  kg/m2 20-25 kg/m2 
    Kragelund 2004  (Men) RR 0.83 (0.76 to 0.90) P<0.001 0.93 (0.85 to 1.03) p>0.05 1996 1613 
    Kragelund 2004  (Women) RR 0.86 (0.77 to 0.98) P<0.05 0.78 (0.68 to 0.89) p<0.001 610 989 
    Batty 2006 HR NA  1.11 (1.00 to 1.22) 0.24 1132 1336 
    Lopez -Jimenez 2008 HR NA  0.96 (0.69 to 1.34) 0.8 872 528 
    Rana 2004 RR 0.54 (0.50 to 0.59) P<0.05 1.14 (.80 to 1.62) p<0.05 832 607 
Table 2.4a.  Extreme anthropometric nutrition markers risk on mortality continued 
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 Study Effect Unadjusted (95% CI)  p-value Adjusted (95% CI) p-value Extreme  
Group (n) 
Comparison 
Group (n) 
Underweight and Mortality      BMI<20 kg/m2 20-25 kg/m2 
    Kragelund 2004  (Men) RR 1.73 (1.23 to 2.44) P<0.01 1.28 (0.87 to 1.90) p>0.05 41 1613 
    Kragelund 2004  (Women) RR 1.70 (1.37 to 2.06) P<0.001 1.45 (1.17 to 1.80) p<0.001 120 989 
    Lopez -Jimenez 2008 HR NA  1.77 (1.00 to 3.12) 0.05 84 528 
Weight Loss and mortality      weight loss No weight loss 
    Sierra Johnson 2008 HR 0.59 (0.31 to 1.10) 0.101 0.63 (0.33 to 1.20) 0.17 220 157 
Table 2.4a. Extreme anthropometric nutrition markers risk on mortality 
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Study Effect Unadjusted (95% CI) p-value Adjusted (95% CI) Adjusted 
p-value 
Extreme 
group (n) 
Comparison 
 Group (n) 
Biochemical markers & Mortality        
 Low Serum Albumin        
    Gariballa 1998  OR NA  1.13 (1.01 to 1.27) 0.035 38 163 
 High Serum Albumin        
   Gariballa 1998 (≥ 35g/l) HR NA  0.91 (0.84 to 0.99) 0.03 38 163 
   Carter 2007 (38-40 g/l)* HR 0.78 (0.59 to 1.09) 0.15 0.79 [0.57 to 1.11] 0.144 174 330 
   Carter 2007 (>43 g/l)* HR 0.45 (0.32 to 0.65) <0.001 0.65 [0.44, 0.96] 0.031 267 330 
 High Serum Creatinine        
   Carter 2007 (82-97 mmol/l) HR 1.39 (0.94 to 2.05) 0.096 1.60 (1.05 to 2.45) 0.03 240 330 
   Carter 2007 (98-117 mmol/l) HR 1.62 (1.12 to 2.34) 0.010 1.51 (1.01 to 2.27) 0.045 196 330 
   Carter 2007 (>117 mmol/l) HR 2.26 (1.58 to 3.24) <0.001 1.85 (1.25 to 2.73) 0.002 109 330 
High Serum Osmolality        
  Bhalla 2000 (>296 mmol/kg) OR NA NA 2.40 (1.00 to 5.9 0.05   
Table 2.4b.  Extreme biochemical nutrition marker and nutrition assessment tools on mortality continued 
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Study Effect Unadjusted (95% CI) p-value Adjusted (95% CI) Adjusted 
p-value 
Extreme 
group (n) 
Comparison 
 Group (n) 
Nutrition Assessment tools        
    Davis 2004 OR 3.1 (1.3  to 7.7)  3.2 (1.0 to 10.4)  30 155 
    Food Trial Coll. 2003  OR 2.32 (1.78 to 3.02) <0.0001 1.82 (1.34 to 2.47) 0.0001 275 2149 
Table 2.4b.  Extreme biochemical nutrition marker and nutrition assessment tools on mortality 
*Target: extreme of the nutrition marker examined (Obesity, overweight, underweight, and weight loss in anthropometric markers, low and high serum 
albumin and high serum creatinine in biochemical markers, under nutrition in nutrition assessment tools).  *comparison: normal range of nutrition 
marker in question (normal weight for anthropometrics or no weight loss), serum albumin ≤34 g/L. 
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Study Effect unadjusted (95% CI) p-value adjusted  p-value extreme normal  
Obesity & recurrent events        
   Buettner 2009 HR NA  0.66 (0.26 to 1.66)* 0.012 292 551 
Weight loss and recurrent events        
  Sierra Johnsson 2008 HR 0.60 (0.40 to 0.89) 0.013 0.59 (0.39 to 0.90) 0.015 220 157 
Biochemical Nutrition Markers        
Low Serum Albumin and length of hospital stay        
  Hirakawa 2006 HR NA  1.01 (1.00 to 1.01) P>0.05 629 962 
High serum osmolality and disability        
  Bhalla 2000 OR NA  2.34 (0.65 to 8.44) 0.2 50 117 
High Serum osmolality and thromboembolism        
  Kelly 2004 OR 2.7 (1.1 to 7.0) 0.04 4.7 (1.4 to 16.3) 0.02 24 78 
Nutrition assessment tools        
Undernutrition and complications        
  Yoo 2008 OR NA  4.49 (1.07 to 18.94) 0.04 26 105 
Table 2.4c.  Extreme anthropometric, biochemical nutrition markers and nutrition assessment tool risk on secondary outcomes continued 
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Study Effect unadjusted (95% CI) p-value adjusted  p-value extreme normal  
Undernutrition and disability        
  Davis 2004 OR 3.4 (1.3 to 8.7) 0.01 2.7 (0.7 to 9.0) 0.18 30 155 
  Davalos 1996 OR NA   3.5 (1.2 to 10.2) p<0.05 24 67 
Table 2.4c.  Extreme anthropometric, biochemical nutrition markers and nutrition assessment tool risk on secondary outcomes. 
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2.5.4 Anthropometric nutrition markers studies description 
 
Nine studies (Table 2.2 a) examined the prognosis of anthropometric nutrition markers 
in cardiac patients with myocardial infarction, four studies in cardiac patients with 
coronary heart disease, and one study in cardiac patients with stroke.  The 14 studies 
total participant population was 63,476 of which 13,295 (20.9%) were women.  Nine 
studies came from the USA, one from each Spain, Germany, Canada, United Kingdom, 
and France.    
 
Validity:  Two studies had missing data (Table 2.2).   None of the studies adjusted for 
all factors I considered in the validity tool at once.  Eleven studies adjusted for gender, 
three did not adjust (122, 123), and gender adjustment was not applicable for one study 
(118) as all were men.  One study adjusted for socioeconomic status (124).  All studies 
adjusted for baseline co-morbidities.  Of the 14 studies only three did not adjust for 
smoking (120, 122, 128).  Table 2.2 presents details on the validity of all studies 
included in this systematic review.  
 
Authors also adjusted for other confounder that were presented in their sample baselines 
characteristics, but were not specified in my data form.  These included lifestyle related 
behaviours (118, 119, 123, 124, 130-132, 134, 136) such as tea and alcohol 
consumption (124) and physical activity (118).  Other studies adjusted for blood 
pressure either systolic or diastolic blood pressure or both (118, 123, 128, 130-132, 134, 
136).  Some studies also adjusted for biochemical parameters such as total cholesterol 
(118, 123, 130), hyperlipidaemia (131), C-reactive protein (134), and 
hyperhemocystenemia (136), and haematological parameters (122).  Some studies 
adjusted for invasive treatment (119, 123, 124, 130, 131, 134) and medications (119, 
124, 130, 132, 136) additionally.   
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 2.5.4.1 Risk of obesity compared to normal weight on mortality and secondary 
outcomes  
 
Individual study results examining the risk of obesity compared to normal weight are 
presented in Tables 2.3 a & b.  Only five studies used normal weight (20-25 kg/m2) as 
the comparison group category. Other studies used a comparison group of BMI<25 
kg/m2 including underweight and normal weight subjects in the same category therefore 
were not included in the meta-analysis.  Of the five studies in the meta-analysis two 
used relative risk ratio (RR), and three used hazard ratio (HR).   The forest plot in 
Figure 2.2 shows the meta-analysis sub grouped by risk estimate type for the risk of 
obesity compared to normal weight on mortality.  There were no studies which reported 
odds ratio.  Heterogeneity was assessed by I2 and it was 75% in studies reporting hazard 
ratio and 58% in studies reporting the effect as a relative risk.  This suggested a 
moderate to high level of variation between studies.  This level of heterogeneity makes 
it difficult to interpret the overall effect of the relationship between obesity and 
mortality compared to normal weight.  There are clear variations between studies 
included in the meta-analysis.  Due to moderately high level of heterogeneity, there is 
no confidence in providing an evidence to aid in decision making that can be withdrawn 
from this meta-analysis.   
 
I did not have at least 10 studies to carry out secondary subgrouping.  The largest set of 
data for single forest plot was available from examining the risk of obesity compared to 
normal weight on mortality (presented above).  Only secondary sub grouping by 
baseline CVD event (myocardial infarction) and age examining the risk of obesity 
compared to normal weight on mortality was possible.  The relative risk suggested a 
reduced risk of mortality with no statistical significance.  Heterogeneity was moderate 
at 67%.  The risk of obesity compared to normal BMI decreased with increasing age.  
Table 2.5 presents the results of primary and secondary subgrouping for the risk of 
obesity compared to normal weight on mortality.   
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Not enough studies examined the risk of extreme anthropometric nutrition marker on 
secondary outcomes (no more than one study) to allow meta-analysis subgrouping by 
risk estimate (Table 2.3c).
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Figure 2.2.  Forest plot showing the risk of obesity compared to normal weight on mortality post-CVD sub grouped by relative risk ratio, and odds 
ratio for the most adjusted risk estimates of studies included in the meta-analysis. In the relative risk subgrouping the diamond can be seen on the right 
side of the forest plot axis suggesting increased risk of obesity on mortality, while in the hazard ratio subgrouping the diamond is on the left size side 
of the axis suggesting reduced risk of obesity on mortality; both compared to normal weight. 
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Mortality   No. studies Effect size p-value Obese Normal weight Heterogeneity 
 Type of Risk estimate       
  Relative Risk Ratio 2 1.02 (0.84 to 1.24) 0.83 1258 3209 58% 
  Odds Ratio  NA     
  Hazard Ratio 3 0.79 (0.48 to 1.32) 0.37 1120 2415 75% 
 Age       
  50-59 years 3 1.09 (0.92 to 1.28) 0.34 1287 2471 69% 
  60-69 years 2 0.95 (0.81 to 1.11) 0.51 836 2164 85% 
  70-79 years NA      
 Gender       
  Men NA      
  Women NA      
 Baseline CVD event       
  Myocardial Infarction (MI) 5 0.98 (0.89 to 1.08) 0.67 2378 5624 67% 
Table 2.5.  Meta-analysis result for studies that examined the risk of obesity on mortality post CVD event sub grouped by type of risk estimate, age, 
gender, baselines CVD event (only MI), and the risk of obesity on morbidity relationship between obesity and mortality post-CVD event sub group by 
morbidity defined as recurrent event (secondary outcomes); no other secondary outcomes were examined.    
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2.5.4.1.1 Sensitivity analysis   
 
Studies that reported unadjusted risk estimates were entered into a meta-analysis sub 
grouped by effect type (relative risk ratio, hazard ratio, and odds ratio).  The sensitivity 
analysis (entering unadjusted risk estimates only) results for the risk of obesity 
compared to normal weight on mortality decreased by 6% suggesting but confidence 
intervals were wide to suggest that obesity (n=1258) may reduce the risk of mortality 
compared to normal weight (n=3209); RR 0.94 (95% 0. 86 to 1.93; p=0.19).  Obesity 
lost its protective effect once other confounders were considered. The contribution of 
other confounders to the effect size may have outweighed that of obesity resulting in a 2% 
increase in the risk mortality in obese participants compared to participants with normal 
weight (in adjusted analysis).  However, it cannot be said that obesity reduces the risk of 
mortality as this does not hold any statistical significance (as in adjusted meta-analysis).   
Furthermore, the level of heterogeneity was high at 95%, and therefore it was 
impossible to draw any conclusion from these findings.  
 
2.5.4.2 Risk of mortality in overweight patients compared to normal weight patients 
post CVD event 
 
Only four studies examined the risk of mortality in overweight patients (25-29.9 kg/m2) 
compared to the comparison group of interest, normal weight (20-25 kg/m2) post CVD 
event (myocardial infarction).  One study presented both unadjusted and adjusted 
relative risk ratios.  Meta-analysis for the risk of mortality in overweight patients 
compared to normal weight patients sub grouped by type of risk estimate is shown in 
Figure 2.4.  Studies reporting the effect as RR suggested a 10% reduced risk of 
mortality in overweight patients compared to normal weight patients.  A high level of 
heterogeneity was observed.  Studies reporting the risk as hazards ratio suggested 
increased risk by 9% with a 0% heterogeneity.  Not enough studies were available for 
secondary subgrouping to be possible as indicated in the analysis plan.   
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2.5.4.2.1 Sensitivity analysis for the risk of overweight compared to normal weight on 
mortality post CVD event 
 
I carried out a sensitivity analysis for the risk of overweight compared to normal weight 
on mortality post CVD event by including only unadjusted risk estimates.   The result 
showed reduced risk but heterogeneity was high (97%) suggesting that evidence cannot 
be drawn despite statistical significance; RR 0.71 (95% CI 0.67 to 0.74; p<0.05).  Total 
overweight was 832 and normal weight was 607.  Despite statistical significance the 
high level of heterogeneity makes such risk estimate not one that can provide evidence 
on the reduced risk of mortality in overweight patients.   
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Figure  02.3.  Meta-analysis forest plot for risk overweight (25-29.9 kg/m2) compared to normal weight (20-25 kg/m2) mortality.  In the relative risk 
subgrouping you can see the effect (diamond) going to the left of the forest plot suggesting reduced risk of overweight on mortality, while in the hazard 
ratio subgrouping diamond can be seen on the right side of the axis suggesting increased risk of overweight on mortality; both compared to normal 
weight. 
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2.5.4.3 Risk of mortality in underweight patients compared to normal weight patients 
post CVD event   
 
Two studies examined the risk of mortality in underweight patients (<19 kg/m2) 
compared to normal weight (20-25 kg/m2) patients post CVD event.  All studies 
suggested increased risk of mortality in underweight patients.  Both studies examined 
the risk of mortality in underweight patients compared to normal weight patients post 
myocardial infarction.  Figure 2.4 presents the meta-analysis results of studies 
examining the risk of mortality in underweight patients compared to normal weight 
patients post CVD event sub-grouped by risk estimate type, no studies reported odds 
ratio or relative risk; only hazard ratio.  Heterogeneity was low suggesting that they 
provide the same outcome which was increased risk of mortality.    
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Figure 2.4.  meta-analysis forest plot of studies examining the risk of underweight (BMI<19 kg/m2) compared to normal weight (BMI 20-25 kg/m2) on 
mortality compared to normal weight patients post CVD event.  In the relative risk and hazard ratio subgrouping you can see the diamond on the right 
size of the forest plot axis suggesting increased risk of underweight on mortality; both compared to normal weight. 
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2.5.4.4 Risk of weight loss compared to weigh loss absence on mortality and morbidity 
post CVD event   
 
Only one study (103) examined the risk of weight loss during acute hospital stay (Table 
2.4 a) compared to no weight loss on mortality and recurrent CVD event (Table 2.4 c).  
The result suggested no association with mortality in patients experiencing weight loss 
post CVD event compared to those with no weight loss HR 0.63 (0.33 to 1.20; p=0.116) 
and reduced risk of recurrent CVD event 0.59 (0.39 to 0.90; p=0.015). 
 
2.5.5 Biochemical Studies description 
 
There were six studies examining the effect of malnutrition assessed by biochemical 
nutrition marker on outcome. The total number of participants was 2911 participants 
(42.7%, n=1188 women.  Two studies examined the risk of high serum albumin 
compared to its normal range on mortality (55, 135) and one of which also examined 
the risk of high serum creatinine on mortality compared to its normal value on mortality 
(135). One study examined the risk of low serum albumin compared to normal serum 
albumin on secondary outcome length of hospital stay (102), and one examined the risk 
of high serum osmolality compared to its normal value on mortality (98).  Of those 
studies one was on baseline myocardial infarction (102).  Four studies came from the 
United Kingdom and one from Japan (102).  The median follow up period ranged 3 
months (55, 98, 126) to 7.4  years(135).   
 
Validity assessment:  no study had missing data.  Only one study did not adjust for  
gender (102) and none of them adjusted for socioeconomic status. Of the six studies, 
two did not adjust for co morbidities (55, 126) and three did not adjust for smoking (98, 
102, 126).  Funding and author affiliation was all assessed as NO suggesting low risk of 
bias.   
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2.5.5.1 Risk of high or low biochemical nutrition marker compared to normal values on 
mortality and secondary outcomes post CVD event 
 
Gariballa e al 1998 (55) and Carter et al 2007 (135) examined the risk of high serum 
albumin compared to low serum albumin on mortality post CVD event (stroke).  Meta-
analysis results suggested a reduced risk of mortality HR 0.91 (0.84 to 0.98); p=0.01.  
The result of the meta-analysis is presented in Figure 2.5.  The heterogeneity was absent.  
Not enough studies were available to carry out secondary sub grouping by baselines 
CVD event, gender, or age.  All high serum albumin studies were presented risk 
estimates as hazard risk and none presented odds ratio or relative risk.  Only study 
examined the risk of low serum compared to normal serum albumin values and 
suggested an increased risk of mortality OR 1.13 (1.01 to 1.27; p=0.035).  Only one 
study Hirakawa 2006 examined the risk of low serum albumin (<35 g/L) compared to 
higher serum albumin (≥35 g/L) on secondary outcome length of hospital stay.  The 
outcome suggested no increased or decreased risk in length of hospital stay in those 
with low serum albumin compared to those with higher serum albumin OR 1.01 (1.00 to 
1.01) p>0.05.     
 
Not enough studies were available to carry out a meta-analysis sub grouped by risk 
estimate type (primary subgrouping) for the risk of low serum albumin, high serum 
osmolality, or high serum creatinine compared to normal values on mortality. One study 
for each of those nutrition makers was available.  Risk of low serum albumin on 
mortality compared to high serum albumin suggested an increased risk by 13% (OR 
1.13, 95% CI 1.01 to 1.27; p=0.035).  The risk of increased serum osmolality (>296 
mOsm/kg) compared to normal serum osmolality on mortality resulted in an increased 
risk of death by more than two fold OR 2.40 (95%CI 1.00 to 1.59; p=0.05).   Bhalla 
2000 examined the risk of high serum osmolality (>296 mOsm/kg) compared to low 
serum osmolality on disability and found no risk OR 2.34 (0.65 to 8.44); p=0.2.  Rowat 
and colleagues examined the risk of high serum osmolality compared to its normal 
values on thromboembolism and found an almost five fold increased risk OR 4.7 (95% 
CI 1.4 to 16.3; p=0.02).   
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The risk of high serum creatinine (82-97 mmol/L) compared to low serum creatinine 
(<82 mmol/L) suggested a statistically insignificant (with wide confidence interval 
range) increased risk of mortality by at least 30% HR 1.39 (95% CI 0.94 to 2.05; 
p=0.096).  The same study examined higher parameters of serum creatinine at 98-117 
mmol/L and >117 mmol/L compared to low serum creatinine and showed an increased 
risk of mortality with a HR of 1.62 (95% CI 1.12 to 2.34; p=0.01) and 2.26 (95% CI 
1.58 to 2.24; p=<0.001), respectively.   
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Figure 2.5.  Forest plot for the adjusted risk of high serum albumin (≥35 g/L) compared to low serum albumin (<35 g/L)  on mortality post baselines 
CVD sub grouped by risk estimate type, for studies examining the event for adjusted risk estimate. The diamond is moving toward the left of the forest 
plot axis suggesting reduced risk of high serum albumin on mortality.  
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2.5.6 Nutrition assessment tools study description:  
 
Studies which reported the association between the nutritional assessment tools and 
outcome used a combined biochemical and anthropometrics nutrition markers or a 
validated nutrition assessment tool (e.g. MNA and SGA).  The total number of 
participant in this category was 3,432 of whom 1663 (48.5%) were women.  The follow 
up period ranged from 30 days (117) to 3 months (55, 126).  There were four studies, 
one each from Spain, Australia, and South Korea, and one was a multi-centre global 
study.  
 
Validity assessment:  no missing data were reported.  Of the four studies only one study 
did not adjust for age (54) and one did not adjust for gender (117).  None of the four 
studies adjusted for socioeconomic status.  Only one study adjusted for co morbidities 
and one for smoking (54).   
 
2.5.6.1 Risk of under nutrition compared to normal nutritional status on mortality and 
secondary outcomes post-CVD event:   
 
Two studies examined the risk of under nutrition compared to the normal nutrition on 
mortality in patients with stroke.  Both unadjusted and the adjusted risk estimates 
suggested the increased odds of mortality in patients diagnosed with under nutrition 
compared to those without the diagnosis of under nutrition.  The meta-analysis results 
suggested 89% relative increase in odds; OR 1.89 (95% CI 1.40 to 2.56).  The I2 value 
was “0” suggesting that the two studies did not differ in the interpretation of their 
findings. Figure 2.6 presents the meta-analysis result of the two studies examining the 
risk of under nutrition compared to normal nutrition on mortality after stroke.   No 
studies reported hazard or relative risk estimates for the risk of under nutrition 
compared to normal nutrition on mortality.  Secondary subgrouping was not possible.  
There were not enough studies to carry out subgrouping by baseline CVD event, age, or 
sex.   
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Two studies were possible to include in a meta-analysis examining the risk of under 
nutrition on disability.  The meta-analysis of Davis 2004 and Davalos 1996, suggested 
an increased risk of disability associated with under nutrition compared with patients 
with no under nutrition OR 2.83 (95% CI 1.59 to 2.03).  I2 was ‘0’ suggesting the 
absence heterogeneity.  The results of the meta-analysis are presented in Figure 2.7.  
One study examined the risk of under nutrition compared to normal nutrition on 
complications and suggested increased risk OR 4.49 (1.07 to 18.94; p=0.04).  No 
studies reported hazard or relative risk.   
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Figure 2.6.  Meta-analysis forest plot for adjusted risk of under nutrition compared to normal nutritional status on mortality post CVD event.  The 
diamond is on the right of the forest plot axis suggesting increased risk of mortality. 
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Figure 2.7.  Forest plot of the studies that examining the risk of under nutrition compared normal nutritional status on disability.  The diamond is on the 
right side of the axis suggesting increased risk. 
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2.5.6.1.1 Sensitivity analysis   
 
I carried out a sensitivity analysis, meta-analysis using unadjusted risk estimate, for 
studies examining the risk of under nutrition (n=305) compared to normal nutrition 
(n=2,349) on mortality post CVD event sub-grouped by risk estimate type.  The result 
suggested an increased risk of mortality with no heterogeneity observed; OR 2.38 (1.84 
to 3.06) p<0.05.  This result is coherent with adjusted risk estimate examined earlier.  
Undernutrition is an independent predictor of mortality post CVD event.   
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2.6 Discussion   
 
2.6.1 Summary of Study finding  
 
There were a total of 23 studies with a total population of 69,817 (women: 16,146, 
23.1%).  Fourteen studies examined extreme anthropometric nutrition marker risk, five 
examined extreme serum biochemistry risk, and four examined under nutrition assessed 
by nutrition assessment tool risk, compared to their normal corresponding values on 
primary and secondary outcomes. 
 
Meta-analysis results for the risk of obesity compared to normal weight on mortality 
suggested no risk on mortality among obese patients RR 1.02 (0.84 to 1.24; p=0.83) as 
opposed to hazard risk of 0.79 (0.48 to 1.32; p=0.37).   None of the risk estimates were 
statically significant and heterogeneity was moderate when subgrouping by RR (58%) 
and high when subgrouping by HR (75%) suggesting variability among studies entered 
in the meta-analysis to lead similar finding.  
 
In secondary subgrouping by age no risk of obesity compared to normal weight on 
mortality was observed.  The risk of mortality in the 50-59 years old age 1.09 (0.92 to 
1.28; p=0.34) and the 60-69 years old was 0.95 (95% CI 0.81 to 1.11; p=0.51) (Table 
2.4).  In both of the meta-analysis by age heterogeneity was moderate for the 50-59 
years old subgrouping (69%) and high for the 60-69 years old subgrouping (75%) 
suggesting variability among studies making it difficult to draw a coherent conclusion.  
Further none of these studies risk estimates were statically significant.  
 
 In myocardial infarction patients on baseline obesity compared to normal weight did 
not show any risk on mortality 0.98 (95% CI 0.89 to 1.08; p=0.67) n obese myocardial 
infarction patients compared to normal weight myocardial infarction patients with 
moderate heterogeneity of 67%.     
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In studies that examined the risk of overweight compared to normal weight on mortality 
no effect was observed when subgrouping by relative risk of hazard risk ratio RR 0.90 
(95% CI 0.76 to 1.96; p=0.20) and HR 1.09 (0.99 to 1.20; p=0.06).  For studies 
examining the risk of overweight compared to normal weight on mortality sub grouped 
by relative risk heterogeneity was 69% and for those examining the risk of overweight 
compared to normal weight sub grouped by hazard risk heterogeneity was 0%, but no 
statically significant effect was observed.   
 
There was an increase by 41% (RR 1.41, 95% CI 1.17 to 1.70) in the relative risk of 
underweight compared to normal weight on mortality in CVD patient s (p<0.05) and 
absence of heterogeneity.  The risk of underweight on mortality increased by 41% post 
myocardial infarction RR 1.44 (95% CI 1.20 to 1.72; p<0.0001) and heterogeneity was 
absent suggesting coherence in studies risk estimate direction (increase) in included 
studies. 
 
Meta-analysis of studies examining the risk of high serum albumin compared to normal 
serum albumin suggested that there was a statistically significant reduced risk of 
mortality HR 0.91 (95% CI 0.84 to 0.98; p=0.01) with both studies providing the same 
conclusion (risk reduction) with heterogeneity being absent (0%).  For the nutrition 
markers low serum albumin, high serum osmolality, and high serum creatinine 
compared to their normal values one study was available for each making it not enough 
evidence to base a conclusion upon.  Only study examined the risk of low serum 
compared to normal serum albumin values and suggested an increased risk of mortality 
OR 1.13 (1.01 to 1.27; p=0.035).   The risk of increased serum osmolality (>296 
mOsm/kg) compared to normal serum osmolality on mortality resulted in an increased 
risk of death by more than two fold OR 2.40 (1.00 to 1.59; p=0.05).   The risk of high 
serum creatinine (82-97 mmol/L) compared to low serum creatinine (<82 mmol/L) 
suggested a statistically insignificant (with wide confidence interval range) increased 
risk of mortality by at least 30% HR 1.39 (95% CI 0.94 to 2.05; p=0.096).  The same 
study examined higher parameters of serum creatinine at 98-117 mmol/L and >117 
mmol/L compared to low serum creatinine and suggested an increased risk of mortality 
with a HR of 1.62 (95% CI 1.12 to 2.34; p=0.01) and 2.26 (95% CI 1.58 to 2.24; 
p=<0.001) respectively.   
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The final nutrition markers examined was nutrition assessment tool (a combination of 
biochemical and anthropometric nutrition markers) or a validated nutrition assessment 
tools such as SGA and MNA (see introduction).  Meta-analysis risk of under nutrition 
compared to normal nutrition on mortality post CVD event suggested a statistically 
significant increased risk OR 1.88 (95% CI 1.40 to 2.53, p=0.0001) with no 
heterogeneity observed.  The risk of under nutrition assessed using nutrition assessment 
tools on disability suggest an increased risk with no heterogeneity observed and 
statistical significance.    
 
2.6.2 Interpretation 
  
Obesity and overweight can be associated with pro-inflammatory and pro- thrombotic 
states (137) increasing the risk for conditions such as  diabetes, hypertension, high 
systolic and/or diastolic blood pressure, and glucose intolerance.  Abdominal obesity is 
related to CVD events (138).   The results of the meta-analysis suggest that underweight 
patients are at increased risk of mortality compared to normal weight patients post CVD 
event.   
 
Underweight is a form of under nutrition and may serve as a marker of frailty. Evidence 
presented earlier in the introduction suggests it can increase the risk of poor outcomes.  
Edington et al 1999 examined the relationship between BMI as a nutrition marker in 
community strictly, among patients with cardiovascular diseases, including coronary 
heart disease, angina, myocardial infarction, stroke, transient ischaemic attack on 
selected outcomes including hospital admissions and mortality.  This study was not 
included in this systematic review as it did not specify the effect of BMI on each 
individual CVD condition individually.  They found that CVD patients with a BMI of 
<20 kg/m2 had the highest hospital admission rates (p<0.001) and had their risk of death 
increased by two fold (p<0.001) compared to those with a BMI of >25 kg/m2 (139).   
 
Weight loss as suggested in the one study seemed to have no association with mortality, 
but reduces the risk of recurrent event.  If weight loss occurred in obese or overweight 
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patients it can improve their health and post-CVD event outcomes as it can place them 
within the healthy weight range.  On the contrary, if patients were already malnourished 
weight loss could cause further deterioration in their nutritional status increasing the 
risk of poor outcomes.   
 
No meta-analysis was possible for the relationship between low serum albumin and 
mortality.  However, one study (126) suggested that low serum albumin increases the 
risk of mortality.  One study cannot provide conclusive evidence.  Low serum albumin 
may not be related all the time to deteriorating nutritional status (140).   On the contrary, 
high serum albumin compared to normal serum albumin suggested reduced risk of 
mortality regardless of subgrouping with absence of heterogeneity. In-vivo studies 
suggest that albumin synthesis ceased when nutritional intake decreased or was 
inadequate (141).    
 
High serum creatinine compared to normal serum creatinine suggested increased risk on 
mortality.  Serum creatinine is suggested to be related to lean body mass (142, 143).  
Therefore such elevation in serum creatinine may be related to muscle breakdown as 
fuel substrates due to under nutrition, or such elevation in serum creatinine could be due 
to an increase in lean body mass.  Evidence to date suggest that the relationship between 
lean body composition and health outcome is limited and studies have shown that the 
contribution of lean body mass to serum creatinine is minimal (84) to suggest that 
serum creatinine reflect nutritional status.  It may be that the elevation in serum 
creatinine is related to glomerular filtration rate which also decreases with age (143) and 
the included study by Carter et al (135) was conducted in an ageing population (mean 
age 76 years, range 69-82 years) making it difficult to draw conclusion based on one 
study.   
 
Increased serum osmolality reflects hydration status and suggests dehydration.   In the 
one study included in this systematic review high serum osmolality compared to its 
normal value increased the risk of mortality as well as disability.  Dehydration seems to 
be a potential marker for poor outcomes including mortality.  The result of the serum 
osmolality study examined was coherent with other studies that suggest a strong 
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association between dehydration and poor outcomes.  A study by Rowat et al suggested 
that from the 2,549 stroke patients included in the study, of the 43% (687/1580) 
diagnosed as dehydrated on admission died in hospital or were discharged to 
institutional care compared with 177 of 969 of patients without dehydration (χ2=170.5; 
P<0.0001 (144).   This study was not included in this review as it uses a serum urea to 
creatinine ratio and I am interested in individual nutrition markers and their normal 
values as a comparison group and the study did not report any risk estimate. 
 
When evaluating studies assessing the prognosis of under nutrition assessed by nutrition 
assessment tool, all studies provided coherent outcomes.  In all of the studies the risk of 
under nutrition compared to normal nutrition was associated with mortality and poor 
outcomes.  These finding are consistent with findings from other studies.  Martineau et 
al examined the malnutrition diagnosed using SGA in 73 stroke patients and found that 
19.2% of patients were malnourished further malnourished patients had longer length of 
stay of 13 days (compared to 8 days in well nourished patients; p<0.001) and higher 
rates of complications (infections, tachycardia, pressure ulcers and falls)  at 50%  
(compared to 14% in well nourished patients; p=0.003) (46).  Another study examined 
the length of hospital stay in malnourished stroke patients compared to stroke patients 
with no malnutrition in a rehabilitation unit (n=49) and reported that length of hospital 
stay was significantly lower in patients with no malnutrition (44.9±14.4 days; n=10) 
compared to malnourished patients (58.9±14.9 days; n=18); p=0.011 (145).  
Malnutrition was diagnosed by the presence of at least two of the following assessed 
parameter on admission, body weight ≤90% of reference weight or ≤95% of usual 
weight or BMI < 20 kg/m2, or the total mean of four skinfold thickness < 5th percentile, 
or mid arm muscle circumference < 5th percentile, or serum albumin <35 g/L, or serum 
transferrin <2.0 g/L, or total lymphocyte counts <1,800 n/mm3.  The result of meta-
analysis for studies assessing the risk of under nutrition compared to normal nutrition on 
mortality and secondary outcomes included in my systematic review were coherent with 
these result and similar in their assessment of malnutrition.   
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2.6.3 Strengths and Limitations  
 
The main strengths of this study is that it examined prospective cohort studies only, 
allowing for better homogeneity in study designs and quality and clearer assessment of 
the validity of each study, by focusing on assessing the validity of one of study design.   
The other strengths include using the same comparison groups (normal nutrition marker 
value), which makes sure that extracted risk estimates included in the meta-analysis for 
each predictor (nutrition marker) share the same comparison group characteristics.      
 
The main limitation of this study was that there were not a large number of studies for 
primary and secondary subgrouping of each nutrition marker examined.  In addition 
there were not enough studies examining secondary outcomes of interest.  Many studies 
assessed in this review selected to be included in the systematic review were excluded 
from final meta-analysis due to not using the comparison group of interest.  Sometimes 
there was only one study for specific nutrition marker of interest that examines primary 
or secondary outcomes making it not applicable for subgrouping in a meta-analysis.  
These limitations make it difficult to reach firm conclusions and thus this review could 
not provide conclusive evidence based on systematic review of existing evidence.   
 
Other limitations and weaknesses of the studies included in this systematic review are 
related to the differences in confounders adjusted in individual studies.  As discussed in 
the risk of bias section in the methodology I chose age, gender, socioeconomic status, 
co morbidities (diabetes, hypertension, or renal diseases), and smoking status as factors 
that might influence the outcomes of studies.  One study did not adjust for age (54), four 
studies did not adjust for gender (102, 117, 122, 123), seven studies did not adjust for 
smoking (56, 98, 117, 120, 122, 126-128), only one study adjusted for socioeconomic 
status (124), five studies did not adjust for co morbidities (diabetes, hypertension, and 
Kidney disease) (55, 56, 117, 126, 127).    Adjustment for other possible confounders 
also varied between studies (see Appendix IVa & IVb) making the risk estimates being 
affected by the level of adjustment.   
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The length of follow up varied between studies (Appendix IVa & IVb); one month 
(117), 3 months ((55, 98, 126), and some more than a year (119, 124).  This variability 
in follow up may attenuate the risk estimates.  Prognosis of post-CVD event may not be 
related to nutritional status diagnosed during hospital stay, but can be related to many 
other factors that occurred after hospital discharge which were not considered.   
In summary, limited number of studies to allow primary and secondary subgrouping, 
not enough studies examining secondary outcomes, not all studies using the same 
reference group (i.e. normal nutrition), differences in confounder adjustment, between 
studies and variability in the length of follow up periods contributed to the limitations 
and weaknesses.    
 
2.6.4 Relevance to Clinicians  
 
Malnutrition is prevalent among patients with CVD events.  Diagnosing malnutrition in 
patients with CVD is important as evidence suggest malnutrition is a prognostic 
indicator for outcomes.  In this systematic review morbidity (functional status, length of 
hospital stay, hospital readmission) and mortality were selected to assess the prognostic 
value of malnutrition assessed using specific nutrition markers.  Malnutrition 
contributes to impaired immunity (146) and increases the risk of morbidity.  
Malnutrition also affects physical strength (147).  Weight loss experienced in 
malnutrition contributes to weakness resulting in increase in dependency and decline in 
functional status.  The loss of functional capacity contributes to patient inability to 
perform their previous activities affecting daily life.  Malnutrition also affects mental 
health (148).  Malnutrition thus increases the costs on the health system (149).  Based 
on this systematic review finding diagnosing malnutrition should be based on a 
comprehensive assessment of different nutrition markers ranging from anthropometric, 
biochemical and others makers such as dietary intake to detect any abnormal nutrition 
markers parameters that can indicate nutritional status deterioration.   If malnutrition is 
diagnosed nutrition intervention followed by nutritional status monitoring must be a 
priority.   
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2.6.5 Conclusion  
 
The risk of obesity compared to normal weight on mortality resulted in variable results 
with no statistical significance and moderate to high heterogeneity, which was also 
apparent when carrying out secondary subgrouping.  There was no risk associated for 
obesity or overweight compared to normal weight on mortality but, I cannot draw a firm 
conclusion on obesity or overweight risk on mortality considering that heterogeneity 
was high suggesting variability in study's findings and no statistical significance.   
 
The risk of underweight (compared to normal weight) and under nutrition (assessed 
using nutrition assessment tools compared to normal nutrition) on mortality suggested 
an increased risk while the risk of high serum albumin (compared to normal serum 
albumin) decreases the risk of mortality.  There were two studies for each of the 
mentioned nutrition markers.  Despite the absence of heterogeneity and statistical 
significance there are not enough studies to draw firm conclusion that can suggest that 
was systematic evidence.  Similarly the result of the meta-analysis assessing the risk of 
under nutrition compared to normal nutrition on disability which suggested an increased 
risk is based on two studies not enough to draw on concrete evidence.  
 
For low serum albumin, high serum osmolality, and high serum creatinine their risk on 
mortality compared to their normal parameter suggested increased risk on mortality.  
These were individual studies and systematic evidence cannot be drawn from them 
therefore confirmatory studies are required and future systematic review is 
recommended.  
 
Main limitation was that there were not enough studies to carry out subgrouping for 
each nutrition marker resulting in carrying only subgrouping for the nutrition marker 
(obesity) with the large set of data.  Most studies that met the inclusion criteria did not 
have the right comparison group resulting in excluding them from any meta-analysis.   
Due to the limitations and the fact that there are not enough studies to draw firm 
conclusion, clinicians must rely on diagnosing malnutrition through monitoring 
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different nutrition markers ranging from anthropometric and biochemical nutrition 
markers.  Further prospective cohort studies to understand association between 
nutritional status and outcomes after acute CVD event are required to allow for the 
generation of evidence through the synthesis of larger systematic review and meta-
analysis.   
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CHAPTER 3: Body composition changes after stroke and their 
relationship with short and longer term outcomes 
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Abstract  
 
Background:  Malnutrition after stroke is common and can lead to tissue catabolism and 
body composition changes and may have impact on stroke recovery.  This study seeks 
to evaluate these relationships using multi-frequency bioelectrical impedance analysis 
(MF-BIA).    
 
Methodology:  Ischaemic stroke patients admitted to an acute unit were prospectively 
recruited between January-July 2011. Patients’ demographics, anthropometric measures, 
biochemistry and body composition variables (BioScan 920-2, Maltron International 
Ltd, Essex, United Kingdom) were measured on admission and discharge.  Mean fat 
free mass (FFM), fat mass (FM), and protein mass change and mean changes/day 
between admission and discharge were compared between (soft mashed/pureed and Nil-
By-Mouth (NBM)) vs. normal feeding and between soft mashed/pureed vs. NBM.  
They were followed up at 6 months after discharge using Patient Administrative System 
(PAS) and by postal questionnaires for mortality, discharge destination and other 
functional outcomes including Barthel Index, Health Related Quality of Life using 
Short-Form-36 version 2.0 (SF-36v2), and Stroke Impact Scale (SIS).   
 
Results:   Total number of participant was 40, men=22(55%), mean age 69.8(±10.5) 
years, range 50-89 years, mean length of stay=4±4.1) days, range 2-24 days. There were 
17 Lacunar, 12 posterior circulation, 5 partial anterior circulation, and 6 total anterior 
circulation infarcts.  Average NIHSS score was 5.0 (range 1-22). Noticeable differences 
included higher protein mass loss for patients on modified diets (soft mashed/pureed) or 
nil by mouth -1.0 (-2.0 to 0.1) kg, compared to patients on normal oral diet -0.3 (-0.9 to 
0.3) kg.  Lager fat free mass loss was observed in patients prescribed nil-by-mouth 
(NBM) feeding regimen -1.9 (-4.3 to 0.5) kg compared to non-NBM (normal oral/soft 
mashed/pureed) (-0.3 (-1.1 to 0.5) kg.  NBM group experienced higher fat mass gains 
1.4 (-1.8 to 4.6) kg compared to non-NBM 0.1 (-0.64 to 0.9) kg. Further stratification by 
stroke subtype did not result in any statistically significant differences between or 
within groups. Eighteen participants responded to follow up questionnaire (45%).  
Those with fat free mass, protein mass, muscle mass, and body cell mass losses and fat 
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mass gain follow up questionnaire result was no statistically significantly different from 
those with fat free mass, protein mass, muscle mass, and body cell mass gains and fat 
mass loss.   
 
Conclusion: While the body composition changes observed in acute stroke were not 
statistically significant due to relatively small sample size, understanding these changes 
may, however, help designing targeted interventions in post-stroke nutritional care. 
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3.1 Background 
 
Stroke is a condition associated with several complications ranging from inability to 
swallow, to becoming completely dependent.  Of 1,259 stroke patients in the South 
London register assessed one week and 3 months post stroke, a wide range of 
disabilities were reported.  They reported 1-2 impairments in 6% of patients, 3-5 
impairments in 31% of patients, 6-10 impairment in 51% of patients, and ≥10 
impairments in 11% of patients with dysphagia and upper limb weakness being the most 
frequent impairments in 44% and 77% of patients, respectively (150).  The physical 
limitations that stroke incurs on its survivors may affect their activities of daily living 
and hence the quality of life.  While initial neurological damage can relate to these 
limitations, it is also important to note that recovery from stroke may be influenced by 
the body composition changes such as fat free mass loss, muscles mass loss, and other 
tissue losses, during acute stroke phase, resulting in reduced functional capacity in 
longer term.   
 
Understanding the extent of the occurrence of these body composition changes early 
after stroke may therefore help to understand the relationship between these changes 
and stroke outcomes including functional health. In this part of my investigation, I used 
multi-frequency bioelectrical impedance analysis (MF-BIA) to examine these changes.  
MF-BIA method is a swift, simple, and non-invasive method that can provide an 
evaluation of different body compartments.  Body composition measurement can be 
carried out on stroke patients on admission and discharge to evaluate the extent of 
changes occurring during their acute hospital stay using MF-BIA machine.  This 
technology can be used in clinical setting to understand body composition changes 
immediately after stroke if it is practical to so in acute setting.   Possible relationship 
between body composition changes and outcomes such as morbidity and mortality, and 
outcomes reported by patients, such as quality of life, can then be investigated.   
 
In this Chapter, I present the results of a prospective longitudinal cohort study which 
examined the extent of body composition changes in patients with an acute ischaemic 
stroke during their hospital admission and explored if any association existed between 
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these changes during acute hospital stay and short (at discharge) and longer term 
outcomes at six month post discharge.     
 
3.1.3 Stroke Complications and dietary intake 
 
Stroke can have various effects on the body including daily dietary intake.  Reduced 
dietary intake can result in weight loss and can further affect body composition in stroke 
patients.  Hence body composition can provide information on the nutritional status and 
adequacy.  The focus of this dissertation is on examining body composition changes 
after stroke as to date no studies has examined which body component is most affected 
after stroke.   
 
Dietary intake in acute stroke is often inadequate, which is usually attributed to high 
incidence of dysphagia after stroke, and a range of other secondary complications such 
as cognitive problems affecting eating behaviours, reduced ability to feed oneself 
independently, disorientation, paralysis, and depression (151, 152).  Reduced dietary 
intake can lead to weight loss, which is well documented after stroke (153, 154).   
 
Dysphagia is one of the commonest complications after stroke.  In a recent review, 
Martino and colleagues (155), reported the incidence of dysphagia as varying from 37% 
to 78%; using different dysphagia diagnostic criteria including cursory (water 
swallowing test), clinical (clinical scores), and instrumental (video fluoroscopy) 
methods.  The authors concluded that dysphagia after stroke is common regardless of 
diagnostic method used. Dysphagia is considered as the primary cause of reduced 
dietary and fluid intake in stroke patients (151, 152).  
  
There is also a direct association between dysphagia and malnutrition in stroke patients. 
The proportion of dysphagic patients suffering from malnutrition, assessed using the 
patient’s self-reported Subjective Global Assessment (SGA) tool was 71% (10/14) 
compared to non-dysphagic patients (19/59; 32%) in acute stroke, p=0.007 (46).  One 
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week after admission to an acute stroke unit, dysphagic patients were more likely to be 
malnourished (16/24; 67%) compared to non-dysphagic patients (15/67; 24%; p<0.001) 
(56).  The association between dysphagia and malnutrition is prevalent not only in acute 
settings, but also in care home settings.  A study carried out in stroke patients residing 
in a care home reported a significantly higher prevalence of malnutrition in dysphagic 
patients (4/20; 20%) compared to non-dysphagic patients (4/40; 10%); p=0.044 (156).  
The prevalence of malnutrition was also significantly higher in dysphagic compared to 
non-dysphagic patients (62.5% vs. 32.0% respectively) on admission to a rehabilitation 
unit; p<0.032) (157).    
 
There are other reasons why stroke patients may have reduced dietary intake in longer 
term.  The physical and mental impairments associated with disabilities in stroke 
patients can alter dietary intake; making the eating process physically, socially, and 
mentally difficult.  Hoarding and leakage of food from the mouth, and chewing 
problems contributed to eating difficulties after stroke in 44% of patients with eating 
problems (154).  Other problems contributing to eating difficulty include food spills, 
difficulty to sit appropriately for eating, inability to concentrate, prolonged eating time, 
and inability to control foods in the plate (158).   
 
The eating difficulties that stroke patients experience could make the whole process an 
unpleasant experience for them.   There is some evidence to suggest that their new 
disability and limitations may put stroke patients into a state of depression.  In an 
observational study by Axelssen et al. (154) the authors reported that 65% of the 
patients in their study entered into a denial phase not accepting their new condition i.e. 
inability to eat as before. The authors postulated that the denial phase caused patients to 
enter into depression and increased the risk of anorexia (up to 50% in their series) (154).  
A mean weight loss of 2.6 kg was reported in the 78% of patients with eating 
difficulties in their study (154).   Gariballa et al reported a statistically significant 
decline in average weight between week 0 (63.7±13.6 kg), week 2 (62.4±13.7 kg) in 48% 
(96/201), week 4 (61.6±12.5 kg) in 25%(51/201) of the 225 patients in their study; 
p=0.002 (55).   
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Weight loss may still occur long term after stroke.  A more recent population based 
study documented weight loss of ≥3.0 kg in 24% and 26% of stroke patients four 
months and one year post-stroke respectively (153).   If weight loss persists for a long 
duration it can contribute to severe body mass index (BMI) changes that can be 
classified as malnutrition; BMI <18.5 Kg/m2 in <65 years old population and a BMI 
<22 Kg/m2 in ≥ 65 years old population (159). 
 
Stroke complications resulting in reduced dietary and fluid intake lead to high incidence 
and prevalence of malnutrition among stroke patients.  In the next section I discuss the 
prevalence and incidence of malnutrition in stroke patients.  
 
3.1.4 Malnutrition in stroke 
 
The European Society of Parententeral and Enteral Nutrition  (ESPEN) which is also 
known as the European Society of Clinical Nutrition and Metabolism defines 
malnutrition as “a state in which a deficiency or excess (or imbalance) of energy, 
protein, and other nutrients causes measurable adverse effect on tissue/body form (body 
shape, size, and composition) and function, and clinical outcome”(65).   
 
Malnutrition is shown to be prevalent among stroke patients on admission to a stroke 
unit.  This may be partly due to the fact that malnutrition is common in older age and 
the majority of patients with stroke are older people. The reported rates of malnutrition 
varied between different studies depending on the different methods used to assess 
malnutrition. Unosson and colleagues reported that 8.0% of their study subjects (≥70 
years old) were protein malnourished on admission; based on serum protein 
concentrations (48).  However, they did not use a validated malnutrition assessment tool 
such as the Subjective Global Assessment (SGA) or the Mini Nutritional Assessment 
(MNA) used in other studies (46, 47, 160, 161).  These studies also reported variable 
malnutrition prevalence rates on admission to an acute stroke unit.  The prevalence of 
malnutrition using SGA was reported to be 19.0% in one study (46) and 32.1% in 
another study (47).  The two studies that used both SGA and MNA tool reported 
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malnutrition to be at 16.0% (160) and 26.3% (161) respectively at the time of admission 
to stroke unit.  A consistent finding in all these studies, however, is that malnutrition 
seems to be prevalent among stroke patients on admission with acute stroke thereby 
increasing the risk of further deterioration of nutritional status during their hospital stay.  
The proportion of stroke patients with malnutrition also appear to increase during acute 
hospital care (49, 56).  One study reported a 6.0% increase in the prevalence of 
malnutrition from 16.0% at the time of hospital admission to 22.0% at the time of 
discharge measured anthropometrically using Triceps Skin Fold thickness (TSF), Mid 
Arm Circumference (MAC), weight and biochemical parameters including albumin (49).  
Another study involving 104 patients with acute stroke reported that malnutrition 
prevalence changed from 16.4% at admission to 26.4% of surviving patients (n=91) and 
35% of patients who remained in hospital (n=43) at one and two weeks post admission 
respectively (see below for implication of malnutrition in this study).   Malnutrition was 
assessed using three measurements of MAC, TSF, and serum albumin (56).  Another 
study showed consistent findings reporting a constant decline in BMI (p=0.006), 
Triceps and biceps skin fold thicknesses (both p<0.0001 MAC (p=0.001), albumin 
(p<0.0001), and transferrin (p=0.02) between week 2  and week 4 post admission in 
stroke (55).  
  
In a more recent prospective observational study that included 131 ischaemic stroke 
patients,  malnutrition 24 hours post-admission was diagnosed in 12.2% of patients 
compared to 19.8% of patients at one week post admission; p=0.03 (54).  The study 
used five criteria including a 10% weight loss in the past 3 months and/or 6% weight 
loss one week post admission, weight index (actual weight compared to reference 
weight) less than 80%, serum albumin <3.0g/dL, prealbumin <10.0 mg/dL, or 
transferrin < 150mg/dL.  Malnutrition in the acute phase also increased the risk of 
malnutrition subsequently for example on discharge to rehabilitation services. The 
proportion of patients diagnosed with malnutrition on admission to stroke rehabilitation 
services ranged from 35% to 67% (157, 159, 162).   
 
I have summarised the prevalence of malnutrition in stroke.  In the next section I present 
how the immobility and stress response in stroke can affect body composition.         
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3.1.5 Immobility, stress response, and body composition 
 
In acute illness bed rest alone can contribute to body composition changes mainly fat 
free mass loss.  One study showed total lean mass loss of 0.84±0.34 kg (-1.7±0.6 %) 
(p<0.05) and fat mass gain of 0.48±0.16 kg (6.6±2.3%) (p<0.03) after a 14 days of bed 
rest in six healthy men (mean age 30± 6) years old) (163).  Lean tissue loss is further 
exacerbated with the stress response instigated in acute illness.  Patients with acute  
stroke have been shown to have a increased stress response; they have high cortisol 
levels, resulting in the deterioration of their nutritional status (56).   
 
Elevated cortisol levels further induce catabolic process in the body resulting in lean 
tissue loss.  By injecting cortisol in volunteering healthy subjects (n=5) to mimic the 
stress response in acute condition, Gelfand and colleagues reported muscle breakdown 
to be evident by the increased appearance of amino acids in blood (164).  These finding 
were further supported by Brillon and colleagues, when hydrocortisone was inject in 
nine healthy volunteers up to 5-20% in muscle protein breakdown occurred evident by 
increased appearance of plasma amino acids (Leucine and Phenylalanine) in blood 
circulation (165). Ferrando and colleagues conducted a study to examine the effect of 
cortisol on the catabolic processes during a period of bed rest.  Hydrocortisone sodium 
succinate was infused in healthy men (n=6) to mimic the cortisol response in trauma, a 
level of approximately 31 g/L of cortisol in plasma.  Blood samples were withdrawn 
and muscle biopsy was obtained from the vastus lateralis (largest muscle of the 
quadriceps femoris) at different times.  Participants then entered into a 14 day bed rest.  
Loss of total leg lean mass was (0.51±0.23 kg; p= 0.04), and intracellular glutamine 
concentration decreased significantly in response to cortisol on day 14 of the bed rest 
being at 8711±525 µmol/L compared to 9850±783 µmol/L pre bed rest; p= 0.03).  
Amino acid appearance rate in the circulation also increased; amino acid efflux 
increased from 302 ±60 to 508±180 nmol·min−1·100 ml leg−1 for phenylalanine, 
3037±891 to 3716 ±1225 nmol·min−1·100 ml leg−1 for glutamine, and from 2230± 603 
to 2876 ± 1038 nmol·min−1·100 ml leg−1 for alanine (166).    
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In older people with stroke, sarcopenia, another physiological change is taking place 
exacerbating the body composition changes such as fat free mass loss, muscle loss and 
fat mass gain, in addition to stress response and immobility due to stroke.  Sarcopenia is 
defined as muscle loss that occurs with the aging process leading to general weakness 
(61, 167).  The resulting changes in body composition due to the stress response, bed 
rest, and sarcopenia can have negative consequences on stroke outcomes is further 
compounded by the poor dietary intake discussed above.  Hence there is no doubt that 
the combination of immobility, heightened stress response, and malnutrition all 
contribute to body composition changes in acute stroke.  It was also documented that an 
increase in fat mass was associated with functional limitations in older people (61, 168).   
Interventions to prevent loss of tissue in acute condition such as stroke are important to 
prevent any possible poor prognosis of such changes on outcomes.  In the following 
section I discuss some nutritional interventions which primarily targeted promotion of 
feeding in people with dysphagia in stroke.   
 
3.1.6 Nutritional intervention studies in stroke 
  
Studies assessing the effects of enhanced nutritional interventions in people who have 
had an acute stroke have provided variable results to date.  Bath and colleagues carried 
out a review (169) of the available studies to understand the effect of different enteral 
feeding methods on stroke outcomes and concluded at the time of the review that further 
studies were required for a solid conclusion.  
 
A randomized controlled trial reported lower treatment failure defined as death at six 
weeks in the PEG group (0/16, 0%) compared to the NG group (3/14, 21.4%) and 
reported that six of the 16 patients in PEG group were discharged by six weeks after 
PEG insertion compared to none in the NG group; p<0.05.  Six week case fatality in the 
PEG group was 12.0% compared to 57.0% in the NG group; p<0.05 (170). Further the 
trial reported significant improvement in nutritional status extrapolated from albumin 
levels in those who received Percutaneous Endoscopic Gastrostomy (PEG) compared to 
Nasogastric (NG) tube feeding at six weeks after commencement of feeding regimes.  
Albumin levels improved from 27.1g/L to 30 g/L in the PEG group compared to 
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reduction from 31.4 g/L to 22.4 g/L in the NG group; p<0.003 (167).  Despite these 
reported favourable outcomes with PEG intervention it was difficult to draw any firm 
conclusion for several reasons.  The sample size was relatively small (n=30) to make it 
generalizable and the authors indicated that all patients were in stable condition without 
specifying the extent of the stability of patients’ condition before randomizing their 
patients making it difficult to know if more stable patients were randomized to PEG 
feeding regimen. There was no clear sample size calculation for the reported outcome as 
the first 30 patients who fulfilled the study inclusion criteria (cerebrovascular accident 
with dysphagia for more than 8 days) were recruited.   
 
A recent randomized controlled trial by Hamidon et al compared the effects of PEG and 
NG feeding on patients’ nutritional status up to 4 weeks post intervention.  In PEG fed 
patients (n=10) albumin levels were significantly higher than NG tube fed patients 
(n=12); p=0.045.  Within groups, PEG fed patients’ albumin levels rose more than NG 
fed patients; PEG group (p=0.025) vs. NG group (p=0.047) 4 weeks post intervention 
indicating better improvement in nutritional status in PEG compared to NG patients 
(171).  Better treatment outcomes were also reported in the PEG group compared to the 
NG group; the treatment failure frequency was reported to be 50% in the NG group 
compared to no failure in the PEG group; p<0.036.  The authors concluded that PEG 
feeding improves nutritional status more than NG feeding (171).  
The FOOD trial, the largest nutritional intervention trial in stroke patients to date, 
reported a different outcome. The FOOD trial studied the effect of early vs. none and 
type of nutritional support (PEG vs. NG feeding) on long term stroke outcomes; up to 6 
months post discharge (172).  Patients were randomised to either no enteral tube feeding 
or enteral tube feeding 7 days post-admission to stroke unit, or randomised to PEG vs. 
NG tube feeding 7 days post admission.  Poor outcome (defined as modified Ranking 
scale (mRs) score of 4-5) and death were evaluated 6 months post discharge.  There was 
no statistically significant difference in effect between early or no tube feeding on the 
risk of death (42% mortality for early tube feeding vs. 48% mortality rate for no tube 
feeding; n=429, OR=0.79, CI 95% 0.60-1.03) or combined  death or poor outcome (79% 
and  80%, respectively; n=429, OR=0.93, 95%CI 0.67-1.30) (172).   Similarly, no 
statistically significant differences in the effects of the two nutritional support regimens 
on death and poor outcome were observed.  Six months after admission 89% of patients 
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who had been randomised to PEG (n=162) compared to 81% of those given NG feeding 
(n=159) experienced death or poor outcome (OR=1.86, 95% CI 0.99-3.50) (30).  The 
effect on mortality of the different nutritional regimens was not statistically significant 
either (49% and 48% for the PEG and NG feeding; OR= 1.04, 95% CI 0.67-1.61) (172).   
 
The effect of early nutritional supplementation on death or poor outcome (mRs score of 
3-5) at 6 months post discharge were also examined in the FOOD Trial (173).  Patients 
were randomly allocated to normal hospital diet or normal diet with additional oral 
nutritional supplementation (360 ml oral protein supplement of 6.27 kJ/ml and 62.5 g/L 
in protein daily) during hospital stay until discharge.  There was no effect of 
supplementation on mortality outcome. Death was reported at 13% and 12% for the 
non-supplemented (n= 2012) and supplemented (n=2000) groups respectively; OR=0.94, 
95% CI 0.78-1.13.  As for death or poor outcome it was reported at 58% and 59% for 
the non-supplemented (n=1995) and supplemented (n=2009) groups respectively 
indicating no effect of supplementation; OR= 1.03, 95% CI 0.91-1.17 (173).  Nutrition 
interventions as reported by the FOOD Trials did not have any important or significant 
impact on stroke outcomes up to 6 months post stroke.   
 
The FOOD trial adjusted for several prognostic variables including age, gender, pre-
morbid status before stroke (living alone and independence), condition after stroke 
(ability to talk, lift arms, and walk), and ability to swallow. The FOOD trial while being 
a multicentre study has its strengths and weaknesses. The strengths as reported by the 
authors include its large sample size, at least 10 times larger than any previous trial, and 
the recruitment of patients from various centres; and thus increased generalizability.  
There are several weaknesses as suggested by the authors.  Weaknesses included 
informal methods in assessing nutritional status, failure to record the total number of 
eligible subjects in each centre, and inability to have an onsite source to report change in 
nutritional status and patient nutrient intake. The lack of a universal method in 
classifying malnourished patients may have contributed to MF-MF-BIAs in 
categorizing malnourished patients, inability to report nutritional status improvement in 
malnourished patients assigned to tube feeding (172) or nutritional supplements (173) 
initially, and inability to record systematically patients nutrient intake that could be 
mostly met through oral hospital diet masking the benefits of tube feeding (172) or 
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nutritional supplements (173) initially. Furthermore, being a pragmatic multicentre trial 
the investigators did not adopt targeted intervention approach i.e. tailoring nutritional 
management according to needs for example based on monitoring of body composition 
changes.  
 
It remains unclear which is the preferred type of nutritional intervention.  These 
limitations may have influenced outcomes.  The FOOD trial despite being a large 
multicentre study cannot help in providing evidence to help clinicians in decision 
making considering the inability to record and follow confounding factors that could 
have contributed for the reported outcomes.  
 
From the existing literature, it is evident that the prevalence of malnutrition among 
acute stroke patients is common and may result in poor outcomes.  I have presented the 
impact of malnutrition on health outcomes after stroke and the summary of evidence 
from the nutritional intervention studies in stroke.  In the next section I present methods 
which are used to assess nutritional status.  
 
3.1.7 Assessing nutritional status and body composition in stroke 
  
Given the prevalence of malnutrition in stroke patients, the stress response associated 
with the trauma from stroke, and the expected bed rest and their possible influence on 
body composition changes after stroke, assessing body composition in stroke patients 
may be useful in guiding nutritional interventions in stroke.  It may be argued that we 
can always calculate BMI or asses weight change, both are relatively easily measurable 
in clinical setting, but neither of them can provide information on the actual constituent 
of body composition changes.  Despite BMI being normally used to assess malnutrition 
(BMI< 18.5 kg/m2 for general population and a BMI<22 kg/m2 for and older population) 
(174), BMI as well as weight, cannot predict body composition changes. If an increase 
in BMI occurs it could be attributed to increased fat mass and extracellular water 
content due to cellular dehydration (60) and not necessarily due to improved nutritional 
status. BMI and weight change do not reflect changes in body composition such as fat 
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mass, fat free mass and total body water changes (dehydration in stroke patients is 
discussed in details in the Chapter 4).    
 
Different methods of assessing body composition are described in details in the Chapter 
5 of the Thesis. In this section I briefly present the standard methods or measurements 
which can be used in routine clinical practice for monitoring of nutritional status and 
evaluating of treatment success as well as in clinical trial settings.  
 
Upper arm anthropometric measurements have been used to reflect body composition 
changes associated with nutritional status (46).  Mid Arm Circumference (MAC) and 
Triceps Skin Fold (TSF) thickness are being suggested to reflect fat free mass and fat 
mass respectively. However, the accuracy of these anthropometric measures is 
questionable. Furthermore, there are disadvantage in using upper arm anthropometric 
measures. The poor reproducibility of TSF due to margin of error between 
measurements makes the validity of this method questionable (175).  Measurement of 
TSF requires a level of skill and training.  In addition, TSF body fat values were biased 
when compared to reference measurement produced by underwater weighing (176); see 
Chapter 5 for details of underwater weighing method.  On the contrary MAC is a 
relatively easy procedure making its measures more reproducible (177), but MAC 
utility in assessing whole body composition of fat free mass is questionable.  It is 
because MAC is more of a localized measure to evaluate arm muscle area and not 
whole lean mass tissue (178).  Its measures did not show a strong correlation with lean-
tissue masses measured by dual x ray absorptiometry (DEXA); the correlation was 
relatively poor  (r = 0.26-0.34) (178).   
 
It may be argued that biochemical makers of nutrition can also be used to assess 
nutritional adequacy. Biochemical measures such as albumin are traditionally used to 
assess nutritional status (179).  However, many studies demonstrated that their 
usefulness in evaluating protein malnutrition is questionable (180-182). Serum albumin 
synthesis appears to rise with an increase in protein intake (80) hence its serum values 
does not necessarily reflect the actual composition of lean body tissue or fat free mass. 
As discussed in the section above on the stress response and body composition, it is the 
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rise in amino acids such as alanine, phenyl nine, and glutamine in serum that are 
indicative of lean body tissue catabolism, but such diagnostics tests are not routinely 
carried out in clinical settings.  Therefore, routinely available biochemical tests cannot 
be used to predict changes in important components of the body such as fat mass or fat 
free mass (174).  The bioelectrical impedance analysis (MF-BIA) may provide an ideal 
tool in assessing body composition.    
 
3.1.8 Body composition and its assessment using multi-frequency bioelectrical 
impedance analysis (MF-BIA) 
  
Body composition describes the constituents of the human body from the different types 
of tissues to water (also see Chapter 4 for details).  For the purpose of this Chapter body 
composition is referred as the proportion of fat and lean tissues in the human body.  
Lean tissue represents all the non-fat tissue including muscle, body organs, and bone. 
Fat free mass consists of any tissue other than fat (183).  The non-fat tissue or fat free 
mass is an important component of the body as it is metabolically active and is involved 
in all the functional and structural characteristic of the human body. On the other hand, 
fat tissue or fat mass provides energy reserves and cushioning to internal organs.  
However, obesity characterised by excess amount of fat tissue is a risk factor for many 
chronic diseases.  
 
Clarys and colleagues dissected 25 cadavers (age range 44-94 years) and compared 
them to 19th and 20th century cadaver data of similar age range.  Mean skin, muscle and 
bone proportion of current day cadavers were 8.5%, 50.0%, and 20.6% respectively in 
their Brussels study, similar to that of the 19th century data  (mean proportion of skin, 
muscle and bone were 7.5%, 49.2%, and 21.3% respectively), but slightly different than 
the 20th century data (mean proportion of skin, muscle and bone were 8.6%. 44.4%, and 
18.4% respectively) suggesting that these variations in proportions of body components 
can be attributed to nutritional state (184).   
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The approach of viewing body composition as two main components, fat mass and fat 
free mass, is known as the two component model (2-C model).  Viewing the body as 
compartment allows deciding on which body composition components to measure and 
what assessment method to be utilized (assessment methods are discussed in details in 
the Chapter 5).  The two component model (2-C model) was first evaluated using under 
water weighing method (185).  The 2-C model is not the only model used to assess body 
composition.  Fat free mass consists of other components such as bone, minerals, water, 
and proteins.  These components can also be measured.  When total body water is 
included in addition to fat mass and fat free mass the resulting model is known as a 
three component model (3-C model).  The 3-C model can be assessed using the dilution 
method to assess total body water in addition to under water weighting for fat mass and 
fat free mass (please also refer to the Chapter 5 for details of these methods).  Including 
bone density and body water in addition to fat mass and fat free mass results in the four 
component model (4-C model).   In the 4-C model, dual X-ray absorptiometry (DEXA) 
is required to assess bone density (it also provides measurement of fat mass allowing 
calculation of fat free mass dependent on weight) and dilution methods for example is 
required for total body water assessment (186).    
 
Measuring additional component of fat free mass increases the body component model 
with additional or different assessment methods required (discussed in the Chapter 5).  
When more than four components are being measured the model becomes a multi 
component model and this can be assessed using bioelectrical impedance analysis.  
Bioelectrical impedance analysis can measure several components without the need for 
other expensive methods. This method has been previously validated in selected patient 
populations. I validated the multi-frequency bioelectrical impedance analysis (MF-BIA) 
machine I used in this study against DEXA and also conducted internal validation 
studies. The rationale, methods and results of these validation studies are presented in 
the Chapter 5.    
 
The principle underlying MF-BIA analysis is also described details in the Chapter 5. It 
is based on the resistance imposed by certain components of the human body; body 
impedance, to a flowing electrical current.  Body fat is non-conductive to the electrical 
current while lean body mass, consisting of electrolytes and water, is conductive.  When 
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an electrical current passes through the human body it faces resistance from the adipose 
tissue, impedance, while passing through the non-adipose tissue component to complete 
its circuit. The difference in conductivity, current input and output, is used to calculate 
fat mass and fat free mass using a validated formula already programmed in the MF-
BIA analysis equipment (43). For this study I chose MF-BIA BioScan 920-2 model by 
Maltron International; software (MiStat 920 Software; www.maltronint.com).   
Using the MF-BIA methodology body composition can be measured using a single 
frequency current (SF-BIA) or a multi-frequency current (MF-BIA).  In SF-BIA a 
single current of a known quantity, usually 50 kHz, passes through the body tissue and 
the difference in current input and output is used to calculate fat free mass and total 
body water (44).  In MF-BIA, currents of several frequencies (1, 5, 50, 100, and 200, up 
to 500 kHz) are passed through the body tissue separately and impedance is generated, 
currents input and output difference is measured and used in different validated 
equations already integrated in the equipment to extrapolate body composition variables.  
MF-BIA gives measurement of fat free mass, total body water, and extracellular and 
intracellular water (44); fat free mass is then used to calculate fat mass by subtracting it 
from body weight.   
 
MF-BIA is relatively cheap compared to other methods that can be used to measure 
body components (please refer to Chapter 5 for the different methods in assessing body 
composition).  It is simple to perform, non-invasive (187), and quick in providing 
reproducible results with less than 1.0% error (188).  Its simplicity lies in the fact that 
no more than proper operating of the equipment is required and can be performed at 
bed-side with minimal requirement of the training to use the device.  It produces results 
instantly and time efficient. The MF-MF-BIA method, therefore, is convenient to use in 
the busy clinical setting. 
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3.2 Study objectives and rationale 
 
3.2.1 Study Objectives 
 
The primary objective of this study presented in this chapter was to describe changes in 
fat free mass and the body composition after acute stroke while considering the 
magnitude of these changes by type of feeding regimen, ischaemic stroke subtype, and 
the stroke severity.  Other study objectives included examining if body composition 
changes are correlated with or influenced objective outcomes including hospital 
readmission, discharge destination, morbidity and mortality.  This study also examine if 
body composition changes had a prognostic influence on subjective outcomes such as 
health related quality of life and functional capacity up to 6 month follow up post 
hospital discharge. 
 
3.2.2 Rationale  
 
I hypothesized that body composition changes after stroke do occur and the magnitude 
and proportion of changes occurring in various components of the body (fat mass, fat 
free mass etc.) are different depending on stroke type and severity.  Evidence indicates 
that a proportion of stroke patients are malnourished on acute admission and their 
nutritional status deteriorates during acute hospital stay.  Malnutrition combined with 
possible extended bed rest and stress response in acute conditions results in body tissue 
catabolism.  The human body tries to generate energy from the available energy 
reserves and this result in catabolic process that result in body composition changes.  
 
Second, I hypothesized that negative body composition changes (defined as reduced fat 
free mass, increased fat mass) occurs after stroke.  The body composition changes after 
stroke are influenced by the timing and methods of feeding independently of stroke 
severity. The reasoning for such hypothesis stems from the fact that studies on elderly 
populations, main stroke population, suggested that sarcopenia (loss of lean body mass), 
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leads to loss of functional capacity compounded by immobility. Additionally, 
malnutrition of stroke patients and the stress response in acute stroke phase can result in 
major body composition changes (hypothesis I) with fat free mass being the most 
affected component.   
 
Third, I hypothesized that fat free mass and body composition changes correlate with 
increased risk of mortality, readmissions to secondary care settings, admission to care 
homes, and reduced functional capacity. It would be reasonable to predict that changes 
in fat free mass correlate with stroke outcome.  Fat free mass or lean body mass loss, 
results in reduced strength and mobility and overall functional capacity.  Fat free mass 
loss, therefore, can result in disability.  Fat free mass loss indicates the severity of the 
illness.  I hypothesized that fat free mass loss during acute stroke phase will have long 
term effect after stroke that can be measured by objective outcome measures of 
readmission to secondary care after hospital discharge location, mortality outcome and 
functional limitation measured by Barthel Index (BI) controlling for case mix and 
prognostic indicators. 
 
Further it was hypothesized that fat free mass loss is associated with reduced functional 
capacity and quality of life as measured by the Stroke Impact Scale, Short Form Survey 
36v2, and Barthel Index Scores at six months post hospital discharge.  The catabolic 
process that results in fat free mass could lead to delayed recovery and may be 
associated with poor outcomes.  The loss of fat free mass in acute stroke is further 
compounded in older people who constitute the main stroke populations who may be 
experiencing sarcopenia (loss of lean body mass).  Fat free mass or lean body mass loss, 
results in reduced strength which results in reduced functional capacity.  Therefore such 
body composition changes may be associated with negative on long term outcomes 
affecting health related quality of life.  Three different standard self reported 
questionnaires were therefore used to assess long term functional capacity and health 
related quality of life.  These included the Barthel Index Score (BI), the Stroke Impact 
Scale (SIS), and the Short Form Survey 36 version 2 (SF36v2) (see methods for 
description and references).   
 
  
112 
 
The decision to use SF36v2 in the follow up period was because it can provide a 
detailed assessment of a participant’s physical and mental health providing a 
comprehensive health related quality of life assessment.  As for the SIS, it was selected 
because it can provide information on what current activities are being carried out by 
participant, and if a participant can perform favoured activities of the past (integral to 
their life quality) and the instrument was specially designed to be used in stroke patient 
population (please also refer to methods).   Finally and for evaluating minimal daily 
activities level, I chose the Barthel Index score.  The Ability to perform minimal daily 
activities is essential for daily living.  Minimal activities that we cannot perform basic to 
our living can have a deep impact on our feeling and life quality.   
 
The reason I chose the six month recruitment and six month follow up is for pragmatic 
reason as my project is limited by the period of PhD study.  This follow-up period 
required amendment of initially submitted protocol (with 9 month follow-up) due to 
some technical delay in the time period between receiving the ethical approval (end of 
July 2010) and Research and Development approval which was gained at the end of 
November of 2011.  Therefore, after consultation and suggestion from my thesis 
supervisors, the follow-up of the study was carried out 6 months later after appropriate 
approvals were obtained (Appendix IV: Longitudinal Study protocol).   
 
I chose a longitudinal study design as it provides me with the opportunity to monitor the 
sample population overtime and observe any possible outcomes.  A longitudinal study 
allows reporting the prognosis of body composition changes on long term outcome and 
simply not a snapshot of their prognosis (as would be the case in cross sectional studies).  
In addition, studies examining body composition changes in stroke patients and it 
prognosis were not carried out before.  No effect size or conclusion can be drawn 
without observed associations.  Therefore a clinical trial will not be appropriate (for 
example providing amino acid supplements to one group vs. placebo for control and 
then examine body composition changes and their prognosis) as such trial will not be 
based on a concrete evidence.  Trial risks on participants are not understood yet, and 
sample size selection is not possible given that we do not know the estimate of a sample 
we need with the objective of drawing a conclusion or seeing an effect of statistical 
significance for clinically meaningful effect size for relevant outcomes.    
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Carrying out a case-control study may not be appropriate.  The purpose is to understand 
the extent of body composition changes after stroke.  My cases would be stroke patients, 
but controls would be difficult to choose given that it is not possible to determine 
controls (patients with no body composition changes after stroke).  Further if I decide to 
choose controls with no stroke this simply defeats the purpose of my whole comparison 
in a case-control study.    
 
Therefore longitudinal study design is the ideal study design given the lack of data on 
body composition changes after stroke.  It allows for monitoring participants over a 
period of time to understand the prognosis of such changes on the daily lives of stroke 
patients.    
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3.3 Methodology 
 
3.3.1 Ethics   
 
The study was approved by Cambridgeshire I research ethics committee.  The final 
protocol submitted to the committee is available in Appendix VI.   
 
3.3.2 Settings 
 
This prospective longitudinal cohort study which form part of my PhD project was 
conducted in acute hospital setting at the Norfolk and Norwich University Hospital 
National Health Services (NHS) Foundation Trust (www.nnuh.nhs.uk). The hospital has 
a catchment population of approximately 750,000. It covers city of Norwich and the 
surrounding rural areas.  The participants were recruited from the Acute Stroke Unit 
(then Gunthorpe Ward) located at the main hospital site.  The unit admits approximately 
900- 1000 acute stroke patients annually.   
 
The acute stroke ward is a 36 bedded unit.  The average length of acute hospital stay 
was 13 days (usually ranged between 5 and 20 days at the time of study) with the 
average length of stay for milder stroke is ~5 days.  In-patient mortality rate is ~ 22% 
(189) with one year mortality rate of ischaemic strokes is 35% (190).  At the beginning 
of the study stroke patients were admitted to the Acute Medical Admission Unit (AMU) 
via Accident and Emergency Medicine Department (A&E) or referred to AMU by 
General Practitioners (GP) first before being admitted to the ward. The admission 
pathways changed halfway through the study and all acute stroke patients were directly 
admitted from A&E to the acute stroke unit from May 2011.  
 
 
 
  
115 
 
3.3.2 Study Design  
  
The study design was a longitudinal observational cohort study conducted over a period 
of 12 months.  Patients admitted to Gunthorpe Acute stroke unit at Norfolk and 
Norwich University Hospital (NNUH) between January and July 2011 and diagnosed 
with either type of stroke (ischaemic or haemorrhagic stroke) were recruited to the study.  
Eligibility criteria are detailed below. Patients with transient ischemic attack (TIA) were 
excluded specifically for the longitudinal prospective cohort study (but included for the 
MF-BIA external validation study as described in the Chapter 5).    
 
The study participants were recruited over the period of first six months of the study and 
they were followed up six months post discharge.   The following eligibility criteria 
were used for inclusion in the study 
 
• Age 17 years or over  
 
• Newly diagnosed stroke (either first or recurrent).  The objective is to investigate 
what body composition changes occur after an incident stroke.  Patients with 
only confirmed stroke are included in the study.  Stroke diagnosis was 
confirmed by a specialist in stroke medicine based on history, clinical 
examination and neuroradiological imaging (computed tomography (CT) or 
magnetic resonant imaging (MRI).     
 
• Participants were recruited within 48 hours of hospital admission.  Forty-eight 
hours was chosen as a sufficient enough period to allow for the medical team to 
evaluate patients’ state of health and decide their survival chances, carry out all 
necessary tests such as blood tests (biochemistry measures) and 
neuroradiological imaging (CT/MRI) to confirm the diagnosis of stroke and type 
of stroke.   The 48 hours period allowed for recruiting participants that meet the 
eligibility criteria without interrupting the flow of essential routine immediate 
and urgent health care provision to the participants. 
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For validation against DEXA scan only, I also recruited patients diagnosed with 
transient ischaemic attack (TIA) (participants can participate in the DEXA validation 
part without taking part in the longitudinal study, which examined body composition 
changes and the relationship between these changes and outcomes at 6 months).   
Patients were not approached if they met the study exclusion criteria detailed below:  
 
• Patients with very severe stroke who were appropriate for palliation only 
(expected survival of less than 48 hours).   
 
• Severe stroke defined as National Institute of Health Stroke Scale (NIHSS) ≥30 
(http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf) whose likelihood of 
survival ≥7 days is small (<50%) as judged by the stroke physician.  If survival 
chances of a patient are very low and their likelihood of dying within 7 days is 
high, it was not appropriate to be recruited into this study. Carrying out research 
in such circumstances was unethical especially the participants of the study were 
unlikely to be benefited directly and immediately from participating in the study.  
 
• Life expectancy was less than 3 months prior to the event.  If life expectancy 
prior to the onset of stroke is less than 3 months then the longer term outcome at 
6 month after stroke would have been biased by this.  Furthermore, it may be 
confounded by the fact that the body composition changes that were unrelated to 
stroke but to the overall deteriorating health status that resulted in such a short 
life expectancy might have been already occurring in such patients.   
 
• If they had other potential confounding conditions that might have been 
masking/exaggerating the effect of post stroke nutrition on body composition 
changes. These conditions were defined as co-existing terminal illness e.g. 
advanced cancer, end stage chronic diseases such as end stage renal failure and 
end stage chronic obstructive pulmonary disease (COPD).  Existence of such 
illnesses may influence the variables of interest, components of the body 
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composition, long-term outcomes, and can contribute to confounding effect as 
findings may not be related directly to stroke, but to these conditions and their 
treatment.   
 
 
3.3.3 Recruitment procedure 
  
Patients who had confirmed diagnosis of stroke who were potentially eligible to the 
study were informed about the study by a clinical team member (medical, nursing or 
therapy staff) and they were specifically asked whether they would agree to speak to the 
investigator.  Those who were interested in talking to the investigator about the study 
were then approached by the investigator. 
The investigator, PhD student, used the information provided by the clinical staff and 
screened the eligibility of the patient to the study in those who expressed interest to the 
study.  The following information were checked for patient eligibility;- 
• Date and time of patient’s symptom onset  
• Date and time of hospital admission 
• The final diagnosis of the patient 
 
At the first contact with the potentially eligible participant I   introduced myself, and 
obtained verbal consent from them to explain the study. Once the patient agreed, I 
briefly explained the study objectives, relevance and importance of the study for stroke 
patients specifically stating that the participants themselves might not directly benefit 
from it.  If the patient remained interested in participating in the study, I then went 
through each of the study procedure using the study Participant Information Sheet (PIS) 
(Appendix VII), the letter to participant general practitioner (Appendix VIII) and 
consent form (Appendix IX) both of which a copy was provided to participants upon 
consent with the a copies as well placed in the consented patient medical notes).    
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Consenting patients to participate in a study in acute stroke setting is complex. 
Therefore I followed the inclusion and exclusion criteria strictly.  In case of any doubt 
with regards to the capacity of the patient to participate, I involved an independent third 
person, usually a nurse who looks after the patient, as a witness.   
 
After going through each measurement procedures, I summarised additional 
information written in the PIS including the fact that the patient could seek an 
independent advice from the Patient Advice Liaison Services (PALS) if he/she would 
like to complain, Ethics approval status, who were research team members, that the 
refusal of participation would not affect their treatment, and data protection procedures 
for their identifiable personal and clinical data.  The PIS was left with the patient to read 
and go over for as long as required to them. I returned to them later and asked whether 
they remained interested in participating in the study.   
 
If the response was positive I provided the patient with a consent form to initial and sign 
according to NHS ethics committee guidelines.  If necessary, I read out and explained 
the consent form to the patient. Upon receiving patient’s written informed consent, 
patient medical notes were reviewed and I recorded data including admission date and 
time, onset of symptoms date and time, presence of co-morbid conditions, 
anthropometric, and blood biochemistry data.  In addition I recorded data ascertained 
from the speech therapists’ entry and observation and fluid and food charts which was 
assessed in <48 hours of patient admission by the speech therapist including presence or 
absence of dysphagia, initial type of diet (pureed, soft, mashed, NBM) on admission and 
type of fluid if they were nil by mouth. Once I finished these baseline data recording I 
carried out anthropometric and body composition measurements as detailed below.  
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3.3.4 Anthropometric, biochemistry and clinical, and body composition measurements 
data 
  
3.3.4.1 Anthropometric measurements  
 
All anthropometric measurements were repeated three times (except weight and height) 
both at the time of admission and on discharge. Averages of these three measurements 
were used for analyses.  Standard Operating Procedures (SOPs) used in this study (as 
well as hydration study presented in Chapter 4) are presented in Appendix X.     
 
Weight   
Participant’s weight was measured by the researcher if it was not measured by a nurse 
on admission upon study recruitment and patient consent. If the participant’s weight has 
been already measured at the time of admission by the nursing staff prior to recruitment, 
it was taken as baseline weight and was recorded. If the patient was unable to get on the 
weighing machine due to immobility weight was measured using a hoist (Loco-motor 
multi-lift hoist, MEDISAVE, WYEMOUTH, UK). Weight was measured while 
participant was wearing light clothing (hospital gown) with barefoot.  If participant was 
able to get up from their bed a weighting chair (SECA 955 electronic scale, 
MEDISAVE, WYEMOUTH, UK) was used where the participant was asked to sit on 
the chair upright and place their legs on designated leg rest position.  Weight in 
kilograms was recorded to the nearest decimal point.  Weight measurement was 
repeated at the time of discharge.   
   
 Height 
 Height in cm was recorded for each participant on admission. If height has not already 
been recorded by a nurse at the time of recruitment, the investigator carried out height 
measurement. The participant was asked to remove footwear and stand upright with 
their back facing stadiometer placed on a wall.  Participants were asked to stand with 
heels, back of the buttock, and back the head touching the stadiometer erect board with 
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the arms on their side. I made sure that all three points (heels, back of the buttock, and 
back the head) were touching the stadiometer before moving the head piece of the meter 
from above until it was comfortably touching the top point of the head; height was 
recorded to the nearest decimal point; 0.1 cm (191). 
 
In the case of bedridden patients (n=5), height was estimated using forearm length. To 
measure forearm length participant was asked to tuck their hand to the chest facing 
inward with arm straight.  The distance between the ulna bones, olecranon process, at 
the elbow and the distal end of the ulna at the styloid process of the ulna was measured 
using a standard tape measure. Standardized charts available on the ward were used to 
estimate height based on forearm length for men and women respectively according to 
their age (under and over 65 years) (BAPEN 1985).  Height measurement was not 
repeated on discharge as it is unlikely to change during the participant’s in-patient 
hospital stay.  
 
Body mass index 
Body mass index was calculated using the MF-BIA machine using the formula BMI = 
weight/ (height) 2 with weight measured in kilograms (kg) and height in meters (m) 
squared.  BMI calculation was repeated for discharge using repeated weight 
measurement on discharge and height measurement on admission (see standard 
procedure for measuring weight and height above).  
  
 Mid Arm Circumference (MAC) 
Mid Arm Circumference (MAC) was measured at a centre point of the upper arm mid 
way between acromion process of the scapula and olecranon process of the ulna using a 
measuring tape(192).  The MAC was measured twice, at baseline and on discharge with 
each measurement repeated three times.  Mean values of MAC at admission and 
discharge was calculated respectively.   
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Triceps Skin Fold (TSF) Thickness 
A skinfold calliper (Harpenden Skinfold Calliper, Harpenden, UK) was used to measure 
skinfold thickness of triceps.   The midpoint on the posterior aspect of the right upper 
arm was identified first by the investigator by defining the midpoint at the back of the 
participant triceps; length of upper arm measured and midpoint located.  Then a 
skinfold was grasped avoiding including any underlying muscle.  The calliper was 
placed at a 90-degree angle and grasping a pinch full of skin with any muscle and the 
measurement recorded in millimetres(192).    
 
Waist Circumference (WC) 
 The highest point of the iliac crest of the hip bone was identified and then the midpoint 
between the highest point of the iliac crest and the lowest point of the rib cage end was 
identified; Waist circumference was measured around the smallest circumference 
between the ribs and the iliac crest.  When it was not possible to find a natural waistline 
it was measured at the level of “the navel”.  The tape was wrapped horizontally around 
the waist to measure the waist circumference (192).   
 
Hip Circumference 
 The widest point of the buttocks was located in a standing position(192).  The 
measuring tape was placed on the widest point of the buttock and wrapped horizontally 
around the hip to measure the hip circumference.  Waist and hip circumferences were 
recorded for patients who were able to stand only.    
 
Waist to hip ratio calculations 
The averages of the three waist and hip measurements were calculated.  The waist to hip 
ratio (WHR) was calculated by dividing the average waist circumference by average hip 
circumference.  
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Handgrip strength 
Handgrip strength of unaffected side was measured using a dynamometer (GRIP-D 
TKK 540, TAKEI PHYSICAL FITNESS, CHINA).  If no arm was affected the grip 
strength of dominant hand was measured.  The dynamometer was set at 0.0 and the 
patient was asked to squeeze with as much power as possible and the measurement was 
recorded once the dynamometer showed no further increase in measurement as the 
participant could no longer increase grip power.  The same procedure was repeated 
three times.   
 
3.3.4.2 Measurement of Body Composition 
  
In this study, body composition measures were assessed using Multi frequency 
Bioelectrical Impedance Analysis (MF-BIA) equipment (Maltron BioScan 920-2, 
Maltron International Co. Essex, United Kingdom)).  The MF-BIA measures body 
composition components based on the extent of resistance to a harmless electrical 
current as it travels through the body.  The electrical current travels freely through 
muscle tissue and body fluids, but experiences resistance from some of the body 
components such as fat tissue. The amount of resistance with the specification of age, 
height, weight, and gender of the subject allows the calculation of body composition 
components using an already programmed built-in formula in the equipment; for more 
detailed information refer to the validation chapter where MF- MF-MF-BIA 
measurement was validated against Dual X-ray Absorptiometry (DEXA) in 10 subjects 
in the Chapter 5. The internal validity of the MF-BIA machine used in this study was 
also assessed and reported in the Chapter 5. 
 
The electrodes from the MF-BIA equipment were attached to the patient using sticky 
patches similar to ECG patches.  The investigator first placed the patches on the hands, 
at the wrist and on the knuckles between the middle and ring fingers, and on the feet 
with one patch on the talus bone and the other horizontally between the third and fourth 
metatarsals.  The cables of the MF-MF-BIA machine were then attached to the patches 
with the red coloured cable (positive) being closer to the heart and the black coloured 
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cable (negative) farthest.  Patient’s characteristic demographic information including 
study identification number (study ID), age, gender, height, weight, and ethnicity, were 
all entered prior to measurement and the body composition measurements listed below 
were recorded.  The MF-MF-BIA measurement was repeated twice, < one minute apart 
for internal validation purposes of MF-MF-BIA (please refer to Chapter 5 for details).  
The average of the two consecutive measurements was used for the analysis in this 
study.  
 
From MF-MF-BIA measures data on fat free mass (Kg), fat free mass percentage, fat 
mass (Kg), fat mass percentage, total body water (L), total body water percentage, extra 
and intracellular water (L), extra to intracellular water ratio, body cell mass (Kg) and 
per cent, extracellular mass (Kg) and percentage, estimates of Creatinine clearance rate 
(ml/min) and glomerular filtration rate (ml/min), protein mass (Kg), mineral mass (Kg), 
mineral mass percentage, total body calcium and potassium (g), muscles mass (Kg), 
glycogen mass (g), dry weight (Kg), extracellular fluid (L), plasma fluid-intravascular 
(L), interstitial fluid-extravascular (L), body volume (L), and body density (Kg/L) were 
collected and recorded.   
 
MF-BIA measurements were carried out twice at the baseline (within 48 hours of 
admission) and at the time of discharge (usually within 6-48 hours before discharge) as 
described above. In addition to baseline (at enrolment) and discharge measurements for 
each participant, MF-BIA measurement was repeated in participants who received a 
new feeding regimen within 48 hours of the commencement of the new regimen. There 
was no published literature on when best to measure body composition changes after a 
change in feeding regimen in stroke patients, and the selection of this time frame was 
for pragmatic reasons and based on the advice by the clinicians using consensus 
approach. Therefore, it was decided that 48 hour duration should be elapsed before 
carrying out the repeat MF-BIA measurements to allow the participant to adapt changes 
occurred in body composition due to the new feeding regimen.  The average of the 
consecutive two measurements was used for the analysis in this study.   
 
3.3.4.3 Biochemistry and Clinical Data 
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Other variables collected at the baseline (at the study enrolment) included routine full 
blood count including Haemoglobin, Leucocytes (Neutrophils, Basophils, Eosinophil, 
and Lymphocytes counts), Platelets, mean corpuscular volume (MCV), mean 
corpuscular haemoglobin (MCH), and Erythrocytes sedimentation rate (ESR) (if 
available).  Routine urea and electrolyte test data were also collected including Sodium, 
Potassium, Urea, Creatinine, and liver function test (albumin, total protein, alkaline 
phosphatase, alanine transaminases (serum glutamic pyruvic transaminase) and gamma 
glutamyl transpeptidase (GGT).  Serum lipids levels were also recorded whenever 
available and included total cholesterol, high density lipoprotein (HDL), low density 
lipoprotein (LDL) cholesterols and triglycerides (TG).  In addition, glucose (non-
fasting), haemoglobin A1C (HbA1C) in those with diabetes, and C - reactive protein 
(CRP) (whenever available) were also collected.  All blood test results were collected 
using the ICE-Desktop system, a software system that records patient information and 
clinical test reports.  
Other relevant clinical data were collected from medical records at the time of 
enrolment to the study and described briefly below.  
 
Stoke severity as assessed by the National Institute of Health Stroke Scale (NIHSS)  
 
NIHSS (Appendix XI), http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf, 
evaluates the severity of stroke using a score which ranges from 0-42 with increasing 
score indicating an increase in stroke severity.  NIHSS evaluates the level of 
neurological deficit after stoke using 15 items based on neurological examination.  Each 
item is valuated using a 3 to 5 grading with 0 being normal including the levels of 
consciousness, language, neglect, visual-field loss, extra ocular movement, motor 
strength, ataxia, dysarthria, and sensory loss.  
 
Premorbid modified Rankin Score (pre stroke mRs) evaluates the extent of disability or 
dependence before the stroke.  A clinician usually carries out the assessment.  A number 
(a rank score) is given depending on clinician judgment.  These rank are designated as 0 
for no symptoms, 1 for no significant disability (can carry out usual activities), 2 for 
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slight disability (cannot carry out all usual activities), 3 for moderate disability (can 
walk without assistance but requires help with most activities), 4 for moderately severe 
disability (requires assistance including walking), 5 for sever disability (requires 
continuous assistance, nursing and attention), and 6 for dead.   Pre-stroke mRs provides 
a good understanding of a patient level of mobility before stroke to understand the 
impact of stroke on their physical functioning. The inter observer agreement of mRs is 
moderate with 70% agreement (193).  Pre-stroke mRs correlation with other measures 
was varied (spearman rho) showing a strong correlation with the frailty index 0.82 (95% 
CI, 0.78–0.86) but mild correlation with the Charlson comorbidity index 0.50 (95% CI, 
0.40–0.59) (193).   
 
The Malnutrition Universal Screening Tool (MUST) which evaluates nutritional status 
was collected from clinical notes as recorded by the dietician.  MUST identifies patients 
at risk of malnourishment using a five-domain method, domain one is recording body 
mass index and giving it a score; BMI of ≥20, 18.5-20, and <18.5 are given scores of 0, 
1, and 2, respectively.  Unplanned weight loss in past 3-6 months is also considered in 
the scoring system as step two. A score of 0, 1, or 2 was given for a 5%, 5-10% or ≥10% 
unintentional weight loss in the past 3-6 months respectively.  The third domain is to 
donate a score of 2 for acute disease if no nutritional intake is likely for more than 5 
days due to the illness.  In domain four and five scores are all added to give a total score 
and risk of malnutrition respectively.  Zero score suggest low risk of malnutrition, one 
suggests medium risk of malnutrition, and score of ≥2 corresponds to high risk of 
malnutrition (Appendix XII). 
 
3.3.6 Data collection at the time of hospital discharge  
 
On participant’s discharge, discharge date was recorded.  Apart from repeating weight 
and body composition measurements as indicated earlier, I collected data on discharge 
destination (early support discharge services, home, or rehabilitation) and discharge 
status (dead or alive) upon hospital discharge.   
 
  
126 
 
3.3.7 Follow up data collection 
 
Final follow up data was collected six months post discharge between August and 
December 2011.  Follow up data consisted of subjective and objective outcomes 
measures described below.   
 
3.3.7.1 Objective outcomes 
 
I collected objective outcome data from the Patient Administrative System (PAS) and 
medical records of patients.   Objective outcomes at six months included morbidity 
(recurrence of stroke, incidence of other cardiovascular events), hospital readmissions 
(and reason for re-admissions), and mortality during the follow up.  
3.3.7.2 Subjective Outcomes 
 
I collected subjective outcomes of self-reported functional health measured using 
patient reported outcome measure (PROM) using Stroke Impact Scale (SIS) (MAPI 
research incorporation, Lyon, France), and disability index using Barthel Index 
(Mahoney 1965), and Health Related Quality of Life (HRQL) questionnaire, using  
Short Form -36  survey version 2 (SF-36v2) (Quality Metric International Corporation, 
Lincoln, Rhode Island, USA).   
    
3.3.7.1 Short Form Survey 36v2 (SF36v2) 
 
To evaluate the quality of life I used the SF36v2 questionnaire (Appendix XIII).  The 
SF36v2 evaluates eight dimensions of the respondent’s health that reflect health related 
quality of life. These eight dimensions are summarised as two summary scores (physical 
health component and mental health component summary (PCS and MCS) scores).   
Each dimension assessed in the SF36v2 carries a different weight.  These weights are 
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calculated to provide the overall PCS and MCS summary scores (194).  In the next 
sections I will discuss the PCS and MCS components of SF-36 and describe the scoring 
respectively.  
 
The Physical Health Component Summary (PCS) is the product of the total weights of 
four components.  The four components are Physical Functioning (PF), Role Physical 
(RP), Bodily Pain (BP), and General Health (GH).  The first component is Physical 
functioning (Question 3).  It is assessed by the total weight aggregated from ten items 
evaluating the extent of physical limitations.  Each item can be given a value from 1-3.  
One reflects maximum of physical limitation while three no physical limitations at all.  
Items evaluated concern ability to carry out vigorous activities, moderate activities, 
carry grocery items, and be able to climb stairs, walk a certain distance, and carry out 
personal care activities such as bathing and dressing.   The next item is Role Physical 
(Question 4).  Role Physical component weight is aggregated by four items examining 
the extent at which daily physical activities are being limited after the onset of stroke 
symptoms.  Each item is given a value of 1-5 with 1 being the worst possible value and 
5 being the best possible value indicating that daily physical activities are not affected.   
Items evaluated activities carried before stroke are being limited and to what extent, and 
difficulties experienced carrying previous activities after the onset of stroke.  Bodily 
Pain (BP) is assessed as in other components but in two questions (question 7 and 8).  
Question 7 asks about the extent of pain experienced in the past month giving a value 
from 1-6 with one being no pain and six being severe pain, and question 8 asks about 
the interference of pain with daily activities given values 1-5 with one being no 
interference and 5 being all the time.  The last component to provide an input into the 
PCS summary component is the General Health component (GH).  GH weight is 
aggregated through values donated to question 1 and 11 (consisting of four items). In 
question one general health is evaluated by being given values 1-5 with one being 
excellent health and five being poor health.  In question 11 values are given on a scale 
of 1-5 donated to each statement about health with one being completely false and five 
being completely true statement. The four items (statements) are if the patient feels they 
are ill more than anyone else, feel they are healthy as anybody else, expect health to get 
worse by time, and if they feel their health is excellent.   
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The Mental Component Summary (MCS) is evaluated through four different 
components these include Vitality (VT), Social functioning (SF), Mental Health (MH), 
and Role-Emotional (RE).   Each component as in the PCS component carries different 
weight.   Four items in question nine evaluate the vitality component regarding how the 
respondent feel.  Each item is can be given a value of 1-5 with the value of 1 indicating 
the highest frequency and 5 indicating no frequency in experiencing the concerned 
feeling inquired about in the item.  The four items ask about the frequency of feeling 
full of life, full of energy, worn out, and tired in the past four weeks.   Question six and 
ten evaluate social functioning.  There is one item per question.  Both questions 
evaluate how emotional feeling and physical health interfere with everyday social 
interaction and social time.  Items are can have values of 1-5 with one being highest 
frequency meaning all the time and 5 being lowest frequency or none of the time.   Role 
emotional is another component that solely evaluates the influence of mental health on 
daily activities.  The three items are given values between 1-5 with 1 being the worst 
and five being no interference at all.  The three items evaluate how mental health affect 
the frequency of doing daily activities, accomplishing tasks, and interference with 
ability to carry out such activities.  The final component is more specific to the actual 
state of mental health.  It is evaluated in question 9.  Evaluated components are given 
values from 1-5 with one being highest frequency and five being the least frequency of 
the event occurring. Items evaluated the extent of feeling nervous, down, peaceful, 
depressed, and happy respectively.     
 
Calculating the final score is not a simple procedure and is a complex mathematical 
process.  First, items number one and eleven scores must be recoded.  The purpose of 
recoding is to allow universal scale across all items in which increased score per item 
means better health.  In item one and 11 increased score means poorer health; as 
opposed to other items.  Once recoded according to the scoring guide (the guide is 
provided by quality metric upon purchase of the SF36v2), each health domain, mental 
and physical health, and raw score is calculated.  For MCS the raw scores for each 
Vitality (VT), Social functioning (SF), Mental Health (MH), and Role-Emotional (RE) 
items are determined.  For PCS the raw scores for General Health (GH), Role Physical 
(RP), Physical Functioning (PF), and Bodily Pain (BP) items are determined.  After the 
determination of each component raw scores each component raw score is converted to 
a 0-100 score using the following formulae 
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(Actual Raw Score - Lowest possible Raw Score)   x 100 
Raw score range 
 
The resultant scores (on a scale of 0-100) are further converted to z-scores.  The 
conversion to z-scores is to allow an understanding of the extent of deviation of the 
component score from the reference group score mean.  The mean score of the 1998 
United States general population is used as the reference.  Mathematically this is done 
by dividing the standard deviation of 0-100 scores of the 1998 United States general 
population mean by the difference between my study population component score mean 
and the reference (1998 US general population) mean.  
  
Z-score component = (component (0-100) mean score - reference mean score) 
SD of the general population 
 
To calculate the Physical Component summary and the Mental component summary T-
scores, the z-score of each item is multiplied by 10 (standard deviation of the reference 
group) and the sum of each multiplication for each item in the PCS and MCS are added 
to 50 (mean of the reference group) respectively.  The reasoning for converting z-scores 
to t-scores is to allow the comparison between the studied group mean and standard 
deviation with the mean and standard deviation of the US general population or the 
reference group (194).   
 
PCS T-score=50 + ((GHzx10) +(RPzx10) +(BPzx10) +(PFx10)) 
MCS T-score=50+ ((VTzx10) +(SFzx10) +(MHzx10) +(Rezx10)) 
 
The same procedure can also be used to calculate the T-score of each item alone, but 
instead of aggregating the scores it is required to take each item z score, then multiply it 
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by reference SD of 10 and add 50 (reference group mean).  The use of T-scores came to 
provide a standard interpretation in which the T-score for an item or summary score can 
provide information on how different a studied group differ in their SF36v2 scores than 
the reference group (the 1998 US general population normative score).  A T-score 
allows for comparing the deviation in a studied population from the norm (194).  
 
The SF36v2 can be used to assess the quality of life post illness or condition to evaluate 
the efficacy of a treatment (195, 196) or even how a population is coping with certain 
living environment (197).  The scoring of the SF36v2 using T-scores while using a 
comparison group in the 1998 US general population as a normal disease free 
population makes it a very useful tool for my study.  Using the SF36v2 allows me to 
draw conclusions on the extent to which it has been affected after a condition that can 
cause substantial changes on the health related quality of life.     
 
3.3.7.2 The Stroke Impact Scale 
  
The stroke impact scale (Appendix XIV) includes questions which ask the respondent to 
evaluate how stroke have impacted on their health and life.  It consists of nine questions 
that include several items in each.  Question one through 8 ask the patient about their 
post stroke physical and mental status. The first question asks the respondents to 
evaluate the strength of the most affected side from stroke.  The strength question have 
four components with a possible values of 1-5 with the lower score indicating that the 
impact was high (score of 1 denotes no strength).  The next areas assessed in question 
two are memory and thinking capacity.  There are seven items with each having a 
possible value from 1-5 with the lowest suggesting the greatest impact.  Items assess a 
respondent’s ability to remembering chores such as medication time or appointments, 
remembering past day events and things being told, problem solving, concentrating, and 
thinking quickly.   Emotions are another domain evaluated through using nine items.  
Items in the emotion domain evaluate feeling of being happy, sad, nervous, and self-
worth.  Scoring in the emotion domain differ slightly as three of the nine items scores 
must be recoded (described below) while others follow the same rule having a score of 
1-5 with the lowest score suggesting the highest impact.  Question four evaluates 
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communication skills.  There are seven items assessing ability to engage in 
conversations, communicate via telephone, listen, and understand what was being said.   
The daily activities question consists of ten items.  The items in the question evaluate 
the extent and the ability of the respondent to engage in daily activities such as bathing, 
dressing, grooming, shopping, toilet use, handling money, carrying house chores, and 
eating. Each item of daily activities response can have  one possible value from 1-5 that 
can be given with a score of one being the highest impact on daily living and five no 
impact.    The mobility is assessed through nine items.  Items in the question concerning 
mobility assess basics activities including ability to maintain balance while sitting and 
walking, getting into and out of the car, climbing stairs and walking.  Question seven 
assesses ability to use affected hand in daily activities such as picking up money, 
turning door knob, tying a shoe lace, opening a jar of food.  The final question evaluated 
social participation.  It consists of eight items and evaluates the ability of the respondent 
in participating in activities which he/she could participate in before the stroke.  The 
range of activities includes work, sports, family, social, and spiritual activities.  All of 
the components can be given a score of 1-5 with the lowest score i.e. a score of one 
suggest the highest impact on the respondent.  
 
Before scoring the SIS, and to make the scoring universal across all domains, three 
items in the emotion domain have to be recoded.  As mentioned previously the scoring 
from 1-5 is possible for each item and with the lowest score of one suggesting highest 
impact, this is not the case for three items for emotion, the lowest score suggest lowest 
impact therefore they need to be recoded.  A score of 1 is recoded to 5, 2 to 4, 3 to 3, 4 
to 2, and 5 to 1, respectively.  To calculate each dimension score the following formulae 
is used to have each dimension scored out of 100 or 100% (198).   
 
(Raw score - minimum score)/ (Maximum - minimum score) x 100 
 
Row scores each question are the total sum of the item scores.  So for strength (a four 
item dimension the minimum score is 4 (four items being scored as 1) and maximum 
score is 20 (four items being scored as 5).   For missing data and if <50% of the items 
score are missing then mean of the scores is used in the following formulae   
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(Mean score - minimum score)/ (Maximum-minimum score) x 100 
 
If ≥50% of item scores are missing then the whole dimension scoring is considered 
missing (198).   
 
The stroke impact scale (SIS) is a measure that allows to see if the impact of stroke is 
still apparent in stroke patients even after recovery (199).  It is a very reliable score in 
which high degree of internal consistency (α-coefficient=0.9) was observed when 
testing and re-testing the same patients again (200).  The SIS is a very useful tool for 
my study that allows me to evaluate the extent of recovery in patients with different 
extent of body composition changes while taking into account of the stroke severity.  
 
3.3.7.3 Barthel Index    
 
The Barthel Index (Appendix XV) is the most widely used measure of physical 
disability in carrying out activities of daily living (ADL). The Barthel Index can be used 
in clinical and rehabilitation settings (201) and for research purposes,  (202, 203).  The 
inter-ratter agreement was shown to be reasonable (n=94 elderly patients) (204) and 
good (n=25) (205).  Review of previous studies suggest that the Barthel Index scores 
can reasonably predict physical disability level post stroke (206). 
 
The self-reported or observer rated ten specific areas of assessment include feeding, 
bathing, grooming, dressing, bowel control, bladder control, self-toilet use, and transfer 
to bed, mobility, and stair use.  For each item a score of 0, 5, or 10 was given for each 
activity of daily living with 0 indicating complete dependence or inability, 5 when 
assistance is needed or occasional accidents (in case of bladder and bowel function), and 
10 refers to the independence or complete control.   Barthel index scoring is straight 
forward and unlike SF36v2 or SIS described above. Scores are added up for each item 
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assessed to give a final maximum score out of 100.  The higher the score the more 
independent a patient is in carrying out daily activities (207).  
 
I sent the follow-up questionnaire to all study participants by post at six month after 
discharge.  The follow up questionnaire package included a newsletter, the SF36v2, SIS 
questionnaires and Barthel Index.  The newsletter included a brief introduction about 
my background and a reminder about the study and its objectives in lay language 
understandable to the general public. My work contact details as the contact information 
of the investigator was also included in the postal package in case if they wished to 
receive any further information. A guidance note for participants on how to complete 
each questionnaire was also included in the postal package.  A pre-paid envelope was 
also included for the questionnaires to be returned to the investigator.  
 
On receipt of the completed questionnaires, the responses were scored according to the 
scoring algorithm as per developer for each questionnaire.  Results of each component 
of individual scale and the summary scores (e.g. PCS and MCS for SF-36v2) were 
recorded in the database.  If a participant did not respond to initial mailing within two 
weeks, they were contacted by telephone on two occasions, two and four weeks after 
initial postage, to find out if any help was required and also to encourage their response, 
and record reasons for not responding. 
 
Statistical analysis  
 
Baseline data were presented descriptively.  Body composition changes between 
admission and discharge were calculated for each participant by subtracting admission 
values from the discharge values to understand if an increase or a decrease in these body 
components had occurred during the acute hospital stay. The difference was divided by 
duration between admission and discharge MF-BIA measurements in days to calculate 
rate of change per day.  
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Further sensitivity analyses were conducted after excluding all participants in whom the 
duration between MF-BIA measurements was <48 hours. These sensitivity analyses 
were carried out using changes in the body components as percentages of body weight.   
 
Descriptive statistics for fat free mass, fat mass, body cell mass, protein mass, muscle 
mass on admission and discharge were calculated stratified by type of feeding regimen 
(Normal Oral Diet, Soft mashed/Pureed diet, and Nil-by-Mouth (NBM), stroke severity 
by NIHSS scores of <10 vs. ≥10 (not enough data to stratify by higher NIHSS score), 
and type of ischaemic stroke (Total Anterior Circulation Infarct (most severe form of 
stroke) vs. other types).    
 
Univariate logistic regression analysis was carried out to examine if there was an 
association between fat free mass loss, fat mass gain, muscle mass loss, body cell mass 
loss, and protein mass loss with the predictor variables Nil-by-Mouth (reference 
category being other types of diet; normal oral and soft mashed/pureed), modified 
diet(reference category being normal oral diet), total anterior circulation infarct 
(reference group non-TACI stroke subtypes), and more severe strokes with the an 
NIHSS ≥10 (reference category NIHSS <10).   
 
Linear regression analysis was also carried out to examine if there is an association 
between predictors fat free mass loss, fat mass gain, muscle mass loss, body cell mass 
loss, and protein mass loss and outcomes length of hospital stay.  Basically I was trying 
to examine if such body composition changes have influence on length of hospital stay.  
If any results were of significance multivariate logistic and linear regression analysis 
was carried out.  
 
The individual component summary score of SF36v2 was calculated using the program 
provided by the supplier (see above section for calculation details and supplier 
information).  Average scores for each component, PCS and MCS of the SF36v2 were 
all presented descriptively separately for those who gained and those who lose fat free 
mass, fat mass, muscle mass, body cell mass, and protein mass respectively.  Mean 
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difference was calculated for each body composition measures and p-values are 
presented to examine any statistically significant differences between those who gained 
and lose these components of body for MCS and PCS respectively.  For the Stroke 
Impact Scale (SIS) each dimension score was calculated.  Average scores for each 
component of the SIS (PCS and MCS) and patient reported overall stroke recovery 
(question 11 of the SIS) were presented for those with fat free mass, fat mass, muscle 
mass, body cell mass, and protein mass gains and losses in respectively.   
 
Mean difference of fat free mass, fat mass, protein mass were calculated for each body 
composition measures and p-values presented to examine any statistically significant 
differences between those with body composition gain and losses for each dimension of 
the SIS and the patient reported overall stroke recovery (question 11 of the SIS).   
Barthel Index scores were calculated and overall average scores were presented for 
those with fat free mass, fat mass, muscle mass, body cell mass, and protein mass gains 
and losses in respectively.     
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3.4 Results 
 
A total of 40 participants were recruited to this study. Their mean age was 70.3±9.9 
years (range 50-89 years); 55.0% of them were men. All study participants had 
ischaemic stroke.  The majority of the study population experienced Lacunar infarct 
(42.5%).  Majority of strokes according to the National Institute of Health Stroke 
Severity (NIHSS) scale were mild strokes with NIHSS <10 (85.7%).   For fat free mass 
(FFM), fat mass (FM), and body cell mass (BCM) data were available in 40 patients.  
For protein mass (PM) and muscle mass (MM) data were available for 39 patients.  
Table 3.1 present the baselines characteristics.   
 
Eighteen study participants responded to follow up questionnaire of which 10 were men 
and eight were women. Mean age was 69.1±9.7) years (range 50-89 years).  Their 
average length of hospital stay was 3.2 day (range 1-8 days), and average NIHSS score 
was 5.9 (range 1-21).  Six of these participants had Lacunar Infarct (LACI), one 
participant Partial Anterior Circulation Infarct (PACI), seven had Posterior Circulation 
Infarct (POCI), and four total anterior Circulation Infarct (TACI).  One participant was 
prescribed nil-by-mouth (NBM) during the acute hospital stay, 16 received normal oral 
feeding, and one was on pureed diet.  On discharge 14 were discharged to home, three 
to rehabilitation, and one was initially transferred to another hospital.   At six month 
post discharge they all resided at their respective home addresses. 
 
There were no statistically significant differences between each of the anthropometric 
measurements recorded on admission and discharge.  Table 3.2 shows mean 
anthropometric measurements on admission and discharge and their differences.   
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 All Men Women 
Number 40 22 18 
Mean age (std) years 70.3 (9.9) 69.7 (10.6) 71.1 (9.2) 
Age Range (years) 50-89 50-89 59-89 
Weight (kg)  77.4 (13.9) 79.5 (14.5) 74.7 (13.1) 
Height (m) 1.7 (0.1) 1.8 (0.08) 1.6 (0.06) 
Body Mass Index  (kg/m2) 26.8 (4.7) 25.7 (4.2) 28.2 (5.0) 
Triceps Skin Fold thickness (mm) 11.2 (3.9) 10.9 (3.8) 11.5 (4.0) 
Mid Arm  Circumference (cm) 28.8 (4.2) 28.4 (3.5) 29.1 (5.0) 
Handgrip Strength (kg)   20.1 (10.8) 24.4 (12) 15.1 (6.7) 
Average length of Hospital say  (range) days 4.1 (1-24) 4.8 (1-24) 3.1 (1-7) 
Premorbid Rankin Score*    
0 =No symptoms 20 8 12 
1 =No significant disability 14 9 5 
2 = Slight disability.  2 1 1 
3 = Moderate disability.  1 1 0 
4 = Moderately severe disability  - - 
5 =Severe disability - - - 
Total Anterior Circulation Infarct 6 4 2 
                Left Side 4 2 2 
                Right Side 2 2 0 
Partial Anterior Circulation Infarct 5 2 3 
                Left Side 2 1 1 
                Right Side 3 1 2 
Lacunar Infarct 17 9 8 
                Left Side 10 3 7 
                Right Side 7 6 1 
Table 3.1. Baselines (admission) characteristics of the study population including 
demographic, anthropometric, and clinical data, continued 
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 All Men Women 
Posterior Circulation Infarct 12 7 2 
                   Left Side 5 3 1 
                   Right Side 7 4 1 
NIHSS Score (n=37) categories    
           1 to 9 (mild stroke) 30 15 14 
           10 to 20 (moderate stroke) 4 2 2 
           ≥20 (severe stroke) 1 1 1 
Table 3.1.   Baselines (admission) characteristics of the study population including 
demographic, anthropometric, and clinical data. 
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Anthropometric Measure Admission Discharge Mean difference (95% CI) p-value 
Weight (kg)     
All 77.4 (13.9) 77.1 (13.7) 0.29 (-0.23 to 0.81) 0.26 
Men 79.5 (14.5) 79 (14.3) 0.55 (-0.41 to 1.51) 0.25 
Women 74.7 (13.1) 74.7 (13.1)  -0.02 (-0.09 to 0.03)  0.33 
Body Mass Index  (kg/m2)     
All  26.8 (4.7) 26.6 (4.7) 0.22 (-0.1 to 0.6) 0.20 
Men 25.7 (4.2) 25.3 (4.2) 0.4 (-0.3 to 1.0) 0.24 
Women 28.2 (5.0) 28.1 (5.0) 0.04 (-0.01 to 0.08) 0.10 
Triceps Skinfold Thickness (mm)     
All  11.2 (3.9) 11.2 (3.9) 0.01 (-0.02 to 0.03) 0.55 
Men 10.9 (3.8) 10.9 (3.8) -0.01 (-0.03 to 0.02) 0.70 
Women 11.5 (4.0) 11.5 (4.0) 0.02 (-0.02 to 0.06) 0.31 
Mid Arm Muscle Circumference (cm)     
All  28.8 (4.2) 28.7 (4.3) -0.04 (0.002 to 0.07) 0.04 
Men 28.4 (3.5) 28.4 (3.6) 0.03 (-0.02 to 0.1) 0.24 
Women 29.1 (5.0) 29.1 (5.0) 0.04 (-0.002 to 0.08) 0.06 
Table 3.2. Admission and discharge anthropometric measurements by sex-specific analysis continued 
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Anthropometric Measure Admission Discharge Mean difference (95% CI) p-value 
Handgrip Strength (kg)     
All   20.1 (10.8)  20.4 (11.7) 0.24 (-1.4 to 1.0) 0.69 
Men 24.4 (12) 24.7 (13.4) 0.4 (-2.6 to 1.9) 0.74 
Women 15.1 (6.7) 15.3 (6.5) -0.1 (-0.7 to 0.5) 0.75 
                                     Table 3.2.  Admission and discharge anthropometric measurements by sex-specific analysis. 
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There were no statistically significant changes in any of the body composition indices 
during the acute hospital stay between the admission and discharge in all as well as for 
men and women separately.  Fat free mass decreased in the whole population, with men 
showing an increase and women showing a decrease as a group.  All population 
regardless of gender showed an increase in fat mass, a decrease in protein mass and 
body cell mass.  Muscle mass increased in men but decrease in women, but the whole 
study population overall average change suggested muscle mass increase.  Table 3.3 
describes the body composition changes between admission and discharge and their 
average change during hospital stay for the whole recruited study population, and then 
men and women separately.  
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Body Composition Admission Discharge Mean difference (95% CI) p-value 
Fat Free Mass (kg)     
All  51.6 (9.6) 51.1(9.2) -0.5 (-1.22 to 0.23) 0.18 
Men 56.6 (8.7) 55.9 (8.8) 0.7 (-0.3 to 1.6) 0.16 
Women 45.6 (6.9) 45.3 (5.7) -0.3 (-1.6 to 1.0) 0.62 
Fat Mass (kg)     
All  25.7(10.2) 26 (10.3) 0.3 (-1.01-0.44) 0.43 
Men 22.9 (8.3) 23.2 (8.8) 0.3 (-1.2 to 0.6) 0.49 
Women 29.2 (11.3) 29.4 (11.3) 0.2 (-1.1 to 1.6) 0.68 
Protein Mass (kg)     
All  7.5 (2.9) 7.0 (2.9) -0.5 (-0.97 to 0.01) 0.06 
Men 9.1 (2.6) 8.5 (2.7) -0.6 (-1.3 to 0.23) 0.16 
Women 5.4 (1.8) 5.0 (1.7) -0.4 (-1.1 to 0.25) 0.20 
Body Cell Mass (kg)     
All  28.7 (7.6) 27.7 (6.2) -1.0 (-3.2 to 1.2) 0.36 
Men 30.3 (4.9) 30.2 (6.7) -0.1 (-1.8 to 1.7) 0.94 
Women 26.8 (9.8) 24.7 (4.0) -2.1 (-6.7 to 2.4) 0.34 
Table 3.3. Body composition values on admission and discharge, continued 
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Body Composition Admission Discharge Mean difference (95% CI) p-value 
Muscle Mass (kg)     
All  23.0 (5.7) 24.4 (13.0) 1.4 (-5.55-2.75) 0.50 
Men 26.6 (4.9) 26.3 (6.1) -0.3 (-1.8 to 1.1) 0.63 
Women 18.4 (2.4) 22.1 (18.4) 3.7 (-13.5 to 6.1) 0.44 
Table 3.3.  Body composition values on admission and discharge and their average change during hospital stay for the whole study population and 
men, and women separately. 
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3.4.1 Extent of fat free mass and other body composition changes by type of feeding 
regimen  
  
Fat free mass losses with both groups (normal oral diet and modified diet) were not 
statistically significant.  Fat mass gain was observed in the majority of the normal oral 
diet group (55%) and modified diet group (64%) with higher gains in the modified diet 
group; p>0.05.   Larger proportions of patients in each the normal oral diet (62%) and 
modified diet (82%) groups experienced protein mass loss with more pronounced losses 
seen in the modified diet group.  On the contrary, the more pronounced losses were 
observed in the normal diet group with regards to body cell mass losses with higher 
proportion in both groups experiencing such losses.   Extent of muscle mass loss was 
higher in the modified diet group (p=0.05) with the normal oral diet group experiencing 
muscle mass gains.  Table 3.4 describes body composition changes of the study 
population stratified by normal oral diet and modified diet groups showing average 
changes between admission and discharge within groups.  
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
(between 
MF-BIA 
tests) 
Fat Free Mass (kg)        
 Normal oral 16 (55%) 13 (45%) 52.1 (9.7) 51.6 (8.9) -0.5 (-1.1 to 0.3) 0.23 -0.4 (1.4) 
 Modified diet 8 (73%) 3 (27%) 50.3 (9.7) 49.8 (10.2) -0.4 (-2.0 to 1.2) 0.57 -0.4 (0.9) 
Fat mass (kg)        
 Normal oral 13 (45%) 16(55%) 26.1 (10.1) 26.3  (10.2) 0.2 (-0.7 to 1.1) 0.66 0.3 (1.6) 
 Modified diet 4 (36%) 7 (64%) 24.8 (10.9) 25.3 (11.1) 0.5 (-0.9 to 1.9) 0.44 0.4 (0.9) 
Protein mass (kg)*        
 Normal oral 18 (64%) 10 (36%) 7.5 (2.8) 7.3 (3.0) -0.3 (-0.9 to 0.3) 0.32 -0.3 (1.2) 
 Modified diet 9 (82%) 2 (18%) 7.3 (3.1) 6.3 (2.7) -1.0 (-2.0 to 0.1) 0.07 -0.5 (0.6) 
Body Cell Mass (kg)        
 Normal oral 17 (59%) 12 (41%) 29.3 (8.3) 28.1 (6.3) -1.2 (-4.3 to 1.8) 0.40 -1.8 (6.4) 
 Modified diet 7 (64%) 4 (36%) 27.2 (5.5) 26.9 (6.2) -0.3 (-1.5 to 1.0) 0.64 -0.1 (1.4) 
Table 3.4.  Body composition changes between admission and discharge for patient on normal oral diet and modified diet, continued 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
(between 
MF-BIA 
tests) 
Muscle Mass (kg)*        
 Normal oral 16 (55%) 12 (45%) 23.2 (5.7) 25.6 (14.7) 2.4 (-3.4 to 8.2) 0.40 0.4 (5.2) 
 Modified diet 8 (73%) 3 (27%) 22.7 (5.9) 21.5 (6.3) -1.2 (-2.3 to 0.0) 0.05 -0.5 (1.1) 
Table 3.4.  Body composition changes between admission and discharge for patients on normal oral diet and modified type of diet.  Modified type of 
diet includes soft mashed and pureed diets, and nil-by-mouth NBM. 
 
Body cell mass admission (normal oral diet) not normally distributed (Shapiro-Wilk: p<0.05); Median=27.8 g, Interquartile range=22.7 to 33.1 g 
Body cell mass discharge (modified diet) not normally distributed (Shapiro-Wilk: p=0.05); Median=26.1 g, Interquartile range=22.3 to 28.9 g 
Muscle mass admission (normal oral diet) not normally distributed (Shapiro-Wilk: p=0.04) Median 23.4 g, Interquartile range = 23.9 to 31.2 g 
Muscle mass discharge (normal oral diet) not normally distributed (Shapiro-Wilk: p<0.05) Interquartile range = 17.6 to 27.9 g  
Muscle mass discharge (modified diet) Not Normally distributed (Shapiro-Wilk: p=0.01); Median=19.6 g, Interquartile range= 17.4 to 22.7 g 
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When analyses was stratified by non-NBM and NBM, majority of participants 
experienced fat free mass, protein mass, body cell mass, and muscle mass losses and fat 
mass gains.   All participant in the NBM group, and majority of non-NBM experienced 
fat free mass losses (54%).  The Extent of fat free mass losses was higher in the NBM 
group compared to non-NBM groups.   Majority of participant in the non-NBM group 
(54%) and 80% of participants in the NBM group experienced fat mass gains.  The 
extent of fat mass gain was higher in NBM compared to non-NBM.   Both groups 
experienced protein mass loss with a proportion of 68% 80% in the non-NBM and 
NBM respectively; the extent of protein mass losses higher in the NBM group.   Only 
the non-NBM group experienced body cell mass losses with 62% of the group 
experiencing loss.   The non-NBM group experienced body cell mass losses while such 
losses were almost absent in the NBM group.   The non-NBM group experienced 
muscle mass gains and the NBM group experienced loss.  None of the body 
composition changes between admission and discharge were statistically significant 
within groups.  Table 3.5 describes body composition changes of the study population 
stratified by non NBM and NBM types of feeding regimen showing p-values of change 
within groups. 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
(between 
MF-BIA 
tests) 
Fat Free Mass (kg)        
 non-NBM 19 (54%) 16 (46%) 52.1 (9.9) 51.8 (9.4) -0.3 (-1.1 to 0.5) 0.45 -0.4 (1.4) 
 NBM 100% (5) 0 (0%) 48.5 (7.5) 46.6 (7.3) -1.9 (-4.3 to 0.5) 0.09 -0.9 (1.0) 
Fat mass (kg)        
 non-NBM 16 (46%) 19 (54%) 26.6 (10.2) 26.7 (7.6)  0.1 (-0.6 to 0.9) 0.74 0.3 (1.5) 
 NBM 1 (20%) 4 (80%) 19.4 (7.8) 20.8 (8.2) 1.4 (-1.8 to 4.6) 0.29 0.8 (1.1) 
Protein mass (kg)*        
 non-NBM 23(68%) 11 (32%) 7.6 (2.9) 7.2 (2.9) -0.4 (-1.0 to 0.1) 0.13 -0.3(1.1) 
 NBM 4 (80%) 1 (20%) 6.5 (3.0) 5.6 (2.8) -0.9 ( -2.1 to 0.4) 0.12 -0.6 (0.8) 
Body Cell Mass (kg)        
 non-NBM 21 (62%) 14 (38%) 29.1 (7.9) 28.0 (6.4) -1.1 (-3.6 to 1.3) 0. 35 -1.5 (6.3) 
 NBM 3 (60%) 2 (40%) 26.0 (4.9) 26 (5.5) 0.01 (-2.8 to 3.0) 0.93 -0.1 (1.5) 
Table 3.5.  Body composition changes between admission and discharge stratified by non-NBM vs. NBM, continued 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
(between 
MF-BIA 
tests) 
Muscle Mass (kg)*        
 non-NBM 20 (59%) 14 (41%) 23.3 (5.8) 25.1 (13.7) 1.8 (-2.9 to 6.6) 0.44 0.3 (4.8) 
 NBM 4 (80%) 1 (20%) 21.5 (5.1) 20.1 (5.2) -1.4 (-3.4 to 0.6) 0.12 0.9 (1.2) 
Table 3.5.  Body composition changes between admission and discharge for patients on non nil-by-mouth feeding regimen and those on nil-by-mouth 
(NBM) feeding regimen; non-NBM includes normal oral diet, soft-mashed, and pureed diets. 
 
Body cell mass admission (non-NBM) not normally distributed (Shapiro-Wilk: p<0.05); Median=27.5 g, interquartile range=23.0 to 30.0 g 
Body cell mass discharge (non-NBM) not normally distributed (Shapiro Wilk: p=0.03); Median=26.8 g, interquartile range=23.8 to 30.6 g 
Muscle mass discharge (non-NBM) not normally distributed (Shapiro-Wilk: p<0.05); Median=22.1 g; Interquartile range= 17.7 to 27.8 g 
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3.4.2 Extent of body composition changes by type of stroke  
 
When analyses were stratified by TACI and non-TACI subtype of stroke, majority of 
participants experienced fat free mass, protein mass, body cell mass, and muscle mass 
losses and fat mass gains.   More than half of participant with TACI (67%), and non-
TACI (59%) experienced fat free mass losses.  The Extent of fat free mass losses was 
higher in the TACI group compared to non-TACI groups.   The majority of patients in 
each group experienced fat mass gain with the extent of fat mass gains being more 
pronounced in the TACI group.  All participants in the TACI group and 64% in the non-
TACI group experienced protein mass loss, with statistically significant protein mass 
losses (p=0.05) seen in the TACI group between admission and discharge.   Similarly 
body cell mass loss extent was higher in the TACI compared to non-TACI study 
participants with majority in both groups experiencing muscle mass (56% in non-TACI 
vs. 83% in TACI).   Muscle mass loss was experienced in 83% of patients with TACI 
(p=0.05) as opposed to non-TACI patients who had muscle mass gains.    Table 3.6 
shows body composition changes between admission and discharge in patients with 
Total Anterior Circulation infarct (TACI) and those with other types of infarct. .   
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
(between 
MF-BIA 
tests) 
Fat Free Mass (kg)        
non-TACI 20 (59%) 14 (41%) 50.8 (9.7) 50.4 (9.3) -0.4 (-2.1 to 0.4) 0.34 -0.4 (1.4) 
TACI 4 (67%) 2 (33%) 56.2 (7.8) 55.1 (8.2) -1.1 (-3.1 to 1.0) 0.23 -0.3 (1.0) 
Fat mass (kg)        
non-TACI 15 (44%) 19 (56%) 25.7 (10.9) 25.9 (11.1) -0.2 (-0.7 to 1.0) 0.68 0.4 (1.5) 
TACI 2 (33%) 4 (67%) 25.9 (3.8) 26.9 (4.1) 1.0 (-1.2 to 3.1) 0.30 0.2 (1.0) 
Protein mass (kg)        
non-TACI 21(64%) 12 (36%) 7.2 (3.9) 6.8 (3.1) -0.3 (-0.2 to 0.9) 0.22 -0.3 (1.0) 
TACI 6 (100%) 0 (0%) 9.2 (1.8) 7.9 (1.6) -1.3 (--2.5 to 0.03) 0.05 -0.9 (1.3) 
Body Cell Mass (kg)        
non-TACI 19 (56%) 15 (44%) 28.3 (7.9) 27.4 (6.5) -0.9 (-3.5 to 1.7) 0.49 -1.4 (6.4) 
TACI 5 (83%) 1 (17%) 31.2 (4.9) 29.6 (4.8) -1.7 (-3.4 to 0.2) 0.07 -0.9 (1.0) 
Table 3.6.  Body composition changes between admission and discharge by type of stroke, continued 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
(between 
MF-BIA 
tests) 
Muscle Mass (kg)        
non-TACI 19 (58%) 14 (42%) 22.4 (5.5) 24.4 (14.0) 2.0 (-2.9 to 6.9) 0.41 0.4 (4.8) 
TACI 5 (83%) 1 (17%) 26.8 (5.5) 24.8 (5.0) -2.0 (-4.1 to 0.04) 0.05 -1.3 (1.7) 
Table 3.6.  Body composition changes between admission and discharge for patients with Total Anterior Circulation Infarct (TACI) and those with 
non-TACI stroke subtype. 
 
Body cell mass admission (non-TACI) not normally distributed (Shapiro-Wilk: p<0.05); Median=26.7 g, interquartile range=22.5 to 30.3 g 
Body cell mass discharge (non-TACI) not normally distributed (Shapiro Wilk: p=0.01); Median=26.1 g, interquartile range=22.5 to 30.4 g 
Muscle mass discharge (non-TACI) not normally distributed (Shapiro-Wilk p<0.05); Median=20.0 g; Interquartile range= 17.7 to 26.7 g 
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3.4.3 Extent of body composition changes by stroke severity  
 
When analyses was stratified by stroke severity mild (NIHSS 1-9) and severe 
(NIHSS≥10) strokes, both patients experiencing mild and severe stroke experienced fat 
free mass losses with sever strokes extent of losses being higher.   Half the individuals 
in each group experienced fat free mass losses.  Similarly, both mild and sever strokes 
experienced fat mass gains with the extent of fat mass gain being twice as much in 
severe stroke compared to mild strokes.  Fifty eight percentage of mild and 67% of 
severe strokes experienced fat mass gains.  Extent of protein mass losses were higher in 
severe strokes with similar proportion of participant experiencing protein mass losses in 
both groups.  Only body cell mass losses were experienced in the mild strokes as 
opposed to sever strokes that experienced gains (see discussion).  No muscle mass 
losses were observed in either group.  None of any of the body composition changes 
was statistically significant.  Table 3.7 describes body composition changes between 
admission and discharge in patients with mild strokes (NIHSS≤9) and severe stroke 
(NIHSS≥10). 
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Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission 
(kg) 
Discharge 
(kg) 
mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Fat Free Mass (kg)        
NIHSS score <10 17(57%) 13 (43%) 51.2 (10.1) 50.7 (9.6) -0.4 (-1.2 to 0.4) 0.32 -0.5 (1.4) 
NIHSS score ≥10 3 (60%) 2 (40%) 55.7 (10.5) 53.8 (10.6) -2.0 (-5.7 to 1.8) 0.22 -0.4 (1.4) 
Fat mass (kg)        
NIHSS score <10 12 (40%) 18 (60%) 27.2 (10.8) 27.6 (11.0) 0.3 (-0.6 to 1.2) 0.45 0.4 (1.6) 
NIHSS score ≥10 3 (60%) 2 (40%) 25.9 (3.1) 26.5 (2.8) 0.6 (-3.0 to 4.2) 0.65 0.2 (1.5) 
Protein mass (kg)        
NIHSS score <10 20 (69%) 9 (31%) 7.0 (3.0) 6.8 (3.1) -0.2 (-0.7 to 0.3) 0.40 -0.3 (1.0) 
NIHSS score ≥10 4(80%) 1 (20%) 8.8 (2.1) 7.7 (1.8) -1.1 (-2.8 to -0.5) 0.13 -0.8 (1.3) 
Body Cell Mass (kg)        
NIHSS score <10 18 (60%) 12 (40%) 28.9 (8.4) 27.2 (5.6) -1.7 (-4.4 to 1.0) 0.20 -1.8 (6.7) 
NIHSS score ≥10 3 (60%) 2 (40%) 30.5 (5.9) 33.9 (9.4) 3.4 (-5.3 to 12.1) 0.34 0.6 (1.7) 
Table 3.7.  Body composition changes between admission and discharge by stroke severity continued 
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Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission 
(kg) 
Discharge 
(kg) 
mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Muscle Mass (kg)        
NIHSS score <10 17 (59%) 12 (41%) 22.5 (5.9) 24.6 (14.5) 2.1 (-3.5 to 7.6) 0.46 0.4 (5.1) 
NIHSS score ≥10 2 (40%) 3 (60%) 26.0 (6.3) 26.6 (9.3) 0.6 (-8.4 to 7.3) 0.85 0.9 (2.3) 
Table 3.7.  Body composition changes between admission and discharge stratified by stroke severity by NIHSS score for patients with an NIHSS≤9 
and NIHSS≥10. 
 
Body cell mass admission (NIHSS<10) not normally distributed (Shapiro-Wilk: p<0.05); Median=26.8 g, interquartile range=22.5 to 31.5 g 
Muscle mass admission (NIHSS<10) not normally distributed (Shapiro Wilk: p=0.03); Median=20.1 g, interquartile range=17.7 to 27.7 g 
Muscle mass discharge (NIHSS<10) not normally distributed (Shapiro-Wilk: p<0.05); Median=20.0 g; Interquartile range= 17.1 to 27.6 g 
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3.4.4 Difference in fat free mass and body composition changes between groups  
 
No statistically significant differences were observed between groups.  Fat free mass 
losses were higher in NBM, TACI, and NIHSS ≥10 from non-NBM, non-TACI, and 
NIHSS 1-9 as shown in the positive mean difference observed in table 3.8 (NBM, TACI, 
and NIHSS ≥10 were subtracted from the average mean of non-NBM, non-TACI, 
NIHSS 1-9) respectively.  Fat mass gains were higher in the   modified diet, NBM, 
TACI, and NIHSS ≥10 compared to their corresponding normal oral diet, non-NBM, 
non-TACI, and NIHSS 1-9 respectively; negative mean difference.  Protein mass losses 
were higher in the modified diet, NBM, TACI, and NIHSS ≥10 compared to their 
corresponding respective groups of normal oral diet, non-NBM, non-TACI, and NIHSS 
1-9.   There were no consistent finding in gains and losses of body cell mass and muscle 
mass for the modified diet, NBM, TACI, and NIHSS ≥10 compared to their respective 
normal oral diet, non-NBM, non-TACI, and NIHSS 1-9 as can be seen from tables 3.5 
to 3.7.   Table 3.8 present the mean difference and their 95% Confidence interval 
between fat free mass, fat mass, protein mass, muscle mass, and body cell mass for 
normal oral diet vs. modified diet groups, non-NBM vs. NBM groups, non-TACI vs. 
TACI stroke classification, and NIHSS 1-9 vs. NIHSS≥9 scores. 
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 Mean difference 95% CI p-value 
Fat Free Mass (kg)    
  Normal Oral Diet vs. Modified diet 0.1 -1.7 to 1.6 0.91 
  non-nil by mouth vs. NBM 1.6 -0.54 to 4.0 0.14 
  non-TACI vs. TACI 0.7 -1.4 to 2.8 0.50 
  NIHSS 1-9 vs. NIHSS≥10 1.5 -0.72 to 3.8 0.18 
Fat Mass (kg)    
 Normal Oral Diet vs. Modified diet -0.3 -2.0 to 1.3 0.70 
 non-nil by mouth vs. NBM -1.3 -3.5 to 0.92 0.25 
 non-TACI vs. TACI -0.8 -2.9 to 1.3 0.44 
 NIHSS 1-9 vs. NIHSS≥10 -0.3 -2.7 to 2.1 0.8 
Protein Mass (kg)    
 Normal Oral Diet vs. Modified diet 0.7 -0.39 to 1.8 0.20 
 non-nil by mouth vs. NBM 0.4 -1.1 to 1.9 0.56 
 non-TACI vs. TACI 0.9 -0.44 to 2.3 0.18 
 NIHSS 1-9 vs. NIHSS≥10 0.9 -0.35 to 2.2 0.15 
Muscle Mass (kg)    
 Normal Oral Diet vs. Modified diet 3.6 -5.7 to 12.8 0.44 
 non-nil by mouth vs. NBM 3.2 -9.3 to 15.8 0.61 
 non-TACI vs. TACI 4.1 -7.5 to 15.7 0.48 
 NIHSS 1-9 vs. NIHSS≥10 1.5 -12.2 to 15.2 0.82 
Body Cell Mass (kg)    
 Normal Oral Diet vs. Modified diet -1.0 -5.9 to 4.0 0.69 
 non-nil by mouth vs. NBM -1.2 -7.9 to 5.4 0.71 
 non-TACI vs. TACI 0.8 -5.4 to 7.0 0.80 
 NIHSS 1-9 vs. NIHSS≥10 3.4 -12.1 to 1.9 0.15 
Table 3.8.  The mean difference and their 95% Confidence intervals between fat free 
mass, fat mass, protein mass, muscle mass, and body cell mass for normal oral diet vs. 
modified diet groups, non-NBM vs. NBM groups, non-TACI vs. TACI stroke 
classification, and NIHSS 1-9 vs. NIHSS≥10 scores.
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3.4.5 The effect of type of feeding regimen, type of stroke, and stroke severity on extent 
of body composition changes after stroke  
 
Univariate logistic regression analysis between NBM (reference group non-NBM), 
TACI (reference non-TACI) or stroke severity (NIHSS≥10) (reference NIHSS <10) did 
not show any statistically significant increased or decreased risk on fat free mass loss, 
protein mass loss, muscle mass loss, body cell mass loss and fat mass gain.  Table 3.9 
presents the results of the Univariate logistic regression analysis for the risk of NBM, 
TACI, and NIHSS≥10 risk on fat free mass loss, protein mass loss, muscle mass loss, 
and fat mass gain in NBM, TACI, and NIHSS≥10 (stroke severity) patients. 
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 OR 95% CI p-value 
Nil-by Mouth 
Fat Free Mass loss NA* NA ≥0.1 
Fat Mass gain 3.4 0.34-33.3 0.30 
Protein Mass loss 1.9 0.19-19.2 0.60 
Muscle Mass loss 2.8 0.28-27.8 0.38 
Body Cell Mass loss 1 0.15-6.7 1 
Modified diet    
Fat Free Mass loss 2.2 0.5 to 9.9 0.32 
Fat Mass gain 1.4 0.3 to 5.9 0.63 
Protein Mass loss 2.5 0.5 to 13.9 0.30 
Muscle Mass loss 2.0 0.5 to 9.2 0.37 
Body Cell Mass loss 1.2 0.3 to 5.2 0.77 
Table 3.9.  Unadjusted Risk of body composition  changes, 
continued 
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 OR 95% CI p-value 
TACI 
Fat Free Mass loss 1.4 0.2 to 8.7 0.72 
Fat Mass gain 1.6 0.2 to 9.8 0.60 
Protein Mass loss <0.923 NA 0.99 
Muscle Mass loss 3.7 0.4 to 35.1 0.26 
Body Cell Mass loss 4 0.4 to 37.5 0.23 
NIHSS≥10 
Fat Free Mass loss 1.63 0.3 to 10.3 0.61 
Fat Mass gain 0.71 0.1 to 4.1 0.70 
Protein Mass loss 0.8 0.1 to 5.3 0.82 
Muscle Mass loss 0.65 0.1 to 3.8 0.63 
Body Cell Mass loss 0.31 0.1 to 2.0 0.21 
Table 3.9.  Unadjusted Risk of fat free mass, protein mass, muscle mass, and body cell mass loss and fat mass gain in patients who have a NBM 
feeding regimen, or modified diet, or total anterior circulation infarct or sever stroke NIHSS≥10.  *OR=1.9E9
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3.4.5.1 Results of sensitivity analysis  
 
In the sensitivity analysis difference in the selected body composition changes 
between admission and discharge were not statistically significant within group or 
between groups.  Tables 3.10 to 3.15 present sensitivity analysis for the difference 
between admission and discharge body composition changes stratified by men and 
women (Table 3.10) modified diet and normal oral diet (Table 3.11), non-NBM and 
NBM feeding regimen (Table 3.12), type of stroke being non-TACI and TACI (Table 
3.13), stroke severity by NIHSS<10 and NIHSS ≥10 (Table 3.14), mean differences 
between body composition variables in all of the examined (groups presented in 
Tables 3.10 to 3.14) are presented in Table 3.15. 
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 Participants 
with body 
composition 
loss (%) 
Participants with 
body 
composition 
gain (%) 
Admission 
(kg) 
Discharge 
(kg) 
mean difference 
(95% CI) kg 
p-value Change rate kg/day 
Fat Free Mass (%)        
Men 6 (55%) 5 (45%) 72.3 (7.0)  72.3 (6.5) 0.0 (-1.9 to 1.8) 0.97 1.4 (0.9) 
Women 2 (33%) 4 (67%) 57.5 (7.2) 58.3 (8.0) 0.8 (-5.4 to 6.9) 0.76 <0.01 (2.3) 
Fat mass (%)        
Men 4 (36%) 7 (64%) 27.7 (7.0) 28.4 (6.9) 0.7 (-1.2 to 2.6) 0.44 0.2 (0.9) 
Women 4 (67%) 2 (33%) 42.5 (7.2) 41.6 (8.3) -0.9 (-7.4 to 5.5) 0.73 0.1 (2.4) 
Protein mass (kg)        
Men 5 (45%) 6 (55%) 10.4 (3.1) 9.7 (2.4) -0.7 (-2.7 to 1.2) 0.42 0.1 (0.7) 
Women 4 (67%) 2 (33%) 6.6 (2.6) 6.7 (2.3) 0.1 (-2.1 to 2.2) 0.92 0.1 (0.8) 
Body Cell Mass (%)        
Men 6 (55%) 5 (45%) 38.9 (3.5) 39.8 (7.4) 0.9 (-4.2 to 6.0) 0.88 0.1 (1.4) 
Women 2 (40%) 3 (60%) 31.1 (4.0) 32.2 (6.4) 1.1 (-1.9 to 4.2) 0.36 0.5 (1..1) 
Table 3.10.  Sensitivity stratified analyses of selected body composition by sex, continued 
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 Participants 
with body 
composition 
loss (%) 
Participants with 
body 
composition 
gain (%) 
Admission 
(kg) 
Discharge 
(kg) 
mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Muscle Mass (%)        
Men 6 (55%) 5 (45%) 33.8 (3.4) 34.1 (5.5) 0.3 (-3.9 to 4.6) 0.70 0.1 (1.3) 
Women 3 (60%) 2 (40%) 19.0 (2.1) 18.2 (1.1) -0.8 (-2.7 to 1.3) 0.36 0.5 (1.2) 
Table 3.10.  Stratified analyses of selected body composition mean daily changes by percentages of body weight for men and women whom test dates 
on admission and discharge were ≥48 hours. 
 
Fat free mass admission (men) not normally distributed (Shapiro-Wilk: p=0.013), Median=71.9%, Interquartile range=67.4 to 72.8% 
Fat free mass discharge (men) not normally distributed (Shapiro-Wilk: p=0.03), Median=70.9%, Interquartile range=68.2 to 72.7% 
Fat mass admission (men) not normally distributed (Shapiro-Wilk: p=0.02), Median=28.2%, Interquartile range=27.2 to 32.5% 
Fat mass admission (men) not normally distributed (Shapiro-Wilk: p=0.04), Median= 29.9%, Interquartile range=27.5 to 32.8% 
Muscle mass discharge (men) not normally distributed (Shapiro-Wilk: p<0.0001), Median=32.8%, Interquartile range=31.0 to 34.8% 
Body cell mass discharge (men) not normally distributed (Shapiro-Wilk: p<0.0001), Median=37.5%, Interquartile range=35.5 to 39.8% 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Fat Free Mass (%)        
Normal oral 5 (56%) 4 (44%) 65.4 (8.1) 65.9 (7.3) 0.5 (-2.7 to 3.8) 0.74 0.2 (1.4) 
Modified diet 5 (63%) 3 (37%) 69.0 (12.0) 69.0 (12.2) 0.02 (-3.2 to 3.2) 0.99 0.4 (1.6) 
Fat mass (%)        
Normal oral 5 (56%) 4 (44%) 34.7 (8.1) 33.9 (7.4) - 0.8 (-4.2 to 2.8) 0.63 0.3 (1.5) 
Modified diet 3 (37%) 5 (63%) 30.9 (12.0) 32.1 (12.2) 1.1 (-2.0 to 4.2) 0.43 0.6 (1.5) 
Protein mass (%)        
Normal oral 4 (44%) 5 (56%) 9.1 (3.1) 9.3 (2.8) 0.2 (-1.35 to 1.8) 0.74 0.1 (0.8) 
Modified diet 6 (75%) 2 (25%) 9.2 (4.0) 8.0 (2.5) -1.2 (-3.7 to 1.3) 0.29 0.2 (0.5) 
Body Cell Mass (%)        
Normal oral 4 (44%) 5 (56%) 36.0 (5.1) 37.6 (9.9) 1.6 (-5.6 to 8.8) 0.61 01 (1.7) 
Modified diet 5 (63%) 3 (37%) 37.0 (5.4) 37.3 (5.6) 0.3 (-2.2 to 2.9) 0.77 0.4 (1.0) 
Table 3.11.  Sensitivity stratified analyses of selected body composition by normal oral vs. modified diet 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Muscle Mass (%)        
Normal oral 5 (63%) 3 (37%) 30.6 (6.3) 31.7 (8.9) 1.1 (-4.6 to 6.8) 0.66 0.1 (1.7) 
Modified diet 6 (75%) 2 (25%) 30.8 (6.0) 29.5 (5.2) -1.3 (-4.2 to 1.5)  0.31 0.3 (1.0) 
Table 3.11.  Sensitivity stratified analyses of selected body composition mean daily changes by percentages of body weight for normal oral diet and 
modified diet for patients and whom duration between admission and discharge MF-BIA test was ≥48 hours 
 
Muscle mass (normal oral diet) not normally distributed (Shapiro-Wilk: p=0.001), Median=32.1%, Interquartile range=26.4 to 33.6 % 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Fat Free Mass (%)        
non-NBM 6 (46%) 7 (54%) 65.2 (9.9) 65.9 (10.0) 0.7 (-1.5 to 3.0) 0.49 0.2 (1.2) 
NBM 4 (100%) 0 (0%) 73.1 (8.6) 71.8 (8.3) -1.3 (-9.0 to 6.5) 0.63 1.1 (1.9) 
Fat mass (%)        
non-NBM 8 (62%) 5 (38%) 34.9 (9.9) 34.0 (10.0) -0.9 (-3.2 to 1.5) 0.43 0.3 (1.3) 
NBM 1 (25%) 3 (75%) 26.7 (8.5) 30.0 (9.1) 3.3 (-2.6 to 9.3) 0.17 1.5 (1.6) 
Protein mass (%)        
non-NBM 7 (54%) 6 (46%) 9.3 (3.6) 8.9 (2.6) -0.4 (-2.2 to 1.3) 0.61 <0.1 (0.7) 
NBM 3 (75%) 1 (25%) 8.6 (3.3) 8.1 (3.3) -0.5 (-2.9 to 1.9)  0.54 0.4 (1.4) 
Body Cell Mass (%)        
non-NBM 7 (54%) 6 (46%) 35.4 (5.3) 37.3 (8.8) 1.9 (-3.2 to 7.1) 0.42 0.5 (2.2) 
NBM 2 (50%) 2 (50%) 38.8 (3.8) 41.0 (4.4) 2.2 (-1.4 to 5.7) 0.15 0.9 (1.2) 
Table 3.12.  Sensitivity stratified analyses of selected body composition by non-NBM vs. NBM, continued 
        
        
  
167 
 
 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Muscle Mass (%)        
non-NBM 7 (54%) 6 (46%) 29.7 (6.7) 38.7 (31.4) 9.0 (-10.8 to 28.9) 0.34 3.0 (10.9) 
NBM 3 (75%) 1 (25%) 32.1 (2.5) 31.5 (5.0) -0.6 (-5.4 to 4.3)  0.74 0.5 (1.4) 
Table 3.12.  Sensitivity stratified analyses of selected body composition mean daily changes by percentages of body weight for nil-by-mouth (NBM) 
and non-NBM diet for patients and whom duration between admission and discharge MF-BIA test was ≥48 hours 
 
Fat mass discharge (NBM) not normally distributed (Shapiro-Wilk: p=0.01), Median=30.6%, Interquartile range=22.0 to 31.4% 
Body cell mass discharge (non-NBM) not normally distributed (Shapiro-Wilk: p=0.01), Median=35.9 %, Interquartile range=31.1 to 38.0 % 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change 
kg/day 
Fat Free Mass (%)        
non-TACI 8 (57%) 6 (43%) 66.7 (11.0) 67.1 (10.7)  0.4 (-1.9 to 2.7) 0.72 0.1 (1.6) 
TACI 2 (67%) 1 (33%) 68.7 (2.8) 68.3 (2.9) -0.4 (-10.7 to 9.9) 0.87 <0.1 (0.6) 
Fat mass (%)        
non-TACI 8 (57%) 6 (43%) 33.3 (11.0) 32.9 (10.7) -0.4 (-2.8 to 2.0) 0.72 0.1 (1.7) 
TACI 1 (33%) 2 (67%) 31.2 (3.0) 33.7 (1.7) 2.5 (-6.6 to 11.7) 0.35 0.1 (0.9) 
Protein mass (%)        
non-TACI 7 (50%) 7 (50%) 8.6 (3.6) 8.2 (2.8) -0.4 (-2.0 to 1.2) 0.62 <0.1 (0.8) 
TACI 3 (100%) 0 (0%) 11.4 (0.6) 10.7 (1.2) -0.7 (-4.0 to 2.6) 0.46 0.1 (0.2) 
Body Cell Mass (%)        
non-TACI 7 (50%) 7 (50%) 36.0 (5.6) 37.4 (8.6) 2.8 (-1.9 to 7.3) 0.45 0.8 (2.1) 
TACI 2 (67%) 1 (33%) 38.7 (1.3) 37.5 (2.8) -1.1 (-10.7 to 8.4) 0.66 0.1 (0.5) 
Table 3.13.  Sensitivity stratified analyses of selected body composition by type of stroke, continued 
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 Participants 
with body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission (kg) Discharge (kg) mean difference 
(95% CI) kg 
p-value Change 
kg/day 
Muscle Mass (%)        
non-TACI 7 (54%) 6 (46%) 29.9 (6.3) 30.0 (7.8) 0.1 (-3.3 to 3.6) 0.93 0.1 (1.3) 
TACI 2 (67%) 1 (33%) 34.1 (1.2) 32.9 (2.6) -1.2 (-9.8 to 7.5) 0.62 0.1 (0.4) 
Table 3.13.   Stratified analyses of selected body composition mean daily changes by percentages of body weight for patients with TACI vs. non-TACI 
stroke sub classification and whom duration between admission and discharge MF-BIA test was ≥48 hours. 
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 Participants with 
body 
composition loss 
(%) 
Participants with 
body 
composition 
gain (%) 
Admission 
(kg) 
Discharge 
(kg) 
mean difference 
(95% CI) kg 
p-value Change rate kg/day 
Fat Free Mass (%)        
NIHSS score <10 5 (50%) 5 (50%) 64.7 (10.9) 65.1 (10.1) 0.4 (-2.8 to 3.6) 0.79 0.1 (1.5) 
NIHSS score ≥10 3 (75%) 1 (25%) 66.8 (6.6) 66.1 (6.9) -0.7 (-8.1 to 6.7) 0.78 0.7 (2.0) 
Fat mass (%)        
NIHSS score <10 5 (50%) 5 (50%) 35.4 (10.8) 34.8 (10.2) -0.6 (-4.0 to 2.7) 0.69 0.2 (1.6) 
NIHSS score ≥10 2 (50%) 2 (50%) 33.0 (6.7) 35.7 (5.8) 2.7 (-3.5 to 8.9) 0.26 1.0 (1.9) 
Protein mass (%)        
NIHSS score <10 5 (50%) 5 (50%) 7.7 (3.2) 8.2 (3.3) 0.5 (-0.7 to 1.7) 0.38 0.3 (0.6) 
NIHSS score ≥10 3 (75%) 1 (25%) 10.2 (1.1) 9.8 (1.9) -0.4 (-3.0 to 2.1) 0.61 0.3 (0.7) 
Body Cell Mass (%)        
NIHSS score <10 5 (50%) 5 (50%) 34.9 (5.6) 36.3 (7.2) 1.3 (-3.3 to 5.9) 0.53 0.6 (2.1) 
NIHSS score ≥10 1 (25%) 3 (75%) 36.4 (3.3) 43.9 (11.7) 7.5 (-11.4 to 18.2) 0.22 1.8 (1.7) 
Table 3.14.  Sensitivity stratified analyses of selected body composition by stroke severity, continued 
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 Participants with 
body composition 
loss (%) 
Participants with 
body 
composition gain 
(%) 
Admission (kg) Discharge 
(kg) 
mean difference 
(95% CI) kg 
p-value Change rate 
kg/day 
Muscle Mass (%)        
NIHSS score <10 6 (67%) 3 (33%) 29.1 (6.3) 28.7 (6.0) 0.4 (-2.0 to 1.2) 0.61 <0.1 (0.6) 
NIHSS score ≥10 2 (50%) 2 (50%) 30.4 (4.0) 33.8 (11.5) 3.4 (-11.4 to 18.2) 0.52 0.2 (2.2) 
Table 3.14.  Stratified analyses of selected body composition mean daily changes by percentages of body weight for patients with National Institute of 
Health Stroke Severity Score (NIHSS) of  NIHSS<10 vs. NIHSS≥10 and whom duration between admission and discharge MF- 
 
  
172 
 
 
Mean 
difference 95% CI p-value 
Fat Free Mass (%)    
  Men vs. Women -0.8 -5.2 to 3.6 0.71 
  Normal Oral Diet vs. Modified diet 0.5 -4.0 to 4.7 0.80 
  non-nil by mouth vs. NBM 2.1 -2.8 to 6.9  0.38 
  non-TACI vs. TACI 0.8 -4.7 to 6.3 0.75 
  NIHSS<10 vs. NIHSS≥10 1.1 -4.7 to 6.9 0.69 
Fat Mass (%)    
 Men vs. Women  1.6 -3.0 to 6.2 0.46 
 Normal Oral Diet vs. Modified diet -1.9 -2.5 to 6.2 0.37 
 non-nil by mouth vs. NBM -4.2 -0.5 to 8.9 0.08 
 non-TACI vs. TACI -3.0 -2.6 to 8.6 0.28 
 NIHSS<10 vs. NIHSS≥10 -3.3 -2.4 to 9.1 0.23 
Protein Mass (%)    
 Men vs. Women -0.8 -3.7 to 2.0 0.55 
 Normal Oral Diet vs. Modified diet 1.5  -1.2 to 4.1 0.26 
 non-nil by mouth vs. NBM 0.1 -3.2 to 3.3  0.96 
 non-TACI vs. TACI 0.3 -3.3 to 3.9 0.85 
 N NIHSS<10 vs. NIHSS≥10 0.9 -1.1 to 3.0 0.36 
Muscle Mass (%)    
  Men vs. Women 1.3 -5.0 to 7.7 0.67 
 Normal Oral Diet vs. Modified diet 2.4 -3.3 to 8.2 0.38 
 non-nil by mouth vs. NBM 0.6 -6.2 to 7.4 0.86 
 non-TACI vs. TACI 1.3 -6.2 to 8.9 0.71 
 NIHSS<10 vs. NIHSS≥10 -3.8 -10.6 to 3.1 0.48 
Table 3.15.  Sensitivity analysis mean difference, continued 
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Mean 
difference 95% CI p-value 
Body Cell Mass (%)    
 Men vs. Women -0.2   -7.8 to 7.3 0.95 
 Normal Oral Diet vs. Modified diet  3.2 -4.6 to 11.0 0.40 
 non-nil by mouth vs. NBM -1.6 -9.6 to 6.1 0.67 
 non-TACI vs. TACI  2.6 -6.2 to 11.4 0.54 
 NIHSS<10 vs. NIHSS≥10 -8.2 -15.8 to 3.4 0.20 
Table 3.15.  Presents the mean difference and their 95% Confidence intervals between 
selected body composition changes (as percentages of body weight) for men vs. 
women, normal oral vs. modified diet, non-NBM vs. NBM, non-TACI vs. TACI 
stroke classification, and  NIHSS <10 vs. NIHSS≥10 scores groups, and whom 
duration between admission and discharge MF-BIA test was ≥48 hours 
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3.4.5 Objective outcomes  
 
Of the 40 participants 29 were discharged to home, seven discharged to rehabilitation, 
two died during acute stay, and two transferred to another hospital (at city of usual 
residence).   
 
Statistically significant changes between admission and discharge were observed for 
patients with fat free mass loses discharged to home, but no statistically significant 
changes in fat free mass loss occurred among patient discharged to rehabilitation or died 
(n=2) during hospital stay (referred to as poor outcomes).  Table 3.16 presents mean fat 
free mass, protein mass, muscle mass, and body cell mass losses and fat mass gains on 
admission and discharge and their mean change between admission and discharge per 
group.    
 
As opposed to patients discharged to home, muscle mass loss was statistically 
significant among patients with poor outcomes.  Table 3.17 shows average differences 
in fat free mass, protein mass, muscle mass, and body cell mass losses and fat mass 
gains between participants discharged to home and those discharge to rehabilitation or 
dead at discharge.   
 
The result of the linear regression analysis examining the relationship between fat free 
mass, protein mass, muscle mass, and body cell mass losses and fat mass gain impact on 
length of hospital stay found no statistically significant relationships.  Table 3.18 
presents the results of the linear regression analysis for the impact of fat free mass, 
protein mass, muscle mass, and body cell mass losses and fat mass gains on length of 
hospital stay.   
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Sensitivity analysis by discharge destination after excluding all participant where the 
duration between admission and discharge MF-BIA test was <48 hour stratified analysis 
for body composition change on admission and discharge for patients discharged to 
home and those discharged to rehabilitation or died during acute hospital stay are 
presented in Table 3.19.   There were no statistically significant differences.   
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 Participants with 
body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission 
(kg) Discharge (kg) 
average change 
(95% CI) kg p-value 
Change rate 
kg/day 
Fat Free Mass (kg)        
Discharge to Home 17 (58.6%) 12 (41.4%) 53.6 (9.8) 52.9 (9.4) -0.7 (-1.4 to 0.0) 0.05 0.3 (0.7) 
Discharge to Rehabilitation or death 2 (22.2%) 7 (77.8%) 46.2 (7.0) 45.1 (6.6) -1.1 (-2.5 to 0.2) 0.1 0.3 (0.5) 
Fat mass (kg)        
Discharge to Home 12 (41.4%) 17 (58.6%) 25.9 (9.1) 26.3 (9.4) 0.4 (-0.3 to 1.1) 0.2 0.2 (0.8) 
Discharge to Rehabilitation or death 3 (33.3%) 6 (66.7%) 26.9 (13.3) 27.8 (13.1) 0.8 (-0.8 to 2.4) 0.3 0.3 (0.5) 
Protein mass (kg)        
Discharge to Home 19 (65.5%) 9 (35.5%) 8.1 (2.6) 7.8 (2.8) -0.4 (-0.9 to 0.2) 0.2 0.2 (0.6) 
Discharge to Rehabilitation or death 7 (77.8%) 2 (22.2%) 5.4 (2.5) 4.8 (2.2) -0.6 (-1.1 to 0.1) 0.08 0.2 (0.2) 
Body Cell Mass (kg)        
Discharge to Home 17 (58.6%) 12 (41.4%) 30.1 (8.1) 28.5 (6.5) -1.8 (-4.5 to 1.2) 0.3 1.4 (6.4) 
Discharge to Rehabilitation or death 6 (66.7%) 3 (33.3%) 25.1 (4.2) 24.8 (4.9) -0.3 (-1.7 to 1.1) 0.7 0.1 (0.5) 
Table 3.16.  Selected body composition changes by discharge destination, continued 
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Participants with 
body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission 
(kg) Discharge (kg) 
average change 
(95% CI) kg p-value 
Change rate 
kg/day 
Muscle Mass (kg)        
Discharge to Home 16 (55.2%) 12 (44.8%) 24.2 (5.7) 23.9 (6.6) -0.3 (-1.5 to 0.8) 0.6 0.3 (1.0) 
Discharge to Rehabilitation or death 7 (77.8%) 2 (22.2%) 19.8 (4.4) 18.7 (4.4) -1.0 (-2.1 to 0.0) 0.05 0.3 (0.4) 
Table 3.16.   Presents difference in body composition changes between admission and discharge for patients by the outcome categories of discharged to 
home and patients discharge to rehabilitation or were dead on discharge. *n=38 two patients were excluded for this outcome as they were transferred to 
another hospital (at area of residence) making it not possible to carry out a discharge MF-BIA measurement.  n=37 for MM and PM measurements as 
equipment failed to record MM and PM at discharge for one patient discharged to home.  
 
Body cell mass admission (home discharge) not normally distributed (Shapiro-Wilk: p<0.0001), Median= 27.9 g, Interquartile range=24.7 to 33.3 g 
Body cell mass (home discharge) not normally distributed (Shapiro-Wilk: p=0.02), Median=27.0 g, Interquartile range=23.9 to 31.2 g 
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 mean difference 95% Confidence Intervals p-value 
Fat Free Mass (kg) 0.4 -1.0 to 1.8 0.6 
Fat Mass (kg) -0.4 -1.9 to 1.1 0.6 
Protein Mass (kg) 0.2 -0.9 to 1.2 0.7 
Muscle Mass (kg) 0.7 -1.4 to 2.8 0.5 
Body Cell Mass (kg) -1.4 -6.5 to 3.8 0.6 
Table 3.17.   Mean differences in fat free mass, protein mass, muscle mass, and body cell mass losses and fat mass gains between participants 
discharged to home and those discharge to rehabilitation or dead at discharge. 
 
 
 
 
 
 
 
 
 
  
179 
 
 Length of Hospital Stay 
 OR 95% Confidence Interval p-value 
Fat Free Mass loss (kg) -0.36 -19.3 to 7.9 0.87 
Fat Mass Gain (kg) -0.27 -0.37 to 0.081 0.17 
Protein mass loss (kg)  0.34 -0.26 to 0.37 0.74 
Muscle mass loss (kg)  0.076 -0.11 to 0.15 0.72 
Body Cell Mass loss (kg)  0.024 -0.033 to 0.0.65 0.51 
Table 3.18.   Linear regression analysis results for the impact of fat free mass, protein mass, muscle mass, and body cell mass losses and fat mass gains 
on length of hospital stay. 
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 Participants with 
body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission 
(kg) Discharge (kg) 
mean difference 
(95% CI) kg 
p-
value 
Change 
rate 
kg/day 
Fat Free Mass (%)        
Discharge to Home 5 (63%) 3 (37%) 68.2 (5.4) 67.8 (4.8) -0.4 (-2.6 to 1.9) 0.72 0.4 (2.7) 
Discharge to Rehabilitation or death 3 (60%) 2 (40%) 64.3 (12.8) 63.6 (12.1) -0.7 (-4.1 to 2.6) 0.61 0.6 (1.5) 
Fat mass (%)        
Discharge to Home 3 (37%) 5 (63%) 31.9 (5.4) 32.1 (4.7) 0.3 (-2.0 to 2.4) 0.81 0.2 (2.6) 
Discharge to Rehabilitation or death 3 (43%) 4 (57%) 35.6 (12.8) 37.5 (11.6) 1.9 (-1.2 to 5.0) 0.18 0.9 (1.4) 
Protein mass (%)        
Discharge to Home 4 (50%) 4 (50%) 10.4 (1.4) 10.3 (1.4) -0.1 (-1.6 to 1.4) 0.87 0.1 (1.8) 
Discharge to Rehabilitation or death 4 (57%) 3 (43%) 7.0 (3.2) 6.7 (3.0) -0.3 (-1.3 to 0.7) 0.48 0.2 (0.5) 
Body Cell Mass (%)        
Discharge to Home 5 (63%) 3 (37%) 37.1 (3.4) 38.8 (8.8) 1.6 (-5.6 to 6.8) 0.62 1.6 (8.6) 
Discharge to Rehabilitation or death 2 (29%) 5 (71%) 34.5 (6.6) 35.7 (7.3) -1.2 (-0.7 to 3.1) 0.17 0.5 (1.0) 
Table 3.19.  Sensitivity stratified analyses of selected body composition changes by discharge destination 
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 Participants with 
body 
composition 
loss (%) 
Participants 
with body 
composition 
gain (%) 
Admission 
(kg) Discharge (kg) 
mean difference 
(95% CI) kg 
p-
value 
Change 
rate 
kg/day 
Muscle Mass (%)        
Discharge to Home 5 (63%) 3 (37%) 32.2 (3.8) 33.3 (7.1) 1.1 (-5.6 to 8.8) 0.66 1.1 (6.8) 
Discharge to Rehabilitation or death 3 (43%) 4 (57%) 27.4 (6.1) 27.0 (6.6) -0.4 (-2.4 to 1.7) 0.68 0.3 (1.0) 
Table 3.19.  Sensitivity stratified analyses of selected body composition mean daily changes by percentages of body weight for patients discharge to 
home vs. discharge to rehabilitation or dead and whom duration between admission and discharge MF-BIA test was ≥48 
 
Muscle mass discharge (home) not normally distributed (Shapiro-Wilk: p=0.02), Median=32.16%, Interquartile range=30.2 to 33.6% 
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3.4.6 Subjective outcomes  
 
Eighteen study participants responded to follow up questionnaire of which 10 were men 
and eight were women.  Mean age was 69.1±9.7 years (range = 50-89 years).  Their 
average length of hospital stay was 3.4 day (range 1-8 days), and average NIHSS score 
was 5.9 (range 1-21).  Six of the participant had Lacunar Infarct (LACI), one participant 
Partial Anterior Circulation Infarct (PACI), seven had Posterior Circulation Infarct 
(POCI), and four total anterior Circulation Infarct (TACI).  One participant was 
prescribed nil-by-mouth (NBM) during acute stay, 16 normal oral feeding, and one on 
pureed diet.  On discharge 14 were discharged to home, three to rehabilitation, and one 
initially transferred to another hospital.   There was statistically significant difference 
between discharge weight of those who responded compared to those who did not 
respond (non-respondents) with non-respondents weight being less than those who 
responded.  Table 3.20 shows characteristics of those who responded to follow up 
questionnaire and those who did not.  There were no statistically significant differences 
except the discharge weight; those who did not respond has significantly lower weight 
at the time of discharge compared to those who  responded.   
 
There were no statistically significant differences between those with fat free mass loss 
and gain in the SF36v2 scores.  Similar observation was made with respect to fat mass 
gain and loss.  No statistically significant difference was observed in the SF-36v2 
individual component scores for patients with protein mass loss or gain.  Body cell mass 
and muscles mass scores were similar with no statistically significant differences 
between each individual component scores.  Table 3.21 a-e present the SF36v2 items 
scores for patients with fat free mass, fat mass, protein mass, muscle mass, and body 
cell mass loos and gain with the average differences between groups and p-values.    
 
 
 
 
  
183 
 
Respondents Non-respondent p-value 
Number 18 (45%) 22 (55%)  
Females (%) 8 (44%)   
Mean age (std) years 69.1 (9.7) 71.3 (10.1) 0.64 
Age Range (years) 50-89 56-89  
Weight (kg)  82.6 (13.2) 70.6 (13.3) 0.02 
Height (m) 1.7 (0.1) 1.7 (0.1) 0.40 
Body Mass Index  (kg/m2) 27.9 (4.9) 25.4 (4.5) 0.11 
Triceps Skin Fold thickness (mm) 10.7 (3.3) 11.9 (4.3) 0.34 
Mid Arm  Circumference (cm) 30.1 (3.5) 27.6 (4.8) 0.08 
Handgrip Strength (kg)   23.8 (9.1) 18.5 (13.4) 0.18 
Average length of Hospital say  (range) 
days 
3.4 (1-8) 4.6 (1-24) 0.33 
Premorbid Rankin Score (n=38)   0.21 
0 =No symptoms 11 9  
1 =No significant disability 6 8  
2 = Slight disability.  0 2  
3 = Moderate disability.  0 1  
4 = Moderately severe disability 0 0  
5 =Severe disability 0 0  
Total Anterior Circulation Infarct 4 2  
                Left Side 2 2  
                Right Side 2 0  
Partial Anterior Circulation Infarct 4 4  
                Left Side 3 1  
                Right Side 1 3  
Lacunar Infarct 6 11  
                Left Side 5 5  
                Right Side 1 6  
Posterior Circulation Infarct 7 5  
                   Left Side 3 2  
                   Right Side 4 3  
NIHSS Score (n=35) categories   0.37 
           1 to 9 (mild stroke) 14 16  
           10 to 20 (moderate stroke) 1 2  
           ≥20 (severe stroke) 1 0  
Type of Feeding Regeimen     
Normal Oral 16 13  
Soft/mashed  0 4  
Pureed 1 1  
Nil-by-Mouth (NBM) 1 4  
Table 3.20 presents the  characteristics of participants who responded to follow up 
questionnaire and those who did not respond.  
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Participants with 
FFM Loss (n=6) 
mean score 
Participant with 
FFM Gain 
(n=10)mean score 
Mean difference (95% CI) p-value 
Fat Free Mass      
Physical Functioning 39 (23.4 to 55.4) 38.7 (23.4 to 57.0) 0.25 (-13.2 to 13.8) 0.97 
Role Physical 38.5 (17.7 to  56.9) 36.9 (22.6 to 47.1) 1.63 (-12.5 to 15.7) 0.81 
Bodily Pain 44.7 (29.2 to 62.1) 55.2 (37.2 to 62.1) 10.6 (-2.1 to 23.2) 0.09 
General Health 45.8 (33.9 to 60.1) 45.0 (37.2 to 62.1) 0.80 (-7.5 to 9.2) 0.84 
Vitality 44.6 (20.9 to 58.3) 42.2 (30.2 to 52.1) 2.40 (-9.6 to 14.4) 0.68 
Social Functioning 44.3 (18.7 to 56.9) 37.7 (13.2 to 56.9) 6.5 (-9.4 to 22.5) 0.39 
Role Emotional 37.3 (9.2 to 55.9) 44.2 (32.5 to 55.9) 8.3 (-11.0 to 24.9) 0.42 
Mental Health 48.4 (19.0 to 58.5) 43 (21.9 to 58.5) 5.4 (-9.6 to 20.4) 0.45 
Table 3.21a.  Short Form Survey (SF36v2) mean scores for patients experiencing fat free mass (FFM) loss and gain respectively and the mean 
difference between both groups of patients who responded to follow up at 6 month post hospital discharge. 
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Participants with 
FM Loss (n=7) 
mean score 
Participants with 
FM Gain 
(n=9)mean score 
Mean difference (95% CI) p-value 
Fat Mass      
Physical Functioning 36.5 (23.4 to 57.0) 40.7 (23.4 to 55.4) 4.2 (-8.8 to 17.1) 0.50 
Role Physical 34.1 (17.7 to 47.1) 40.8 (17.7 to  56.9)  6.7 (-6.5 to 19.9) 0.29 
Bodily Pain 55 (37.2 to 62.1) 43.7 (29.2 to 62.1) 5.5 (-0.52 to 23.2) 0.06 
General Health 45.4 (38.6 to 55.3) 45.6 (33.9 to 60.1) 0.11 (-8.1 to 8.3) 0.98 
Vitality 43.2 (30.2 to 52.1) 44.1 (20.9 to 58.3) 1.0 (-10.9 to 12.7) 0.87 
Social Functioning 36.6 (13.2 to 56.9) 45.9 (18.7 to 56.9) 9.3 (-5.7 to 24.4) 0.20 
Role Emotional 39.2 (9.2 to 55.9) 40.8 (9.2 to 55.9) 1.6 (-16.5 to 19.7) 0.85 
Mental Health 44 (21.9 to 58.5) 48.2 (19.0 to 58.5) 4.2 (-10.5 to 19.0) 0.55 
Table 3.21b.  Short Form Survey (SF36v2) mean scores for patients experiencing fat mass (FM) loss and gain respectively and the mean difference 
between both groups of patients who responded to follow up at 6 month post hospital discharge. 
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Participants with 
PM Loss (n=5) 
mean score 
Participants with 
PM Gain 
(n=11)mean score 
Mean difference (95% CI) p-value 
Protein Mass      
Physical Functioning 39.7 (23.4 to 57.0) 37 (23.4 to 48.1) 2.7 (-11.4 to 16.7) 0.69 
Role Physical 40.8 (17.7 to 56.9) 31.4 (17.7 to 56.9) 9.4 (-4.3 to 23.1) 0.16 
Bodily Pain 49.9 (29.2 to 62.1) 45.7 (37.2 to 53.7) 4.2 (-6.5 to 14.9) 0.54 
General Health 44.7 (33.9 to 60.10 47.2 (38.6 to 55.3) 2.5 (-11.1 to 6.1) 0.55 
Vitality 44.7 (20.9 to 58.3) 41.5 (27.1 to 49.0) 3.2 (-9.3 to 18.7) 0.54 
Social Functioning 45.5 (18.7 to 56.9) 33.9 (13.2 to 45.9) 11.5 (-4.3 to 27.3) 0.14 
Role Emotional 41.9 (9.2 to 55.9) 36.4 (9.2 to 55.9) 5.4 (-13.4 to 24.3) 0.54 
Mental Health 45.7 (19.0 to 58.5) 47.7 (30.3 to 58.5) 2.0 (-18.0 to 13.9) 0.79 
Table 3.21c.  Short Form Survey (SF36v2) mean scores for patients experiencing protein mass (PM) loss and gain respectively and the mean difference 
between both groups of patients who responded to follow up at 6 month post hospital discharge. 
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Participants with 
BCM Loss 
(n=6) mean score 
Participants with 
BCM Gain 
(n=10)mean score 
Mean difference (95% CI) p-value 
Body Cell Mass     
Physical Functioning 39.2 (23.4 to 57.0 ) 38.3 (23.4 to 52.8) 0.95 (-12.6 to 14.4) 0.88 
Role Physical 38 (17.7 to 56.9) 37.7 (17.7 to 56.9) 0.33 (-13.8 to 14.4) 0.96 
Bodily Pain 47.9 (29.2 to 62.1) 49.8 (29.2 to 62.1) 1.9 (-11.9 to 15.7) 0.78 
General Health 43.4 (33.9 to 60.1) 50 (38.6 to 55.3) 5.5 (-2.2 to 13.3) 0.15 
Vitality 43 (20.9 to 58.3) 44.8 (33.4 to 52.1) 1.8 (-10.3 to 13.8) 0.76 
Social Functioning 45.4 (18.7 to 56.9) 36 (13.2 to 51.4) 9.5 (-6.0 to 24.9) 0.21 
Role Emotional 39.9 (9.2 to 55.9) 40.3 (9.2 to 55.9) 0.43 (-18.0 to 18.8) 0.96 
Mental Health 43.3 (19.0 to 58.5) 51.4 (35.9 to 58.5) 8.1 (-4.6 to 20.8) 0.19 
Table 3.21d.  Short Form Survey (SF36v2) mean scores for patients experiencing body cell mass (BCM) loss and gain respectively and the mean 
difference between both groups of patients who responded to follow up at 6 month post hospital discharge. 
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Participants with 
MM Loss 
(n=6) mean score 
Participants with 
MM Gain 
(n=10)mean score 
Mean difference (95% CI) p-value 
Muscle Mass     
Physical Functioning 39.2 (23.4 to 57.0 ) 38.3 (23.4 to 52.8) 0.95 (-12.6 to 14.4) 0.88 
Role Physical 38 (17.7 to 56.9) 37.7 (17.7 to 56.9) 0.33 (-13.8 to 14.4) 0.96 
Bodily Pain 47.9 (29.2 to 62.1) 49.8 (29.2 to 62.1) 1.9 (-11.9 to 15.7) 0.78 
General Health 43.4 (33.9 to 60.1) 50 (38.6 to 55.3) 5.5 (-2.2 to 13.3) 0.15 
Vitality 43 (20.9 to 58.3) 44.8 (33.4 to 52.1) 1.8 (-10.3 to 13.8) 0.76 
Social Functioning 45.4 (18.7 to 56.9) 36 (13.2 to 51.4) 9.5 (-6.0 to 24.9) 0.21 
Role Emotional 39.9 (9.2 to 55.9) 40.3 (9.2 to 55.9) 0.43 (-18.0 to 18.8) 0.96 
Mental Health 43.3 (19.0 to 58.5) 51.4 (35.9 to 58.5) 8.1 (-4.6 to 20.8) 0.19 
Table 3.21e.  Short Form Survey (SF36v2) mean scores for patients experiencing muscle mass (MM) loss and gain respectively and the mean 
difference between both groups of patients who responded to follow up at 6 month post hospital discharge. 
  
  
189 
 
No statistically significant mean differences in each of the stroke impact scale domain 
scores were observed between participants with fat free mass, fat mass, protein mass, 
muscle mass, and body cell mass losses and gains at 6 months post discharge.   Table 
3.21a-e present the stroke impact scale items scores for participants with fat free mass, 
fat mass, protein mass, muscle mass, and body cell mass losses and gains who provide a 
response at 6 months post discharge. 
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Average scores 
Participants with 
FFM loss mean score 
Participants with 
FFM gain mean 
score 
Mean difference (95% CI) p-value 
Fat Free Mass      
Strength SIS*  83.3 (56.3 to 100) 68.8 (31.3 to 100) 14.6 (-24.2 to 53.4) 0.38 
Memory SIS** 80 (42.9 to 100) 74.5 (39.3 to 100) 5.5 (-16.9 to 28.0) 0.61 
Emotion SIS 66.7 (22.2 to 94.4) 64.2 (44.4 to 83.3) 2.4 (-20.7 to 25.5) 0.83 
Communication SIS*** 89 (57.1 to 100) 90.3 (67.9 to 100) 1.4 (-16.3 to 13.6) 0.85 
Activities of Daily living£ 80.3 (50 to 100) 85.0 (52.5 to 100) 4.7 (-15.3 to 24.7) 0.62 
Mobility SIS# 79.3 (36.1 to 100) 85.7 (66.7 to 100) 6.4 (-14.5 to 27.2) 0.53 
Hand Function SIS** 82.5 (65.6 to 100) 72.1 (0.00 to 100) 10.4 (-26.2 to 46.9) 0.53 
Social Participation SIS x 91.1 (65.6 to 100) 90.6 (81.3 to 57.0) 0.5 (-27.0 to 28.1)  0.97 
Table 3.22a.  Stroke Impact Scale Score (SIS) mean scores for patients experiencing fat free mass (FFM) loss and gain respectively and the mean difference 
between both groups of patients who responded to follow up at 6 month post hospital discharge. 
 
 
*Loss n=9, Gain n=5; ** Loss n=10, Gain=7;*** Loss n=11, Gain n=7; £ Gain n=8, Loss n=7; # Loss n=11, Loss n=6; x Gain n=6, Loss n=2.   
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Average scores Participants with FM 
loss mean score 
Participants with 
FM gain mean 
score 
Mean difference (95% CI) p-value 
Fat Mass     
 
Strength SIS*  68.8 (31.3 to 100) 85.2 (56.3 to 100) 16.4 (-10.1 to 42.9) 0.20 
Memory SIS** 71.9 (39.3 to 100) 83 (42.9 to 100) 11.1 (-10.4 to 32.6) 0.29 
Emotion SIS 66.3 (44.4 to 83.3) 65.1 (22.2 to 94.4) 1.2 (-24.0 to 21.6) 0.91 
Communication SIS*** 86.2 (57.1 to 100) 92.1 (60.7 to 100) 6.0 (-8.3 to 20.3) 0.39 
Activities of Daily living£ 81.3 (52.5 to 100) 83.9 (50 to 100) 2.7 (-17.4 to 22.8) 0.78 
Mobility SIS# 78.6 (36.1 to 100) 83.6 (52.8 to 100) 5.0 (-15.3 to 25.4) 0.61 
Hand Function SIS** 72.5 (0.00 to 100) 83.3 (40 to 100) 10.8 (-18.7 to 40.4) 0.45 
Social Participation SIS x 88.5 (81.3 to 100)  92.5 (65.6 to 100) 4.0 (-20.4 to 28.3) 0.70 
Table 3.22b.  Stroke Impact Scale Score (SIS) mean scores for patients experiencing fat mass (FM) loss and gain respectively and the mean difference 
between both groups of patients who responded to follow up at 6 month post hospital discharge  
 
*Loss n=6 Gain n=8; ** Loss n=8, Gain=9;*** Loss n=8, Gain=10; £ Gain n=8, Loss n=7; # Loss n=7, Loss n=10; x Gain n=3, Loss n=5 
  
 
  
192 
 
Average scores 
Participant with PM 
 loss mean score 
Participant with PM gain 
 mean score 
Mean difference (95% CI) p-value 
Protein Mass     
Strength SIS*  80 (31.3 to 100) 73.5 (37.5 to 100) 6.6 (-24.3 to 37.4) 0.65 
Memory SIS** 83.1 (39.3 to 100) 67.9 (53.6 to 89.3) 10.2 (-6.5 to 37.0) 0.16 
Emotion SIS 66.7 (27.8 to 94.4) 63.9 (22.2 to 88.9) 2.8 (-21.0 to 26.6) 0.81 
Communication SIS*** 93.8 (60.7 to 100) 81 (57.1 to 100) 12.8 (-1.1 to 26.7) 0.07 
Activities of Daily living£ 83.4 (50.0 to 100) 80 (55.0 to 100) 3.4 (-19.2 to 26.1) 0.75 
Mobility SIS# 85.7 (52.8 to 100) 71.7 (36.1 to 97.2) 14.0 (-6.8 to 34.8) 0.17 
Hand Function SIS# 79.6 (0.00 to 100) 75 (35.0 to 100) 4.6 (-28.3 to 37.5) 0.77 
Social Participation SIS x 91.1 (65.6 to 100) 90.6 (84.4 to 96.9) 0.5 (-27.0 to 28.1) 0.97 
Table 3.22c.  Stroke Impact Scale Score (SIS) mean scores for patients experiencing protein mass (PM) loss and gain respectively and the mean difference 
between both groups of patients who responded to follow up at 6 month post hospital discharge  
 
*Loss n=10 Gain n=4; ** Loss n=11, Gain n=6;*** Loss n=12, Gain=6; £ Gain n=11, Loss n=4; # Loss n=12, Loss n=5; x Gain n=6, Loss n=2 
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Average scores 
Participant with 
BCM loss mean 
score 
Participant with 
BCM gain mean 
score 
Mean difference (95% CI) p-value 
Body Cell Mass     
Strength SIS*  78.9 (37.5 to 100) 77.1 (31.3 to 100) 1.8 (-26.6 30.2) 0.89 
Memory SIS** 77.1 (39.3 to 100) 78.6 (53.6 to 100) 1.4 (-21.2 to 24.1) 0.90 
Emotion SIS 60.3 (22.2 to 94.4) 73.4 (52.8 to 88.9) 13.1 (-8.8 to 35.1) 0.22 
Communication SIS*** 92.5 (60.7 to 100) 84.7 (57.1 to 100) 7.8 (-6.5 to 22.2) 0.26 
Activities of Daily living£ 83.8 (50.0 to 100) 81.1 (52.5 to 100) 2.7 (-17.4 to 22.8) 0.78 
Mobility SIS# 82.1 (52.8 to 100) 80.6 (36.1 to 100) 1.5 (-19.6 to 22.7) 0.88 
Hand Function SIS*** 78.5 (35.0 to 65.6) 77.9 (0.00 to 100) 0.64 (-29.9 to 31.2) 0.97 
Social Participation SIS x 86.7 (65.6 to 100) 95.3 (84.4 to 100) 8.6 (-13.7 to 30.9) 0.38 
Table 3.22d.  Stroke Impact Scale Score (SIS) mean scores for patients experiencing body cell mass (BCM) loss and gain respectively and the mean 
difference between both groups of patients who responded to follow up at 6 month post hospital discharge 
 
*Loss n=8 Gain n=6; ** Loss n=10, Gain n=7;*** Loss n=11, Gain=7; £ Gain n=8, Loss n=7; # Loss n=11, Loss n=6; x Gain n=4, Loss n=4 
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Average scores 
Participant with 
muscle mass loss 
mean score 
Participant with 
muscle mass ain 
mean score 
Mean difference (95% CI) p-value 
Muscle Mass     
Strength SIS*  78.9 (37.5 to 100) 77.1 (31.3 to 100) 1.8 (-26.6 30.2) 0.89 
Memory SIS** 77.1 (39.3 to 100) 78.6 (53.6 to 100) 1.4 (-21.2 to 24.1) 0.90 
Emotion SIS 60.3 (22.2 to 94.4) 73.4 (52.8 to 88.9) 13.1 (-8.8 to 35.1) 0.22 
Communication SIS*** 92.5 (60.7 to 100) 84.7 (57.1 to 100) 7.8 (-6.5 to 22.2) 0.26 
Activities of Daily living£ 83.8 (50.0 to 100) 81.1 (52.5 to 100) 2.7 (-17.4 to 22.8) 0.78 
Mobility SIS# 82.1 (52.8 to 100) 80.6 (36.1 to 100) 1.5 (-19.6 to 22.7) 0.88 
Hand Function SIS*** 78.5 (35.0 to 65.6) 77.9 (0.00 to 100) 0.64 (-29.9 to 31.2) 0.97 
Social Participation SIS x 86.7 (65.6 to 100) 95.3 (84.4 to 100) 8.6 (-13.7 to 30.9) 0.38 
Table 3.22e.  Stroke Impact Scale Score (SIS) mean scores for patients experiencing muscle mass (MM) loss and gain respectively and the mean difference 
between both groups of patients who responded to follow up at 6 month post hospital discharge. 
 
*Loss n=8 Gain n=6; ** Loss n=10, Gain=7;*** Loss n=11, Gain=7; £ Gain n=8, Loss n=7; # Loss n=11, Loss n=6; x Gain n=4, Loss n=4 
  
195 
 
In patients with fat free mass loss SIS overall stroke recovery scores did not show any 
statistical significance differences compared to those with fat free mass gain. Patients 
with fat free mass loss however scored higher in BI scores than patients with fat free 
mass gain.  This was opposite to the findings for the PCS.  MCS scores were higher in 
patients with fat free mass loss.   
 
SIS overall stroke recovery and BI scores were lower in patients with fat mass loss 
compared to fat mass gain with statistical significance (p=0.05).  The PCS were not 
coherent with SIS overall stroke recovery and BI scores.  However, no statistically 
significant difference was observed between the two groups.    
 
The mean difference in the overall SIS stroke recovery for participants with protein 
mass loss and protein mass gain was statistically significant (p=0.02).  A mean 
difference of 0.22 (-33.7 to 33.2) was observed with those having protein mass gains 
mean score being higher than participants with protein mass loss.  The Barthel Index 
scores were higher in patients with protein mass loss compared to those with protein 
mass gain with the PCS following the same trend. Interestingly patients with muscle 
mass loss and body cell mass loss scored higher in the SIS overall patients reported 
stroke recovery and BI compared with patients with body cell mass and muscle mass 
gains (difference muscle mass p=0.05 and difference body cell mass p=0.01).    The 
PCS and MCS scores were marginally different showing no statistically significant 
differences between the two groups.   
 
Table 3.22 shows the differences in the mean scores of Barthel Index Score (BI), Stroke 
Impact Scale (SIS) overall stroke recovery, the SF36v2 Physical Component Summary 
(SF36v2 PCS), and the SF36v2 Mental Component Summary (SF36v2 MCS) scores for 
patients who responded to the six month follow up questionnaire evaluation.    
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Average scores 
Participant with Body 
Composition loss 
Participant with Body 
Composition Gain Mean difference (95% CI) p-value 
Fat Free Mass      
SIS overall  83.3 (30 to 100)  82.0 (4 to 100)  6.9 (-15.4 to 29.1) 0.52 
BI scores 89.7 (60 to 100) 76.4 (50 to 95) 7.7 (-25.6 to 41.1) 0.61 
SF36v2 PCS 41.0 (28.7 to 58.1)  43.5 (33.4 to 59.1)  2.5 (-13.2 to 8.2) 0.62 
SF36v2 MCS 46.1 (14.0 to 68.3) 42.7 (31.7 to 54.9) 3.4 (-11.6 to 18.4) 0.64 
Fat Mass      
SIS overall  70.6 (30 to 95)  90 (70 to 100)  19.4 (-0.11 to 38.9) 0.05 
BI scores 79.3 (4 to 100)  94.67 (25 to 75)  15.4 (-15.5 to 46.4) 0.30 
SF36v2 PCS 42.5 (33.4 to 59.1)  41.6  (28.7 to 58.1)  0.9 (-11.4 to 9.7) 0.86 
SF36v2 MCS 41.8 (31.7 to 54.9)  47.2 (14.0 to 68.3)  6.7 (-19.8 to 9.1) 0.44 
Protein Mass      
SIS overall  85.8 (4 to 100) 86.0 (60 to 100) 0.22 (-33.7 to 33.2) 0.02 
BI scores 87.7 (50 to 100) 64.0 (30 to 90) 23.7 (-2.9 to 50.4) 0.90 
SF36v2 PCS 43.4 (28.7 to 59.1) 38.9 (33.4 to 49.2) 4.5 (-6.5 to 15.5) 0.40 
SF36v2 MCS 45.9 (14.0 to 68.3) 42.4 (36.4 to 51.1) 3.5 (-8.7 to 15.6) 0.64 
Table 3.23.  Follow questionnaire responses mean scores stratified by body composition changes, continued 
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Average scores 
Participant with Body 
Composition loss 
Participant with Body 
Composition Gain Mean difference (95% CI) p-value 
Muscle Mass      
SIS overall  89.5 (70 to 100) 65 (30 to 90) 24.5 (0.7 to 48.3) 0.05 
BI scores 94.8 (75 to 100) 74 (4 to 100) 20.8 (-18.9 to 60.4) 0.24 
SF36v2 PCS 42 (28.7 to 59.1) 41.9 (33.8 to 54.7) 0.15 (-10.7 to 10.9) 0.98 
SF36v2 MCS 44.3 (14.0 to 68.3) 45.7 (31.7 to 56.0) 1.5 (-16.5 to 13.7) 0.84 
Body Cell Mass     
SIS overall  89.5 (70 to 100) 65 (30 to 90) 24.5 (0.7 to 48.3) 0.01 
BI scores 94.8 (75 to 100) 74 (4 to 100) 20.8 (-18.9 to 60.4) 0.24 
SF36v2 PCS 42 (28.7 to 59.1) 41.9 (33.8 to 54.7) 0.15 (-10.7 to 10.9) 0.98 
SF36v2 MCS 44.3 (14.0 to 68.3) 45.7 (31.7 to 56.0) 1.5 (-16.5 to 13.7) 0.84 
Table 3.23. Stroke impact scale (SIS) overall stroke recovery, barthel index, and physical component (PCS) and mental component (MCS) summary 
mean scores for patients experiencing fat free mass, fat mass, protein mass, muscle mass, and body cell mass loss and gains respectively and the mean 
difference between both groups of patients who responded to follow up at 6 month post hospital discharge.   
SIS: Stroke Impact Scale; BI: Barthel Index Score; SF36v2: Short Form Survey 36 version 2
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3.5 Discussion 
 
Although there were observed differences within and between groups in fat free mass 
and body composition changes between normal oral diet vs. Modified diets, non-NBM 
vs. NBM, non-TACI vs. Non-TACI, and NIHSS 1-9 vs. NIHSS≥10, none of these 
difference were statistically significant except for muscle mass losses for modified diet, 
muscle mass and protein mass losses for TACI.   Except for muscle mass loss for 
patients discharged to rehabilitation and fat free mass loss for patients discharged to 
home that were statistically significant (p=0.05), no other statistically significant 
differences in body composition changes were observed between participants 
discharged to home vs. participants discharge to rehabilitation or dead during acute stay.  
 
Those who responded had higher weight on discharge compared to non-responders 
With respect to responses, the only statically significant scores were reported in the SIS 
overall patients reported stroke recovery scores.  They were reflected by higher scores 
observed for participants with fat mass gain compared to those with fat mass loss 
(p=0.05), for participants with muscle mass and body cell mass loss compared to those 
with muscle mass (p=0.05) and body cell mass (p=0.01) gains, and marginally lower 
scores participants with protein mass loss compared to those with participant with 
protein mass gain (p=0.02).  No other results were statically significant.  Most results in 
the subjective outcomes were inconsistent, did  not correlate with the finding that 
suggest loss of lean body mass tissue and gain of fat mass can jeopardize functional 
status and overall activity level (61, 167, 168).   
    
3.5.1 Other studies findings  
 
To the best of my knowledge this is the first study which attempted to understand the 
changes in body composition in acute stroke setting using a portable, validated method. 
With small sample size, I did not find significant results except marginally significant 
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protein mass loss (p=0.06) was observed in the whole sample and also a significant 
muscle mass loss was observed in those who underwent modified diet regimen. This is 
reflected as significantly higher proportion of people who were discharged to a 
rehabilitation setting/died had muscle mass loss compared to proportion of people who 
had muscle mass gain in this group.  
 
Fat free mass, protein mass, muscle mass losses and fat mass gains observed in 
modified diet, NBM, TACI, and NIHSS ≥10  groups can be related to the severity of 
their condition rendering them bedridden, with a heightened stress response and making 
such body composition changes inevitable and this observation is in line with the 
existing evidence. Being inactive and bedridden can contribute to lean tissue mass 
losses (163), and the stress response evident by  increased serum cortisol level in acute 
stroke patients (56) may explain the loss in lean body tissues  (166).  In addition, the 
increased fat mass gain can be related to their inactive bedridden state.   Their use of 
active tissue such as muscles is very minimal which may result in fat tissue 
accumulation and active tissue loss (164, 165).  
 
Smithard et al. (208) examined the effect of nutritional status markers in patients with 
swallowing difficulties and reported a deterioration in anthropometric indices and 
albumin levels over a month period (208).  The decline in upper arm anthropometric 
and serum albumin levels in the Smithard’s study are also seen in the body composition 
changes observed in our study population considering that these measures are used to 
assess lean body tissue (209, 210).  Davalos et al  also reported a similar finding 
showing decline in MAC, TSF, and serum albumin between admission and week one 
and two of hospitalization  (56).   
 
To my knowledge this is first study which assessed the changes in individual body 
components examined as a whole perhaps more accurately than regional anthropometric 
measures.  The regional anthropometric measurements require some training. The lack 
of reproducibility of TSF due to margin of error between measurements makes the 
validity of this method questionable (175).  MAC utility in assessing whole body 
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composition of fat free mass is also questionable.  MAC is a localized measure to 
evaluate arm muscle area and thus unlikely to represent whole body lean mass tissue 
(178).  Including serum albumin in assessing protein malnutrition is limited by the fact 
it is influenced by intake and loss (e.g. proteinuria) (80, 81).   
 
3.5.2 Study Limitations 
 
The main limitation of my study is the relatively small sample size. This in combination 
with requirement to analyse the data by feeding regimen or categorisation by other 
characteristics such as stroke severity made the sample even smaller to make any firm 
conclusions. Nevertheless, I have shown that patients with stroke on modified diet, 
NBM feeding regimen, and patients with TACI had consistent body composition 
changes with the majority experiencing fat free mass loss, fat mass gain, and muscle 
mass, and protein mass losses.   
 
The length of hospital stay was not long enough to observe statistically significant 
changes across all examined body composition indices (mean 3.9, range 1-24 days) only 
three patients had a length of hospital stay ≥10 days (11, 12, and 24 days respectively).  
This is due to development of stroke services locally with extra bed capacity for acute 
rehabilitation in the community had impact on the patient flow and hence length of stay 
in acute unit situated at the main hospital site had become much shorter during the study 
data collection period compared to the study protocol development stage. 
 
Objective outcomes in the form of discharge destination or death did not provide a 
statically significant interpretation although higher frequency of those discharged to 
rehabilitation services or those who died experienced fat free mass loss and fat mass 
gain compared to those discharge to home.  Given that even in stroke patients on normal 
oral diet showed changes in their body composition during their acute hospital stay, 
MF-BIA may be used to tailor the individual nutritional needs in severe strokes which 
are associated with immobilization and swallowing difficulty. Whether such targeted 
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nutritional assessment and appropriate nutritional support would be associated with 
clinical and cost effectiveness need to be tested in a randomised trial setting. Whether 
particular type of nutritional supplementation is better than other may also require 
investigation.  
 
3.5.3 Conclusion and future research:  
 
Consistent results of fat free mass loss, fat mass gain, and protein mass, muscles mass, 
and body cell mass losses were only observed in patient with NBM feeding regimen and 
TACI stroke classification.  Fat free mass loss, fat mass gain, and protein mass, muscles 
mass, and body cell mass loss were observed more in patients receiving NBM feeding 
regimen and patients with TACI suggesting that the severity of their condition may 
contributed to such body composition changes. Most patients with a stroke severity 
score NIHSS ≥10 had fat free mass loss, fat mass gain, and protein mass loss (and 
higher than those with NIHSS 1-9), but there were body cell mass and muscle mass 
gains making such results unrealistic and may be due to chance.  These varied findings 
seen in NIHSS ≥10 strokes do not allow to draw conclusions or observe trends unlike 
NBM or TACI patients.   
 
Equipment malfunction was suspected. Follow up data did not lead to any conclusion 
regarding the relationship between the body composition changes that occurred during 
the acute hospital stay and the longer term subjective outcomes.  This may be due to the 
fact that patients on NBM, those experienced TACI, or with NIHSS≥10 patients did not 
respond to questionnaires examining subjective outcomes.  Only the most medically fit 
patients with none of the former described condition mainly responded with a low 
response rate <50% (18 out of 40 participants).   Objective outcomes in the form of 
discharge destination or death did not show a trend although higher frequency of those 
discharged to rehabilitation services or those who died experienced fat free mass loss 
and fat mass gain compared to those discharge to home.  This could be simply due to 
small sample size. 
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In summary, my investigation shows interesting observations regarding body 
composition changes in patient on modified diet, NBM feeding regimen, patients who 
experienced TACI, and those with a moderately severe stroke assessed by NIHSS ≥10.  
Due to a small sample a firm conclusion on the relationship between body composition 
changes and type of feeding regimen, stroke classification, stroke severity, and objective 
outcomes such as mortality cannot be drawn.  Nevertheless my work is novel and 
provides some normative data of body composition changes occurring during an acute 
hospital stay which lay the foundation for sample size calculations and deriving 
minimally clinically significant change for future studies. My research contribution is 
therefore novel and future research can be built on this foundation of new knowledge. 
Further research is required to observe statistically significant findings warrant of 
further research in the form of clinical trials to understand the impact of targeted 
intervention on body composition changes in acute stroke.   
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Chapter 4:  The diagnostic accuracy of Maltron BioScan 920-2 multi-
frequency bioelectrical impedance analysis in diagnosing dehydration 
after stroke 
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Abstract 
 
Background and aims:  Non-invasive methods for detecting water-loss dehydration 
following acute stroke would be clinically useful.  I evaluated the diagnostic accuracy of 
multi-frequency bioelectrical impedance analysis (MF-BIA) against the reference 
standards, serum osmolality and osmolarity.   
Methods: Patients admitted to an acute stroke unit were recruited over six months from 
April to October of the year 2011.  Blood samples for electrolytes and osmolality were 
taken within 20 minutes of MF-BIA.  Total body water (TBW%), intracellular water 
(ICW%) and extracellular water (ECW%) were calculated using MF-BIA equipment 
and also calculated from MF-BIA generated impedance measures using published 
equations for older people.  These were compared to hydration status (based on 
measured serum osmolality and also calculated osmolarity).  The most promising 
Receiver Operating Characteristics curves were plotted. 
Results: A total of 27 stroke patients were recruited (mean age 71.3 years ± 10.7 years).  
Only a TBW% cut-off at 46% was consistent with current dehydration (serum 
osmolality >300mOsm/kg) and TBW% at 47% with impending dehydration (calculated 
osmolarity ≥295-300mOsm/L) with sensitivity and specificity both >60%.  Even here 
diagnostic accuracy of MF-BIA was poor, a third of those with dehydration were 
wrongly classified as hydrated and a third classified as dehydrated were well hydrated. 
Conclusions: MF-BIA appears ineffective at diagnosing water-loss dehydration after 
stroke and cannot be recommended as a test for dehydration.    
 
 
 
 
 
 
 205 
 
4.1 Background 
 
4.1.1 Dehydration prevalence and prognosis 
 
Stroke complications such as dysphagia, associated medication and depression, may 
make the maintenance of adequate dietary fluid intake difficult after stroke.  Scarce data 
is available on the prevalence of dehydration in stroke patients.  However with the 
available evidence from stroke and non-stroke studies one can understand the 
importance of such condition on outcomes.    
 
Studies report that dehydration is common after stroke.   Bhalla (98) found that 30% of 
their 167 stroke patients had raised serum osmolality (>296 mOsm/kg).  This was 
further reflected in another later study that suggested that almost a quarter of patients 
(n=102) were dehydrated during their hospital stay (on day nine post admission) (121).  
Although both studies were carried out in small samples they raised attention on the 
magnitude of the problem.      A more recent study by Rowat and colleagues (2012) that 
examined stroke patients clinical data register of two hospital (n=2591) reported that 
dehydration was present in 62% of this population (211).   
 
Dehydration in general and stroke specifically can increase the risk of poor outcome and 
mortality.  In care homes, it was reported that very high serum osmolality (>308 
mOsml/kg) in elderly residents, living in a continuing care, predicted marginally 
significant increased mortality (75% of 20 residents with high serum osmolality, 
compared to 53% of 38 residents with lower osmolality, p=0.053), and median survival 
time was significantly reduced (p=0.025) (212).    In stroke the risk is similar.  Bhalla et 
al 2000 suggested that the risk of mortality increased by more than two fold in 
dehydrated patients (n=50) compared to those not dehydrated (n=117); (OR 2.4, 95%CI 
1.0 t 5.9) (98).    
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The prognosis of dehydration post-stroke is not limited to mortality only but also to 
morbidity.  In the 102 acute ischaemic stroke patients included, raised serum osmolality 
(>297mOsm/kg, in 24% of their patients) on day 9 following admission was associated 
with increased odds of venous thromboembolism (OR 4.7, 95% CI 1.4 to 16.3) (121).   
The largest study examining the prevalence and prognosis of dehydration in stroke 
patients (n=2591) suggested that dehydrated patient have higher probability of being 
dead or dependent at hospital discharge compared to those not dehydrated (p<0.0001) 
(211).   
 
Dehydration may not only affect objective outcome of mortality but may also have poor 
prognosis on full recovery and quality of life.   The risk of mortality and poor outcomes 
of dehydration diagnosed in hospital settings can have negative prognosis on short and 
long term outcomes.  Patients discharged from hospital and diagnosed with dehydration 
on admission were more likely to die at 30 day (p=0.037) and six months (p=0.002), 
with a suggested increase in dehydration incidence rate of 3.5% during hospital stay 
(n=1416) reaching to a 533 dehydrated patient in the four year study periods; 67% of 
the dehydrated patients had available data and were entered in the final outcome 
analysis(213).    Dehydration can also affect the quality of life.  It could be that 
dehydration decreases muscular strength through initiating active tissue, fat free mass 
and mainly muscles mass, loss resulting in general weakness.  Finn et al 1996, 
suggested that fat free mass loss is initiated by cellular dehydration in sepsis and 
critically ill patients, and such changes in fat free mass are associated with reduced 
functional capacity (214).   
 
Given that dehydration is prevalent after stroke and its prognostic significance, 
diagnosing dehydration becomes a priority in its management.  There are several 
methods to assess water-loss (or hypertonic) dehydration including clinical and 
biochemical assessments some of which I will discuss briefly in the following section. 
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4.1.2 Dehydration in clinical Setting: physical and biochemical assessment 
 
Despite the dehydration council creating the DEHYDRATION mnemonic listing 12 
indicators to be used in dehydration screening (64), the diagnosis of dehydration 
remains a dilemma.  Physicians misdiagnosed dehydration in a third of patients 
admitted to a hospital (215).   This can be attributed to the variety of available methods 
in diagnosing dehydration.   Methods used to assess water-loss dehydration in clinical 
settings in older people include urinary, haematological, and physical assessments (216).  
Using serum osmolarity (>295 mOsm/l) and sodium (>145 mmol/L) as a reference for 
dehydration Thomas found that of those patients diagnosed as dehydrated using 
physical assessment, only 17% had a serum osmolarity >295 mOsm/l (217).  Physical 
assessment differs from physician to physician and may include some or all of the 
following: capillary refill time, skin turgor, longitudinal tongue furrows, tongue dryness, 
orthostatic hypotension, urine colour and volume and many more.  This may be 
exacerbated by poor inter-observer agreement, as with capillary refill time.  Anderson 
found only 70% agreement in classifying patients as normal vs. abnormal (Kappa=0.38) 
in their study on clinically stable emergency department patients (n=209) (218, 219).    
 
Capillary refill time have proven to be unreliable as a recent review suggested (220) and 
is also affected by environmental factors, with a decrease in capillary refill time as the 
temperature rises, showing the importance of training and standardising the use of such 
tests (218).  Skin turgor is another method used in assessing dehydration in adults, but 
again skin elasticity changes with ageing reduces the validity of the test, as results can 
rely on physiological skin changes rather than state of dehydration (221).  There are 
indications that tongue dryness and longitudinal tongue furrows may be more reliable.  
Gross et al evaluated 38 signs of dehydration among 60+ year old patients at two 
teaching hospitals.  They evaluated medical records to judge whether patients were 
dehydrated and used this as the dehydration reference (but did not report serum 
osmolality) (191).  Tongue dryness and longitudinal tongue furrows strongly correlated 
with dehydration severity as two strong indicators of dehydration (p<0.001 for both) 
(191). 
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Elevated serum osmolality, sodium, creatinine, and urea are used in evaluating 
dehydration.  In general Individual components of serum osmolality, such as urea, 
creatinine and sodium have also been used to assess dehydration, but have been found 
to be inaccurate (215, 222).  Serum sodium, creatinine, urea may not reflect actual 
dehydration.  The presence of a high serum creatinine can be related to high muscle 
mass and muscle tissue turnover, a state of muscle metabolism and not necessarily 
dehydration.  Creatinine serum levels are also associated with different pathologies.  For 
example, a rise in creatinine levels can be associated with gastrointestinal bleeding, 
septic shock, and renal function (222) giving misleading diagnosis of dehydration.   
Serum sodium is another indicator used in evaluating hydration status.  Thomas et al 
warned the use of sodium in evaluating dehydration that serum sodium may not reflect 
true intracellular dehydration but rather volume depletion (217).  Bowker et al 1992 
(219) examined urea level in patient with pre-renal condition including dehydration.  
They found that only in 50% of those patients urea was higher than normal 13.2 
mmol/L.  In addition, urea level increased in 80% of the patients with post renal 
obstruction or pathology (222).  These findings suggest that urea does not always reflect 
the presence or absence of dehydration.  
 
Of all Biochemical indicators of dehydration, serum osmolality is most frequently used 
as a reference standard (64, 223).  Serum osmolality is the osmolar concentration or 
osmotic pressure of serum, so reflects the number of dissolved particles (whether they 
are able to permeate cell membranes or not) per kilogram of serum.  Serum osmolality 
reflects the osmolality of intracellular fluid as cell walls are permeable to water, and as 
osmolality is carefully controlled by the body any change in osmolality suggests 
important alterations in body biochemistry.  Serum osmolality is sensitive to hydration 
status changes.  It is sensitive to change after the first day of hydration status changes 
(224).  Where body fluids are lost along with electrolytes (through loss of blood or 
sweat for example) then fluid may be lost without alteration of osmolality, this state is 
termed “water and salt-loss” dehydration. Following stroke it is possible that there will 
be a reduction in fluid intake, with or without increased fluid losses associated with use 
of diuretics, fever, uncontrolled diabetes mellitus, etc. In such situations where body 
fluids are lost overall, the result is likely to be that of increased osmolality, or “water-
loss” dehydration.  Serum osmolality can be used alone, and without prior measurement, 
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as a hydration status marker (223), unlike weight change as a reference standard which 
depends on other body components (216).  Thus serum osmolality is probably the best 
reference standard method to measure water-loss dehydration and the diagnostic 
standard against which the accuracy of other measures should be judged (64) .    
 
While studies have used slightly varying cut-off points for serum osmolality to define 
dehydration (98, 121) the Dehydration Council’s definition is specific to older people, 
with a serum osmolality 295-300 mOsm/kg equates to impending dehydration and > 
300 mOsm/kg with current dehydration and this definition is used in this study.   In 
clinical practice serum osmolality is often not assessed, but estimated from the 
combined concentrations of serum sodium, potassium, glucose and urea, referred to as 
serum osmolarity (2Na+2K+Urea+Glucose, all in mmol/L).  There is a difference 
between measured serum osmolality and calculated osmolarity, known as the osmolar 
gap (as some components of osmolality are not included in the formula to calculate 
osmolarity) (225).  In addition, and given that urea and sodium measurements may not 
be accurate, serum osmolarity may not reflect the true state of dehydration compared to 
measured serum osmolality.     
 
Given that serum osmolality is not routinely performed in clinical practice, an 
alternative swift dehydration monitoring test is essential.  Bioelectrical impedance 
analysis (MF-BIA) is one method that maybe able to help in monitoring and diagnosing 
dehydration.  MF-BIA measurement is fairly simple, non-invasive, and can be 
performed in clinical settings while the patient is lying down.   The MF-BIA can 
measure total body water (TBW), intracellular water (ICW), and extracellular water 
(ECW) volumes.  ICW reflects water volume within body cells, and so may reflect how 
well the body is hydrated.   
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4.1.3 Evaluating dehydration using bioelectrical impedance analysis  
 
Total body water is another component that can be assessed by bioelectrical impedance 
analysis.  Total body water can provide information on the degree of dehydration.  
Physiological changes occurring in the ageing process increases the risk of dehydration.  
These physiological changes are related to reduced capacity in retaining water; such 
changes include but are not limited to reduced renal filtration rate, increased proximal 
tubular filtration absorption, and decreased free water clearance (64).   Total body water 
consists of intracellular and extracellular water.  Loss of intracellular water is usually 
defined as dehydration (226, 227).  Assessing dehydration using MF-BIA can predict 
not only total body water, but also specific intracellular and extracellular components.  
Evaluating intracellular and extracellular water can provide information on the extent of 
tissue catabolism. As indicated earlier acute/chronic inflammation instigated during 
illness leads to catabolism of lean body mass resulting in fat free mass loss (174).  Fat 
free mass loss leads to loss of cellular fluids as tissue catabolism results in intracellular 
fluid loss and expansion of extracellular fluid; cellular dehydration (60).  Based on 
intracellular and extracellular water changes related to lean tissue catabolism, caloric 
and nutritional needs can be modified to allow tissue anabolism and prevent further 
catabolism.  Assessing dehydration through measuring body composition values may 
provide information on the nutritional status and management needs of patients.   
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4.2 Study Objective  
 
This study aimed to assess the levels of dehydration after stroke using the reference 
standard of serum osmolality and to assess whether MF-BIA can be substituted for 
serum osmolality in diagnosing dehydration after stroke.   
 
Methods to assess hydration status which do not require obtaining blood samples would 
be helpful in situations where there is no quick and easy access to laboratory facilities 
such as care homes and rehabilitation services.  Multi frequency bioelectrical impedance 
analysis (MF-BIA) can provide estimates of total body water (TBW), intracellular water 
(ICW), and extracellular water (ECW) volumes and as percentages of body weight, 
which theoretically should correspond to hydration status.  If so the composition of 
these compartments would suggest MF-BIA as a useful non-invasive method of 
diagnosing dehydration that does not require medical training in operating in daily 
clinical practice.  This chapter presents the study which assessed the diagnostic 
accuracy of Maltron BioScan 920-2 MF-BIA to monitor hydration status in patients 
with stroke. 
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4.3 Methodology  
  
 
This cross sectional study was carried out in an acute stroke unit in the East of England 
(as in Chapter 3).  A total of 45 stroke patients admitted within 48 hours of symptom 
onset were recruited between 1st April and 15th October 2011. Patients were included if 
older than 17 years, with newly diagnosed stroke (first ever or recurrent).  Exclusions 
included those with severe stroke by National Institute of Health Stroke Scale (NIHSS) 
score >30, co-existing terminal illness, or expected survival <48 hours as judged by a 
stroke physician, and those who were unable to give informed consent.  Routine 
medical, nursing and therapist care was unaffected by entry into the study.  All eligible 
patients who provided informed consent during the study period were enrolled in the 
study. 
 
Upon consent a venous blood sample was taken for serum osmolality, sodium, 
potassium, random glucose, creatinine and urea and the sample was analysed 
immediately. Co-morbidities including diabetes and renal impairment were noted. 
Serum osmolality was analysed by the hospital pathology laboratory using freezing 
point depression on an Advanced Instruments model 2020 osmometer (Advanced 
Instruments Inc., Massachusetts 02062 USA), and all other measures were standardised 
and automated.   Two consecutive MF-BIA measurements (BioScan 920-2, Maltron 
International Ltd, Essex; using brand new equipment) were taken within 20 minutes of 
the blood sampling with the subject supine, before serum osmolality results were 
available (the assessor was blinded to hydration status).   MF-BIA measurements were 
undertaken using the manufacturers recommended method with two electrodes attached 
to the skin between the talus and the 3rd and 5th digits of the foot and two more attached 
to the same side between the 3rd and 5th knuckles of the hand and the wrist.   Participant 
information including anthropometrics (measured by investigator or nurse as described 
in details in the previous chapter), age, gender, and race were entered into the device 
and the measurements made over a couple of seconds.  The recording was repeated a 
few minutes later.  All measurements including blood samples, MF-BIA, and 
anthropometric measures were carried out in the acute stroke unit at the patients’ bed 
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location.  In the stroke unit meals are provided at specific times and patients maybe 
consuming snacks provided by their visitors at anytime.  After measurements were 
recorded and saved, data were downloaded onto a laptop with Maltron MF-BIA 
software installed.  Impedances at 5, 50 and 100 kHz, and MF-BIA calculations of total 
body water as a percentage of body weight (TBW%), intracellular water as a percentage 
of TBW (ICW%) and extracellular water as a percentage of TBW (ECW%) were noted 
for each recording.  Modified Rankin scores (mRs, a measure of disability) were 
recorded by an occupational therapist.    
 
Ethical Approval for this study was gained from Cambridgeshire I Research Ethics 
Committee; REC reference number 10/H0304/18 in April 2011. This part of my 
research was funded by the European Hydration Institute.   The funder had no role in 
designing or conducting the study.   
 
4.3.1 Statistical analysis  
 
All statistical analyses were carried out using PASW 18 for Windows (Polar 
Engineering and Consulting, formerly known as SPSS).   Mean, standard deviation (SD) 
and range were presented for continuous and number (percentages) were presented for 
categorical data (hydration status; hydrated, impending, and current dehydration). 
Percentages of patients diagnosed with impending (serum osmolality 295-300mOsm/kg 
or serum osmolarity 295-300 mOsm/L) and current dehydration (serum 
osmolality >300mOsm/kg or serum osmolarity >300 mOsm/L) were calculated.  An 
average was calculated for each two consecutive measurements taken by MF-BIA of 
same variable for use in subsequent calculations. For the one participant where the two 
consecutive estimates of TBW% varied by>3% the first data set was used.  
 
The internal consistency of MF-BIA was assessed by carrying out a reliability analysis 
of the 2 separate measurements of impedance at 5 kHz for each individual; this was 
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repeated for impedance measures at 50 and 100 kHz, and the MF-BIA equipment 
calculation of TBW (L).    
Impedance outputs (mean from the two readings) were used to calculate TBW (L) and 
ECW (L) using equations developed for use in older people by Vaché (228) and Visser 
(229)  (as quoted in  Ritz(230)), and  TBW%, ECW% and ICW% were calculated as 
percentages of body weight. 
 
TBW%, ECW%, ICW% and ECW: ICW ratio from the internal calculations of the MF-
BIA equipment, and those calculated from equations derived specifically for older 
people were each plotted in 2x2 tables against impending and current serum osmolality 
and calculated serum osmolarity.  These tables were used to calculate sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV), pre- and 
post-test probability of each for impending and current dehydration(231).  Where any of 
these values were not calculable due to the presence of zeros in the 2x2 table, 0.1 was 
added to each cell of the table. As published cut-off points of TBW, ECW and ICW for 
dehydration are not readily available, three arbitrary cut-off points were selected for 
each measure (TBW%, ECW%, ICW% and the ratio).   
 
Receiver operating characteristic (ROC) curves were created for both impending and 
current dehydration, then additional promising cut-off points (where cut-offs may 
possibly have both sensitivity and specificity >60%) were added to fill in the ROC 
curves.  At the ends of the ROC curve, once either sensitivity or specificity was below 
50%, no further outlying points were added. An acceptable cut-off point was considered 
to be one with both sensitivity and specificity greater than 60% and represented by the 
point closest to the top left corner of the ROC plot. There is no definition of “good 
enough” sensitivity and specificity but we chose a minimum of 60% for both as 
suggesting that the measure was at least promising (232).   For all cut-off points I also 
calculated positive predictive value (PPV), negative predictive value (NPV), and 
positive and negative post-test probabilities.  The results have been reported in line with 
the STARD reporting guidelines (233) . 
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4.3.2 Sample Size  
 
This is an observational cross sectional study.  No power calculation was performed as 
there was no data available previously reporting diagnostic accuracy of MF-BIA against 
serum osmolality. Forty five participants were a realistic sample given the time frame 
we were able to use for this study. I performed thorough literature search and to my 
knowledge, there are no previous studies of similar nature performed in this field to 
allow us to do formal sample size calculations.  There are no data on body water values 
which have been shown to be related to serum osmolality.  
 
Therefore, the objectives of this cross sectional study was to assess the diagnostic 
accuracy of MF-BIA, to help understand whether MF-BIA can be used to monitor 
hydration status in place of serum osmolality after stroke. 
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4.4 Results 
 
4.4.1 Characteristics of the participants 
 
The data from the last 18 of the 45 participants had to be discarded as their TBW% was 
recorded as 75% or greater (extremely high and unrealistic readings) suggesting an error 
in MF-BIA impedance readings occurred.  This group did not differ in their clinical 
characteristics (such as type of stroke, age, biochemistry, or presence of peripheral 
oedema) from other participants.  Incorrect data for these last 18 participants were 
removed leaving 27 participants for analysis (59% males); average age 71.3 (10.7) years.  
There was a technical malfunctioning in the equipment.  No adverse events occurred as 
a result of any of the tests used.   
 
Of the 27 remaining subjects 12 (44%) were well hydrated (serum osmolality 275 to 
<295mOsm/kg), 9 (33%) had impending dehydration (serum osmolality 295-
300mOsm/kg) and 6 (22%) were dehydrated (serum osmolality >300mOsm/kg), see 
Table 4.1.  Stratified by calculated serum osmolarity 8 (30%) were well hydrated (275 
to <295 mOsm/L), 7 (26%) had impending dehydration, and 12 (44%) had current 
dehydration (>300mOsm/L) (Table 4.1).  11% (n=3) were receiving a nil-by-mouth 
feeding regimen because of dysphagia.  One patient was on pureed diet and 19% (n=5) 
on soft-mashed diets due to mild dysphagia.   Sixty seven percentage (n=18) were on 
normal oral diets without needing alteration of food texture.  
 
4.4.2 Internal consistency and reliability of MF-BIA measurements 
 
Cronbach’s alpha was 0.960 for the reproducibility of the two impedance measures at 5 
kHz (n=27), suggesting excellent internal consistency.  Cronbach’s alpha was similarly 
excellent for impedance at 50 kHz, and 100 kHz, and TBW (L) (0.974, 0.978 and 0.995 
respectively).    
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 Serum osmolality (mOsm/kg) Serum osmolarity (mOsm/L) 
  Hydrated 
Impending 
dehydration 
Current 
dehydration Hydrated Impending dehydration 
Current 
dehydration 
Number of participants 12 (44.4%) 9 (33.3%) 6 (22.2%) 8 (29.6%) 7 (25.9%) 12 (44.4%) 
Mean Age (SD), yrs.  72.3 (12.5) 68.7 (8.0) 73.5 (11.4) 71.0 (14.5) 71.1 (9.9) 71.7 (9.1) 
Age Range, yrs. 46-92 59-81 59-88 46-92 59-82 59-88 
Weight (SD), kg 80.5 (17.1) 74.3 (9.0) 90.0 (13.6) 78.2 (19.6) 81.2 (9.9) 81.7 (14.5) 
Height (SD), m 1.7 (0.1) 1.6 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.8 (0.1) 
Body Mass Index (SD), kg/m2 29.1 (5.4) 27.7 (2.4) 31.1 (4.2) 28.6 (5.4) 29.0 (4.2) 29.5 (4.1) 
Pre-morbid Rankin Scorea        
0 (No symptoms). 6 3 1 3 3 4 
1-2  (No significant to slight) disability 5 2 2 5 2 2 
3-4 (Moderate to moderately severe disability)  0 1 2 0 0 3 
5 (Severe disability) 1 0 0 0 1 0 
Normal Food 9 6 3 6 5 7 
Pureed or soft mashed 1 3 2 1 1 4 
Table 4.1.  Baseline characteristics 
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Table 4.1. Baseline characteristics of the 27 included participants stratified by serum osmolality (directly measured) and serum osmolarity (calculated) 
as being hydrated or having impending or current dehydration. 
Table 4.1.  an=23 as not all participants were assessed. 
bn=24 as not all participants were assessed. 
       
 Serum osmolality (mOsm/kg) Serum osmolarity (mOsm/L) 
  Hydrated 
Impending 
dehydration 
Current 
dehydration Hydrated Impending dehydration 
Current 
dehydration 
NIHSS score (stroke severity)b       
1-9 9 7 3 6 5 8 
10-20 1 1 2 1 0 3 
>21 1 0 0 0 1 0 
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4.4.3 Dehydration status, osmolality and osmolarity 
 
Current dehydration (>300 mOsm/L) diagnosed on serum osmolarity criteria was twice 
as common as when based on serum osmolality (>300 mOsm/kg), the reference 
standard (Table 4.2).  As calculated osmolarity (in mOsm/L) is considered to be 
equivalent in clinical practice to measured osmolality (in mOsm/kg) we directly 
compared the two for individuals.  Mean calculated serum osmolarity was 298.2±6.9 
mOsm/L while mean measured serum osmolality was 295.5±7.5 mOsm/kg.  When they 
were directly compared there was a significant difference of 2.72 (95% CI 0.6 to 4.8; 
p=0.014).  When stratified by hydration status serum osmolarity was greater than 
osmolality for hydrated participants (mean difference 4.7, 95% CI 1.1 to 8.2, p=0.02) 
and those with impending dehydration (mean difference 2.9, 95% CI 0.2 to 5.6, p=0.04) 
but not for those with current dehydration (mean difference -1.4, 95% CI -7.4 to 4.5, 
p=0.57).    
 
Mean serum sodium, potassium, Creatinine, urea and glucose values were always 
higher in those with current dehydration than those who were well hydrated, but the 
mean values for impending dehydration were not always between those of hydrated and 
currently dehydrated groups.  There were few clear patterns in TBW%, ECW%, ICW% 
or ECW: ICW ratio by serum osmolality or calculated serum osmolarity (Table 4.2).  
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 Serum Osmolality (mOsm/kg) Serum Osmolarity (mOsm/L) 
 Average (SD) Hydrated 
Impending 
dehydration  
Current 
dehydration 
Hydrated Impending 
Dehydration 
Current 
Dehydration 
Total Population (%) 12 (44.4%) 9 (33.3%) 6 (22.2%) 8 (29.6%) 7 (25.9%) 12 (44.4%) 
Total Body Water% a 51.9 (4.0) 52.5 (5.8) 50.7 (4.2) 52.3 (3.7) 51.5 (3.6) 51.7 (5.9) 
Extracellular Water % a 45.4 (2.8) 46.1 (2.3) 45.3 (1.0) 45.9 (3.1) 44.8 (2.5) 45.9 (1.5) 
Intracellular Water% a 54.6 (2.8) 53.9 (2.3) 54.7 (1.0) 54.1 (3.1) 55.2 (2.5) 54.1 (1.5) 
ECW:ICW  0.83 (0.1) 0.86 (0.1) 0.83 (0.03) 0.85 (0.1) 0.82 (0.08) 0.85 (0.05) 
Serum Osmolality mOsm/kg  288.6 (4.3) 298.4 (1.7) 305.0 (2.6) 287.6 (4.8) 296.7 (6.5) 300.1 (5.1) 
Serum Osmolarity mOsm/L 293.2 (5.8) 301.3 (4.3) 303.6 (5.2) 290.2 (3.6) 297.1 (1.1) 304.3 (3.9) 
Serum Sodium mmol/l 135.8 (2.0) 140.4 (2.0) 138.7 (3.4) 134.9 (1.7) 137.9 (1.1) 140.1 (2.9) 
Serum Potassium mmol/l 4.1 (0.3) 4.4 (0.3) 4.6 (0.5) 4.2 (0.43) 4.3 (0.6) 4.4 (0.3) 
Serum Creatinine µmol/L 74.3 (15.1) 72.7 (6.6) 90.3 (20.6) 75.4 (10.8) 75.3 (16.9) 79.8 (18.2) 
Serum Urea mmol/L 5.1 (1.1) 5.5 (1.4) 8.4 (6.6) 5.1 (1.2) 5.7 (1.0) 6.7 (4.9) 
Serum Glucose mmol/L b  8.4 (4.3) 6.3 (1.8) 8.8 (3.9) 7.0 (2.6) 7.3 (1.7) 8.7 (4.8) 
Table 4.2.  Body fluid compartments and serum components stratified by hydration status (serum osmolality (measured) and osmolarity (calculated)) 
for the 27 participants with valid MF-BIA data.a expressed as a percentage of body weight, b n=26 
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4.4.4 Diagnostic accuracy of MF-BIA vs. dehydration by Serum Osmolality 
 
No cut-off point for TBW%, ICW%, ECW% or ECW: ICW ratio (calculated by the 
MF-BIA equipment) had both a sensitivity and specificity above 60% for impending 
(Table 4.3) or current (Table 4.4) dehydration assessed by (measured) serum osmolality.  
None of the impending dehydration ROC curves neared the upper left hand corner. 
Figure 4.1 shows the ROC plot for ICW% for impending dehydration by serum 
osmolality and Figure 4.2 shows the ROC plot for ECW% for current dehydration by 
serum osmolality).  
 
 
Figure 4.1. ROC curve assessing the diagnostic accuracy of MF-BIA assessment of 
intracellular water as a percentage of total body water (ICW% by the Maltron 
equations) in estimating impending dehydration (≥295 mOsm/kg). 
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Figure 4.2. ROC curve assessing diagnostic accuracy of MF-BIA assessment of 
extracellular water as a percentage of total body water (ECW%) in estimating current 
dehydration (>300 mOsm/kg). 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test Probability    
(-ve) 
Post-test probability 
(+ve) 
TBW%         
45%  0.13 0.92 0.67 0.46 0.56 0.54 0.67 
50%  0.33 0.75 0.63 0.47 0.56 0.53 0.63 
52%  0.40 0.67 0.6 0.47 0.56 0.53 0.60 
54%  0.80 0.25 0.57 0.50 0.56 0.50 0.57 
55%  0.87 0.08 0.54 0.33 0.56 0.67 0.54 
57%  0.93 0.08 0.56 0.50 0.56 0.50 0.56 
ICW%         
53%  0.20 0.75 0.50 0.43 0.56 0.57 0.50 
54%  0.40 0.50 0.50 0.40 0.56 0.60 0.50 
55%  0.67 0.50 0.63 0.55 0.56 0.46 0.63 
56% 0.93 0.42 0.67 0.83 0.56 0.17 0.67 
57%  0.93 0.33 0.64 0.80 0.56 0.20 0.64 
Table 4.3. Diagnostic accuracy of MF-BIA in diagnosing impending dehydration (295-300 mOsm/kg), continued 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test Probability    
(-ve) 
Post-test probability 
(+ve) 
ECW%         
42% 0.00 0.92 0.00 0.42 0.56 0.58 0.00 
45%  0.33 0.50 0.46 0.38 0.56 0.63 0.46 
46%  0.60 0.50 0.60 0.50 0.56 0.50 0.60 
47%  0.80 0.33 0.60 0.57 0.56 0.43 0.60 
50%  1.00 0.08 0.58 1.00 0.56 0.00 0.58 
ECW:ICW        
0.60 a  0.01 0.99 0.50 0.45 0.56 0.56 0.50 
0.80  0.13 0.58 0.29 0.35 0.56 0.65 0.29 
0.85  0.60 0.50 0.60 0.50 0.56 0.50 0.60 
0.90  0.80 0.25 0.57 0.50 0.56 0.50 0.57 
1.10 a  0.99 0.01 0.56 0.50 0.56 0.50 0.56 
Table 4.3.  Diagnostic accuracy of MF-BIA measures (at several cut-off points) in diagnosing impending dehydration (295-300 mOsm/kg). Based on 
internal Maltron equations for TBW, ICW and ECW, and on the 27 participants with reliable MF-BIA data.  a 0.1 fraction added to all 4 cells of the 
2x2 table due to the presence of a zero in one of the cells that prevents at least one of the properties being calculated.   PPV: positive predictive value.  
NPV: negative predictive value.  TBW was expressed as a percentage of body weight (TBW %), and ICW and ECW were expressed as a percentage of 
total body water (ICW%, ECW%).   
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
probability    (-ve) 
Post-test probability 
(+ve) 
TBW%        
45%  0.17 0.91 0.33 0.79 0.22 0.21 0.33 
50%  0.33 0.71 0.25 0.79 0.22 0.21 0.25 
52%  0.33 0.62 0.20 0.77 0.22 0.24 0.20 
53%  0.67 0.48 0.27 0.83 0.22 0.17 0.27 
54% 1.00 0.29 0.29 1.00 0.22 0.00 0.29 
55% 1.00 0.14 0.25 1.00 0.22 0.00 0.25 
ICW%        
53% 0.00 0.71 0.00 0.71 0.22 0.29 0.00 
55%  0.50 0.38 0.19 0.73 0.22 0.27 0.19 
56% 1.00 0.29 0.28 1.00 0.22 0.00 0.29 
57%  1.00 0.23 0.27 1.00 0.22 0.00 0.27 
Table 4.4.  Diagnostic accuracy of MF-BIA measures in diagnosing current dehydration (>300mOsm/kg), continued 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
probability    (-ve) 
Post-test probability 
(+ve) 
ECW%        
42%  0.00 0.95 0.00 0.77 0.22 0.23 0.00 
45%  0.50 0.62 0.27 0.81 0.22 0.19 0.27 
46%  0.67 0.48 0.27 0.83 0.22 0.17 0.27 
47% 1.00 0.33 0.30 1.00 0.22 0.00 0.30 
49%  1.00 0.10 0.24 1.00 0.22 0.00 0.24 
ECW:ICW        
0.60 a  0.02 1.00 0.50 0.78 0.23 0.22 0.50 
0.75 0.00 0.71 0.00 0.71 0.22 0.29 0.00 
0.85   0.67 0.48 0.27 0.83 0.22 0.17 0.27 
0.90  1.00 0.29 0.29 1.00 0.22 0.00 0.29 
0.95  1.00 0.14 0.25 1.00 0.22 0.00 0.25 
Table 4.4.  Diagnostic accuracy of MF-BIA measures (at several cut-off points) in diagnosing current dehydration (>300mOsm/kg). Based on internal 
Maltron equations for TBW, ICW and ECW, and on the 27 participants with reliable MF-BIA data. 
a
 0.1 fraction added to all 4 cells of the 2x2 table due to the presence of a zero in one of the cells. 
PPV: positive predictive value.  NPV: negative predictive value. TBW was expressed as a percentage of body weight (TBW %), and ICW and ECW 
were expressed as a percentage of total body water (ICW%, ECW%).   
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Diagnostic accuracy for TBW%, ICW%, ECW% and ECW: ICW calculated using the 
equations specifically developed for older people (228-230)(rather than those 
programmed into the MF-BIA equipment) compared to serum osmolality resulted in 
one cut-off point with both sensitivity and specificity >60% for current dehydration 
(Table 4.5), and none for impending dehydration (Table 4.6).  TBW% with a cut-off at 
46% of body weight, was diagnostic of current dehydration by osmolality with 
sensitivity of 67% (95% CI 49% to 85%), specificity 62% (95% CI 44% to 80%) (Table 
5, Figure 4.3).  The positive likelihood ratio (LR+) for this cut-off was 1.75 and negative 
likelihood ratio (LR-) was 0.54.  
 
 
Figure 4.3. ROC curve assessing diagnostic accuracy of TBW% calculated from 
equations for older people15 against current dehydration by serum osmolality (>300 
mOsm/kg).  The 46% cut-off point had a sensitivity of 67% (95% CI 49%-85%), and 
specificity of 62% (95% CI 44%-80%).  
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
Probability (-ve) 
Post-test probability 
(+ve) 
TBW%        
45% 0.50 0.76 0.38 0.84 0.22 0.16 0.38 
46% 0.67 0.62 0.33 0.87 0.22 0.13 0.33 
47% 0.83 0.52 0.33 0.92 0.22 0.08 0.33 
48% 0.83 0.33 0.26 0.88 0.22 0.13 0.26 
50% 0.83 0.29 0.25 0.86 0.22 0.14 0.25 
52% 1.00 0.10 0.24 1.00 0.22 0.00 0.24 
55% 1.00 0.05 0.23 1.00 0.22 0.00 0.23 
ICW%        
25% 0.33 0.76 0.29 0.8 0.22 0.20 0.29 
26% 0.50 0.71 0.33 0.83 0.22 0.17 0.33 
27% 0.67 0.52 0.29 0.85 0.22 0.15 0.29 
28% 0.67 0.33 0.22 0.78 0.22 0.22 0.22 
29% 0.83 0.29 0.25 0.86 0.22 0.14 0.25 
30% 1.00 0.14 0.25 1.00 0.22 0.00 0.25 
Table 4.5.  Diagnostic accuracy of Ritz measures (at several cut-off points) in diagnosing current dehydration (>300mOsm/kg), 
continued 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
Probability (-ve) 
Post-test probability 
(+ve) 
ECW%        
18% 0.33 0.76 0.29 0.80 0.22 0.20 0.29 
19% 0.50 0.67 0.30 0.82 0.22 0.18 0.30 
20% 0.67 0.48 0.27 0.83 0.22 0.17 0.27 
21% 0.83 0.19 0.23 0.80 0.22 0.20 0.23 
22% 1.00 0.14 0.25 1.00 0.22 0.00 0.25 
ECW:ICW        
0.60 0.02 1.00 0.50 0.78 0.22 0.22 0.50 
0.70 0.33 0.67 0.22 0.78 0.22 0.22 0.22 
0.75 0.67 0.52 0.29 0.85 0.22 0.15 0.29 
0.80 0.67 0.38 0.24 0.80 0.22 0.20 0.24 
0.85 1.00 0.19 0.26 1.00 0.22 0.00 0.26 
Table 4.5.  Diagnostic accuracy of Ritz measures (at several cut-off points) in diagnosing current dehydration (>300mOsm/kg) based on alternate 
equations for TBW, ICW and ECW in older people (Ritz 2001), and on the 27 participants with reliable MF-BIA data.  
a
 0.1 fraction added to all 4 cells of the 2x2 table due to the presence of a zero in one of the cells that prevents at least one of the properties being 
calculated.  PPV: positive predictive value.  NPV: negative predictive value.  TBW, ICW and ECW were all expressed as percentages of body weight 
(TBW%, ICW%, ECW%).   
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test Probability       
(-ve) 
Post-test probability 
(+ve) 
TBW%               
45% 0.40 0.83 0.75 0.53 0.56 0.47 0.75 
46% 0.53 0.67 0.67 0.53 0.56 0.47 0.67 
47% 0.67 0.58 0.67 0.58 0.56 0.42 0.67 
48% 0.80 0.42 0.63 0.63 0.56 0.38 0.63 
50% 0.87 0.42 0.65 0.71 0.56 0.29 0.65 
51% 0.93 0.17 0.58 0.67 0.56 0.33 0.58 
52% 0.93 0.08 0.56 0.50 0.56 0.50 0.56 
ICW%               
25% 0.33 0.83 0.71 0.5 0.56 0.50 0.71 
27% 0.60 0.58 0.64 0.54 0.56 0.46 0.64 
28% 0.73 0.42 0.61 0.56 0.56 0.44 0.61 
29% 0.80 0.33 0.60 0.57 0.56 0.43 0.60 
30% 0.93 0.17 0.58 0.67 0.56 0.33 0.58 
32%* 0.99 0.01 0.56 0.50 0.56 0.50 0.56 
Table 4.6.  Diagnostic accuracy of Ritz measures (at several cut-off points) in diagnosing impending dehydration (295-
300mOsm/kg), continued 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test Probability       
(-ve) 
Post-test probability 
(+ve) 
ECW%               
20% 0.60 0.50 0.60 0.50 0.56 0.50 0.60 
21% 0.87 0.25 0.59 0.60 0.56 0.40 0.59 
22% 0.93 0.17 0.58 0.67 0.56 0.33 0.58 
23% 0.93 0.08 0.56 0.50 0.56 0.50 0.56 
25% a 0.93 0.01 0.54 0.08 0.56 0.92 0.54 
ECW:ICW               
0.60 0.01 0.99 0.50 0.45 0.56 0.56 0.50 
0.75 0.53 0.50 0.57 0.46 0.56 0.54 0.57 
0.80 0.60 0.33 0.53 0.40 0.56 0.60 0.53 
0.85 0.80 0.08 0.52 0.25 0.56 0.75 0.52 
0.90 a 0.99 0.01 0.56 0.50 0.56 0.50 0.56 
Table 4.6.  Diagnostic accuracy of Ritz measures (at several cut-off points) in diagnosing impending dehydration (295-300mOsm/kg) based on 
alternate equations for TBW, ICW and ECW in older people (Ritz 2001), and on the 27 participants with reliable MF-BIA data. 
a
 0.1 fraction added to all 4 cells of the 2x2 table due to the presence of a zero in one of the cells that prevents at least one of the properties being 
calculated.  PPV: positive predictive value.  NPV: negative predictive value. TBW, ICW and ECW were all expressed as percentages of body weight 
(TBW%, ICW%, ECW%).   
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4.4.5 Diagnostic Accuracy of MF-BIA vs. dehydration assessed by calculated Serum 
Osmolarity 
 
Diagnostic accuracy for water fractions calculated using the equations for older people 
used in Ritz 2001 against calculated serum osmolarity resulted in one cut-off point with 
both sensitivity and specificity of at least 60%.  TBW% at 47% of body weight was 
diagnostic of impending dehydration by calculated osmolarity with sensitivity and 
specificity of 63% (95% CI 45% to 81%) (Table 4.7; Figure 4.4).  The LR+ and LR – 
were 1.7 and 0.6 respectively for this cut-off.   No cut-offs were accurate for current 
dehydration (Table 4.8). 
 
 
Figure 4.4.  ROC curve assessing diagnostic accuracy of TBW% calculated from Ritz 
2001 equations for older people against impending dehydration as calculated by serum 
osmolarity (≥295 mOsm/L).  The 47% cut off point had a sensitivity and specificity of 
63% (95%CI 45% to 81%) each.  
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No cut-off points for TBW%, ICW%, ECW% or ECW: ICW as calculated by the MF-
BIA equipment against calculated serum osmolarity had a sensitivity and specificity 
above 60% for impending (≥295 mOsm/L serum osmolarity, (Table 4.9) or current 
dehydration (>300 mOsm/L, Table 4.10).    
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Cut-off 
point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability       (-
ve) Post-test probability (+ve) 
TBW%               
45% 0.37 0.88 0.88 0.37 0.70 0.63 0.88 
46% 0.53 0.75 0.83 0.40 0.70 0.60 0.83 
47% 0.63 0.63 0.80 0.42 0.70 0.58 0.80 
48% 0.74 0.38 0.74 0.38 0.70 0.63 0.74 
49% 0.79 0.38 0.75 0.43 0.70 0.57 0.75 
50% 0.79 0.38 0.75 0.43 0.70 0.57 0.75 
51% 0.90 0.13 0.71 0.33 0.70 0.67 0.71 
52% 0.95 0.13 0.72 0.50 0.70 0.50 0.72 
Table 4.7.  Diagnostic accuracy of Ritz measures (at several cut-off points) in diagnosing impending dehydration (295-
300mOsm/l), continued 
        
        
 235 
 
Cut-off 
point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability       (-
ve) Post-test probability (+ve) 
ICW%               
25% 0.32 0.88 0.86 0.35 0.70 0.65 0.86 
27% 0.53 0.50 0.71 0.31 0.70 0.69 0.71 
28% 0.68 0.38 0.72 0.33 0.70 0.67 0.72 
29% 0.74 0.25 0.70 0.29 0.70 0.71 0.70 
30% 0.95 0.25 0.75 0.67 0.70 0.33 0.75 
ECW%               
20% 0.58 0.50 0.73 0.33 0.70 0.67 0.73 
21% 0.84 0.25 0.73 0.40 0.70 0.60 0.73 
22% 0.90 0.13 0.71 0.33 0.70 0.67 0.71 
23% 0.95 0.13 0.72 0.50 0.70 0.50 0.72 
Table 4.7.  Diagnostic accuracy of Ritz measures (at several cut-off points) in diagnosing impending dehydration (295-
300mOsm/l), continued 
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Cut-off 
point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability       (-
ve) Post-test probability (+ve) 
ECW:ICW               
0.6 0.01 0.99 0.50 0.30 0.70 0.70 0.50 
0.75 0.53 0.50 0.71 0.31 0.70 0.70 0.71 
0.8 0.63 0.38 0.71 0.30 0.70 0.70 0.71 
0.85 0.84 0.13 0.70 0.25 0.70 0.75 0.70 
0.9 a 0.99 0.01 0.70 0.50 0.70 0.50 0.70 
Table 4.7.  Diagnostic accuracy of Ritz measures (at several cut-off points) in diagnosing impending dehydration (295-300mOsm/l) based on 
alternate equations for TBW, ICW and ECW in older people (Ritz 2001), and on the 27 participants with reliable MF-BIA data. 
a
 0.1 fraction added to all 4 cells of the 2x2 table due to the presence of a zero in one of the cells that prevents at least one of the properties being 
calculated.  PPV: positive predictive value.  NPV: negative predictive value.  TBW, ICW and ECW were all expressed as percentages of body 
weight (TBW%, ICW%, ECW%).   
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability    (-
ve) Post-test probability (+ve) 
TBW%        
45% 0.42 0.80 0.63 0.63 0.44 0.37 0.63 
46% 0.50 0.60 0.50 0.60 0.44 0.40 0.50 
47% 0.67 0.53 0.53 0.67 0.44 0.33 0.53 
48% 0.83 0.40 0.53 0.75 0.44 0.25 0.53 
50% 0.91 0.01 0.42 0.08 0.44 0.37 0.63 
ICW%        
25% 0.33 0.80 0.57 0.60 0.44 0.40 0.57 
26% 0.42 0.73 0.56 0.61 0.44 0.39 0.56 
27% 0.58 0.53 0.50 0.62 0.44 0.38 0.50 
28% 0.75 0.40 0.50 0.67 0.44 0.33 0.50 
29% 0.83 0.33 0.50 0.71 0.44 0.29 0.50 
30% a 0.92 0.13 0.46 0.67 0.44 0.33 0.46 
Table 4.8.  Diagnostic accuracy of MF-BIA (Ritz 2001) against measured serum osmolality (current dehydration), continued 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability    (-
ve) Post-test probability (+ve) 
ECW%        
19% 0.42 0.67 0.50 0.59 0.44 0.41 0.50 
20% 0.58 0.47 0.47 0.58 0.44 0.42 0.47 
21% 0.83 0.20 0.46 0.60 0.44 0.40 0.46 
22% a 0.92 0.13 0.46 0.67 0.44 0.33 0.46 
ECW:ICW        
0.75 0.50 0.47 0.43 0.54 0.44 0.46 0.43 
0.8 0.58 0.33 0.41 0.50 0.44 0.50 0.41 
0.85 0.83 0.13 0.44 0.50 0.44 0.50 0.44 
0.9 a 0.99 0.01 0.45 0.50 0.44 0.50 0.45 
Table 4.8.  Diagnostic accuracy of MF-BIA (Ritz 2001) against measured serum osmolality (current dehydration) at several cut-off points in 
diagnosing current dehydration based on alternate equations for TBW, ICW and ECW in older people (Ritz 2001) against serum  
 Osmolarity (>300 mOsm/L).   a 0.1 fraction added to all 4 cells of the 2x2 table due to the presence of a zero in one of the cells that prevents at 
least one of the properties being calculated.  PPV: positive predictive value.  NPV: negative predictive value.  TBW, ICW and ECW were all 
expressed as percentages of body weight (TBW%, ICW%, ECW%).   
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
TBW%        
45%  0.16 0.99 0.97 0.34 0.70 0.67 0.97 
50%  0.32 0.75 0.75 0.32 0.70 0.68 0.75 
52%  0.37 0.63 0.70 0.29 0.70 0.71 0.70 
53%  0.53 0.38 0.67 0.25 0.70 0.75 0.67 
54%  0.79 0.25 0.71 0.33 0.70 0.67 0.71 
55%  0.90 0.13 0.71 0.33 0.70 0.67 0.71 
ICW%        
53%  0.16 0.63 0.50 0.24 0.70 0.76 0.50 
55%  0.58 0.38 0.69 0.27 0.70 0.73 0.69 
57%  0.84 0.25 0.73 0.40 0.70 0.60 0.73 
59% 0.99 0.01 0.70 0.50 0.70 0.50 0.70 
Table 4.9. Diagnostic Accuracy of MF-BIA against calculated serum osmolarity (impending dehydration), continued 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
ECW%        
50%  1.00 0.13 0.73 1.00 0.70 0.00 0.73 
47%  0.84 0.38 0.76 0.50 0.70 0.50 0.76 
46%  0.21 0.99 0.98 0.35 0.70 0.65 0.98 
45%  0.42 0.63 0.73 0.31 0.70 0.69 0.73 
42%  0.00 0.88 0.00 0.27 0.70 0.73 0.00 
ECW:ICW        
0.6  0.01 0.99 0.50 0.30 0.70 0.70 0.50 
0.75  0.16 0.63 0.50 0.24 0.70 0.76 0.50 
0.80   0.21 0.63 0.57 0.25 0.70 0.75 0.57 
0.9  0.84 0.38 0.76 0.50 0.70 0.50 0.76 
1.1 0.99 0.01 0.70 0.50 0.70 0.50 0.70 
Table 4.9.  Diagnostic Accuracy of MF-BIA against calculated serum osmolarity (impending dehydration) diagnostic accuracy of MF-BIA 
measures (at several cut-off points) by Maltron BioScan 920-2 in diagnosing impending dehydration against calculated serum osmolarity 
 (>295mOsm/L). 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
TBW%        
45%  0.25 0.99 0.97 0.62 0.45* 0..38 0.97 
50%  0.33 0.73 0.50 0.58 0.44 0.42 0.5 
52%  0.42 0.67 0.50 0.59 0.44 0.42 0.5 
53%  0.42 0.67 0.47 0.58 0.44 0.42 0.47 
54%  0.75 0.20 0.43 0.50 0.44 0.5 0.43 
55%  0.83 0.07 0.42 0.33 0.44 0.67 0.42 
ICW%        
53%  0.17 0.73 0.33 0.52 0.44 0.48 0.33 
55%  0.67 0.47 0.50 0.64 0.44 0.36 0.5 
57%  1.00 0.33 0.55 1.00 0.44 0.00 0.55 
Table 4.10. Diagnostic accuracy of MF-BIA measures in diagnosing current dehydration against calculated serum osmolarity 
(>300mOsm/L), continued 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
        
ECW%        
49%  0.92 0.13 0.46 0.67 0.44 0.33 0.46 
47%  0.83 0.26 0.48 0.67 0.44 0.33 0.48 
46%  0.58 0.47 0.47 0.58 0.44 0.42 0.47 
45%  0.33 0.53 0.36 0.50 0.44 0.50 0.36 
42%  0.00 0.93 0.0 0.54 0.44 0.46 0.00 
ECW:ICW        
0.6  0.01* 0.99 0.50 0.56 0.45* 0.44 0.50 
0.75  0.00 0.60 0.00 0.43 0.44 0.57 0.00 
0.85   0.58 0.47 0.47 0.58 0.44 0.42 0.47 
0.9  0.83 0.27 0.48 0.67 0.44 0.33 0.48 
0.95  0.92 0.13 0.46 0.67 0.44 0.33 0.46 
Table 4.10.  Diagnostic accuracy of MF-BIA measures by Maltron BioScan 920-2 (at several cut-off points) in diagnosing current dehydration 
against calculated serum osmolarity (>300mOsm/L). 
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4.4.6 Diagnostic accuracy of MF-BIA by men and women:  
 
Tables 4.11 a and 4.11 b present the diagnostic accuracy of MF-BIA against measured 
serum Osmolality (impending dehydration) in men and women, TBW% (as a 
percentage of body weight) are based on internal equations in Maltron Bio-Scan 92-2 
for TBW.  None of the cut off points for either men or women had a sensitivity and 
specificity >60% respectively.  Tables 4.12 a and 4.12 b presents the diagnostic 
accuracy of MF-BIA for men and women at several TBW% cut off points (as a 
percentage of body weight) against measured serum osmolality in diagnosing current 
dehydration (>300mOsm/kg).  None of the cut off points for either men or women had a 
sensitivity and specificity >60% respectively.  
 
Tables 4.13 a and 4.13 b presents the diagnostic accuracy of MF-BIA for men and 
women at several TBW% cut off points (as a percentage of body weight) based on 
alternate equations for TBW in older people (Ritz 2001)  against measured serum 
osmolality in diagnosing impending dehydration (295-300mOsm/kg).   In men only at 
TBW of 47% cut off sensitivity and specify was >60%, but no TBW% cut off for 
women was >60%.   Tables 4.14 a and 4.14 b presents the diagnostic accuracy of MF-
BIA for men and women at several TBW% cut off points (as a percentage of body 
weight) based on alternate equations for TBW in older people (Ritz 2001)  against 
measured serum osmolality in diagnosing current dehydration (>300mOsm/kg).   In 
men only sensitivity and specificity was >60% at 46 and 47% TBW% cut off points.   
 
Tables 4.15 a and 4.15 b presents the diagnostic accuracy of MF-BIA for men and 
women at several TBW% cut off points (as a percentage of body weight) based on 
alternate equations for TBW in older people (Ritz 2001)  against calculated serum 
osmolarity in diagnosing impending dehydration (295-300mOsm/L).   In women only 
sensitivity and specificity was >60% at 45% TBW% cut off points.   Tables 4.16 a and 
4.16 b presents the diagnostic accuracy of MF-BIA for men and women at several 
TBW% cut off points (as a percentage of body weight) based on alternate equations for 
TBW in older people (Ritz 2001)  against calculated serum osmolarity in diagnosing 
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current dehydration (>300mOsm/L).   In men only sensitivity and specificity was >60% 
at 47% TBW% cut off points.   
 
Tables 4.17 a and 4.17 b presents the diagnostic accuracy of MF-BIA for men and 
women at several TBW% cut off points (as a percentage of body weight) based on MF-
BIA internal equations for TBW against calculated serum osmolarity in diagnosing 
impending dehydration (295-300mOsm/L).   In women only sensitivity and specificity 
was >60% at 49%, 50%, and 52% TBW% cut off points showing very similar 
sensitivity and specificity.  Tables 4.18 a and 4.18 b presents the diagnostic accuracy of 
MF-BIA for men and women at several TBW% cut off points (as a percentage of body 
weight) based on MF-BIA internal equations for TBW against calculated serum 
osmolarity in diagnosing current dehydration (>300mOsm/L).  None of the TBW% cut 
off points showed a sensitivity and specificity >60%.    
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test Probability    
(-ve) 
Post-test probability 
(+ve) 
TBW%         
45%  0.13 0.99 0.92 0.53 0.50 0.47 0.92 
50%  0.13 0.88 0.50 0.50 0.50 0.50 0.50 
52%  0.25 0.75 0.50 0.50 0.50 0.50 0.50 
53% 0.38 0.50 0.43 0.44 0.50 0.56 0.43 
54%  0.75 0.38 0.55 0.6 0.50 0.40 0.55 
55%  0.88 0.13 0.50 0.50 0.50 0.50 0.50 
Table 4.11a.  The diagnostic accuracy of MF-BIA against measured serum Osmolality (impending dehydration) in men at several TBW% cut off 
points (as a percentage of body weight) are based on internal equations in Maltron Bio-Scan 92-2 for TBW. 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test Probability    
(-ve) 
Post-test probability 
(+ve) 
TBW%         
45%  0.14 0.75 0.50 0.33 0.64 0.67 0.50 
50%  0.57 0.50 0.67 0.40 0.64 0.60 0.67 
52%  0.57 0.50 0.67 0.40 0.64 0.60 0.67 
54%  0.57 0.50 0.67 0.0.40 0.64 0.60 0.67 
55%  0.86 0.02 0.60 0.09 0.63* 0.92 0.60 
Table 4.11b.  The diagnostic accuracy of MF-BIA against measured serum Osmolality (impending dehydration) in women at several TBW% cut 
off points (as a percentage of body weight) based on internal equations in Maltron Bio-Scan 92-2 for TBW. 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
probability    (-ve) 
Post-test probability 
(+ve) 
TBW%        
45%  0.34 0.99 0.92 0.86 0.20* 0.14 0.92 
50%  0.33 0.92 0.50 0.86 0.19 0.14 0.5 
52%  0.33 0.77 0.25 0.83 0.19 0.17 0.25 
53%  0.67 0.62 0.29 0.89 0.19 0.11 0.29 
54% 1.00 0.38 0.27 1.00 0.19 0.00 0.27 
55% 1.00 0.15 0.21 1.00 0.19 0.00 0.21 
Table 4.12a.  The diagnostic accuracy of MF-BIA in men at several TBW% cut off points (as a percentage of body weight) against measured 
serum osmolality in diagnosing current dehydration (>300mOsm/kg). 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
probability    (-ve) 
Post-test probability 
(+ve) 
TBW%        
45%  0.00 0.75 0.00 0.67 0.27 0.33 0.00 
50%  0.33 0.38 0.17 0.60 0.27 0.40 0.17 
52%  0.33 0.38 0.17 0.60 0.27 0.40 0.17 
53%  0.67 0.25 0.25 0.67 0.27 0.33 0.25 
54% 1.00 0.13 0.30 1.00 0.27 0.00 0.30 
55% 1.00 0.13 0.30 1.00 0.27 0.00 0.30 
Table 4.12b.  The diagnostic accuracy of MF-BIA in women at several TBW% cut off points (as a percentage of body weight) against measured 
serum osmolality in diagnosing current dehydration (>300mOsm/kg). 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability Post-test Probability       (-ve) Post-test probability (+ve) 
TBW%               
45% 0.13 0.99 0.92 0.53 0.50 0.47 0.92 
46% 0.38 0.88 0.75 0.58 0.50 0.42 0.75 
47% 0.63 0.75 0.71 0.67 0.50 0.33 0.71 
48% 0.75 0.50 0.60 0.67 0.50 0.33 0.60 
49% 0.88 0.50 0.64 0.80 0.50 0.20 0.64 
50% 0.88 0.50 0.64 0.80 0.50 0.20 0.64 
51% 0.88 0.25 0.54 0.67 0.50 0.33 0.54 
52% 0.88 0.13 0 .50 0.50 0.50 0.50 0.50 
Table 4.13a.  The diagnostic accuracy of MF-BIA in men at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against measured serum osmolality in diagnosing impending dehydration (295-300mOsm/kg). 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability Post-test Probability       (-ve) Post-test probability (+ve) 
TBW%               
40% 0.29 0.50 0.50 0.29 0.64 0.71 0.50 
43% 0.29 0.50 0.50 0.29 0.64 0.71 0.50 
44% 0.43 0.50 0.60 0.33 0.64 0.67 0.60 
45% 0.71 0.50 0.71 0.50 0.64 0.50 0.71 
47% 0.71 0.25 0.63 0.33 0.64 0.67 0.63 
48% 0.86 0.25 0.67 0.50 0.64 0.50 0.67 
50% 0.86 0.25 0.67 0.50 0.64 0.50 0.67 
52% 0.99 0.02 0.63 0.50 0.63* 0.50 0.63 
Table 4.13b.  The diagnostic accuracy of MF-BIA in women at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against measured serum osmolality in diagnosing impending dehydration (295-300mOsm/kg). 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
Probability (-ve) 
Post-test probability 
(+ve) 
TBW%        
45% 0.34 0.99 0.92 0.86 0.20* 0.14 0.92 
46% 0.67 0.85 0.50 0.92 0.19 0.08 0.50 
47% 1.00 0.69 0.43 1.00 0.19 0.00 0.43 
48% 1.00 0.46 0.30 1.00 0.19 0.00 0.30 
50% 1.00 0.39 0.27 1.00 0.19 0.00 0.27 
52% 1.00 0.15 0.21 1.00 0.19 0.00 0.21 
55% 1.00 0.08 0.20 1.00 0.19 0.00 0.20 
Table 4.14a.  The diagnostic accuracy of MF-BIA in men at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against measured serum osmolality in diagnosing current dehydration (>300mOsm/kg). 
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Cut-off point Sensitivity Specificity PPV NPV Pre-test Probability 
Post-test 
Probability (-ve) 
Post-test probability 
(+ve) 
TBW%        
40% 0.33 0.63 0.25 0.71 0.27 0.29 0.25 
43% 0.33 0.63 0.25 0.71 0.27 0.29 0.25 
44% 0.33 0.50 0.20 0.67 0.27 0.23 0.20 
45% 0.67 0.38 0.29 0.75 0.27 0.25 0.29 
47% 0.67 0.25 0.25 0.67 0.27 0.33 0.25 
48% 0.67 0.13 0.22 0.50 0.27 0.50 0.22 
50% 0.67 0.13 0.22 0.50 0.27 0.50 0.22 
52% 0.97 0.01 0.28 0.50 0.28* 0.50 0.28 
55% 0.97 0.01 0.28 0.50 0.28* 0.50 0.28 
Table 4.14b.   The diagnostic accuracy of MF-BIA in women at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against measured serum osmolality in diagnosing current dehydration (>300mOsm/kg) 
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Cut-off 
point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test  
Probability    (-ve) 
Post-test  
probability (+ve) 
TBW%               
45% 0.09 0.98 0.92 0.34 0.68* 0.66 0.92 
46% 0.37 0.98 0.98 0.42 0.68* 0.58 0.98 
47% 0.55 0.80 0.86 0.44 0.69 0.56 0.86 
48% 0.64 0.40 0.70 0.33 0.69 0.67 0.70 
49% 0.72 0.40 0.73 0.40 0.69 0.60 0.73 
50% 0.72 0.40 0.72 0.40 0.69 0.60 0.73 
51% 0.82 0.20 0.69 0.33 0.69 0.67 0.69 
52% 0.91 0.20 0.71 0.50 0.69 0.50 0.71 
Table 4.15a.   The diagnostic accuracy of MF-BIA in men at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against calculated serum osmolarity in diagnosing impending dehydration (295-300mOsm/L). 
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  Cut-off 
point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability       (-
ve) Post-test probability (+ve) 
TBW%               
40% 0.38 0.67 0.75 0.29 0.73 0.71 0.75 
43% 0.38 0.67 0.75 0.29 0.73 0.71 0.75 
44% 0.50 0.67 0.80 0.33 0.73 0.67 0.80 
45% 0.75 0.67 0.86 0.50 0.73 0.50 0.86 
46% 0.75 0.33 0.75 0.33 0.73 0.67 0.75 
47% 0.75 0.33 0.75 0.33 0.73 0.67 0.75 
48% 0.88 0.33 0.78 0.50 0.73 0.50 0.78 
50% 0.88 0.33 0.78 0.50 0.73 0.50 0.78 
52% 0.99 0.03 0.72 0.50 0.72* 0.50 0.72 
Table 4.15b.   The diagnostic accuracy of MF-BIA in women at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against calculated serum osmolarity in diagnosing impending dehydration (295-300mOsm/L). 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability    (-
ve) Post-test probability (+ve) 
TBW%        
45% 0.18 0.99 0.92 0.66 0.38 0.34 0.92 
46% 0.33 0.80 0.50 0.67 0.38 0.33 0.50 
47% 0.67 0.70 0.57 0.78 0.38 0.22 0.57 
48% 0.83 0.50 0.50 0.83 0.38 0.17 0.50 
49% 0.83 0.40 0.46 0.8 0.38 0.20 0.46 
50% 0.83 0.40 0.46 0.80 0.38 0.20 0.46 
Table 4.16a.   The diagnostic accuracy of MF-BIA for men at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against calculated serum osmolarity in diagnosing current dehydration (>300mOsm/L). 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability 
Post-test Probability    (-
ve) Post-test probability (+ve) 
TBW%        
40% 0.33 0.60 0.50 0.43 0.55 0.57 0.50 
43% 0.33 0.60 0.50 0.43 0.55 0.57 0.50 
44% 0.33 0.40 0.40 0.33 0.55 0.67 0.40 
45% 0.67 0.40 0.57 0.50 0.55 0.50 0.57 
46% 0.67 0.20 0.50 0.33 0.55 0.67 0.50 
47% 0.67 0.20 0.50 0.33 0.55 0.67 0.50 
48% 0.83 0.20 0.56 0.50 0.55 0.50 0.56 
49% 0.83 0.20 0.56 0.50 0.55 0.50 0.56 
50% 0.83 0.20 0.56 0.50 0.55 0.50 0.56 
Table 4.16b.  The diagnostic accuracy of MF-BIA in women at several TBW% cut off points (as a percentage of body weight) based on alternate 
equations for TBW in older people (Ritz 2001)  against calculated serum osmolarity in diagnosing current dehydrati 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
TBW%        
45%  0.09 0.98 0.92 0.34 0.68* 0.66 0.92 
50%  0.09 0.80 0.50 0.29 0.69 0.71 0.50 
52%  0.18 0.60 0.50 0.25 0.69 0.75 0.50 
53% 0.36 0.40 0.57 0.22 0.69 0.78 0.57 
54%  0.73 0.40 0.73 0.40 0.69 0.60 0.73 
55%  0.90 0.20 0.71 0.50 0.69 0.50 0.71 
Table 4.17a.  The diagnostic accuracy of MF-BIA for men at several TBW% cut off points (as a percentage of body weight) based on MF-BIA 
internal equations for TBW against calculated serum osmolarity in diagnosing impending dehydration (295-300mOsm/L). 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
TBW%        
45%  0.26 0.97 0.95 0.34 0.72* 0.66 0.95 
48% 0.50 0.67 0.80 0.33 0.73 0.67 0.80 
49% 0.63 0.67 0.83 0.40 0.73 0.60 0.83 
50%  0.63 0.67 0.83 0.40 0.73 0.60 0.83 
52%  0.63 0.67 0.83 0.40 0.73 0.60 0.83 
53% 0.75 0.33 0.75 0.33 0.73 0.67 0.75 
54%  0.87 0.03 0.70 0.08 0.72* 0.92 0.70 
Table 4.17b.  The diagnostic accuracy of MF-BIA for women at several TBW% cut off points (as a percentage of body weight) based on MF-
BIA internal equations for TBW against calculated serum osmolarity in diagnosing impending dehydration (295-300mOsm/L). 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
TBW%        
45%  0.18 0.99 0.92 0.66 0.38* 0.34 0.92 
50%  0.17 0.90 0.50 0.64 0.38 0.36 0.50 
52%  0.33 0.80 0.50 0.67 0.38 0.33 0.50 
53%  0.50 0.60 0.43 0.67 0.38 0.33 0.43 
54%  0.67 0.30 0.36 0.60 0.38 0.40 0.36 
55%  0.83 0.10 0.36 0.50 0.38 0.50 0.38 
Table 4.18a.   The diagnostic accuracy of MF-BIA for men at several TBW% cut off points (as a percentage of body weight) based on MF-BIA 
internal equations for TBW against calculated serum osmolarity in diagnosing current dehydration (>300mOsm/L). 
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Cut-off point Sensitivity Specificity PPV NPV 
Pre-test 
Probability Post-test probability (-ve) Post-test probability (+ve) 
TBW%        
45%  0.34 0.98 0.96 0.55 0.54* 0.45 0.96 
50%  0.50 0.40 0.50 0.40 0.55 0.60 0.50 
52%  0.50 0.40 0.50 0.40 0.55 0.60 0.50 
53%  0.67 0.20 0.50 0.33 0.55 0.67 0.50 
55%  0.82 0.02 0.50 0.08 0.54* 0.92 0.50 
Table 4.18b.   The diagnostic accuracy of MF-BIA for women at several TBW% cut off points (as a percentage of body weight) based on MF-
BIA internal equations for TBW against calculated serum osmolarity in diagnosing current dehydration (>300mOsm/L). 
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4.6 Discussion 
 
 
Only 60% (n=27) participant data was included in the analysis and 40% (n=18).  
Although I tried different ways of calculating TBW, ICW and ECW, and defined 
dehydration using both serum osmolality and serum osmolarity (16 sets of calculations 
assessing at least 5 cut-off points each, for both impending and current dehydration, i. e 
over 160 2x2 tables), only 2 cut-off points had both sensitivity and specificity of at least 
60%.  Limited diagnostic accuracy was observed for TBW% at 46% when calculated 
using equations developed for older people (sensitivity 67%, specificity 62%) for 
current dehydration by measured osmolality (>300 mOsmol/kg), but positive and 
negative likelihood ratios were poor (1.75 and 0.54 respectively).  Similarly TBW at 
47%, only with equations developed for older people, showed limited diagnostic 
accuracy (sensitivity 63% and specificity 63%, LR+ 1.7 and LR– 0.6) for impending 
dehydration as assessed by calculated serum osmolarity (≥295 mOsmol/L).  When 
internal equipment equations for estimating TBW were used no cut off were even 
minimally diagnostic. In this population of 27 people with recent strokes, MF-BIA did 
not fulfil its promise as a diagnostic tool for water-loss dehydration.   
 
Calculated serum osmolarity was not good at predicting those with current dehydration 
by the reference standard, measured serum osmolality, and using calculated osmolarity 
resulted in 44% of our population being labelled as having current dehydration, 
compared to 22% by serum osmolality.   
 
4.6.1 Diagnostic Accuracy 
 
The limited diagnostic accuracy for current dehydration by osmolality at TBW% of 46% 
(sensitivity 67%, specificity 62%) using  the impedance output from MF-BIA to 
calculate TBW% suggests that only 67 of every 100 people with current dehydration by 
serum osmolality will be “positive” using TBW% as the test, meaning that 33 of every 
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100 with current dehydration will be missed.  Similarly the specificity of 62% suggests 
that for every 100 people without current dehydration 62 will have a negative test but 38 
will have a positive test1.  This is a very high level of false positives and negatives, 
suggesting that MF-BIA is not useful in diagnosing water-loss dehydration.  The test’s 
positive (PPV) and negative (NPV) predictive values2  as well as pre and post test 
probabilities provide more information on the utility of TBW% at the 46% cut off point.  
The PPV of 33% (equivalent to the positive post-test probability of 33%) suggests that 
only 33% of those who are diagnosed as having current dehydration by MF-BIA truly 
have current dehydration by serum osmolality.  The NPV of 87% is clearly better, 
meaning that 87% of those diagnosed as not having current dehydration are truly 
without current dehydration (and this is another way of stating the negative post-test 
probability of 13%).  The positive likelihood ratio (LR+) was 1.75 and negative 
likelihood ratio (LR-) 0.543 suggesting that for a person “positive” for dehydration by  
this test the odds are 1.75 that dehydration is present compared to 1.00 for a person 
“negative” for dehydration.   
 
Studies evaluating the utility of MF-BIA in diagnosing dehydration in clinical settings 
are scarce. The findings of my study suggest that MF-BIA is not a useful diagnostic tool 
and are in broad agreement with those of Olde Rikkert et al.  They found that in 
dehydrated geriatric patients (n=53) the sensitivity of diagnosing dehydration using 100 
kHz MF-BIA measurements was only 14% - very poor sensitivity, and sensitivity was 
not improved when other frequencies were tested (234). 
 
 
                                                     
1
 Sensitivity is the proportion of people who have the disorder who test positive. Specificity is 
the proportion of people who do not have the disorder who test negative. 
2
 The positive predictive value is the ratio of true positives to all positives, and 
represents the proportion of those with a positive result that are correctly diagnosed 
(according to the reference standard).   The negative predictive value is the proportion 
of those with a negative result that are correctly diagnosed (so test negative on the 
reference standard). 
3
 The likelihood ratio for a positive result (LR+) tells you how much the odds of 
dehydration increase when a test is positive. The likelihood ratio for a negative result 
(LR-) tells you how much the odds of dehydration decrease when a test is negative. 
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4.6.2 The importance of MF-BIA results 
 
Leaving the mathematics of diagnostic accuracy of MF-BIA aside and observing data 
generated by MF-BIA also suggested that MF-BIA generated outcomes are not coherent 
with the diagnosis of dehydration.  Table 2 suggested no significant difference in MF-
BIA measures between hydrated, impending, and current dehydration groups.  The 
intracellular water content reflects information on the state of hydration at the cellular 
level.  Cellular hydration status can change within minutes under the effects of stress, 
nutrients, hormones, and other factors (235).   
 
Therefore MF-BIA measures do not appear to usefully reflect changes observed in 
serum osmolality or osmolarity or to sensitively identify the dehydrated state at the 
cellular level.    
 
The state of hydration at a cellular level is important.  If MF-BIA fails to identify 
dehydration as a sole method in diagnosing the hydration status this can result in loss of 
body tissue.  Haussinger et al (235) suggested that a well hydrated cell increases 
anabolic processes, but a dehydrated cell shifts metabolism to catabolic processes 
especially at the muscle tissue.   If recovery is to occur in a highly stressed patient after 
stroke, we want to be able to make sure that they are in an anabolic state rather than in a 
catabolic state that can affect liver function and may influence general weakness 
(muscle catabolism) that can influence functional recovery if experienced, or delayed 
rehabilitation recovery.   Dehydration has been documented to correlate with poor 
outcomes after stroke.  Bhalla (98)  found that the 30% of their 167 stroke patients who 
had raised serum osmolality (>296 mOsm/kg) had increased risk of mortality at 3 
months (OR 2.4, 95%CI 1.0 t 5.9).  Kelly (121) found that in their 102 acute ischaemic 
stroke patients raised serum osmolality (>297mOsm/kg, in 24% of their patients) on day 
9 following admission was associated with increased odds of venous thromboembolism 
(OR 4.7, 95% CI 1.4 to 16.3).  
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4.6.3 The Convenience of the Maltron BioScan 920-2 
 
The Maltron website states that “The BioScan 920-2 Multi-frequency Analyser with its 
unique features is a rapid, non-invasive, inexpensive method for evaluating hydration 
and nutrition status” (236) .  Among other things it suggests applications in “fluid 
retention”, “effects of hydration and dehydration” and “estimation of Total Body Water, 
Extra/Intracellular Water”.  I was unable to verify this. 
 
Despite the Maltron website reporting that it is “quick, safe and easy” and “no 
assistance or technical knowledge is required” (236) the machine is not user friendly.  
Without a keyboard, data entry and saving of data are slow and may result in errors and 
data loss. Re-running a second measurement for the same participant requires re-
entering all the same information again or the new test overwrites existing data.  
Analysed data are not easily accessible to visual check without downloading the full 
data set, and there is no warning when unrealistic readings are registered.  On- site 
readout of each variable for each participant was time consuming and unrealistic in an 
acute stroke unit.  All data had to be downloaded first for a swift read out making it 
disadvantageous if discrepancies are present causing data loss.   
 
Approaching the same participant again would ethically require further consent if 
patient is still eligible (48 hours time frame) and would require another serum 
osmolality test; a considerably invasive procedure as it requires venepuncture.   MF-
BIA equipment was used before in a previous research and no discrepancies were 
encountered.   First 20 patients’ data was checked for discrepancies.  None was present 
giving confidence to the investigator.      
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4.6.4 Strengths and weaknesses 
 
Study strengths include the use of both serum osmolality and calculated osmolarity as 
reference standards,  conducted a population with high levels of dehydration, and 
recording serum osmolality and other serum measures (sodium, potassium, glucose, 
urea) within 20 minutes of MF-BIA measurements (enabling me to capture cellular 
hydration status as evaluated by MF-BIA and its coherence with reference serum 
values).   
 
Weaknesses included small sample size and loss of MF-BIA data from several 
participants due to equipment malfunction.  MF-BIA machine malfunction occurred 
unexpectedly. I checked data of first 20 patients for any discrepancies and none was 
present giving me the confidence in the equipment.  The data of the last 18 patients only 
included in this dehydration study was omitted as discrepancies occurred.  The possible 
explanation is that towards the end of my PhD study, other researchers were interested 
to examine the utility of MF-BIA for their own future studies. Therefore a training 
session was provided and they also tested the machine. This might have re-set the 
machine somehow causing error in measurements for the last 18 patients included in the 
hydration study.    
 
In summary MF-BIA is not appropriate for the diagnosis of water-loss dehydration after 
stroke.  Diagnostic accuracy is far too low to usefully diagnose dehydration current or 
impending dehydration at any selected cut-off point.   
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Chapter 5:  Validation studies of the BioScan 920-2 multi-frequency 
bio electrical impedance machine in patients with recent ischaemic 
stroke or transient ischaemic attack against the Dual X-ray 
Absorptiometry  scan 
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Abstract 
 
Introduction: In the clinical study, the assessments of body composition changes were 
conducted using the multi-frequency bioelectrical impedance analysis (MF-BIA) 
(Maltron BioScan 920-2).  However, dual-x ray absorptiometry (DEXA) is considered 
as the Gold Standard measurement. Therefore an external validation study of MF-BIA 
measurement using BioScan against DEXA was conducted. Two internal validation 
studies were also conducted to assess the reproducibility of the MF-BIA machine. 
    
Methods: Ten participants were recruited for the external validation of whom seven 
participated in the longitudinal study (Chapter 3).  Fat free mass and fat mass 
measurements recorded by MF-BIA machine immediately after the Dual X-ray 
Absorptiometry (DEXA) scan were used to validate MF-BIA against DEXA as primary 
measures along with protein mass, muscle mass and body cell mass.  Additionally, two 
internal validation studies were conducted; (1) 10 consecutive measurements of MF-
BIA recorded for each participant after the DEXA scan examination in 10 participants 
attending DEXA examination, and (2) two consecutive measurements recorded on both 
admission and discharge for each participants of the longitudinal study.  Bland and 
Altman analysis was carried out to examine the extent of agreement between MF-BIA 
and DEXA for the external validation.  Cronbach’s-α was calculated for the reliability 
analysis to assess internal validity of MF-BIA.  
 
Results: Of the ten participants included in external validation study, five were of 
normal weight (20.0-25.0 kg/m2), four were overweight (25.0-29.9 kg/m2), and one was 
obese (≥30.0 kg/m2).  There was strong correlation between MF-BIA and DEXA with r2 
values of 0.884 and 0.778 for fat free mass and fat mass, respectively.  According to 
Bland and Altman analysis both MF-BIA and DEXA did not differ in their 
measurements.  Internal consistency of MF-BIA measurement was excellent with fat 
free mass and fat mass assessed on admission and discharge (Cronbach’s Alpha > 0.9 
for both; n=40).  Internal consistency was also excellent for 10 MF-BIA measurements 
measured at the same time of the external validation with (Cronbachs-α value > 0.9). 
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Conclusion: The findings suggested good internal consistency of MF-BIA and also 
showed good agreement and correlation of MF-BIA with DEXA with regards to fat 
mass and fat free mass measurements in stroke and TIA patient population.    
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5.1 Background 
 
The assessment of individual components of the body composition is not carried out 
routinely in daily clinical practice.  Kotler et al highlighted that “the assessment of body 
composition in clinical arena is lagging behind scientific and technological development” 
(237). It has been recognized that assessing nutritional status in clinical setting is useful 
(238). Body composition data can provide an understanding of the nutritional status and 
needs of an individual patient in clinical practice.  Body composition measurement can 
be a complex and time consuming procedure depending on the method used.  Multi-
frequency bioelectrical Impedance Analysis (MF-MF-BIA) can be one simple and swift 
method to measure body composition (please see rationale in the Chapter 3), but its 
validity against reference standard methods in stroke and transient ischaemic attack 
(TIA) patient population is not known.  This chapter presents the validation studies of 
Maltron BioScan 920-2, Multi-frequency BIA machine used in the clinical longitudinal 
study.   
 
5.1.1 Assessment of body composition 
 
Assessment of body composition can be done using simple, low technology methods as 
well as advanced methods.  Established methods that are used to assess body 
composition include skin fold thickness (56), underwater weighing and dilution method 
(174), neutron activation analysis (239), determination of total body potassium (240),  
magnetic resonance imaging (MRI) (241), and dual x ray absorptiometry (DEXA) (63).     
 
5.1.1.1 Upper Arm Anthropometrics: 
 
Upper arm anthropometrics such as triceps skin fold (TSF) and mid arm circumference 
(MAC) are nutritional assessment methods that can provide estimates of fat free mass 
and fat mass of an individual.  Skin fold thickness is used as a nutritional assessment 
method in clinical settings for bedridden or very ill patients who cannot undergo other 
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methods that require a certain level of mobility (242).  Despite the utility of upper arm 
anthropometrics as a nutritional assessment technique in bedridden patients, their 
accuracy and usefulness have been questioned.  In one study, the diagnostic accuracy of 
TSF and MAC in assessing severe malnutrition (<5th percentile for age) was examined 
against that of Body Mass Index (BMI) < 18 kg/m2 and the Subjective Global 
Assessment Tool (SGA) scores of 158 patients admitted to a hospital.  The authors 
found that the sensitivity of TSF in diagnosing severe malnutrition (as defined above) 
compared to similar diagnosis using BMI and SGA was poor with sensitivities of 62% 
and 38% for BMI and SGA, respectively (243).  Sensitivity of the MAC was better 
compared to TSF especially against SGA, but still relatively poor with sensitivity values 
of 66% and 61% for BMI and SGA, respectively (243).  This lack of sensitivity is may 
be related to the fact that both TSF and MAC provide measure of specific fat and 
muscle mass distribution in certain body area (upper arm) unlike BMI which provide a 
measurement of body mass of whole body without providing any estimation in fat or 
muscle mass or the pattern of distribution of fat. Therefore, using BMI or TSF or MAC 
as a criterion or gold standard measure for body composition is clearly not appropriate.   
 
5.1.1.2 Underwater weighing method 
 
One of the more complex methods is underwater weighting or hydrodensitometry 
method.  Underwater weighting relies on the estimation of body fat from calculated 
body density using a validated mathematical equation.  The subject’s body mass is 
calculated by dividing the measured weight by gravitational force in air and while in a 
water tank.  First, subject’s mass is calculated in air (Mair) by dividing weight (kg) by 
gravitational force (N; neutons).   To measure weight in water, the subject sits in a 
stainless steel chair placed on a Toledo platform scale in an aluminium water tank with 
a controlled water temperature between 35-36 oC, and is submerged into water up to the 
neck.  Mass in water is determined (Mwater) by multiplying volume of water times it 
density at 35-36 oC (which equates to 0.994).  The difference between body mass in air 
and water (Mair - Mwater) divided by the density of water at a temperature of 35-36 oC 
(which equates to 0.994) is used to calculate the volume of displaced water which is 
equal to body volume (244).    
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To calculate body volume accurately using this method, correction must be made by 
subtracting residual gas volume (described below) from body volume.  First residual 
volume need to be measured.   This can be done using a nitrogen analyser available in 
the water tank.  The nitrogen analyser consists of a stopcock and spirometer  (244).   
The nitrogen washout method is used to calculate the residual gas lung volume in lungs.  
In this method the subject breathes air through the stopcock. After a full expiration the 
subject is then connected to the spirometer filled with 100% oxygen.  The subject is 
then asked to inhale and exhale once every three seconds. At the third exhalation 
residual air volume is calculated using the formulae used in Rahn 1949 from nitrogen 
concentration percentage in the total volume of exhaled air in the spirometer (245). 
Once residual gas lung volume is subtracted from body volume, body density is 
calculated using the difference between Mair and Mwater (246) (as described above).  
Brozek equation is then used to calculate body fat from body density as below (247);  
 
Body Fat = 4.57/body density − 4.142) × 100 
 
Validation of the Brozek equation for estimating body fat against body fat estimated by 
dual-X ray absorptiometry (DEXA) suggest that it is very accurate in estimating body 
fat (248). Despite its  accuracy (248)underwater weighing is only used for research 
purposes and not for clinical purposes as it is not an easy method to use (174).  
Furthermore because the subject’s body is required to be submerged in the water except 
the head, it is difficult to  use in pregnant women, obese people, elderly, and people 
with disability (246), hence not pragmatic to use across patient populations.  The 
approximation of residual lung volume can be inaccurate sometimes resulting in 
imprecise body volume estimation and making it one of the main limitations of this 
method (249).   
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5.1.1.3 Dilution method 
 
The dilution method is used to measure total body water, extracellular, and intracellular 
water.  Fat free mass (FFM) can be calculated from total body water volume by 
multiplying total body water by 0.732 which is the FFM constant (250); the constant 
value is derived based on the fact that water content of the lean or fat free tissue in 
human is 73%. In this method, measuring of the total body water volume is done by 
administration of a dose of tracer labelled water into the subject either orally or 
intravenously.  The water is usually labelled with tritium, deuterium, or oxygen-18.  
Before the dose is administered a sample of urine, or blood is collected from the subject.  
Two to three hours after the labelled water administration the same pre-dose sample 
type and quantity is collected (251).   The principle behind the dilution method is that 
the tracer will reach equilibrium in the compartments intended to measure by 
distributing equally in these compartments given that this tracer is not metabolized 
(252).   Total body water (TBW) can be calculated as in formulae below.   The formulae 
assumes that the volume of a compartment (total body water (V)) can be calculated 
from ratio of the difference in the administered (D and excreted (E) dose concentrations 
to the difference of the concentration of the collected fluid (dt) after tracer dose 
administration and its concentration before dose administration (d0).   
 
V=k1 x k2 xk3 xk4 x {(D-E)/ (dt-d0)} 
 
Correction factors are k1, k2, k3, and k4 (251).  Fat free mass can then be calculated 
given that total body water is a constant and present in 73% of fat free mass (253).  Fat 
free mass can then be subtracted from body weight to estimate fat mass.  The dilution 
method can also be used to calculate extracellular water (ECW) as the same way as 
calculating total body water by using deuterated bromide or chloride which diffuses in 
ECW space.  ECW can be subtracted from TBW to calculate Intracellular water volume 
(ICW) (174).     
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The dilution method is considered to be one of the reference methods to other body 
composition methods such as Dual X-ray absorptiometry (251). However, the 
requirements for a sophisticated equipment and setting make it difficult to perform in 
daily clinical practice.  In addition, it is not as  a swift body composition assessment in 
clinical  setting as the samples must be relocated to larger facilities for analysis (254). 
 
5.1.1.4 Total Body Potassium 
 
Total body potassium method is used to estimate fat free mass (255, 256).  Potassium 
isotopes known as potassium-40 [40K] is fractionally present in the body and emits 
gamma rays radiation (257). The emission of gamma rays allows for 40K counting and 
body composition assessment given that the potassium isotope content in fat free mass 
is constant (255). For total body potassium counting, the subject lays in a supine 
position between two sodium iodide detectors (which trap gamma rays emission) for 15 
minutes in an enclosed room to allow the trapping of emitted gamma rays from the 
subject only and not radiation from the naturally occurring 40K.  The gamma rays are 
trapped by the sodium iodide (NaI) detectors and converted to total body potassium 
value (186).   
 
Other detectors are also available such as potassium chloride crystal bottles used by 
Kehayias and colleagues (258).  Total body potassium method is a precise method with 
only small variance between the 40K  body pool reflecting actual fat free mass content 
(259).  The precision of total body potassium method was further examined in older 
people by Kehayias and colleagues and they documented that total body potassium was 
precise in showing a decreasing trend with reduced fat free mass and an increasing trend 
with increased fat mass in ageing subjects experiencing sarcopenia (258).  The main 
drawback of total body potassium counting method is that it requires sophisticated and 
expensive set up (detectors, special chamber, etc.) that are not easily available for 
clinical usage.   
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5.1.1.5 Magnetic Resonance Imaging (MRI) 
 
Body composition can be measured using more advanced techniques such as Magnetic 
Resonance Imaging (MRI). MRI method involves exposing the human body 
components to a magnetic field.  The body consists of atoms as the case of all naturally 
occurring subjects.  When the nucleus of an atom, consisting of neutron and protons, is 
exposed to the magnetic field, the protons position themselves perpendicular to the 
magnetic field.  The time taken for the protons to align with the magnetic field is called 
longitudinal relaxation time (T1).  This alignment or orientation is lost once the 
disappearing magnetic causes protons to rotate back to their initial positions. This 
process releases energy as they realign to their pre-exposure position.  The energy 
released can be captured as radiofrequency.  The time for the protons to return to their 
original orientation, before the application of the magnetic field, is expressed as 
transverse relaxation time (T2).  
 
Both T1 and T2 differ between different tissues.  The detection of radiofrequency at 
different interval allows the determination of the volume of each tissue (260, 261).  The 
main advantage of MRI is that it allows for the imaging of each different body tissue 
compartment including subcutaneous and visceral adipose tissue unlike other methods 
discussed so far which allow quantification of fat mass and fat free mass only.  MRI 
also shows good accuracy.  The mean variance between MRI estimated visceral and 
subcutaneous fat and actual weights measured of the three human cadavers was <10% 
(262).  Other validation studies include work by Engstorm and colleagues 
demonstrating that MRI provided accurate measurement of the cross sectional area of 
human cadaver thighs compared to anatomical standard (AN) measurement(263).  The 
high resolution images of MRI allowed for good estimation of muscle volume as MRI 
values were within 7.5% of the AN standard (263). MRI also showed good accuracy in 
estimating body composition volumes in animals (264).  The main disadvantage of MRI 
that it is relatively expensive, not quick to perform, requires a certain extent of subject 
mobility, and it is not advisable to carry out measurement if the person has any medical 
devices such as a pacemaker.   
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5.1.1.6 Dual Energy X-ray Absorptiometry (DEXA)  
 
The Dual Energy X-ray Absorptiometry (DEXA) is used as a reference method in 
evaluating body composition (251).  Therefore it has been increasingly used in both 
research and clinical settings.  DEXA was first used to measure bone and soft tissue 
composition (265).  The DEXA was developed based on the same principles as Dual 
Photon Absorptiometry (DPA) which generates gamma rays through a radionuclide 
source.  The principle behind DPA used in measuring body composition is that when a 
photon is directed at a subject, the intensity of the photons is reduced as they travel 
through the subject body.  The photons exiting the subject can be quantified by the 
detector on the opposite side of the subject allowing for body composition calculation 
using different formulae (251).   
 
The DPA have been shown to have excellent agreement with body fat measured by 
underwater weighing (UWW), total body potassium (TBK), and the dilution methods 
with a fat mass of 16.7±4.9 kg for DPA and a combined average fat mass of the three 
methods of 17.6±5.9 kg leading to a correlation coefficients between 0.79 and 0.99; p 
values= between 0.01 and 0.001(266).  With further technological advancement, the 
photon source of DPA was replaced with X-ray generating tubes resulting in currently 
used DEXA technology (265).   
 
The DEXA is considered to be the best body composition measurement technique with 
a precision error of less than 1.0 kg for fat mass and relative error of less than 0.8 kg for 
fat free mass percentage (63).  It also has low radiation exposure; the radiation exposure 
in each measurement is  less than 0.1 microGy (63) which is less than a whole day 
exposure to radiation emitted from the sun in a sunny summer day in the Western 
Europe such as UK.   While DEXA method is considered to be gold standard 
measurement of body composition, it is still relatively expensive, time consuming to 
perform ranging from 15-20 minutes for one measurement, and inconvenient for 
patients with disability or limited mobility – the person needs to be able to lay flat 
during the examination.  All these factors make DEXA not pragmatic to be used 
routinely in clinical practice for purposes such as screening for all patients.   
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The methods discussed above are costly, challenging, complex and they cannot be 
performed  to everyone in daily clinical practice (237). These methods are not quick as 
they require a patient/person to travel to the location of the facility.  They also require 
the presence of an expert technician and cannot be calibrated by a researcher or a 
clinician without previous appropriate training. This has led to further development in 
new methods which can evaluate body composition accurately that are cheap, 
convenient, easy to perform and easily accessible.  Multi-frequency Bioelectrical 
Impedance Analysis (MF-BIA) is one of the newer methods which were used in my 
thesis work. I discuss briefly below (please refer to Chapter 3 for more details) on the 
MF-BIA method in measuring body composition.     
 
5.1.1.7 Multi-frequency Bioelectrical Impedance Analysis 
 
Multi-frequency bioelectrical impedance analysis (MF-BIA) is one of the newer 
methods that can assess body composition. Body composition data which can be 
collected by MF-BIA include fat free mass (Kg), fat free mass percentage, fat mass (Kg), 
fat mass percentage, total body water (L), total body water percentage, extra and 
intracellular water (L), extra to intracellular water ratio, body cell mass (Kg) and 
percentage, extracellular mass (Kg) and percentage, Creatinine clearance rate (ml/min), 
glomerular filtration rate (ml/min), protein mass (Kg), mineral mass (Kg), mineral mass 
percentage, total body calcium and potassium (g), muscles mass (Kg), glycogen mass 
(g), dry weight (Kg), extracellular fluid (L), plasma fluid-intravascular (L), interstitial 
fluid-extravascular, body volume (L), and body density (Kg/L).   
 
In brief, specific equations programmed in the MF-BIA machine is used to calculate the 
body composition components simultaneously based on the quantitative value of the 
resistance imposed on the flowing electrical current by different components (tissues) of 
the body.   The underlying principle of this measurement method is that while some 
components in the extracellular space impedes the electrical current from flowing  
through the body, the intracellular components allow it to flow freely (267).  For 
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example, body components such as adipose tissue are non-conductive to electrical 
current while lean tissues such as muscle, and other elements such as electrolytes and 
water, are conductive.  Therefore, when an electrical current passes through the human 
body it faces resistance from the adipose tissue, but passes through the non-adipose 
tissue to complete its circuit without any resistance or impedance.   
 
The difference in conductivity  between different tissues is used to calculate fat mass 
and fat free mass using a validated formula already programmed in the MF-BIA 
equipment taking into account of factors such as gender, height, weight, and age (62).  
The MF-MF-BIA technique can measure body composition using a single frequency 
current (SF-MF-MF-BIA) or a multi-frequency current (MF-BIA).  In SF- BIA a single 
current of a known quantity, usually 50 kHz, is used (183), while MF-BIA uses 
electrical currents of several frequencies of incremental values (5, 50, 100, 200, 
etc., ....up to 500 kHz); Maltron BioScan 920-2, MF-BIA machine, I used in my study 
measure the body components using electrical current frequencies of (5, 50, 100, and 
200 kHz).    
 
In MF-BIA currents of various frequencies are passed through the body tissues 
separately and impedance is generated for each frequency. Electrical currents’ input and 
output difference for each frequency is measured and the difference is used in validated 
equations already integrated in the equipment to calculate body compositions.  Both SF- 
BIA and MF-BIA use empirical linear regression equations to generate results and the 
results are available to the investigator instantly (183).  MF-BIA has been previously 
used in clinical settings in several conditions. These include but are not limited to older 
patients (234), patients after coronary artery bypass graft (CABG) (268), patients with 
HIV (269), and those on dialysis (270).   The advantages of MF-BIA  include being 
easy to use, non-invasive, and requires minimal training to operate the equipment (271).  
The main disadvantage of MF-BIA is that there are several manufacturers and not all 
are validated therefore a validation against a reference standard body composition 
assessment method is required to ascertain the reliability and for future clinical use in 
specific patient/participant populations.   
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5.1.2 Validation of MF-BIA against DEXA  
 
The validation studies of MF-BIA were usually conducted against DEXA measurement 
as the gold standard method and therefore, I validated MF-BIA [BioScan 920-2, 
Maltron International Essex, United Kingdom) machine used in my project against 
DEXA.  Previous validation studies of MF-BIA against DEXA are somewhat limited, 
conducted in specific populations’ e.g. healthy volunteers but not in stroke/TIA patient 
population. However, it has been shown that the accuracy of MF-BIA measurement is 
dependent on the participant’s body mass index.  One recent study by Schafer et al (43) 
examined the validity of MF-BIA compared to DEXA in healthy subjects across a range 
of BMI categories. The MF-BIA overestimated fat mass in obese (30.0-30.9 kg/m2) 
subjects compared to DEXA (p<0.0001); difference 4.11 ± 0.34, and in overweight 
(25.0-29.9 kg/m2) subjects (p≤0.006); difference of 0.95 ± 0.33.  Despite MF-BIA’s 
overestimation of fat mass, the authors highlighted that MF-BIA measurements did 
show body fat percentage agreement with DEXA in the normal (18.5-24.9 kg/m2) and 
overweight BMI categories with a mean difference of -1.56% (limits of agreement -6.7% 
to +3.6%) and +0.58% (limits of agreement -3.8% to +5.0%), respectively.   
The agreement with DEXA appears to be weaker in people whose BMI values were in 
obese range (i.e. BMI >30 kg/m2); mean difference was 3.50% (-2.2 to +8.8%).  In their 
study, MF-BIA overestimated fat free mass in subjects with normal and overweight 
BMI categories compared to DEXA with a difference of 2.08 ± 0.32 (p<0.0001) and 
0.71 ± 0.33 (p≤0.04) respectively.  Overall conclusion was that MF-BIA is in agreement 
with DEXA when measuring normal and overweight subjects although overestimation 
occurs in obese subjects, and therefore caution should be taken in interpreting MF-MF-
BIA results in obese subjects (272).   
 
There is a dearth of data on the use of MF-BIA method in evaluating body composition 
changes after stroke/TIA. One study compared body composition changes after stroke 
between the paretic and non-paretic leg of patients (n = 35) (273).  It used the DEXA 
method in evaluating body composition, indicating that significant losses in lean body 
mass and bone density loss occurred in the paretic leg compared to the non-paretic leg 
after stroke; p<0.05 (273).   
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Efforts to have reference FFM and FM values were made mainly on healthy subjects 
(274).   Norm FFM and FM reference values in specific populations are unknown and 
still less well studied. Further validation of available machines should be carried out 
against reference method DEXA in larger studies and across wide range of specific 
populations in clinical setting.    
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5.2 Study Objective 
 
The objective of this study is to externally validate MF-BIA against gold standard 
DEXA in patients with recent stroke/TIA.  The validation of MF-BIA against DEXA 
can provide information on the level of agreement between major components of 
interest, fat mass and fat free mass, measured using MF-BIA and their corresponding 
values estimated by DEXA for the same study participant.  This study not only sought 
to carry out an external validation for MF-BIA against DEXA, but also examined the 
internal consistency of MF-BIA measurements for the same participants recorded 
several times as well as using measurement data from the longitudinal study described 
in Chapter 3.   
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5.3 Methodology 
 
The MF-BIA used in the study (Maltron BioScan 920-2, Maltron International Co. 
Essex, United Kingdom), was validated against DEXA machine (Hologic Discovery, 
Hologic Inc. Massachusetts, USA) located at the Clinical Research Trials Unit in the 
Norwich Medical School of the University of East Anglia (UEA).  The Clinical 
Research Trial Unit at the UEA is a National Health Service affiliated facility that has 
provisional Clinical Trial Unit registration with the National Institute for Health 
Research (NIHR) in England.    
 
5.3.1 External validation study 
 
For external validation of MF-BIA against DEXA (referred in this chapter as MF-BIA 
validation study), 10 participants with recent stroke/TIA who met the inclusion criteria 
were studied.  The majority of participants for external validation (n = 7) were drawn 
from the longitudinal study participants as described in the Chapter 3.  The remaining 
three participants were enrolled into the MF-BIA validation study only because their 
expected acute hospital stay was very short to provide meaningful results for the 
longitudinal study or they were not interested in participating in the longitudinal clinical 
study but agreed to participate in this sub-study.  Study participants were mainly stroke 
patients (n = 8) and the remaining two patients experienced transient ischemic attack 
(TIA). TIA patients were also included in the validation study as the purpose of the sub-
study is to evaluate the agreement of the measurements between two different 
techniques in people with recent cerebrovascular event (stroke or TIA) as opposed to 
assessment of changes in body composition after a stroke. 
 
At the time of study enrolment, I described the objectives of the validation study to 
potentially eligible patients.  I explained that the MF-BIA equipment used in the study 
can be very useful in evaluating body composition but it has not been validated in 
stroke/TIA patient population and this MF-BIA validation study will allow us to 
understand if the values provided by the MF-BIA equipment are reproducible by a gold 
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standard method, DEXA.  I also explained the potential benefit of research that if MF-
BIA could be reliably used to measure fat mass and fat free mass in stroke/TIA 
population, it may allow further research in the future that can lead to recommendation 
of the MF-BIA use in clinical practice considering that it is quick making it a useful tool 
for health care professionals in assessing the nutritional status and needs of patients.  
 
5.3.2 Sample size 
 
For correlation, a sample size of 8 would have 90% power to detect a correlation of 0.9 
at the 5% level of significance. I therefore recruited ten participants, six with a recent 
stroke and 4 with a transient ischaemic attack (TIA), from the acute stroke unit at the 
Norfolk and Norwich University 140 Hospital, UK. 
 
5.3.3 Procedure 
 
Inclusion criteria: The inclusion criteria are the same as the inclusion criteria for the 
longitudinal study described in the Chapter 3, except that TIA patients were also 
eligible for this validation study.    
 
5.3.4 Exclusion Criteria 
 
Exclusion criteria for the MF-BIA validation is the same as the exclusion criteria 
detailed in the longitudinal study in the Chapter 3.   
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5.3.5 Invitations 
 
After hospital discharge, each patient who consented to take part in the MF-BIA 
validation study was contacted by phone to set a convenient date and time for the 
participant and the research team to perform the DEXA scan, and MF-MF-BIA 
measurements for both external validation against DEXA and one of the internal 
validation studies using 10 repeated measures of MF-BIA.  An invitation letter to attend 
the Clinical Research Trials Unit with the information such as direction to CRTU 
(standard UEA campus map with CRTU location clearly marked), the appointment date 
and time was then sent to the participants by post.  The letter also included other 
information such as the duration of the procedure etc.  A car parking pass was also 
included in the postal package.  Attendance was confirmed by contacting participants by 
telephone three days prior to their CRTU visit.   
 
A consultant physician caring for the participant during their stay at the acute stroke 
unit in Norfolk and Norwich University Hospital wrote a request (Appendix XVI) for a 
DEXA scan for each participant as per the requirement of the CRTU Standard 
Operating Procedures (SOP).  Whole body scan was requested from the four options 
available including hip, spine, or forearm, because the indication for the study was to 
measure body composition as opposed to the other purpose, e.g. assessment of 
osteoporosis.  Radiation exposure confirmation of directed dose and appropriate 
approvals checklist was filled by the radiation expert to carry the scans.  
 
Upon participant’s arrival to the Clinical Research Trial Unit (CRTU) on the 
examination date, pre-scan assessment interview was performed by the researcher as 
described in detail below.   
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5.3.5 Pre-DEXA scan interview 
 
The interview was aimed at ensuring participant’s safety (Appendix VII). I used the 
standard SOP documents of CRTU for DEXA examination (Appendix XVIII).  First the 
participant was asked if they had any medical procedure within the last seven days that 
involved the use of contrast media, arterial, iodine, barium, and nuclear medicine 
isotope study.  All participants answered NO.   
 
Participants were also asked if they are wearing any metal device or object such as 
button, zips, belts, mobile phone, etc. The participant was requested to remove them if 
they were wearing or carrying with them any of such items.    
 
Finally the participant was asked if they had any surgery that resulted in having metal 
device fixed on them such as pacemaker leads, radioactive seeds, metal implants, hip 
replacement, surgical staples, or any metal foreign bodies such as shrapnel, radio-
opaque catheters or tubes, and bullets.  If any of the answer was YES it was not an issue 
but the practitioner carrying out the DEXA scan would assess if they interfere with the 
scans (Appendix XIX). 
 
The second informed consent specifically for DEXA procedure was obtained 
immediately prior to DEXA scan examination. This was required for all participants 
intended to take part in any DEXA scan for research purposes as per CRTU SOP 
(Appendix X).   
 
5.3.6 Dual X-Ray Absorptiometry (DEXA) Scan  
 
The DEXA examination was carried out using Hologic Discovery (Hologic Discovery, 
QDR series, Hologic Inc. Massachusetts, USA); image 1.  Patients were asked to lie 
down flat on their back for the scan within the marked area.  It was checked to ensure 
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that the patient lied between the marked lines, one above the head and one below the 
feet.   This marked area guarantees that the all parts of the body are exposed to the X-
ray to obtain a full body scan.  The patient’s feet were tied with a tape to ensure that 
they are kept close together. Once the scan was ready to take place the machine was run 
while the machine operator (the technician who has appropriate qualification to operate 
the scanner) and I stood in the designated area behind a barrier that protect the radiation 
exposure to the examiners.  The duration of the scan was exactly seven minutes.  Once 
the scanning finished the participant was helped to sit upright slowly. 
 
 
Image 5.1. (Hologic Discovery, QDR series, available in the Clinical Research Trial 
Unit (CRTU) at the Norwich Medical School, University of East Anglia 
 
5.3.7 Bioelectrical Impedance Analysis 
 
Immediately after performing the DEXA examination, the participant’s body 
composition measurement was carried out using multi-frequency bioelectrical 
impedance analysis (MF-BIA) as described details in the Chapter 3. Briefly, the 
participant’s weight was recorded by asking to take off their shoes and stand on the 
weight meter while wearing light clothing.  Weight was recorded to the nearest 0.1 
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kilogram (Kg). While on the weight meter, the participant was asked to stand upright 
and straight to measure their height using the stadiometer.  The stadiometer was slid 
from the above until the headpiece of stadiometer touched the top of the skull of the 
participant comfortably.  Height was then recorded to the nearest decimal point in 
centimetre (cm).  
 
The participant was then asked to lie down in a supine position on the bed in the 
examination room at the CRTU and made comfortable.  Participant information, a given 
ID number, age, gender, height, weight, and ethnicity were all entered into MF-BIA 
machine prior to body composition measurement.  This information is used by MF-BIA 
machine to calculate body composition components using pre-programmed formulas as 
described in the Chapter 3 and the introduction section of this chapter.  Once all the 
relevant necessary information was entered the preparation for the measurement was 
carried out.   Electrodes from the equipment were attached to the patients using sticky 
patches similar to ECG patches as described in the Chapter 3.   
 
The reasoning behind placing the patches on the participant after entering the 
information not before is to ensure that they are not contaminated with skin secretions if 
they stay for a longer period of time which may interfere with electrical current flow 
and the accuracy of the body composition measurements.  The cables of the MF-MF-
BIA machine were then attached to the patches with the red coloured cable (positive) 
being closer to the heart and the black coloured cable (negative) farthest.   A total of ten 
MF-BIA measurements were carried out for each participant consecutively.    
 
5.3.8 Internal validation studies of MF-BIA 
 
First Internal Validation Study:  The first for internal validation of MF-BIA came from 
the source of data from the ten MF-BIA measurements recorded in 10 participants who 
attended DEXA examination as described above which were measured for the external 
validation purpose.  The comparison of MF-BIA values among these 10 measurements 
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within an individual were also used to evaluate the internal consistency of MF-BIA.  
The data is presented as First Internal Validation study in the Results section. 
 
Second Internal Validation Study: As described in the longitudinal study of this thesis 
(Chapter 3), two consecutive measurements were made using MF-BIA for each 
participant both at the time of admission and on discharge (n=40).  The purpose of these 
two measurements on each occasion was also to evaluate the internal consistency of 
MF-MF-BIA on both at the time of admission and at hospital discharge separately in a 
larger number of participants.  Therefore, this second internal validation study of MF-
BIA was based on a total of 80 pairs of MF-BIA measurements in 40 participants. 
 
5.3.8 Statistical Analysis 
 
Statistical analysis was performed using Statistical Package for the Social Sciences 
SPSS of the product line Predictive Analytics Software (PASW version 18.0).   
 
5.3.8.1 External Validation of MF-BIA against DEXA 
 
For external validation against DEXA, mean values for fat free mass, fat free mass 
percentage, fat mass and fat mass percentage were calculated from MF-BIA 
measurements and compared to their corresponding values measured by DEXA.  First, 
the means of first two MF-BIA measures (out of 10) was calculated to examine the 
agreement with DEXA.  Then comparisons were made with average of first three MF-
BIA measurements, first four MF-BIA measurements, and so on until the average of the 
all 10 measurements was used.   Therefore, for each participant a total of nine 
comparisons were made between MF-BIA and DEXA measurements. The rationale 
being to explore the number of MF-BIA measurements that provide the optimum level 
of agreement between MF-BIA and DEXA after which strength of correlation did not 
improve further.  This will aid in understanding how many MF-BIA measurement 
should be recorded for an average that results in most precise measurement similar to 
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measurement recorded by the gold standard DEXA for fat mass and fat free mass.   All 
analyses were repeated stratified by BMI category as the existing literature suggests 
some overestimation in obese subjects.   
 
Bland Altman method for assessing agreement between two methods of clinical 
measurements was used for the external validation purpose (275).  The Bland Altman 
method includes a test of linearity step and limit of agreement step.  For the test of 
linearity (Figures 5.11-5.44), each measurement from DEXA for fat free mass, fat mass 
and their percentages were plotted respectively against MF-BIA corresponding 
measurements optimum mean.  A line was fitted and r2 calculated to understand the 
strength of relation (not agreement) between the two variables.   
For limits of agreements, upper and lower limits were first calculated (Mean difference 
± (2 x standard deviation of difference)).   The overall mean of each measurement of fat 
free mass, fat mass, and their percentages from both MF-BIA and DEXA (Optimum 
MF-BIA mean and DEXA measurement) was plotted against the mean difference of 
their corresponding values (difference between optimum mean for each measurement by 
MF-BIA and DEXA).  The plotted points were examined for falling within the limits of 
agreement (upper and lower limits) or beyond the limits of agreement as in Bland 
Altman method (275). 
  
5.3.8.2 Internal validation  
 
For the first internal validation study, ten consecutive measurements of MF-BIA 
recorded were examined for MF-BIA reliability.  The first two MF-BIA fat free mass, 
fat mass, and their percentages measurements Cronbachs Alpha values were calculated 
respectively.  The same step was repeated for the first three, first four and so on until all 
ten measurements Cronbachs Alpha Values were calculated.  The purpose is to find the 
optimum number of measurements of MF-BIA to obtain the highest Cronbachs Alpha 
value (to be most reliable).   
For the second internal validation study, two MF-BIA measurements for admission 
were examined to validate the internal consistency of MF-MF-BIA using reliability 
 289 
 
analysis.  Cronbachs Alpha values, confidence intervals, and p-values were calculated.  
The same reliability analysis was carried out for the discharge measurements.   
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5.4 Results  
 
Ten participants were recruited for the external validation study (mean age 66 years, age 
range 50-82 years, 70% men).  Of the ten participants six were diagnosed with 
ischaemic stroke type and four were diagnosed with Transient Ischaemic attack at the 
time of admission to the acute stroke unit.   Five participants had a normal weight BMI 
20-24.9 kg/m2), four were overweight (BMI 25-29.9 kg/m2), and one participant was 
obese (≥ 30 kg/m2).  The sample characteristics of patients included in the second 
internal validation study are presented in the Table 3.1 of Chapter 3. 
 
5.4.1 External validation 
 
The mean age of the 10 participants for the external validation and the first internal 
validation study was 66 years (SD 11.1 years, range 50-82 years, 70% men), of whom  
six had an ischemic stroke (mean NIHSS = 3.2; range 1-8) and four a TIA.   Five 
participants had a normal weight (BMI 20-24.9 kg/m2), four were overweight (BMI 25-
29.9 kg/m2), and one participant was obese (≥ 30 kg/m2). The mean age of the 40 
patients included in the second internal validation study was 70.3 years (SD 9.9 years, 
range 50-89 years, 55% men), all had an ischemic stroke (mean NIHSS = 5.1; range 1-
22). Three were underweight (<20 kg/m2), eight were normal weight, 21 were 
overweight and 8 were obese. 
 
Table 5.1 shows the comparison between fat fee mass, fat free mass percentage, fat 
mass, and fat mass percentages mean of the ten participants measured MF-BIA BioScan 
920-2 (after calculating optimum mean of ten measurements) compared to the reference 
standard Hologic Discovery DEXA mean for the same ten participants No statistically 
significant differences were observed for all of the body composition indices between 
two measurement methods.  
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  Measurement  Mean difference  (95% CI) p-value 
Fat Free Mass (kg)    
   Mean MF-BIA BioScan 920-2 (std) kg 55.5 (14.1)  0.6 (-2.9 to 4.1) 0.71 
   Mean Hologic Discovery DEXA (std) kg 54.9 (13.7)   
Fat Free Mass %    
   Mean MF-BIA BioScan 920-2 (std) kg 72 .0(11.6) 1.1 (-3.9 to 6.0) 0.64 
   Mean Hologic Discovery DEXA (std) kg 70.9 (8.5)   
Fat Mass (kg)    
   Mean MF-BIA BioScan 920-2 (std) kg 22.0 (10.7) 0.8 (-2.7 to 4.4) 0.61 
   Mean Hologic Discovery DEXA (std) kg 21.2 (8.8)   
Fat Mass %    
   Mean MF-BIA BioScan 920-2 (std) kg 28.0 (11.6) 0.4 (-4.7 to 5.4) 0.9 
   Mean Hologic Discovery DEXA (std) kg 27.7 (9.1)   
Table 5.1.   Fat Free Mass, Fat Free Mass percentage, Fat Mass, and Fat mass percentages mean of the ten participants measured MF-BIA BioScan 
920-2 (after calculating optimum mean of ten measurements)  compared to the reference standard Hologic Discovery DEXA mean for  the same ten 
participants; included are mean differences and 95% Confidence intervals (95% CI).   
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Table 5.2 shows R-squared and mean differences averages values of fat free mass, fat 
mass percentages, fat mass and fat mass percentages measurements for the external 
validation of by MF-BIA BioScan 920-2 against Hologic Discovery Dual X-ray 
absorptiometry for all the study sample population and stratified by Body Mass Index 
kg/m2 categories.  There was a statistically significant correlation between fat free mass, 
fat mass and their percentages with no statically significant mean differences between 
both methods of measurements for all body composition indices measured. When 
stratified by BMI category, only fat free mass (kg) values measured by both DEXA and 
MF-BIA BioScan 920-2 showed statistically significant strong correlation (r-
squared >0.7) in overweight subjects.  No statistically significant mean differences 
between both methods of measurements for all other body composition indices 
measured were observed when stratified analyses were conducted by BMI category.    
 
.   
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  R-squared correlation p-value for correlation Mean Difference p-value 
Fat Free Mass (kg)     
All BMI categories 0.94 <0.0001 0.6 (-2.9 to 4.1) 0.71 
Normal BMI (20-25 kg/m2) 0.435 0.23 2.7 (-4.9 to 10.3) 0.38 
Overweight BMI (25-30 kg/m2 ) 0.943 0.03 1.9 (-1.8 to 5.7) 0.2 
Fat Free Mass %     
All BMI categories 0.805 0.005 1.1 (-3.9 to 6.0) 0.64 
Normal BMI (20-25 kg/m2) 0.128 0.55 4.1 (-6.8 to 14.9) 0.36 
Overweight BMI (25-30 kg/m2 ) 0.882 0.09 2.5 (-2.9 to 7.8) 0.24 
Fat Mass (kg)     
All BMI categories 0.882 0.001 0.8 (-2.8 to 4.4) 0.61 
Normal BMI (20-25 kg/m2) 0.182 0.47 1.0 (-6.9 to 9.0) 0.74 
Overweight BMI (25-30 kg/m2 0.742 0.14 2.7 (-2.1 to 7.5) 0.173 
 Fat Mass %     
All BMI categories 0.794 0.006 0.4 (-4.7 to 5.4) 0.87 
Normal BMI (20-25 kg/m2) 0.225 0.42 2.1 (-9.2 to 13.5) 0.63 
Overweight BMI (25-30 kg/m2 0.757 0.13 3.2 (-3.1 to 9.5) 0.21 
Table  5.2.  Fat free mass, fat mass, and their percentages measured by two different methods, Dual X-ray absorptiometry (DEXA) and Multi-
frequency Bioelectrical Impedance Analysis (MF-BIA) BioScan 920-2 for the entire study sample, and stratified by body mass index . 
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There were excellent correlations between Hologic Discovery DEXA and MF-BIA 
BioScan 920-2 measurements using any of MF-BIA BioScan 920-2 averages of first 
two, first three, first four, and so on until all 10 measurements for all indices measured, 
fat free mass and fat mass and their percentages for each participant in the study sample. 
R2 was > 0.8 and >0.6 for fat free mass and fat free mass percentage respectively.  R2 
was > 0.7 and >0.6 for fat mass and fat mass percentage respectively.  Table 5.3 shows 
r-squared values for fat free mass, fat free mass percentage, fat mass, and fat mass 
percentages of the external validation for each of the averages of the first two, three, 
four, five, six, seven, eight, ninth and all ten measurements recorded by MF-BIA 
BioScan 920-2 against Hologic Discovery Dual X-ray (DEXA) absorptiometry for the 
10 participants who participated in the external validation study.   
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 First two First three First four First five First six First seven First eight First nine All ten 
Fat Free Mass (kg) 0.881 0.882 0.882 0.882 0.881 0.882 0.882 0.882 0.884 
Fat Free Mass % 0.648 0.649 0.649 0.654 0.648 0.649 0.648 0.654 0.648 
Fat Mass (kg) 0.782 0.781 0.782 0.787 0.782 0.783 0.786 0.787 0.778 
Fat Mass % 0.633 0.632 0.633 0.64 0.633 0.634 0.639 0.641 0.63 
Table 5.3.   R-squared values per measurement repetitions for fat free mass, fat free mass percentage, fat mass, and fat mass percentages of the external 
validation for each of the averages of the first two, three, four, five, six, seven, eight, ninth and all ten measurements recorded by MF-BIA BioScan 
920-2 against Hologic Discovery Dual X-ray absorptiometry for each of the 10 participants who participated in the external validation study.   
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Test of linearity  
 
Figure 5.1 shows the test of linearity diagram/plot for fat free mass of DEXA values in 
kg plotted against their corresponding values measured by MF-BIA BioScan 920-2 for 
the 10 study participants using optimum average of 10 measurements for each 
participant.  All points lied along the linearity line.  The correlation coefficient was 
excellent (r=0.940; p<0.0001).  In two participants, the values lied almost on the 
linearity line (i.e. almost exactly the same results between DEXA and MF-MF-BIA) 
indicating a substantial agreement.    
 
Figure 5.1.  Test of linearity diagram for fat free mass of DEXA values in kg plotted 
against their corresponding values measured by MF-BIA BioScan 920-2 for the 10 
study participants  
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Figure 5.2 shows the test of linearity diagram for fat fee mass percentages of DEXA 
values plotted against their corresponding values measured by MF-BIA BioScan 920-2 
for the 10 study participants using the optimum average of 10 measurements for each 
participant.  Fat free mass percentages by DEXA and MF-MF-BIA for all 10 subjects 
were close the linearity line with three participants being very close to the linearity line.  
The correlation coefficient was r=0.805; p=0.005 (table 2).  One point was on the 
linearity line suggesting a 100% agreement between MF-MF-BIA and DEXA 
measurements in that individual.   
 
 
Figure 5.2.  Test of linearity diagram for fat free mass percentage of DEXA values 
plotted against their corresponding values measured by MF-BIA BioScan 920-2 for the 
10 study participants.  
 
 
 298 
 
Figure 5.3 shows the test of linearity diagram for fat free mass of DEXA values in kg 
plotted against their corresponding values measured by MF-BIA BioScan 920-2 for the 
10 study participants using the optimum average of 10 measurements for each 
participant. The correlation coefficient for average fat mass of 10 MF-MF-BIA 
measurements and DEXA was 0.882 (p=0.001).  All values lied either just above or 
below the linearity line, and in no participant the measurements by two methods lied 
exactly at the linearity line to suggest perfect agreement.   
 
 
Figure 5.3. Test of linearity diagram/plot for fat mass of DEXA values in kg plotted 
against their corresponding values measured by MF-BIA BioScan 920-2 for the 10 
study participants  
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Figure 5.4 shows the test of linearity diagram for fat mass percentages of DEXA values 
kg plotted against their corresponding values measured by MF-BIA BioScan 920-2 for 
the 10 study participants using optimum average of 10 measurements for each 
participant.   When plotting fat mass percentage measured by MF-MF-BIA against its 
corresponding values measured by DEXA, I found that no point was on the linearity 
line they were all laying across the linearity line suggesting not an exact agreement. The 
correlation coefficient however was 0.794 indicating a significant correlation (p=0.006).   
 
 
Figure 5.4. Test of linearity diagram for fat mass percentages of DEXA values kg 
plotted against their corresponding values measured by MF-BIA BioScan 920-2 for the 
10 study participants  
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Figure 5.5 shows the difference of fat free mass (kg) mean of 10 MF-MF-BIA 
measurement using the optimum average of 10 MF-BIA measurements and DEXA 
measurement plotted against the mean difference between MF-BIA optimum average 
and DEXA.  Plotting the difference against the mean for fat free mass resulted in all 
points lying within the limits of agreement.  DEXA and MF-MF-BIA results both 
signify the same clinical interpretation according to Bland an Altman with a lower and 
upper limit of –-9.17 to 10.37.   
 
 
Figure 5.5.  Showing the difference of fat free mass (kg) mean of 10 MF-MF-BIA 
measurements and DEXA measurement plotted against the mean difference between 
MF-BIA optimum average and DEXA.   
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Figure 5.6 shows the difference of fat free mass percentage mean of 10 MF-BIA 
measurements using optimum average of 10 MF-BIA and DEXA measurement plotted 
against the mean difference between MF-BIA optimum average and DEXA.  Plotting 
the difference against the mean for fat free mass percentage resulted in all points lying 
within the limits of agreement DEXA and MF-BIA results both signify the same clinical 
interpretation according to Bland an Altman with a lower and upper limit of -12.86 to 
14.98. 
 
 
Figure 5.6.  Limits of agreement plot showing the difference of fat free mass percentage 
mean of 10 MF-MF-BIA measurements and DEXA measurement plotted against the 
mean difference between MF-BIA optimum average and DEXA.   
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Figure 5.7 shows the difference of fat free mass percentage mean of 10 MF-MF-BIA 
measurement using optimum average of 10 MF-BIA and DEXA measurement plotted 
against the mean difference between MF-BIA optimum average and DEXA.  All point 
lied in between the upper and lower limit. Fat mass as in fat free mass all points lied 
within the limits of agreement with the lower -9.19 and upper at 10.87.  This outcome 
suggests that both MF-MF-BIA and DEXA fat mass results provide the same clinical 
interpretation.       
   
 
Figure 5.7.  Limits of agreement FM plot showing the difference of fat mass (kg) mean 
of 10 MF-MF-BIA measurements and DEXA measurement plotted against the mean 
difference between MF-BIA optimum average and DEXA.   
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Figure 5.8 shows the difference of fat mass percentage mean of 10 MF-MF-BIA 
measurement using optimum average of 10 MF-BIA and DEXA measurement plotted 
against the mean difference between MF-BIA optimum average and DEXA.  All point 
lied in between the upper and lower limit.   Fat mass percentages points were within the 
limits of agreement with a lower -13.73 and upper at 14.49.  This outcome suggests that 
both MF-MF-BIA and DEXA fat mass percentage do not vary or provide different 
result interpretation.   
 
 
Figure 5.8.  Limits of agreement FM% plot showing the difference of fat mass 
percentage mean of 10 MF-MF-BIA measurements and DEXA measurement plotted 
against the mean difference between MF-BIA optimum average and DEXA.   
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5.4.2 First Internal Validation of BioScan 920-2 MF-BIA   
In ten participants who were included in the external validation study, the reliability 
analysis to evaluate the internal consistency of MF-BIA BioScan 920-2 to measure fat 
free mass and fat mass and their percentages suggested almost perfect agreement 
between each of the 10 measurements for each component within the same individual.  
The Cronbachs alpha values were excellent as Table 5.4 below demonstrates (In Table 
5.4 individual participants are designated as 1st, 2nd, 3rd, and so on).  No statistically 
significant difference was observed between each single measure for each participant.  
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Individual Cronbachs alpha values for each of the 10 participants 
 
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 
Fat Free Mass (kg) 1 1 1 1 1 1 1 1 1 1 
Fat Free Mass % 1 1 0.99 1 1 1 1 1 1 1 
Fat Mass (kg) 1 1 0.99 1 1 1 1 1 1 1 
Fat Mass % 1 1 0.99 1 1 1 1 1 1 1 
Table 5.4.  The Cronbachs alpha values for each participant’s fat free mass, fat free mass percentage, fat mass and fat mass percentage recorded 
10 times by MF-BIA BioScan 920-2 for the 10 participants who participated in the external validation with DEXA part of the study. 
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5.4.3 Second Internal validation studies of BioScan 920-2 MF-BIA 
 
The internal consistency of BioScan 920-2 MF-BIA for the measurements of fat free 
mass, fat free mass percentage, fat mass, and fat mass percentage, protein mass, muscle 
mass, and body cell mass recorded twice consecutively both on admission and discharge 
were excellent.  Table 5.5 shows the Cronbachs alpha values for each of the two Fat free 
Mass, Fat free mass percentage, fat mass, and fat mass percentage, protein mass, muscle 
mass, and body cell mass recorded on admission and discharge in the longitudinal study 
(Chapter 3) for the 40 participants.   
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  Admission 95% Confidence Intervals Discharge 95% Confidence Intervals 
Fat Free Mass (kg) 0.998 0.997-0.998 0.999 0.997-0.999 
Fat Free Mass % 0.997 0.994-0.998 0.994 0.902-0.973 
Fat Mass (kg) 0.999 0.997-0.999 0.997 0.994-0.998 
Fat Mass% 0.997 0.994-0.998 0.959 0.922-0.978 
Protein Mass (kg)  0.989 0.979-0.994 0.957 0.917-0.978 
Muscle Mass (kg) 0.997 0.994-0.998 0.969 0.940-0.984 
Body Cell Mass (kg) 0.998 0.996-0.999 0.995 0.990-0.997 
Table 5.5.   Internal consistency assessed using Cronbachs alpha values for each of the two fat free Mass, fat free mass percentage, fat mass, and fat 
mass percentage, protein mass, muscle mass, and body cell mass recorded on admission and discharge in 40 patients who participated the  Longitudinal 
study (Chapter 3).   
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The internal consistency of BioScan 920 MF-BIA remained excellent with high 
Cronbachs alpha values when analysis were stratified by quartiles of BMI for both 
admission and discharge measurements (Table 5.62).  BMI quartiles for the study 
sample were first quartile (16.08 to 23.36 kg/m2), second quartile (24.8 to 26.10 kg/m2), 
third quartile (26.12 to 28.86 kg/m2), and fourth quartile (28.92 to 39.35 kg/m2).   There 
was also no significant difference between first and second measures of BioScan 920-
MF-BIA for all measurements conducted.  Table 5.6a and 5.6b present the internal 
consistency Cronbachs-α values for the first and second measurements for fat free mass, 
fat mass, protein mass, body cell mass, and muscle mass estimated by MF-BIA on 
admission and discharge stratified by BMI quartile.   
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 Admission Discharge 
Fat Free Mass (kg)       Cronbachs Alpha  95% Confidence Intervals       Cronbachs Alpha  95% Confidence Intervals 
1st quartile  0.995 0.981 to 0.999 0.999 0.996 to 1.0 
2nd quartile 1 0.998 to 1.0 0.996 0.95 to 0.999 
3rd quartile 0.998 (0.991 to 0.999 1  
4th quartile 1  1  
Fat Free Mass %     
1st quartile 0.988 0.953 to 0.997 0.997 0.987 to 0.999 
2nd quartile 0.998 0.9963 to 1.0) 0.986 0.947 to 0.996 
3rd quartile 0.99 0.959 to 0.997 1  
4th quartile 0.999 0.998 to 1.0 0.683 -0.274 to 0.921 
Fat Mass (kg)     
1st quartile 0.988 0.951 to 0.997 0.983 0.931 to 0.996 
2nd quartile 0.998 0.991 to .999 0.985 0.944 to 0.996 
3rd quartile 0.979 0.917 to 0.995 0.99 0.956 to 0.998 
Table 5.6a.  MF-BIA Internal consistency by BMI quartile, continued  
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Admission Discharge 
Fat Mass %     
1st quartile 0.988 0.953 to 0.997 0.997 0.988 to 0.999) 
2nd quartile 0.999 0.994 to 1.0 0.986 0.947 to 0.996 
3rd quartile 0.989 0.958 to 0.997 0.499 -1.2 to 0.887 
4th quartile 0.999 0.998 to 1.0 0.986 0.945 to 0.997 
Table 5.6a.  MF-BIA Internal consistency by BMI quartile: assessed using Cronbachs alpha value for each of the two Fat free Mass, Fat free mass 
percentage, fat mass, and fat mass percentage recorded on admission and discharge by quartiles of body mass index in the in 40 patients participated in 
the longitudinal study (Chapter 3).
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 Admission Discharge 
Protein Mass (kg)       Cronbachs Alpha  95% Confidence Intervals       Cronbachs Alpha  95% Confidence Intervals 
1st quartile 0.985 0.94 to 0.996 0.994 0.976 to 0.999 
2nd quartile 0.984 0.928 to 0.996 0.728 -0.097 to 0.932 
3rd quartile 0.985 0.983 to 0.996 1 0  0.999 to 1.0 
4th quartile 1 0.998 to 1.0 1.0   0.999 to 1.0 
Muscle Mass (kg)     
1st quartile 0.987 0.948 to 0.997 0.652 -0.401 to 0.914 
2nd quartile 1 0.998 to 1.0 1  
3rd quartile 0.999 0.996 to 1.0) 1  
4th quartile 1 .999 to 1.0 1  
Body Cell Mass (kg)     
1st quartile 0.979 0.916 to 0.995 0.997 0.989 to 0.999 
2nd quartile 0.998 0.991 to 0.999 0.992 0.971 to 0.998 
3rd quartile 1 0.99 to 1.0 0.984 0.928 to 0.996 
4th quartile 0.999 0.996 to 1.0 1 0.99 to 1.0 
Table 5.6b.  Internal consistency assessed using Cronbachs alpha value for each of the two  protein mass, muscle mass, and body cell mass recorded on 
admission and discharge by quartiles of body mass index in the in 40 patients participated in the longitudinal study (Chapter 3).
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5.5 Discussion  
 
This validation study confirms the usefulness of MF-BIA measurement using BioScan 
920-2 in measuring fat and fat free mass other components such as protein mass, muscle 
mass and cell mass in people with recent stroke and TIA. All Cronbachs alpha values 
observed were > 0.9 with no statistical significant differences between any two 
consecutive measurements in all 40 participants of longitudinal study.  The internal 
consistency was also excellent for the first two, three and so on until 10 measurements 
for each of the 10 participants included in the external validation.  Cronbachs alpha 
values suggested excellent MF-BIA BioScan 920-2 reliability.  
 
There was also a high level of agreement between MF-BIA BioScan 920-2 and DEXA 
Hologic Discovery.   When plotted using Bland & Altman methods for a comparing two 
different methods, all of the values of fat free mass, fat mass, and their percentages lied 
within the upper and lower limits suggesting they do not differ significantly.  
 
5.5.1 Fat Free Mass  
 
Fat free mass and fat free mass percentage measured by MF-BIA and DEXA were 
strongly correlated; p<0.0001 and p=0.005 respectively.  The test of linearity suggested 
agreement between the two methods (how well they lie on the linearity line).  All points 
were lying along the linearity (agreement) line (Figure 5.1 & Figure 5.2).  In Bland and 
Altman method, plotting the average of the two methods against the difference, all 
points lied within the limits of agreements (Figure 5.5 & Figure 5.6).  Fat free mass 
measurement using DEXA and MF-BIA can be used interchangeably.  Both methods 
provide similar interpretation of fat free mass constituent in body composition.   
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5.5.1 Fat Mass    
 
There were also strong significant correlations between MF-BIA and DEXA 
measurements for fat mass (p<0.001) and fat mass percentage (p=0.006).  All points 
were lying along the linearity (agreement) line (Figure 5.3 and Figure 5.4) suggesting 
agreement between the two methods.  There were no statistically significant differences 
between the means of two measurements.  In Bland and Altman method, plotting the 
average of the two methods against the difference (Figures 5.7 & 5.8), all points lied 
within the limits of agreements.  This suggests that the interpretation of the 
measurement by MF-BIA and DEXA are similar and thus they can both be used 
interchangeably.   
 
5.5.3 Comparison with other studies:  
 
This study suggests a very good agreement between MF-BIA and DEXA.  This is in 
agreement with previous other studies.  Pate johns et al (2006) demonstrated a 
significantly strong correlation between MF-BIA and DEXA with an r2 values of fat 
mass and fat free mass of 0.81 for both (p<0.001) (276).  The similar strong correlations 
were also demonstrated in our study with an r2  values of 0.88 (p<0.0001) and 0.78 
(p=0.001) for fat free mass and fat mass, respectively.  In Pateyjohns’ study all 
participants were men (n=43), apparently healthy, between age of 25-60 years, and are 
either overweight or obese.  In my study, only one participant was obese which does not 
allow me to draw any meaningful conclusion on obese subjects with recent stroke or 
TIA.  However, the correlation between MF-BIA and DEXA measurement was strong 
for overweight subjects as in Pateyjohns study.   It should, however, be cautioned that 
the overweight population in my study composed only four participants.  The agreement 
between my study results and that of Pateyjohns may suggest that DEXA and MF-BIA 
provide similar result in overweight subjects.    
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Body fat percentage was underestimated in a study by Sun et al (277) with MF-BIA 
measurements of body fat percentage corresponding to 32.89 ± 8.00%, being 
statistically significantly lower than DEXA measurement of 34.72 ± 8.66%; p<0.001.  
These results were contrary to my study findings, which indicated very good agreement 
between average body fat percentage measured by DEXA (27.7±9.1) and MF-BIA 
(27.7±11.5) (p>0.05).  It should be noted that the study by Sun and colleagues was 
much larger than my study with 591 healthy subjects.  The age range, in the study was 
not restricted to older population and they study population’s age ranged between 19 
and 60 years; my study population age range was 50-75 years.  The difference in sample 
characteristics with regard to distribution of age of the population studied may explain 
differing results observed.  
 
My study as opposed to other studies drew its sample from specific patients population; 
stroke/TIA population.  This may suggest that the agreement seen across fat free mass 
and fat mass measured by DEXA and MF-BIA in my study is related to the fact that I 
did not use a wide age range (as in Pateyjohns study), and used a population of similar 
clinical and health characteristics.  The aforementioned studies used apparently healthy 
volunteer population.   
 
5.5.4 Strengths and Weaknesses:  
 
Strengths of this study include that our patients had variable body mass indexes 
covering all body mass index ranges albeit with not many patients in the obese category.  
The DEXA and MF-BIA measurements were carried out consecutively removing MF-
MF-BIAs that may occur due to large time scale gap during which body composition 
may change.  I was able to carry out both internal and validation studies of MF-BIA 
BioScan and the results were consistent. 
 
The main weakness of the study is the relatively small sample size.  There was not 
enough sample size for stratified analyses by BMI categories to allow better comparison 
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with previous studies.  There were difficulties in recruiting older people with a 
condition such as stroke.  Transportation can be a problem for such patients (post stroke) 
with many living in remote areas. 
 
Financial restraint as a PhD studentship project limited the number of DEXA scans I 
can carry out.  DEXA scans are costly and recruiting a larger sample can be expensive.  
In addition, specialized personnel must be available with a clinician during the scans 
making scans only available at certain times and dates.  Therefore, the sample size for 
external validation was conducted in 10 participants. 
 
5.5.5 Clinical Interpretation:  
 
The results of these validation studies indicate strong and significant correlation 
between MF-BIA measurement and DEXA with regards to fat mass and fat free mass.  
When observing the limits of agreement in figures 5.5-5.8, it can be seen that all 
measurements lied within the upper and lower limits (95% Confidence intervals).  This 
suggests that both MF-BIA and DEXA readings do not translate into different clinical 
interpretation.  Only when the measurements are out of the range of limits of agreement 
by both methods, this suggest two different clinical interpretation (275).  Based on these 
findings both DEXA and MF-BIA can be used interchangeably to measure the body 
composition indices examined.  In addition, MF-BIA also has internal consistency thus 
it provides a reliable, easy to perform measurement method to assess fat free mass, fat 
mass, and their percentages in stroke and TIA patient population.   
 
5.5.6 Future work  
 
As indicated in the earlier chapters of the thesis (Chapters 2 and 3) that poor nutritional 
status have negative prognosis on treatment outcomes in patients in general and stroke 
patients specifically.   Given the reliability of MF-BIA BioScan equipment in assessing 
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fat free mass and fat mass, this study sets the basis of further research to confirm these 
findings in a larger sample with various patient populations which are associated with 
malnutrition. Further work should be aim at the feasibility of using MF-BIA in clinical 
settings as quick, simple, and easy to use equipment in assessing body composition 
indices in such patients including stroke patients in long term rehabilitation facilities.   
In particular relevance to the subject of this thesis, body composition changes after 
stroke can vary, and that the ability to measure such changes may aid in the nutritional 
management of stroke patients, allowing clinicians to prevent catabolism commonly 
seen in stroke patients with long term disability.  
 
What is equally important is to carry out further external validation study of MF-BIA 
using different BMI categories.  My study had only normal weight and overweight 
group of stroke/TIA patients (only one obese and none were underweight).  Thus, firm 
conclusions cannot be made due to the small number of patients in each category.    
 
Previously one study compared body composition changes after stroke (n = 35) (273).  
It used the DEXA method in evaluating body composition, indicating that significant 
losses in lean body mass and bone density loss occurred in the paretic leg compared to 
the non-paretic leg after stroke; p<0.05 (273).  This study did show that body 
composition changes occurred in stroke patients (as in my longitudinal study; Chapter 
3).  It lacked the validation of MF-BIA by DEXA as only MF-BIA can be readily 
available in clinical settings and not DEXA.  DEXA is relatively expensive, time 
consuming to perform ranging from 15-20 minutes for one measurement and 
inconvenient for patients with disability or limited mobility.  The authors did not 
consider at time of the study to examine the utility of MF-BIA or its reliability against 
DEXA.  My study provides new evidence that MF-BIA can be a reliable measurement 
tool which has excellent agreement with gold standard method, DEXA.    
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5.5.7 Conclusion 
 
A large number of equipment’s with different specification and formulae to calculate 
body composition indices, many of which were validated, are available at present (183).  
It is very important that the formulae being used in such equipment are known as in 
Kyle 2004 paper (183) in order to carry out validation studies and understand if such 
formulae are useful or not.  The formulae programmed in the equipment I used in my 
study are not known and not revealed by the manufacturer.  Nevertheless, my results 
suggest that MF-BIA BioScan 920-2 is in agreement with DEXA making it an attractive 
candidate for further research and ultimately for use in clinical care of stroke/TIA 
patients.  MF-BIA BioScan 920-2 was not mentioned in Kyle 2004 literature.  
 
 It could be that my study was the first on MF-BIA BioScan 920-2 or it was not reported 
due to the unknown formulae it used to calculate its estimate of Fat free mass, fat mass, 
and their percentages.  As described in Kyle’s 2004 literature review, the validation of 
the different MF-BIA equipment was carried out against several different gold standard 
or reference measure.  Although it is important to examine MF-BIA against several gold 
standard methods for assessing body composition, it is equally important to find a 
universal gold standard method to validate MF-BIA against.  The validation against one 
gold standard method will make it easier for validators to follow one protocol 
eliminating errors that may cause MF-MF-BIAs when following several different 
methods.  Each gold standard method can have its own errors and may contribute to 
larger discrepancies in the agreement with MF-BIA than another.  Having one method 
will possibly allow for filtering of MF-BIA equipment’s to reach the ones that best 
provide an agreement with one reference gold standard.  
    
Future work examining the utility of MF-BIA should aim to achieve larger sample size. 
They should also gather information and evidence on the utility of MF-BIA in other 
chronic long term disabling conditions including long term management of stroke 
considering the scarcity of existing evidence using body composition measurement as a 
monitoring exercise to identify at risk patients and also to monitor progress of the 
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condition i.e. effectiveness of nutritional intervention in addressing malnutrition 
associated with long term illnesses.  In summary, this validation sub-study suggests an 
excellent validity of MF-BIA measures for fat free mass, fat mass, and their percentages.   
A larger sample with wide ranging BMI categories would have been desirable.    
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Chapter 6:  Conclusion 
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My PhD work described in this thesis aimed to better understand selected body 
composition changes in acute stroke and how such changes relate to both objective and 
subjective outcomes. To achieve these aims, I used multi-frequency bioelectrical 
impedance analysis (MF-BIA BioScan 920-2, Maltron International Limited, Essex, UK) 
and performed both internal and external validation studies in participants with a recent 
stroke or TIA. I also examined the utility of MF-BIA in diagnosing dehydration in acute 
stroke.  To better understand the prognostic significance of malnutrition on outcomes in 
patients with cardiovascular disease I conducted a systematic review and meta-analysis 
examining the association between various nutritional markers of malnutrition and 
outcomes in people with a cardiovascular event.  
 
 
6.1 Malnutrition in acute stroke 
 
 
In order to put my research in the clinical context of stroke, it is important to re-
emphasize the prevalence of malnutrition after stroke.  The prevalence of malnutrition 
including dehydration is well documented at the time of admission with an acute stroke, 
and the nutritional status of patients with stroke also often deteriorates during the acute 
hospital stay (17, 20, 61, 65, 70, 71).   The prevalence of malnutrition in stroke is due to 
dysphagia, a common stroke symptom with reported prevalence of at least 40% (120), 
and other cognitive problems.  Dysphagia impedes the ability to swallow while 
cognitive problems may change eating behaviour thereby affecting dietary intake.  
Malnutrition has adverse effects on body composition especially in conditions that 
escalate the stress response in the body and may be associated with immobility such as 
in stroke.   
 
 
The evidence I presented in this thesis deepens the understanding of malnutrition in 
stroke through highlighting its impact on stroke patients.  In Chapter 2, I presented 
evidence on the association between malnutrition on outcomes in people who had a 
cardiovascular event (post-CVD).  In chapter 3, I descriptively presented the impact of 
stroke on body composition changes and further tried to understand how such changes 
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may impact objective and subjective outcomes in stroke patients.  In Chapter 4, I 
examined the utility of multi-frequency bioelectrical impedance analysis in diagnosing 
dehydration after stroke as a non-invasive and swift bedside method, and in Chapter 5 I 
validated MF-BIA estimates for fat free mass and fat mass against DEXA and also 
performed internal validation studies.   
 
 
6.2 Studies findings in the context of the whole thesis 
 
The systematic review and meta-analysis presented in Chapter 2 provided evidence on 
the association between markers of malnutrition and health outcomes after a 
cardiovascular (CVD) event.  This association was assessed in both cardiovascular and 
cerebrovascular diseases. Selected nutrition markers examined included body mass 
index (BMI), weight loss, skin fold thickness, low serum albumin, high serum 
creatinine, increased serum osmolality, and malnutrition assessed by nutrition 
assessment tools such as Subjective Global Assessment (SGA) tool.  My systematic 
review and meta-analysis suggest that there was no association between obesity or 
overweight (both compared to normal weight) and mortality, but there was an 
association between underweight (compared to normal weight) and higher mortality.   
Meta-analysis of studies that examined the association between malnutrition assessed 
using nutrition assessment tools and mortality suggested an association between 
malnutrition and higher mortality.    
 
The one included study that examined weight loss as a marker of malnutrition suggested 
that weight loss had no association with mortality, but reduced the risk of recurrent 
events.  If weight loss occurred in obese or overweight patients it could improve their 
health and post-CVD event outcomes as it can place them within the healthy weight 
range. It will improve their overall health and reduce their adiposity which is considered 
a prothrombotic state thus reducing the risk of recurrent event.  On the contrary, if 
patients were already malnourished weight loss could cause further deterioration in their 
nutritional status thereby increasing the risk of poor outcomes including mortality.   
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Other nutrition markers examined included low serum albumin, high serum osmolality, 
and high serum creatinine and my findings suggested that these markers of malnutrition 
may be associated with higher levels of mortality, but these findings were based on a 
small number of studies.   
 
The aim of the longitudinal study was to examine body composition changes after 
stroke and examine whether they have an impact on outcomes.  As described in detail in 
the rationale and hypothesis of the longitudinal cohort study, I hypothesised that body 
composition changes do occur after stroke due to nutritional inadequacy compounded 
by the stress response and that such changes may have negative prognosis on outcomes.   
The findings of the longitudinal study showed interesting observations regarding body 
composition changes (fat free mass loss, fat mass gain, and protein mass, muscles mass 
and body cell mass losses) in patients on modified diet, NBM feeding regimen, and 
those who were classified as suffering from a total anterior circulation infarct stroke 
(TACI).  Due to a small sample size and short duration of hospital stay a firm 
conclusion on the relationship between body composition changes and type of feeding 
regimen, type of stroke, and objective outcomes or subjective outcomes cannot be made. 
Follow up questionnaires were administered at 6 month post discharge from hospital 
and the response rate was modest with most well participants (with mildest strokes and 
no post-stroke symptoms) responding to the questionnaire. Furthermore, it was 
impossible to know what body composition changes occurred over time within the 
follow up period of 6 months.  As a result, no firm conclusion can be made based on the 
findings.   
 
 
Nonetheless, I have shown what type of body composition changes occur in stroke and 
trends in changes occurring in major body components.  Fat free mass loss, fat mass 
gain, protein mass loss, muscle mass loss, and body cell mass loss were observed in 
patients who were prescribed modified diet (soft mashed diet, pureed diet, or nil-by-
mouth), nil-by-mouth, and patients experiencing total anterior circulation infarct stroke 
subtype (TACI).  Further, fat free mass loss, fat mass gain, and protein mass loss were 
seen mainly in patients with moderate to severe stroke (National Institute of Health 
Stroke Severity score >10).    
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Equally important and relevant in the nutritional care of stroke patients is their 
hydration status; dehydration is prevalent ranging from 30% to more than 60% post-
stroke, and has been shown to have impact on post stroke outcomes.  The literature 
presented in Chapter 2, which examined the association of dehydration diagnosed using 
a serum marker, serum osmolality, and outcomes suggested an association between 
dehydration and mortality, and an association with complications such as 
thromboembolism.  Therefore, diagnosing and monitoring dehydration in stroke patients 
should be a priority.   
 
In Chapter 4, I presented the study findings carried out to examine the diagnostic 
accuracy of MF-BIA BioScan 920-2 in diagnosing dehydration in stroke patients.   I 
found that MF-BIA was not useful to diagnose water-loss dehydration after stroke.  Its 
diagnostic accuracy was far too low to usefully diagnose current or impending 
dehydration at any selected cut-off point. The caveat is that these findings do not 
necessarily translate to mean that MF-BIA does not accurately diagnose cellular 
dehydration, but rather highlight the certain limitations in this study that I will present in 
the limitation section of this chapter.    
 
In the penultimate chapter of this thesis, Chapter 5, I presented findings of the 
validation studies of MF-BIA BioScan 920-2.  The validation of MF-BIA against 
DEXA is essential to understand whether fat free mass and fat mass estimated by MF-
BIA are in agreement with a reference method (DEXA) which will give confidence to 
my study findings of the longitudinal study based on MF-BIA estimates.  In the 
validation study of MF-BIA BioScan 920-2 my results suggested that MF-BIA BioScan 
920-2 is in agreement with DEXA making it an attractive candidate for further research 
and ultimately for use in clinical care of stroke/TIA patients and patients with similar 
situations (e.g. hip fracture patients).  The internal consistency of MF-BIA BioScan 
920-2 measurement for the selected body composition components was excellent.    
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6.3 The contribution of this thesis to stroke research  
 
Given the prevalence of malnutrition in stroke patients my study gathered evidence 
regarding the association between malnutrition and outcomes.  The study also presented 
evidence on the extent of body composition changes that can happen after stroke with 
regards to the type of feeding regimen, stroke severity assessed by NIHSS score, and 
stroke subtype assessed using Oxfordshire Community Stroke Project Classification.  
Whilst these body composition changes occurring during the acute hospital stay can 
have an impact on longer outcomes in stroke I could not make any firm conclusion 
based on my results due to relatively small sample size.  Although MF-BIA can 
estimate water fraction body compartment, it does not seem to be useful in diagnosing 
dehydration after stroke. Nevertheless, MF-BIA may provide valid body composition 
estimates of fat free mass and fat mass as the validation study suggested its agreement 
with reference method DEXA. These findings may be helpful in initiating larger 
validation studies of MF-BIA to examine its agreement with other reference methods. 
 
These findings are relevant to clinicians and health professionals working in the field of 
stroke management. They may be able to improve the nutritional status of malnourished 
patients by understanding their nutritional requirement through observing patient body 
composition changes (e.g. amount of fat free mass loss) and put nutritional management 
on the list of their priorities to avoid poor outcomes; the evidence from my systematic 
review suggests that malnutrition after stroke (or a cardiovascular event) is associated 
with poor outcomes.   
 
Further, my study was novel and provided normative data that can be used for similar 
stroke related future nutritional research.  It can be used in future sample size 
calculations and to help researchers in the field to determine minimally clinically 
significant differences for similar research and to be used in further targeted 
intervention clinical trial.   
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6.4 Limitations 
 
In the systematic review and meta-analysis, not all studies included used the same 
comparison group and there were lack of studies using the particular reference category 
I was interested in i.e. normal nutrition marker parameters, making it impossible to 
include all studies available in the same meta-analysis. Therefore the evidence synthesis 
was based on the results from smaller number of studies.    
 
In the longitudinal study follow up data did not lead to any conclusion regarding the 
association between body composition changes that occurred during acute hospital stay 
and longer term outcomes. It would be impossible to know what body composition 
changes occurred during the follow up period that have impacted health differently at 
final follow up.  For example, if fat free mass loss occurred during hospital stay it might 
have been reversed during the six month follow up period leading to improved strength 
in a participant.  Therefore responses at time of follow up questionnaire administration 
may not reflect that participant physical health during acute hospital stay and while on 
the path to recovery.  This was evident as participants with fat free mass loss scored 
higher than those with fat free mass gains or no gains in the Physical Component 
Summary Scores (PCS) of the short form survey (SF36v2), Barthel Index, and Stroke 
Impact scale selected items. However, the number of participants who completed 
follow-up were small and most of them suffered milder stroke and therefore the findings 
are plausible as they were expected to have relatively good outcome.    
 
I did not find MF-BIA useful in diagnosing dehydration.  This can be attributed to the 
fact that using serum osmolality and serum osmolarity as reference to compare MF-BIA 
BioScan 920-2 estimated and calculated (from Ritz equations) water fraction values 
may not have been appropriate and considering that serum osmolality and osmolarity 
reflect intravascular component rather than cellular dehydration.  In addition, the 
malfunction in the equipment resulted in discarding 40% of my participants’ data 
making the sample small for firm conclusion.  When analysed stratified by sex and 
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using TBW as percentage of body weight, the diagnostic accuracy of MF-BIA improved 
but remained low.  The sample however was further reduced in the stratified analysis.     
 
In Chapter 5, the validation of MF-BIA BioScan 920-2, sample size was relatively small. 
Although the sample was sufficient to show the validity of the machine used, it would 
be preferable to have a larger sample in order to validate MF-BIA estimates across a 
wide range of BMI categories including underweight, normal weight, overweight, and 
obese participants.    
 
With regard to the device I did not find MF-BIA BioScan 920-2 particularly user 
friendly.  It does not have a keyboard for swift data entry.  Data entry (age, sex, etc) and 
saving of data was therefore slow process prone to result in errors and data loss.  Re-
running a second measurement for the same participant also required re-entering of all 
the same information again unless otherwise the new test overwrites previously 
recorded first examination data.  Analysed data were not easily accessible to visual 
check without downloading the full data set, and there is no warning when 
unrealistic/implausible readings are recorded. When I carried out MF-BIA 
measurements I checked initial 20 measurements in the longitudinal and diagnostic 
accuracy study for any discrepancies and none were observed giving me confidence of 
the measurements.  However as it appeared later I had to discard 40% of participant  
data from the diagnostic accuracy study and one patient’s muscle mass and protein mass 
data was not estimated in the longitudinal study.  
 
6.5 Future work 
 
If I had the opportunity to carry out the same longitudinal study I would standardize my 
measurement time points i.e. instead of admission and discharge, measurements can be 
carried out at two fixed time points, for example day one after admission and day five.  
During follow up period, it would have been ideal to carry out serial assessment of body 
composition to monitor changes in body composition after hospital discharge.  It would 
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allow me to observe body composition changes after hospital discharge.  For external 
validation future work examining the utility of MF-BIA should aim to achieve larger 
sample size. A larger sample with participants who are in a wide range of BMI 
categories is desirable to understand the usefulness of MF-BIA agreement with DEXA 
more comprehensively.   
 
Using an alternative device which uses the MF-BIA technique that is more users 
friendly is also advisable.  In addition I would select a machine with known validated 
equations.  In my study, formulae to calculate water compartments are built in the 
device and are not known to the investigators and I do not know if they used validated 
formulae and this is why I also used Ritz formulae developed for older people to 
estimate water compartments.  Therefore it is important to note that many BIA 
machines with different specification and formulae, many of which were validated, are 
available in the market at present.  It is very important that the formulae being used in 
such equipment are known as in Kyle 2004 paper (183) in order to carry out validation 
studies and understand whether such devices are reliable to use in clinical practice. The 
external validation study against DEXA, however, suggested that the MF-BIA machine 
I used may be reliably used for accurate estimations of fat mass and fat free mass.   
 
Summary 
 
My study was novel as it provided new information with regard to body composition 
changes in acute stroke while utilizing new validated equipment in estimating body 
composition component of fat free mass and fat mass.  My study also aimed to 
investigate new non-invasive methods to diagnose dehydration in stroke patients.  It 
contributed new knowledge that can be useful in future research for example sample 
size calculation and can help researchers in the field to determine minimally clinically 
significant differences for similar research and further targeted intervention clinical 
trials.   
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 Appendix I Systematic Review Study Protocol 
 
Malnutrition Markers/assessment tools and their ability to predict long term poor clinical 
outcomes and mortality in Myocardial Infarction, Transient Ischemic Attack, and Stroke: 
a systematic review of Prospective Cohort Studies 
Mohannad Kafri, University of East Anglia, School of Medicine, Norwich, NR4 7TJ 
Abstract:  this is a review protocol not a review and there is not abstract 
Justification:   
Poor recovery outcomes in acute cardiovascular events, mainly in stroke, are well 
documented in patients diagnosed with malnutrition. Although poor outcomes stroke are the 
main acute cardiovascular event reported to be affected by nutritional status acutely.  It is an 
indication that the state of malnutrition plays a major role in other acute cardiovascular event 
such as Transient ischemic attack and Myocardial infarction.   There is a vast array of poor 
outcomes associated poor nutritional status in acute cardiovascular events ranging from an 
increased length of stay to increased mortality frequency.   Hospitalization duration, acute 
complications, quality of life, and death are some of the main outcomes affected by poor 
nutritional status in patients acutely.  Malnutrition diagnosed acutely can have a significant 
influence on recovery outcomes.  Understanding the relationship between nutritional status and 
recovery outcomes associated with acute cardiovascular events can contribute to a better 
appreciation on the role of nutrition care in acute cardiovascular events.  Monitoring nutritionals 
status acutely can provide valuable information on acute care measures that can improve 
recovery outcomes.   
Objectives: 
 Our objective to assess nutrition markers from serum albumin measures of hydration, body 
mass index, body fat, triceps skin fold, and/or serum Creatinine can predict poor outcomes as 
defined by hospital readmission, disability, functional status and/or mortality after acute 
cardiovascular event defined as stroke, transient ischemic attack, or myocardial infarction. 
Methods: 
Criteria for considering studies for this review 
Types of studies:  
Prospect cohort studies examining poor outcomes with evident nutrition markers measured and 
outcomes evaluated as defined in the objectives.   
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Type of Participants:  
Participants aged 18 years and older who have had a stroke, myocardial infarction, or transient 
ischemic attack with the nutrition markers serum albumin measures of hydration, body mass 
index, triceps skin fold, and/or serum Creatinine measured and the outcomes hospital 
readmission, length of hospital stay, discharge destination, disability, functional status and/or 
mortality evaluated.   
Type of exposure: 
Most nutrition markers discussed and analysed in cohort studies are Body Mass Index, Albumin, 
triceps skin fold, and mid upper arm circumference are reported in several studies, and 
hydration measures, serum Creatinine ( rarely included), and studies using variable malnutrition 
assessment tools such as Mini Nutritional Assessment (MNA) or Subjective Global Assessment 
tool (SGA).  Further analysis of the data may result in eliminating some of the exposures and 
elect to focus on those most frequently use to produce a systematic review. 
Types of outcomes measures:  
Most cohort studies report mortality as all cause mortality.  Several studies report other 
outcomes such as length of hospital stay, functional status as defined by Barthel Index scores.  
Very few studies report discharge destination and hospital readmission.  Later revisions of this 
review may result in the exclusion of the outcomes that are inconsistently and/or not frequently 
reported enough to synthesize a systematic review.  
Search methods and identification studies:   
We conducted a sensitive electronic search of MEDLINE and EMBASE since 1950.  Studies 
abstracts were examined for inclusion in the list of studies to be examined for review inclusion.  
Existing reviews bibliographies were examined for any relevant studies for the review.  
Searches were carried out by the PhD student who was trained by an expert systematic review 
and received systematic review training in a recognized course.   
Selection of studies:  
Two reviewers independently selected relevant studies with each synthesizing a list of studies 
with abstracts included.  After discussion, agreement, and consensus the two reviews finalized 
which list of studied meet the inclusion criteria and will be included in the final systematic 
review.  
Data extraction:  the search will find the relevant articles.  Two reviewers will review and 
extract data independently using a Cohort data extraction form.  This is for data duplication to 
make sure that no major discrepancy occurs.  Details for data extraction will include study 
population, type of study, measured outcomes, and validity of the results and methods.   If 
possible Validity of studies will be checked through evaluating if the authors used standardized 
and recognized nutrition assessment markers or tools, if authors diagnosed exposure through 
medically standardized methods, and if outcomes of functional capacity were assessed using 
standardized methods such as Barthel Index and SF-36. 
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Data Analysis: 
Descriptive statistics, linear and logistic regression models will be used to describe the 
relationship between each identified nutrition markers and outcomes including disability, 
morbidity, mortality, readmission, and discharge destination. 95% Confidence intervals and 
correlation coefficient will also be presented in the final results.  
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Appendix II: Search Strategy 
 
Database: EMBASE, MEDLINE, and Web of Science 
Date of Search: from inception to October 2010 
 
Search strategy including indexing terms used in MEDLINE 
1. BMI.mp 
2. body fat distribution/ or body mass index/ or body size/ or body weight/ or waist 
circumference/ or skinfold thickness/ or waist-hip ratio/ 
3. weight change or weight loss 
4. body weight changes/ or weight loss/ or thinness/ 
5. adiposity.mp.  
6. adiposity/ or body weight/ or waist circumference/ or skinfold thickness/ or waist-hip 
ratio/ 
7. Creatinine.mp.  
8. *Creatinine/bl, ur [Blood, Urine] 
9. Malnutrition.mp.  
10. malnutrition/ or deficiency diseases/ or magnesium deficiency/ or potassium 
deficiency/ or protein deficiency/ or protein-energy malnutrition/ 
11. Low albumin or Low prealbumin or Low transferrin. 
 12. Prealbumin/bl [Blood] 
13. *Transferrin/bl [Blood] 
14. *Serum Albumin/bl [Blood] 
15. (hydrat* or dehydrat*).mp.  
16. dehydration/ or hypercalcemia/ or hyperkalemia/ or hypernatremia/ or 
hypocalcemia/ or hypokalemia/ or hyponatremia/ 
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
18. cohort.mp. 
19. cohort studies/ or follow-up studies/ or prospective studies/ 
20. Myocardial Infarction.mp.  
21. myocardial infarction/ or anterior wall myocardial infarction/ or inferior wall 
myocardial infarction/ 
22. stroke.mp.  
23. Brain ischemia/ or hypoxia-ischemia, brain/ or "intracranial embolism and 
thrombosis"/ or intracranial embolism/ or intracranial thrombosis/ or intracranial 
hemorrhages/ or cerebral haemorrhage/ or intracranial haemorrhage, hypertensive/ or 
stroke/ 
24. Transient ischemic attack.mp.  
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25. brain ischemia/ or ischemic attack, transient/ 
26. 20 or 21 or 22 or 23 or 24 or 25 
27. 18 or 19 
28. 17 and 26 and 27 
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Appendix III: cohort data extraction form and validity tool 
Cohort Data Extraction Form 
Nutrition markers and Stroke, MI, and TIA outcomes 
Extractor initials: 
Date of extraction:  
Author  
Journal   
Year  
Study title  
Study Characteristics: 
Country of Origin?  
 
 
Language?  
 
 
Dates for Cohort Enrolment 
 
 
From:                                                            To:    
 
Duration of study follow up  
 
 
Drop out  
Reason for Dropouts  
Subject Characteristics:  
Total population selected  
Total population included in the actual study  
Mean Age  
Females/Males   
Age range  
Inclusion Criteria 
 
 
 
 
Exposure: Which of the following Exposures assessed in the study? 
a. Myocardial infarction b.  Transient ischemic attack                c. Stroke 
Define Malnutrition:  How is malnutrition defined in this study? (If applicable) 
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Nutrition Markers: Which Nutrition markers/assessment tools were measured/evaluated in this study? Tick the space near  
Indicator Tick below if used Cut off values defined as 
malnutrition 
Number below off values Number malnourished 
Body Mass Index 
    
Weight 
    
MNA 
    
Mid Arm 
Circumference 
    
Triceps Skinfold 
    
Other hydration 
(minerals) 
    
Serum Albumin 
    
Serum  Creatinine 
    
 
Outcome Assessment 
Number/percentage in study 
below cut off values defined as 
malnutrition 
Outcome measured* 
 
Outcomes number/percentage 
Malnourished vs. non Malnourished 
Confidence Intervals, Odds Ratio, Relative 
risk, p-values, etc…. 
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*Morbidity, Mortality, Poor outcomes (define below), disability (indicate how it was measured and define), average length of hospital stay, discharge 
destination.  
Add any definitions, comment in the space below:  
 
 
  
Appendix IVa: anthropometric studies included systematic review and meta-analysis description  
Study  Median 
Follow up 
period 
CVD  Age years (mean or 
range) 
Marker Females/ 
Males 
Outcome 
assessed 
Others variable the Model 
Adjusted for 
Batty 2006  35 years Coronary 
Heart 
Disease 
Normal weight: 51.4 
Overweight :53.8 
Obese: 52.1 
BMI 18403  
men only 
0.9% 
Mortality Age 
Employment grade 
Physical activity 
Smoking habit 
Marital status, weight loss in the 
previous year, height adjusted 
FEV,  
Blood pressure 
Diabetes status 
Cholesterol 
Buettner  2007 17 months Stroke Under weight: 66.1 
Normal weight 65.9 
Overweight 64.7 
Obese 62.7 
BMI 480/1196 Mortality Age, segment elevation 
depression, previous MI, 
elevated cardiac troponin T, 
elevated white blood cell count, 
platelet count, kidney function, 
angiography extent of coronary 
artery disease, CRP, obesity. 
Dagenaise 2005  4.5 years Coronary 
heart 
disease, 
peripheral 
artery 
disease, 
stroke 
66 years BMI 2182/662
0 
 sex, age, tobacco smoking, 
previous MI, previous stroke, 
presence of peripheral artery 
disease, known micro 
albuminuria, uses of antiplatelet 
agents, 
Diuretics, lipid-lowering agents, 
h-blockers and calcium-channel 
blockers, and ACE inhibitors.  
  
history of hypertension, 
diabetes, total cholesterol N5.2 
mmol/L, HDL 
b0.9 mmol/L 
Domanski 2006  4.8 years Coronary 
Heart 
Disease 
Men < 30 years: 64.1 
Men > 30 years:  61.8 
Women<30 years: 
66.4 
Women>30 years: 
64.1 
BMI 
 
1171/569
3 
Major adverse 
coronary events 
including CVD 
death, non-fatal 
myocardial 
infarction, 
coronary 
revascularizatio
n, and stroke) 
Age, history of myocardial 
infarction, history of angina, 
history of stroke, current 
smoking, history of smoking, 
systolic BP, diastolic BP, total 
cholesterol, LVEF percentage, 
Ca channel blockers, lipid 
lowering drugs, aspirin, beta 
blockers, history of 
revascularization, history of 
hypertension, and for women 
hormone replacement therapy 
Kragelund 2005 8-10 years Myocardial 
Infarction 
Under weight: 74 
Normal weight: 68 
Over weight: 66 
Obese 63 
 
BMI 2172/450
2 
 Age, smoking, wall motion 
index, history of diabetes, 
history of hypertension, cancer, 
heart failure, previous MI, 
thrombolysis, in hospital atrial 
or ventricular fibrillation, 
previous stroke, WHR 
Lopez-Jimenez 
2008 
186 days Myocardial 
Infarction 
Underweight :67.7  
Normal Weight 63.4  
Overweight 31.9  
Obese 57.8   
 
 
BMI 1022/684 Mortality, 
recurrent 
myocardial 
infarction 
age, gender, creatinine (≥1.3 vs. 
<1.3), systolic and diastolic 
blood pressures, previous MI, 
CABG, congestive heart failure, 
peripheral 
vascular disease, stroke, renal 
insufficiency, pulmonary 
diseases, diabetes, BDI scores, 
CABG treatment after, the index 
MI, and baseline use of 
  
vasodilators 
Mehta 2007 12 months Coronary 
artery 
disease 
<=70 BMI 606/1719 Mortality Normal BMI, age>70, female 
gender, diabetes, hypertension, 
hyperlipidemia, past peripheral 
disease, family history of 
coronary artery disease, current 
tobacco use, family history of 
coronary artery disease, killip 
class> I, ejection fraction, 
baseline heart rate>100,, b-
blocker use, systolic BP  
Nigam 2006  One year Myocardial 
Infarction 
    51-75  BMI 278/616 Mortality, 
recurrent 
Myocardial 
infarction 
Age, gender, diabetes, blood 
pressure, smoking, family 
history of CAD, lipid lowering 
use, beta blocker, aspirin, ACE 
inhibitor use at discharge 
Nikolsky 2006  One year Myocardial 
Infarction 
49-73 BMI 542/1493 Mortality Age, sex, diabetes, 
hypertension, 
hypercholesterolemia, current 
smoking, history of prior MI, 
bypass graft surgery, killip class 
2 or 3, creatinine clearance 
Rana 2004  3.8 years Myocardial 
Infarction 
Normal weight 65.3 
Overweight 60.6 
Obese I 58 
 
BMI 1317/581 Mortality Age, sex, race, current smoking, 
former smoking, thrombolytic 
therapy, tea and alcohol 
consumption serving/week, 
education, income, excluding 
patients with non cardiac 
morbidity 
Rea 2001  
 
3 years Moyocradial 
Infarction 
61.4  BMI 968/1349 Recurrent 
Coronary events 
age, sex, tobacco 
use, physical activity, 
congestive heart 
activity, and aspirin use 
  
 
 
 
 
 
 
 
 
 
Sierra Johnson 
2008 
6.4 years Myocardial 
Infarction 
62 
 
Weight 
loss 
79/311 Mortality Age, sex, smoking, 
dyslipidaemia, diabetes, 
hypertension, myocardial 
infarction and obesity 
Towfighi 2009  14 years Stroke > 25 BMI 275/369 Mortality Hypertension 
antihypertensive medications, 
hypercholesterolemia, diabetes, 
Hyperhomocysteinmia, time 
from stroke occurence 
Wu 2010 
 
16 months 
median (30 
months 
maximum) 
Myocardial 
Infarction 
Group I:  64 
Group 2:  62 
BMI 1885/467
5 
Mortality Age, gender, hypertension, 
diabetes` 
Zeller 2008 One year Myocardial 
Infarction  
Men by tertile: 
 T1, 67; T2 67; T3 61.  
 
Women by tertile: T1, 
77; T2, 76; T3 72. 
BMI 593/1636 Mortality Acute therapy, Killip, prior MI, 
Hypertension, Diabetes, 
hyperlipidaemia, smoking, CRP, 
STEMI, LVEF 
  
Appendix IVb:  other nutrition markers studies included systematic review and meta-analysis description 
Study  Median 
Follow up 
period 
CVD  Age (mean or 
range) 
Marker Females/
Males 
 Model Adjusted  
Bhalla 2000 3 moths Stroke 73.2 Measures of 
hydration: Osmolality 
87/80 Mortality Age, gender, and 
stroke severity, 
stroke subtype, 
and premorbid 
Barthel Index 
Carter 2007 7.4 years Stroke  76 Albumin 271/274 30 day mortality 
post hospital 
discharge 
Age, smoking, 
stroke subtype, 
previous 
stroke/TIA, AF 
IHD, PVD, and 
aspirin use 
Davalos 
1996  
3 month Stroke 66  Variable: MUAC, 
TSF, and Albumin 
37/67 Poor outcomes 
(Barthel 
Index<50) or 
death 
Age, Sex, protein 
energy 
malnutrition, 
mean daily value 
of urinary 
cortisol, CSS 
score 
Davis 2004  30 days stroke <75 or >=75 SGA 87/98 Poor outcomes 
(Modified 
Rankin score 2-
6) 
Mortality Model: 
NIHSS only.  
Poor outcome 
model: NIHSS, 
age, premorbid 
MRS variable 
Food Trial 
Collaboratio
n 
6 months Stroke 73.3 
 
 
Variable 
 
1492/1520 
 
Mortality Age, gender, 
prestrike 
function, living 
  
condition, and 
stroke severity 
Gariballa 
1998  
3 months Stroke 77.9 Albumin 180/81 Mortality and 
functional status 
(barthel index 
scores) 
Age, urine 
incontinence, 
MRs, gender, 
previous illness 
and intake of 
drugs 
Gariballa 
1998 
(AJCN) 
3 months Stroke 77.6 
 
 
Albumin 129/96 Mortality and 
discharge 
destination 
Age, gender, 
MRs, drug intake 
previous illness, 
and smoking 
status 
Hirakawa 
2006 
  
 
 
During 
hospital stay 
Myocardial 
Infarction 
75.62 (0.3) 
years for under 
nutrition 
73.44 (0.22) 
years for 
normal 
 
Albumin 521/1070 Death during 
hospitalization. 
age, activity of 
daily living, 
systolic blood 
pressure, body 
mass index, renal 
failure, bleeding, 
shock, Killip 
class, 
Pulmonary 
edema, location 
of myocardial 
infarction, 
ejection fraction, 
angiographic 
data, 
vasopressor, 
intra-aortic 
balloon pump, 
mechanical 
ventilation, 
  
 percutaneous 
coronary 
intervention. 
 
Kelly 2004 21 days Stroke 70.1 Serum osmolality  47/55 thromboembolis
m 
age, Barthel 
index, leg 
paresis, 
incontinence and 
atrial fibrillation 
Sung H 
Yoo 2008 
One week 
complications 
and 3 months 
poor 
outcomes ( 
stroke 64.8 (10.3) variable 47/84 Clinical 
Complications at 
one week and 
poor outcomes 
(Modified 
Rankin score 2-
6) 
vascular 
risk factors, co 
morbid diseases, 
stroke severity, 
stroke 
subtypes, and 
diet methods and 
amount 
  
Appendix V: PRISMA checklist 2009 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  17 
ABSTRACT    
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
18 
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is already known.  34 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
34 
METHODS    
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
35 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
35 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched.  
35 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
326 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 35 
  
and, if applicable, included in the meta-analysis).  
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
36 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
36 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
37-40 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  36 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
40-42 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reporte
d on 
page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
37-40 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or sub group analyses, meta-regression), if 
done, indicating which were pre-specified.  
41 
RESULTS     
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
43 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
43 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  44 
  
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
53-58 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  62, 63, 
66, 68, 
72, 75, 
76 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  51, 52 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or sub group analyses, meta-regression [see 
Item 16]).  
49, 62 
DISCUSSION     
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
78 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
83 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
84 
FUNDING     
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
NA 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The 
PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Fat Free Mass and Body Composition Changes after Stroke in Assessing and Monitoring of 
Nutritional Status, Nutritional Support Adequacy, and Relationships with Long Term 
Outcomes: an Observational Cohort Study 
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Abstract 
Study Objectives:  1) to describe body composition changes in the acute stroke phase; 2) to 
examine the effect of different methods of nutritional support on body composition changes after 
stroke; and 3) to examine the relationships between body composition changes after stroke and long 
term outcomes. 
Background:  Stroke complications such as dysphagia may make the maintenance of adequate 
dietary intake difficult after stroke. As a result, malnutrition after stroke is common.  Malnutrition 
can lead to tissue catabolism and body composition changes.  Body composition is readily 
measurable. The components which can be estimated consist of fat mass, fat free mass, total body 
water, and mineral contents.  In the catabolic state fat mass and fat free mass is the primary energy 
source for the body. This catabolic state is associated with total body and intracellular water loss 
and can result in dehydration.  Body composition monitoring in the acute stroke phase may help to 
evaluate the degree of tissue loss mainly through fat free mass to understand energy balance and 
nutritional status of patients as malnutrition is associated with poor outcomes including death in 
stroke patients.  Other good indicators of energy balance and nutritional status include fat mass, 
total body water (TBW), and mineral content.  These body composition variables can be measured 
using Bioelectrical Impedance Analysis (MF-MF-BIA).  MF-MF-BIA measurement is simple, non-
invasive, and can be performed in clinical settings while the patient is lying down. 
Methodology:  A cohort of stroke patients admitted to Gunthorpe Acute Stroke Unit at the Norfolk 
and Norwich University Hospital will be prospectively recruited upon consent to the study over 9 
months.  Body composition variables will be evaluated on admission, a week after enrolment to the 
study and at discharge using MF-MF-BIA (BioScan 920-2, Maltron International Ltd, and Essex, 
United Kingdom).  Routine haematological biochemical measures including albumin levels will be 
recorded.  Age, gender, stroke type, co-morbidity, pre-morbid status and any episodes of clinician-
diagnosed dehydration will also be recorded.  Selected patients with feeding regimen change during 
their acute hospital stay will have their body composition evaluated within 24-48 hours post feeding 
regimen change for every feeding regimen change.  Follow up will be carried out at nine months for 
each surviving participant using Patient Administrative System (PAS), medical records review, and 
postal questionnaires.  At follow-up the following outcome data will be collected- mortality, 
hospital admissions, functional status (measured using Barthel and Functional Independence 
Measure, FIM), health related quality of life (SF-36v2), patient reported outcome (PROM) using 
Stroke Impact Scale (SIS), discharge destination, acute hospital length of stay and initiation of 
nutritional support and complication arising from PEG nutritional support.  
Outcomes:  the primary outcome will be change in average fat free mass stratified by stroke type, 
severity and predominant feeding regimen.  Secondary outcomes include average change in body 
composition including fat mass, TBW and mineral content.  The relationships between these 
changes and above outcomes at nine months will also be examined. 
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Background: 
 Stroke is a chronic condition that can have various effects on the body including dietary 
intake.  Dietary intake in acute stroke is often inadequate, which is usually attributed to high 
incidence of dysphagia after stroke, and a range of other secondary complications such as cognitive 
problems affecting eating behaviours, reduced ability to feed oneself independently, disorientation, 
paralysis, depression, and other sensory related factors (1, 2).   Altered dietary intake can lead to 
weight loss, dehydration and malnutrition in stroke survivors. Weight loss after stroke has been well 
documented (3, 4).  In addition, malnutrition in stroke patients is common.   
Malnutrition is commonly defined using Body Mass Index (BMI) cut off points; a BMI of < 
18.5 Kg/m2 in populations aged < 65 years and a BMI of < 22 Kg/m2 in older groups is considered 
to be malnourished (5, 6). Deterioration of nutritional status in stroke patients during hospital care is 
well recognized (7, 8).  Malnutrition is thought to be partly contributed by the nature of the stress 
response instigated in stroke.  Stroke patients have been shown to have a great stress response; they 
have high cortisol levels, resulting in the deterioration of their nutritional status (9).   
Body composition is affected in acute medical illnesses including stroke. Furthermore, 
stroke complications which are associated with altered dietary intake can lead to a negative energy 
balance.  In such circumstances when energy needs were not met, the body will elect to use its own 
energy reserves resulting in tissue loss leading to subsequent body composition changes.  Body 
composition that can be measured easily consists of fat free mass, fat mass, total body water, and 
body mineral content.  Acute/chronic inflammation instigated during illness leads to catabolism of 
body tissue with resultant fat free mass loss (6).  Fat free mass loss leads to loss of cellular fluids as 
tissue catabolism results in intracellular fluid loss and expansion of extracellular fluid; cellular 
dehydration (10).   These changes are not uncommon after stroke.  Prevalence studies of 
malnutrition in stroke showed a proportion of stroke patients at the time of the event were already 
malnourished (10, 11, 12, 14, and 15).  
 
The nutritional status of stroke patients is compounded further by the fact that the 
physiological changes seen in malnutrition are already happening in a proportion of the elderly 
population, and stroke accelerates the process.  One of the most prominent physiological changes in 
older people is sarcopenia or fat free mass loss.  Sarcopenia is defined as muscle loss that occurs 
with the aging process leading to general weakness (15, 16).  In sarcopenia, fat free mass is replaced 
by fat mass.  The inverse correlation of fat mass with functional status has been well documented; 
an increase in fat mass was associated with functional limitations in the older people (16, 17).    
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Dysphagia is one of the commonest complications after stroke.  In a recent review, Martino 
and colleagues (18), reported the incidence of dysphagia as varying from 37% to 78%; using 
different dysphagia diagnostic criteria including cursory (water swallowing test), clinical (clinical 
scores), and instrumental (video fluoroscopy) methods.  The authors concluded that dysphagia after 
stroke is common regardless of diagnostic method used.  Dysphagia is considered the primary cause 
of reduced dietary and fluid intake in stroke patients (1, 2).  There is also a direct association 
between dysphagia and malnutrition in stroke patients. The proportion of dysphagic patients 
suffering from malnutrition, assessed using the Subjective (patient generated) Global Assessment 
(SGA) tool, was (10/14; 71%) compared to non-dysphagic patients (19/59; 32%) in acute stroke, 
p=0.007 (11).  One week after admission to an acute stroke unit, dysphagic patients were more 
likely to be malnourished (16/24) 67% compared to non-dysphagic patients (15/67) 24%; p<0.001 
(9).  The association between dysphagia and malnutrition is prevalent not only in acute settings, but 
also in care home settings.  A study carried out in a Hong Kong care home for stroke patients 
reported a significantly higher prevalence of malnutrition in dysphagic patients (4/20; 20%) 
compared to non-dysphagic patients (4/40; 10%); p=0.044 (19).   
The prevalence of malnutrition was also higher in dysphagic compared to non-dysphagic 
patients (62.5% vs. 32.0% respectively) on admission to a rehabilitation unit; p<0.032) (20).   There 
are other reasons why stroke patients may have an altered dietary intake in longer term, the physical 
and mental impairment and associated disabilities in stroke patients can alter dietary intake; making 
the eating process physically, socially, and mentally difficult.  Hoarding and leakage of food from 
the mouth, and chewing problems contributed to eating difficulties after stroke in 44% of patients 
with eating problems (4).  Other problems contributing to eating difficulty include food spills, 
difficulty to sit appropriately for eating, inability to concentrate, prolonged eating time, and inability 
to control foods in the plate (21).  
The eating difficulties that stroke patients experience could make the whole process an 
unpleasant experience for them (4).   There is some evidence to suggest that their new disability and 
limitations may put stroke patients into a state of depression.   In an observational study by 
Axelssen et al. (4) the authors reported that 65% of the patients in their study entered into a denial 
phase not accepting their new condition i.e. inability to eat as before.   The authors argued that the 
denial phase caused patients to enter into depression and increased the risk of anorexia (up to 50% 
in their series) (4).  A mean weight loss was reported as 2.6 kg in the 78% of patients with eating 
difficulties in their study (4).   Gariballa et al (22) also reported a decline in average weight in 
stroke patients at 2 and 4 weeks post admission to acute stroke unit in 48% (96/201) and 
25%(51/201); p=0.002.  Weight loss may still occur long term after stroke.  A more recent 
 351 
 
population based study documented weight loss of > 3 kg in 24% and 26% of stroke patients four 
months and one year post-stroke respectively (3).   If weight loss persists for a long duration it can 
contribute to severe BMI changes that can be classified as malnutrition; BMI < 18.5 Kg/m2 in < 65 
years old population and a BMI < 22 Kg/m2 in ≥ 65 years old population (5, 6).   
Malnutrition is prevalent among stroke patients on admission to a stroke unit.  However, 
malnutrition rates vary between different studies that used different methods to assess malnutrition.  
Unosson and colleagues reported that 8% of their study subjects (≥70 years old) were protein 
malnourished on admission; based on serum protein concentrations (7).  However, they did not use 
a validated malnutrition assessment tool such as the Subjective Global Assessment (SGA) or the 
Mini Nutritional Assessment (MNA) used in other studies (11, 12, 13, and 14).  These studies also 
reported variable malnutrition prevalence rates on admission to an acute stroke unit.  The 
prevalence of malnutrition using SGA was reported to be 19% in one study (11) and 32.1% in 
another study (12).  The two studies that used both SGA and MNA tool reported malnutrition to be 
at 16% (13) and 26.3% (14) at the time of admission to stroke unit.  A consistent finding, however, 
is that malnutrition seems to be prevalent among stroke patients on admission thereby increasing the 
risk of further deterioration of nutritional status during hospital stay.  
The proportion of stroke patients with malnutrition increases during acute hospital care (8, 
9).  One study reported a 6% increase in the prevalence of malnutrition from 16% at the time of 
hospital admission to 22% at the time of discharge measured anthropometrically using Triceps Skin 
fold thickness (TSF), Mid Arm Circumference (MAC), weight and biochemical parameters 
including albumin (8).  Another study reported that malnutrition prevalence changed from 16.4% at 
admission to 26.4% and 35% at one and two weeks post admission respectively using MAC, TSF, 
and serum albumin measurements (9).  Another study showed consistent findings reporting a 
constant decline in BMI (p=0.006), Triceps and Biceps skin fold thickness (p<0.0001), MAC 
(p=0.001), albumin (p<0.0001), and transferrin (p=0.02) between week 2 and week 4 post 
admission in stroke (22).    
In a more recent prospective observational study that included 131 patients,  malnutrition 
24 hours post-admission was diagnosed in 12.2% of patients compared to 19.8% of patients at one 
week post admission; p=0.03 (23).  The study used five criteria including a 10% weight loss in the 
past 3 months and or 6% weight loss one week post admission, weight index (actual weight 
compared to reference weight) less than 80%, serum albumin <3.0g/dL, prealbumin <10.0 mg/dL, 
or transferrin < 150mg/dL (23).  Malnutrition in the acute phase also increased the risk of 
malnutrition subsequently for example on discharge to rehabilitation services. The proportion of 
patients diagnosed with malnutrition on admission to stroke rehabilitation services ranged from 35% 
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to 67% (5, 20, and 24).  The malnutrition diagnosis criteria in previous studies depended mainly on 
anthropometric measurements such as TSF, weight loss, BMI, and serum albumin.   
The positive relationship between malnutrition and poor outcomes in stroke has been well 
documented.  Hospital length of stay was significantly longer in malnourished compared to well 
nourished stroke patients, nutritional status was evaluated using the SGA tool, by an average 
difference of 5 days; p<0.001 (11).  Another study, which evaluated nutritional status using triceps 
skinfold, madam muscle circumference, serum albumin, and calorimetry, reported a longer duration 
of hospitalization for malnourished (mean = 28 days) compared to well nourished (mean=17 days) 
stroke patients; p=0.001 (9).  The rate of complications were also higher in malnourished stroke 
patients; 50% in the malnourished group compared to 14% in the well nourished group (p<0.0001) 
(11).  Poor outcome, defined as a Modified Rankin Scale ≥3 measured 30 days after stroke, was 
reported in 80% of patients suffering from malnutrition compared to 54% in those with good 
nutritional status; p=0.01 (13).  Malnutrition in stroke patients was associated with higher incidence 
of death compared to non-malnourished stroke patients.  Stroke patients with malnutrition had a 
higher mortality rate (30%) compared to well nourished stroke patients (12%); p=0.02 (13).  The 
authors assessed malnutrition using the validated SGA tool (13).    A recent study by Yoo et al 
confirmed these findings; baseline malnutrition at the time of admission was significantly 
associated with frequent post-stroke complications (p<0.001) (23).  
The effect of malnutrition on outcome was also reported in stroke rehabilitation services.  
Length of stay in rehabilitation services was higher for malnourished compared to well nourished 
patients at admission; t = -1.88, df-47, p=0.033 (25).  Malnutrition in the study was diagnosed by a 
weight ≤ 90th percentile of reference weight or 95% of usual weight or BMI <20 kg/m2, MAC < 5th 
percentile, an average of five skinfold measurements < 5th percentile, low circulating lymphocytes, 
transferrin  (calculated from total iron binding capacity, and serum albumin (bromcesrol binding 
method).  These measures of malnutrition were significantly correlated with lower modified Barthel 
Index (BI).  The BI scores for malnourished stroke patients compared to well nourished patients 
were significantly lower at one month rehabilitation; p=0.032 (26).   
To date, studies assessing the effects of enhanced nutritional interventions in people who 
have had an acute stroke have provided variable outcomes.   Bath and colleagues carried out a 
review (26) of the available studies to understand the effect of different enteral feeding methods on 
stroke outcomes and concluded at the time of the review that further studies were required for a 
solid conclusion.  The authors reported that one study was not completed due to a 58% case fatality 
(27) and another study (28), only published data n=30, reported a significant improvement in 
nutritional status extrapolated from albumin levels in those having Percutaneous Endoscopic 
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Gastrostomy (PEG)  compared to Nasogastric (NG) tube feeding at six weeks post feeding 
administration.  Albumin levels improved from 27.1g/l to 30/1 g/l in the PEG group compared to 
reduction from 31.4 g/l to 22.4 g/l in the NG group; p<0.003.  The randomised controlled trial 
reported lower treatment failure in the PEG group (0/16) compared to the NG group (3/14, 21.4%) 
and reported that six PEG patients were discharged by six weeks after PEG insertion compared to 
none in the NG group; p<0.05.  Six week case fatality in the PEG group was 12% compared to 57% 
in the NG group; p<0.05 (28).  Despite these reported outcomes it would be difficult to draw any 
conclusion for several reasons.  The sample size is small to make it generalizable and the authors 
indicate that all patients were in stable condition without indicating the extent before randomizing 
their patients making it difficult to know if more stable patients were randomized to PEG feeding. 
A recent randomized controlled trial by Hamidon et al (29) compared the effects of PEG 
and NG feeding on patient’s nutritional status up to 4 weeks post intervention.  In PEG fed patients 
(n=10) albumin levels were significantly higher than NG tube fed patients (n=12); p=0.045.  PEG 
fed patients’ albumin levels rose more than those of   (p=0.025) NG fed patients (p=0.047) 4 weeks 
post intervention indicating better improvement in nutritional status in PEG compared to NG 
patients (29).  However, no statistically significant differences were observed in anthropometric 
measurements between the two groups (29).  Better treatment outcomes were reported in the PEG 
compared to the NG group: the treatment failure frequency was reported to be 50% in the NG group 
compared to no failure in the PEG group; p<0.036 (29).  The authors conclude that PEG feeding 
improves nutritional status more than NG feeding.  This is a small study and such generalizability 
cannot be made, PEG feeding could have been contraindicated to patient with GI infection which 
can contribute to lower Albumin count, and PEG fed patients could be in a prefeeding nutritional 
state than NG fed patients allowing better and more swift nutrition improvement in PEF fed patients 
as reflected by albumin.    
While smaller studies, suggest that PEG feeding provides better outcomes compared to NG 
feeding in stroke management although smaller studies can generate more MF-MF-BIAs.  The 
FOOD Trial, the largest nutritional intervention trial in stroke patients to date, reported a different 
outcome.  The FOOD trial studied the effect of early vs. none and type (PEG vs. NG feeding) of 
nutritional support on long term stroke outcomes; up to 6 months post discharge (30).  Patients were 
randomised to either no enteral tube feeding or enteral tube feeding 7 days post-admission to stroke 
unit, or randomised to PEG vs. NG tube feeding 7 days post admission.  Poor outcome (defined as a 
Modified Ranking Scale (MRS) score of 4-5) and death were evaluated 6 months post discharge.  
There was no difference in effect between early or no tube feeding on the risk of death (42% 
mortality for early tube feeding vs. 48% mortality rate for no tube feeding; n=429, OR=0.79, CI 95% 
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0.60-1.03) or combined  death or poor outcome ( 79% and  80%, respectively; n=429, OR=0.93, 95% 
CI 0.67-1.30) (30).   Similarly, no differences in the effects of the two nutritional support regimens 
on death and poor outcome were observed.  Six months after admission 89% of patients who had 
been randomised to PEG (n=162) compared to 81% of those given NG feeding (n=159) experienced 
death or poor outcome (OR=1.86, 95% CI 0.99-3.50) (30).  The effect on mortality of the different 
nutritional regimens was not significant either (49% and 48% for the PEG and NG feeding; OR= 
1.04, 95% CI 0.67-1.61) (30).   
The effect of early nutritional supplementation on death or poor outcome (Modified Rankin 
Scale score of 3-5) at 6 months post discharge were also examined in the FOOD Trial (31).  Patients 
were randomly allocated to normal hospital diet or normal diet with additional oral nutritional 
supplementation (360 ml oral protein supplement of 6.27 kJ/ml and 62.5 g/L in protein daily) 
during hospital stay until discharge.  There was no effect of supplementation on mortality outcome.  
Death was reported at 13% and 12% for the non-supplemented (n= 2012) and supplemented 
(n=2000) groups respectively; OR=0.94, 95% CI 0.78-1.13.  As for death or poor outcome it was 
reported at 58% and 59% for the non-supplemented (n=1995) and supplemented (n=2009) groups 
respectively indicating no effect of supplementation; OR= 1.03, 95% CI 0.91-1.17 (31).  Nutrition 
interventions as reported by the FOOD Trials did not have any important or significant impact on 
stroke outcomes up to 6 months post stroke.   
The FOOD trial adjusted for several prognostic variables including age, gender, premorbid 
status before stroke (living alone and independence), condition after stroke (ability to talk, lift arms, 
and walk), and ability to swallow (32). The FOOD Trial while being a multicentre study has its 
strengths and weaknesses.  The strengths as reported by the authors include its large sample size, 10 
times larger than any previous trial, and the recruitment of patients from various centres; and thus 
increased generalizability.  There are several weaknesses as suggested by the authors.  Weaknesses 
include informal methods in assessing nutritional status, failing to record the total number of 
eligible subjects in each centre, and inability to have an onsite source to report change in nutritional 
status and patient nutrient intake.   These could have contributed to not having a universal method 
in classifying malnourished patients contributing to MF-MF-BIAs in categorizing malnourished 
patients, inability to report nutritional status improvement in malnourished patients assigned to tube 
feeding (30) or nutritional supplements (31) initially, and inability to record systematically patients 
nutrient intake that could be mostly met through oral hospital diet masking the benefits of tube 
feeding (30) or nutritional supplements (31) initially.  
Given the several limitations of the FOOD TRIAL, it remains unclear which is the 
preferred type of nutritional intervention.  These limitations may have influenced outcomes.  The 
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FOOD TRIAL despite being a large multicentre study cannot help in providing raw evidence to 
help clinicians in decision making considering the inability to record and follow confounding 
factors that could have contributed for the reported outcomes.   
Traditionally weight was used to assess the risk of malnutrition with unintentional loss of 
10-15% of body weight as a predictor of malnutrition in disease states, and rapid loss of weight 
indicating dehydration.  Malnutrition can also be evaluated through body mass index (BMI) 
calculations, with a BMI< 18.5 kg/m2 and a BMI<22 Kg/m2 classified as malnutrition for the 
general and older population respectively (6).  However, BMI values cannot predict fat free mass 
and fat mass values in disease states and even if an increase in BMI occurs it could be attributed to 
increased fat mass and extracellular water content due to cellular dehydration as indicated earlier 
(10).  Anthropometric measurements such as Mid Arm Circumference (MAC) and Triceps Skin 
Fold (TSF) have been also used in predicting fat free mass and fat mass respectively.  However the 
disadvantage of TSF and MAC is the requirement for a skilled health professional to carry out these 
measurements because they require good precision and careful assessment of reproducibility, 
increasing room for errors and inaccuracy.   Biochemical tests can also be used to assess 
malnutrition and dehydration, including sodium, potassium, phosphorus, urea, serum albumin, and 
glucose.  However, biochemical tests cannot be used to predict fat mass or fat free mass content (6).  
Body composition measurement using bioelectrical impedance (MF-MF-BIA) analysis is one 
method that can predict fat mass and fat free mass values.  
Total body water is another component that can be assessed by bioelectrical impedance 
analysis.  Total body water can provide information on the degree of dehydration.  Physiological 
changes occurring in the aging process increases the risk of dehydration.  These physiological 
changes are related to reduced capacity in retaining water; such changes include but are not limited 
to reduced renal filtration rate, increased proximal tubular filtration absorption, and decreased free 
water clearance (33).   Total body water consists of intracellular and extracellular water.  Loss of 
intracellular water is usually defined as dehydration (34 and 35).  The diagnosis of dehydration 
through clinical symptoms and signs can be inaccurate and can lack sensitivity and specificity (36).  
Physicians misdiagnosed dehydration in third of patients admitted to a hospital (37) despite the 
dehydration council creating the DEHYDRATION mnemonic listing 12 indicators to be used in 
dehydration screening (33).   
 Assessing dehydration using MF-MF-BIA can predict not only total body water, but also 
specific intracellular and extracellular components.  Evaluating intracellular and extracellular water 
can provide information on the extent of tissue catabolism. As indicated earlier acute/chronic 
inflammation instigated during illness leads to catabolism of lean body mass loss; fat free mass loss 
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(6).  Fat free mass loss leads to loss of cellular fluids as tissue catabolism results in intracellular 
fluid loss and expansion of extracellular fluid; cellular dehydration (10).  Based on intracellular and 
extracellular water changes related to lean tissue catabolism caloric and nutritional needs can be 
modified to allow tissue anabolism and avoid further catabolism.  Assessing dehydration through 
measuring body composition values may provide information on the nutrition and management 
needs of patients.   
There are several methods to assess body composition. Two commonly used methods are 
dual X-ray absorption (DEXA) and bioelectrical impedance analysis (MF-MF-BIA).  DEXA is a 
reliable method and is used in validating other body composition assessment methods, mainly MF-
MF-BIA (38, 39, and 40).  DEXA uses x-ray energy to evaluate fat mass, fat free mass, and bone 
density (6).   However, DEXA is expensive, not readily available, and time consuming for patients 
in clinical settings.  MF-MF-BIA on the other hand is convenient.  It is simple to perform, non-
invasive (41), and quick in providing reproducible results with <1% error (42).  Its simplicity lies in 
the fact that no more than proper operating of the equipment is required by the operator and can be 
performed at bed-side.  It produces results instantly and time efficient.  
 Bioelectrical Impedance Analysis (MF-MF-BIA) 
MF-MF-BIA analysis is based on the resistance imposed by certain components of the 
human body; body impedance.  Body fat is non-conductive to electrical current while lean body 
mass, consisting of electrolytes and water, is conductive.  When a current passes through the human 
body it faces resistance from the adipose tissue, impedance, while passing through the non-adipose 
tissue component to complete its circuit.  The difference in conductivity, current input and output, is 
used to calculate fat mass and fat free mass using a validated formula already programmed in the 
MF-MF-BIA analysis equipment (43).  MF-MF-BIA can measure body composition using a single 
frequency current (SF-MF-MF-BIA) or a multi-frequency current (MF-BIA).  In SF-MF-MF-BIA a 
single current of a known quantity, usually 50 kHz, passes through the body tissue and the 
difference in current input and output is used to calculate fat free mass and total body water (44).  
As for the multi frequency MF-MF-BIA, to be used in this study, currents of several frequencies (0, 
1, 5, 50, 100, and 200, up to 500 kHz) are passed through the body tissue separately and impedance 
is generated, currents input and output difference is measured and used in different validated 
equations already integrated in the equipment to extrapolate body composition variables.  MF-BIA 
gives measurement of fat free mass, total body water, and extracellular and intracellular water (44).  
Both SF-MF-MF-BIA and MF-BIA use empirical linear regression equations to generate results by 
the equipment instantly (44).  MF-BIA has been used in clinical settings in conditions that includes 
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but are not limited to older patients (45), patients after coronary artery bypass graft (CABG) (46), 
patients with HIV (47), and those on dialysis (48).     
MF-MF-BIA validation studies to date, mainly conducted in comparison to the gold 
standard method by DEXA, have produced favourable outcomes.  A study to evaluate body 
composition changes in overweight women on a weight loss program, documented an agreement in 
the measurements between MF-BIA and DEXA (39).  There was no significance difference 
between DEXA and MF-BIA in measuring fat free mass (r2=0.87, p<0.001), fat mass (r2=0.93, 
p<0.001), and body fat % (r2= 0.20, p=0.03); MF-MF-BIA did not differ significantly compared to 
DEXA.  The MF-BIA and DEXA showed an agreement in their measurement, trend of body 
composition changes, although MF-BIA did not give the same exact measurements as DEXA.  The 
study also documented that MF-BIA slightly underestimated fat mass and overestimated fat free 
mass in lean individuals and overestimated fat mass and underestimated fat free mass in obese 
individuals compared to DEXA (FM; r2= 0.17, p=0.05 and FFM; r2= 0.16, p=0.05) (39).   
A recent study by Schafer et al (49) evaluated the validity of MF-BIA across a range of 
BMI in healthy subjects compared to DEXA.  MF-BIA overestimated fat mass in obese subjects 
compared to DEXA (p<0.0001); difference 4.11 ± 0.34, and overweight BMI (p≤0.006); difference 
of 0.95 ± 0.33.  Despite MF-BIA overestimation of fat mass the author highlighted that MF-BIA 
measurements did show body fat percentage agreement with DEXA in the normal and overweight 
BMI category with a mean difference of -1.56% (limits of agreement -6.7% to 3.6%) and 0.58% 
(limits of agreement -3.8% to 5.0%) respectively.  The agreement is weaker with DEXA with 
higher BMI values in obese range (i.e. BMI >30); mean difference was 3.50% (-2.2 to 8.8%) (44). 
MF-BIA overestimated fat free mass in normal and overweight BMI compared to DEXA with a 
difference of 2.08 ± 0.32 (p<0.0001) and 0.71 ± 0.33 (p≤0.04) respectively.  Overall conclusion was 
that MF-BIA is in agreement with DEXA when measuring normal and overweight subjects 
although overestimation occurs, and therefore caution should be taken in interpreting MF-MF-BIA 
results in obese subjects (49).   
There is a lack of data on the use of MF-MF-BIA method in evaluating body composition 
after stroke. One small study compared body composition changes after stroke between Paretic leg 
and the non-affected leg of patients (n = 35) (50).  It used the DEXA method in evaluating body 
composition, indicating that significant losses in lean body mass and bone density loss occurred in 
the paretic leg compared to the non-affected leg after stroke; p<0.05(50).   The study did not 
compare body composition changes after stroke at baseline and after the initiation of nutritional 
support.  While DEXA method is considered to be gold standard measurement of body composition, 
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it is expensive, time consuming to perform, inconvenient for patients and not pragmatic to be used 
routinely in clinical practice.  
In summary, stroke symptoms and complications such as dysphagia, paralysis, and 
depression can reduce dietary intake, leading the body to compensate for such negative energy 
balance by utilizing its own energy reserves and increasing body tissue catabolism resulting in body 
composition changes (51).  Body composition changes can have a great impact on treatment 
outcomes.  There is a significant positive association between malnutrition and dehydration and 
reduced muscle strength, infection resistance, and wound healing in stroke patients (52, 53).   Body 
composition measurement during acute stroke phase may serve to better understand the relationship 
between these changes and stroke outcome.  This may help to gain deeper insight on how such 
changes can be avoided to improve outcome in stroke. 
This study seeks to investigate and describe body composition changes after stroke and 
their effect on long term post stroke outcomes using Bioelectrical Impedance (MF-MF-BIA), which 
can be a useful tool in clinical settings when validated in with the standardized DEXA in this 
population.   This study can add significant knowledge to the already existing literature in 
nutritional aspect of stroke management and improve the understanding of the role of nutrition in 
stroke recovery.  
Objectives:   
This PhD research project aims to add to knowledge in the area of nutritional science in stroke.  The 
project will lead to further research to better understand the role of nutrition as a modifiable 
determinant of long term stroke outcomes. The project will describe body composition changes 
during acute phase of stroke and investigate the relationship between nutritional and hydration 
status and several stroke outcomes as outlined below.  
 
Primary Objectives 
1. to describe fat free Mass changes after acute stroke by stroke subtype and severity during 
the course of acute care 
2.  to examine the effect of different methods of nutritional support on body composition    
changes after stroke and  
3. to examine relationships between body composition changes after stroke and long term 
outcomes at nine months post stroke  
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The design of the study will also allow us to examine the following secondary objectives  
 
Secondary Objectives 
1. to estimate body composition values that define malnutrition using MAC (for fat free mass), 
TSF (for fat mass) and BMI (for both) as standard measures 
2. To assess the predictive value of individual components of body composition (fat mass, fat 
free mass, total body water and some minerals) at baseline and changes occurring and 
during acute care (between baseline and pre-discharge from acute hospital), stratified by 
predominant feeding regimen and stroke subtype and severity.    
3. to assess the effect of hydration status (both at the baseline and change during admission) 
assessed using Intracellular fluid (ICF) measured by MF-MF-BIA in stroke outcome  
4. To validate MF-MF-BIA against DEXA for fat mass, fat free mass, total body water and 
some minerals in stroke patients using purposeful sampling. 
Research Questions:  
1. What body composition changes occur after specific types of stroke?  
2. What are the effects of different nutritional support regimens on body composition changes 
after stroke? 
3. Do body composition at baseline and their changes occurring during acute stroke phase 
have an effect on long term outcomes?  
 Research Questions for Secondary Objectives: 
1. What are the magnitudes of changes in body composition values using MF-MF-BIA which 
define malnutrition benchmarked by standardized MAC, TSF, and BMI values? 
2. What body composition changes or values have a significant effect on long term subjective 
and objective outcomes of stroke?   
3. What extent of cellular dehydration occurs in stroke patients as measured using 
bioelectrical impedance, and what is the relationship between intracellular dehydration and 
stroke outcomes?  
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4. How well the body composition values measured using MF-MF-BIA correlate with body 
composition values measured using DEXA in stroke patients? 
Hypotheses:    
Hypothesis I: Body composition changes after stroke do occur and the magnitude and 
proportion of changes occurring in various components of the body (fat mass, fat free mass 
etc.) are different depending on stroke type and severity.  
Rationale:  Evidence indicates that a proportion of stroke patients are malnourished on acute 
admission and their nutritional status deteriorates during acute hospital stay.  Malnutrition 
combined with the stress response in acute conditions results in body tissue catabolism.  The human 
body tries to generate energy from the available energy reserves and this result in catabolic process 
that result in body composition changes.  
Hypothesis II:  Negative body composition changes (defined as reduced fat free mass, 
increased fat mass and decreased intracellular water) after stroke are associated with both 
objective and subjective poor outcomes.   The body composition changes after stroke are 
influenced by the timing and methods of feeding independently of stroke severity 
Rationale: Studies on the elderly populations, main stroke population, suggested that sarcopenia 
(loss of lean body mass), leads to loss of functional capacity.  Nutritional status of stroke patients 
and stress response in acute stroke phase can result in major body composition changes (hypothesis 
I) with fat free mass being the most affected component as amino acids are being converted to 
pyruvate for energy generation.   
Objective outcomes hypothesis:  Body Composition changes in Fat Free Mass and body water 
correlate with increased risk of mortality, readmissions to secondary care settings, admission 
to care homes, and reduced functional capacity 
Rationale: It would be reasonable to predict that changes in fat free mass and body water correlate 
with stroke outcome.  Fat free mass or lean body mass loss, results in reduced strength which results 
in reduced mobility and overall functional capacity.  Fat free mass loss, therefore, can result in 
disability.  Fat free mass loss indicates the severity of the illness We hypothesise that fat free mass 
loss during acute stroke phase controlling for baseline fat free mass will have long term effect after 
stroke that can be measured by objective outcome measures of readmission to secondary care after 
hospital discharge location, mortality outcome and functional limitation measured by Barthel Index 
(BI) controlling for case mix and prognostic indicators.. 
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Subjective outcomes hypothesis:  Fat free mass loss is associated with reduced functional 
capacity and quality of life as indicated by the Stroke Impact Scale, SF-36, and self rated 
health (5 options) scores/responses. 
Subjective outcome:  Subjective outcomes to be evaluated in this study are related to the quality of 
life.  Patients who suffer from loss of functional capacity or disability (associated with fat free mass 
loss as in hypothesis II) will have lower self rated health when evaluating their quality of life and 
health related QoL (SF-36).   
Hypothesis:  Cellular dehydration, loss of intracellular fluid volume (ICF)) after stroke as 
measured by MF-MF-BIA is associated with increased chances of hospital readmission, 
increased risk of mortality, disability, and reduced quality of life based on patients responses 
and Stroke Impact Scale and SF-36 scores.   
Rationale: Dehydration occurs when intracellular fluid is depleted.  Malnutrition is a result of 
inadequate caloric and nutrient intake leading to a negative energy balance.  Both malnutrition and 
stress cause the body to utilize its own self to generate energy.  The outcome is lean body mass loss.  
Lean body mass loss leads to the release of intracellular fluids into extracellular space causing 
cellular dehydration; cell mass is lost releasing cells contents (10).  We hypothesise that ICF loss 
after stroke, adjusting for baseline ICF status and controlling for case mix and prognostic indicators, 
is related to above outcomes long term after stroke.  
Null Hypothesis:  There is no significant effect of different feeding regimen on long term outcomes 
after stroke.  
The FOOD TRIAL did not show that one feeding method is better than other in terms of poor 
outcomes after stroke up to 6 months. Therefore, the decision of timing and method of feeding is 
purely clinical decision, albeit influenced by the FOOD trial results with less PEG insertions offered 
before 3-4 weeks post stroke. We hypothesise that there is no significant difference in long term 
outcome up to 9 months post stroke (null hypothesis) between different feeding regimens.  
 Study Design:  Observational cohort study 
Study Location:  Norfolk and Norwich University Hospital 
Inclusion Criteria:   
• Age 17 years and over 
• Any newly diagnosed stroke (first or recurrent) 
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• Admitted to the NNUH within 48 hours of stroke onset 
Exclusion Criteria: 
• Severe stroke NIHSS >30 whose likelihood of survival >7 days is <50% as judged by the 
stroke physician  
• Severe stroke; for palliation only (expected survival of less than 48 hours) 
• Very mild stroke or TIA patients who fully recovered within 24 hours of hospital admission  
• Life expectancy is less than 3 months prior to the event   
• Co-existing terminal illness e.g. advanced cancer, end stage chronic disease such as end 
stage renal failure and end stage COPD 
Patient selection criteria for MF-MF-BIA validation against DEXA 
• Eligible to be included in the study as per above inclusion criteria 
• Provide consent to attend DEXA assessment after discharge  
• Able to walk without aids and attend CTRU for DEXA assessment   
Methodology:  
Eligible patients will be recruited over a nine month period (June 2010-end February 2011). 
Follow up data will be collected at nine months (complete follow up in end of November 2011). 
Data collection will be carried out in four stages: on admission, post-admission for feeding regimen 
change, at discharge, at nine months follow up.   
On admission: patients will be recruited within 48 hours of hospital admission.  Informed consent 
will be obtained.  Participants’ demographic details (age, sex, etc.), weight within 3 days of 
admission, height mainly as demi span measurement for bed ridden patients, body mass index 
(BMI), triceps skinfold (TSF), madam circumference (MAC), hand grip strength (non-affected hand) 
using a dynamometer, presence or absence and degree of dysphagia (routinely assessed by speech 
and language therapists), type and consistency of allowed food and fluid (e.g. level A, thickened 
fluid), and body composition measurement (using Bioelectrical Impedance Analysis) will be 
measured upon consent to the study.  Several measurements for triceps skinfold (five skin fold 
measurements (25) (using a skinfold calliper), midarm circumference (three times), and hand grip 
strength (using a dynamometer) (three times) will be carried out and mean value will be used for 
analysis.  
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 From MF-MF-BIA analysis, we will collect data reflecting changes in physical and 
general health these will include fat free mass (Kg), fat free mass percentage, fat mass (Kg), fat 
mass percentage, total body water (L), total body water percentage, extra and intracellular water (L), 
extra to intracellular water ratio, body cell mass (Kg) and percept, extracellular mass (Kg) and 
percept, creatinine clearance rate (ml/min), glomerular filtration rate (ml/min), protein mass (Kg), 
mineral mass (Kg), mineral mass percept, total body calcium and potassium (g), muscles mass (Kg), 
glycogen mass (g), dry weight (Kg), extracellular fluid (L), plasma fluid-intravascular (L), 
interstitial fluid-extravascular, body volume (L), and body density (Kg/L).  MF-MF-BIA data will 
be collected during hospital stay, post admission; changes in body composition will be captured 
using MF-MF-BIA upon initiation of feeding regimen; within two days of feeding initiation and on 
clinician diagnosis of dehydration.  The measurements will be repeatedly carried out each time a 
feeding regimen change is instructed within two days of such change for selected participants.  
There is no published literature on when best to measure body composition changes after change in 
dietary pattern and the selection of this time frame is for pragmatic reason; this is based on the 
research team’s clinical experience of required duration to allow the participant to adapt and reflect 
changes occurred in body composition due to new feeding regimen.  At the time of acute hospital 
discharges: baseline measurements described above will be repeated.   Progression of MF-MF-BIA 
changes will be described and differences between baseline and discharge values will be noted.   
Selected patients meeting the DEXA-MF-MF-BIA validation study inclusion criteria will 
be recruited upon their consent to have their body composition measured using DEXA. DEXA 
measured body composition value will be compared with MF-MF-BIA body composition values 
including fat mass, fat free mass, total body water, and mineral content for validation purposes prior 
to discharge.   
Other routinely performed test results will be collected at baseline (at the time of 
enrolment), day 7 (+/- 2 days) and at discharge. These will include FBC, WCC, Platelets, MCV, 
MCH, Biochemistry data Urea, Creatinine, albumin, total protein, alkaline phosphatase, ALT, GGT, 
CRP, ESR (if measured), total cholesterol, high density lipoprotein (HDL), triglycerides (TG), low 
density lipoprotein (LDL) cholesterols, glucose, HbA1C in those with diabetes, MUST and Barthel 
Index scores.  Other prognostic indicators of stroke will also be recorded. These include, stroke type, 
severity assessed using BAMFORD classification, admission NIHSS, pre-morbid Rankin score, 
pre-morbid Barthel Index, significant co-morbid conditions.  Routinely collected clinical data for 
stroke register will be collected which includes other prognostic indicators such as time of CT, 
duration of stay on stroke unit, physiotherapist and occupational therapist assessment, salt 
assessment, whether or not received thrombolysis, and participation in clinical trials.  
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Post-discharge follow up at 9 months post-discharge will evaluate long term stroke 
outcomes.  Both objective and subjective outcomes will be measured.  Objective outcomes include 
mortality, cardiovascular events (heart attack, another stroke/TIA), hospital readmission, discharge 
location, change in residence (residential or nursing home change), nutritional support initiation and 
change.  
Data linkage and retrieval from the Patient Administrative System (PAS) and review of 
medical records will be carried out to collect these objective outcomes data.  Data related to patient 
activity will also be retrieved from PAS.  Medical records will be reviewed to confirm the evidence 
of initiation of nutritional support, readmission, and change in residence since discharge, other co-
morbidity developing post discharge (e.g. attendance to neurology clinic for treatment of 
contractures).  Those participants who are discharged with PEG or NG? Feeding will also be 
followed up using Dietetic Department’s records for any complications arising as the result of PEG. 
Subjective outcomes will include patients self-reported health related quality of life using 
version 2 of the Short Form-36 (SF-36v2), self rated health using a five option poor to excellent 
scale, Stroke Impact Scale (patient reported outcome measure, PROM) and Barthel Index Scores.  
The self reported patient outcomes will evaluate variables related to patient’s quality of life and 
mainly disability, functional dependence and independence.  Questionnaires will be sent to patients 
9 months post enrolment. 
Sample size calculation:  This is an observational cohort study.  The study team has performed 
thorough literature search and to our knowledge, there are no previous studies of similar nature 
performed in this field to allow us to do formal sample size calculations.  There are no data for body 
composition values which have been shown to be related to clinically meaningful outcomes such as 
mortality. Therefore, the objectives of this observational cohort study is to describe the body 
composition changes that occurred after stroke in the context of stroke severity, patients risk profile 
and nutritional management to better understand the effect of stroke and its management on changes 
in body composition (fat free mass, fat mass and dehydration in particular) and to explore the effect 
of body composition changes on the long term outcomes (both objective and subjective) after stroke.  
Data Analysis: 
Analysis of all data will be carried out using the latest SPSS version available at the time of analysis.  
Adjustments will be made for above variables that can have an effect on outcome.  Below are the 
planned statistical tests to achieve study objectives.  
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Body composition changes in acute care after stroke:  to test primary hypothesis I: Body 
composition changes after stroke do occur and the magnitude and proportion of changes occurring 
in various components of the body (Fat mass, FFM etc.)  is different depending on stroke severity.  
ANOVA will be carried out to test the significance of hypothesis I; p<0.05, 95% CI.   
Body composition changes after stroke and their effect on long term outcome:  to test, 
hypothesis II:  Body composition changes after stroke results in long term reduced functional 
capacity.  The body composition changes after stroke are influenced by the timing and methods of 
feeding independently of stroke severity.  In order to test hypothesis II an ANOVA test will be 
carried out; p<0.05, 95% CI.   
The effect of body composition changes after stroke and long term outcome (subjective 
outcomes):  to test the hypothesis, fat free mass loss is associated with reduced functional capacity 
and quality of life as indicated by the Stroke Impact Scale, SF-36, and self rated health (5 options) 
scores/responses, and  to evaluate the strength of association between body composition changes 
after stroke and long term outcome (subjective) a linear regression analysis will be carried out; to 
understand the probability of the measured outcomes happening (reduced functional capacity and 
quality of life) when fat free mass loss occurs.   
The effect of body composition changes after stroke and long term outcome (objective): to test 
the hypothesis, body composition changes mainly fat free mass loss results in increased risk of 
mortality, readmission to secondary care settings, and admission to rehabilitation services, and to 
evaluate the strength of association between body composition changes and long term outcomes.  A 
linear of logistic regression analysis (depending on the outcome) will be carried out to understand 
the probability of the event happening when fat mass loss occurs.   A Cox-regression model will 
also be designed to take into account the point in time in which an outcome may occur.   
The effect of different nutritional support regimen on body composition changes:  three means 
ANOVA will be carried out to test the significance of different feeding regimen on body 
composition changes.  Three means ANOVA will test the difference between Percutaneous 
Endoscopic Gastrostomy, Naso gastric tube feeding, and a NG feeding with additional oral intake.  
An unpaired t-test will be carried out for two independently different groups NG vs. PEG to 
understand their different effect on body composition changes; p<0.05, 95% CI.  
The impact of the cellular dehydration on long term outcomes:  a logistic or linear regression 
(depending on the outcome) will be carried out to test the hypothesis, cellular dehydration as 
measured by MF-MF-BIA after stroke is associated with increased chances of hospital readmission, 
admission to rehabilitation services, increased risk of mortality, disability, and reduced quality of 
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life based on patients responses and Stroke Impact Scale and SF-36 scores using p<0.05 and 95% 
CI.  A Cox-regression model will also be carried out to understand the effect of cellular dehydration 
on long term outcome at a point in time. 
Multiple Regression for Model Design:  the relationship between body composition and fat free 
mass changes separately with other variables including age, cellular dehydration, stroke severity, 
sex, and nutritional support regimen will be all depicted in a model using multiple regression.  The 
model will try to develop a relationship while understanding the strength of association between fat 
free mass changes and body composition changes (each separately), with age, sex, stroke severity, 
nutritional support, and cellular dehydration.  An example of a regression equation will be  
Y= a + b1x1 + b2x2 + ……. + b5x5 
Where Y is fat free mass or body composition and X1 to X5 are sex, age, nutritional support, cellular 
dehydration, and stroke severity regardless of the order.   
Descriptive Statistics:  In addition to the above analytic methods, descriptive statistics such as 
percentages, median, and means will be calculated to provide a broad understanding and a general 
conclusion on the reported outcomes.  
Study time line:    Study Begins: 01/06/2010 
                            Study Ends:  31/12/2011 
After ethical approval, data collection will commence on the 1st of June 2010 and ends on 30th 
February of 2011 (9 months).  The stroke team in NNUH looks after about 1000 new strokes per 
annum. With conservative estimate of 20% consent rate we expect to recruit approximately 120-150 
patients over 9 months recruitment period. The follow up period will begin from 1st of March 2011 
and end on the 31st December of 2011 (9 months).    
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Schematic Diagram depicting summary of the project 
 
 
•Recruit patients
•consent
•collect demographic data Data
On Admission
•Biochemistry
• dysphagia assessment
•Anthropometrics (MAC, TSF, 
BMI, Weight, Hand grip 
strength)
•Bioelectrical Impdedance 
Measurment (FM, FFM, TBW, 
Mineral Content)
•Bioelectrical Impedance upon 
feeding regimen change (within 
two days)
Within 3 days 
of admission •Repeat 
anthropometric data 
collection
•Repeat Bioelectrical 
Impedance data 
collection
• Body composition 
measurment for 
elegible patients using 
DEXA
Dishcarge
• Data retrieval through PAS
• Medical Records Review
• PEG patients will be followed up 
through Dietetic Dept records
• Self reported health related to 
Quality of life data collection using
•SF-36v2
•Barthel Index
•Stroke Impact Scale
Follow up
Patient recruitment period: nine months 
Patient follow up period: nine months 
Data Analysis: paired or unpaired t-test, Anova, linear 
regression, logistic regression, and/or Cox-regression 
model when appropriate.   
Multiple regression model will be designed to understand 
the relationship between Fat Free Mass and Body 
composition changes and age, sex, cellular dehydration, 
stroke severity, and nutritional support in stroke patients. 
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Appendix VII: Participant Information Sheet 
 
PARTCIPANT INFORMATION SHEET 
Study title: Changes in body composition after acute stroke 
 
Main investigator: Mohannad Kafri 
 
You are invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish.  Ask us if there 
is anything that is not clear or if you would like more information.  Take time to decide whether or 
not you wish to take part. 
  
What is the purpose of this study? 
 
The aim of this study is to understand what body composition changes occur after stroke.  Our body 
is composed of fat, non-fat (muscle, bone and tissues), water, and its contents (for example salt). 
There is limited knowledge of the effect of stroke on body composition changes. 
 
Moreover, changes in these components of body have been shown to relate to health in older 
people. In addition, we do not understand very well the relationship between body composition 
changes after stroke and the long term outcome on people’s life quality.  This study therefore also 
seeks to understand the relationship between body compositions change immediately after stroke 
and the long term outcome up to one year on stroke patient’s quality of life and health.   
 
The findings of this study can assist health care professionals and specialists to understand in what 
ways we can improve the nutritional care after stroke.  
 
 
Why have I been chosen? 
 
You have been invited to this study because you recently sustained a stroke and have been admitted 
to the hospital.  You have been invited because we think you are eligible to take part in this study 
according to our study criteria and you may be interested in helping with the project as a participant. 
 
Do I have to take part? 
 
You do not have to take part in the study if you do not want to. It is entirely voluntary. If you 
decide not to take part in the study, this will not influence your care in any way.   
 
What will happen to me if I take part?  
 
If you decide to take part we would like to assess your body composition values.  It is a procedure 
that is non-invasive, quick, and does not put you in anyway under stress.  We will simply attach the 
machine using sticky patch (which can be easily removed afterwards; similar to sticky patch we use 
to look at your heart tracing) at your wrist and hand, and leg and foot and take the measurements.  
 374 
 
You will not feel anything.  It will only take 5 minutes or less.  We intend to measure at least twice 
before you are discharged from the hospital.  
 
If there were a feeding regimen change, we may repeat the measurement.  This is only for research 
purposes and will not affect your treatment in anyway.  It is possible that frequent body 
composition measurements will be carried out after feeding regimen change.  Please feel free to ask 
the nurse for further information and the investigator will visit you to give you a better picture of 
the measurement if you wish to. 
 
Also we would like to take a measurement of your Skin Fold thickness in upper arm.  It does not 
take more than 5 minutes.  It does not cause you any pain.  We will take five measurements of the 
skin fold thickness. We will also want to take three measurements of the circumference of the arm. 
Again it is a very simple procedure that does not cause any pain and will take less than 5 minutes in 
total.  The last measurement we want to take is your handgrip strength where you simply squeeze a 
gas filled balloon as hard as you can and hold it while the investigator reads the meter.  It does not 
take more than one minute; we might ask you to repeat the hand grip strength measurement three 
times. The measures are repeated so as to make sure we record the most accurate measurement.     
 
We would also like to look at your medical records, case notes, and blood biochemical 
measurements.  Looking at your medical records, case notes, and biochemical measurements will 
help the research team to understand your health status and how it relates to your body composition 
changes and quality of life. This approach does not require any extra blood test and we will be using 
available information which is routinely measured and recorded by the clinicians for your care. 
Please feel free to object and make your decision clear to us if you don’t want us to access your data.   
 
After you are discharged from the hospital we will ask you some questions which will be sent to 
you by mail about 9 months after your stroke. It can be filled in by yourself or with the help of your 
carer/friend or a family member.  You can also refuse to answer all or part of these questions if you 
decide not to. 
 
You may be asked to attend a special measurement for body compositions (called DEXA scan) at 
the University of East Anglia if you are appropriate to be included in that part of the study.  You 
will need to lie-down still on a padded bench while taking the scan.  It is similar to an X-ray.  It is 
quick, simple, and does NOT require any other procedure other than lying down still for few 
minutes.   The amount of radiation you will be exposed to is minimal and is equal to the amount of 
radiation you are exposed to everyday from natural resources in the UK in less than two days.  We 
will organise the transport if you require attending the assessment.  
 
We respect your decision and we appreciate your participation.  Please feel free to make the 
decision you feel most comfortable about.  Any decision you take will in no way affect the quality 
of care you receive.  
 
Your results will remain private and no one except the research team will have access to them.  
These results are only for research purposes and are not for treatment purposes and they will not 
affect the quality of care you will be getting.  
 
Expenses and payments 
 
Taking part in this research project will not incur any expenses to you.  There will be no payment 
for taking part in this research. The follow-up will be carried out through postal questionnaire in 
most cases. However, for the follow-up visits if we need to assess your health we will arrange 
transport for you and provide refreshments.  
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What will I have to do? 
 
If you agree to participate in the study we will need your consent on the official form.  Once 
consented, we will take measurements. You will be assessed upon consenting, then when feeding 
changes happen, and at discharge.   
 
What are the risks and nature of taking part? 
 
There is no risk involved in taking part in the study. The equipment we will use to measure your 
body composition has been checked for its safety by the responsible department of the hospital.  
 
What are the possible benefits of taking part? 
 
It is unlikely that you will directly benefit from the research.  However, this is a project examining 
1) body composition changes after stroke 2) the influence of body composition change on the long 
term outcome after stroke 3) and the effect of different feeding regimens on body composition after 
stroke. Our findings may suggest areas for improvement or intervention which will be of benefit 
stroke patients and improve stroke care in the future.  
 
What happens if I change my mind? 
 
You are free to withdraw from the study at any time. This will not affect the medical treatment you 
receive on the ward.  Any research data collected from you will not be considered and will be 
removed.  
 
 
 
Will my taking part in this study be kept confidential? 
 
All information, which is collected about you during the course of research, will be kept strictly 
confidential. All data will be entered into secure computers located in the hospital with limited 
access measures via a username and password.  Your name and any other identifying information 
will not be included in any study data entered into the computers and your name and address will be 
removed from any information leaving the hospital/surgery.  You will be identified using a specific 
study code and/or number when entering data into the secure computers.  
 
Research Data collected will be stored on the secure computers for a period of more than three 
years as this us a PhD research project that takes at least three years to complete.  
 
What will happen to the tests? 
 
The measurements and responses to questions asked will be kept entirely anonymous.  
 
What will happen to the result of the research study? 
 
The study results may also lead to further studies in this particular area. Any information we collect 
about you will be confidential and used only for the purpose of this study.  The information about 
you will only be available to research staff and the medical staff caring for you. We hope to 
publicise our findings by submitting the research reports to scientific journals and present our 
findings at scientific meetings and patient and public forums. Data presented in all medium will be 
aggregated and anonymised so that no one will be able to identify you based on these publications.  
 
What if something goes wrong? 
 376 
 
 
It is very unlikely that you will be harmed by taking- part in this research project since this project 
does not involve administration of any drugs or use of any invasive instrument. However, if you 
wish to complain in the event of any self-perceived harm as a result of this study, the normal 
National Health Service complaints mechanisms will be available to you.   
 
You can also contact the Patient Advice and Liaison Services (PALS) available in the hospital for 
support, resolving any problems, suggestions, or concerns.  PALS is open weekdays from 9am-5pm 
and can be contacted on the Telephone 01603 289036 or through email: PALS@nnuh.nhs.uk.  
 
 
Who is organising and funding the research? 
 
This study is carried out by a research team consisting of Mr Mohannad Kafri, PhD student in 
Nutritional Epidemiology, University of East Anglia, Dr Phyo Kyaw Myint, Clinical Senior 
Lecturer/Consultant in Stroke Medicine, Dr Lee Hooper, Senior Lecturer in Research Synthesis & 
Nutrition, School of Medicine, Health Policy and Practice, University of East Anglia, and Professor 
John Potter, Professor of Ageing & Stroke Medicine, School of Medicine, Health Policy and 
Practice, University of East Anglia.  The University of East Anglia funded this PhD studentship and 
the study is supported by the Department of Medicine for the Elderly. 
Who has reviewed the study?  
This study has been reviewed and given a favourable opinion by the Cambridgeshire I Research 
Ethics Committee. 
 
 
Contact for further information If you would like to know more, please contact the principal 
investigators of the study Mohannad Kafri, Investigator, 01603 286286. 
 
You must be happy about any decision you make and you will be given a copy of this information 
sheet and signed consent form to keep.  Thank you for taking time to read this information sheet. 
 
Thank you for your help.        
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 PARTICIPANT INFORMATION SHEET (MEASUREMENT DIAGRAMS)  
After you consent to participate we will take the following measurements 
1. Body Composition Measurement  
 
 
 
 
2. Mid Arm Circumference Measurement 
 
 
 
This is the picture of the device (about the size 
of heart tracing machine (ECG)) we will use to 
measure your body composition 
Image source: http://www.habdirect.co.uk/images/productFullsize/BMBF9202.jpg  
While you are lying down we will take your body composition measurement 
by attaching sticky patches (lik  those sed in a heart tracing 
measurement) to your hand and leg 
Image source: http://web.tradekorea.com/upload_file/prod/marketing/mkt_files/new_company//giltron/img_en/o_P276050.jpg 
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3. Triceps Skinfold Measurement Using the tape we will measure your mid arm 
circumference as shown in the picture above. We 
will roll the tape around your arm and take the 
measurement. 
Image source: http://www.squidoo.com/organic-food-eating-right 
To measure your mid arm circumference a 
measuring tape will be used. 
Image source: http://www.northerntool.com/images/product/images/30028_lg.jpg 
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4. Handgrip Strength Measurement 
 
We will take a skin fold from back of your arm (triceps area) 
and measure its thickness using the calliper. 
Image source: http://www.healthgoods.com/v/vspfiles/assets/images/skinfold_caliper_back_arm.gif 
This is the device used to measure the skinfold 
thickness.  It is called a calliper. The open end 
of the instrument is used to hold the skin as in 
the picture below. It will not hurt you.  
Image source: http://www.first4shape.com/prodimg/AM3K_1_zoom.jpg  
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5. DEXA Measurement if we ask you 
To measure your handgrip strength you 
will be asked to squeeze the balloon while 
we make the reading 
Image source: http://altomedical.com/images/photo_91%5B1%5D.jpg 
This is the example of the device which will be used 
to measure your hand grip strength.  It is called a 
dynamometer 
Image source: http://faculty.washington.edu/kepeter/119/images/muscle_strength_bulb.jpg 
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This the example of the DEXA machine 
Image source: http://www.alexanderorthopaedics.com/images/dexa-c.jpg 
This is how the DEXA measurement is performed. 
We will ask you to lie down in a relaxed position on 
a padded surface while we take the measurement.  
It is just like an X-ray. 
Image source: http://houstonmri.com/Libraries/site_pics/dexa2.sflb.ashx 
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AFTER YOUR 
CONSENT AND 
on ADMISSION 
WE WILL 
MEASRUE 
YOUR: TRICEP 
SKINFOLD 
MIDARM 
CIRUMFERENCE
, HAND GRIP 
STRENGTH, and 
BODY 
COMPOISITON
IF YOU HAVE A 
FEEDING 
REGIMEN 
CHANGE WE WILL 
MEASURE YOUR 
BODY 
COMPOSITION
Before YOUR 
DISCHARGE WE 
WILL measure 
your: TRICEP 
SKINFOLD, 
MIDARM 
CIRUMFERENC
E, HAND GRIP 
STRENGTH, and 
BODY 
COMPOISITON
ALSO BEFORE 
DISCHARGE WE 
MIGHT ASK YOU 
TO ATTEND UEA 
TO MEASURE YOU 
BODY 
COMPOSITION 
USING DEXA
WE WILL ALSO 
REVIEW YOUR 
MEDICAL 
RECORDS, 
CASE NOTES, 
AND BLOOD 
BIOCHEMISTRY 
DATA.  FEEL 
FREE TO 
REFUSE THIS 
STEP IF YOU 
WISH
AFTER 9 
MONTHS OF 
YOUR 
DISCAHRGE 
DATE WE 
WILL SEND 
YOU 
QUESTIONS 
BY MAIL TO 
ANSWER 
AND MAIL 
BACK TO US 
IF YOU WISH. 
Admission  
Discharge Follow up 
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Appendix VIII: Letter to participant’s GP 
 
Mohannad Kafri 
Medicine for the Elderly 
      Norfolk and Norwich University Hospital, Colney Lane 
Norwich NR4 7UY 
Tell:  01603 286286 
Direct fax:   01603 286428 
Email: m.kafri@uea.ac.uk 
              Trust website: 
www.nnuh.nhs.uk 
Date:   /    /20 
Dear Dr  
 
Re:  The relationship between body composition changes during acute stroke care and long term 
outcomes study  
Your patient has agreed to take part in the above study.  The study involves assessing body 
composition using bioelectrical impedance analysis. It is a simple procedure that is non-invasive, 
quick, and painless.  
The aim of the study is to find out whether there is any relationship between body composition 
changes during acute stroke care and long term outcomes and it does not interfere with medical 
care the patient is receiving or involve the administration of any medicine.   
If you have any questions please do not hesitate to contact me on above address.  
Yours sincerely, 
 
 
Mohannad Kafri (Investigator),  
PhD student, University of East Anglia 
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Appendix IX: Patients’ consent form 
 
CONSENT FORM 
STUDY ON Body Composition changes after stroke 
Name of Researcher: Mohannad Kafri 
Trust Project number Please initial each box indicate your agreement 
1. I confirm that I have read and understand the patient information document to Trust 
Study Number-------- dated ----------------for the above study and that I have had the 
opportunity to ask any questions that I may have. 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without my medical care or legal rights being affected without giving reasons  
 
 
 
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the Norfolk & Norwich NHS Trust or from the regulatory authorities 
where it is relevant to me taking part in this research project. I give permission for these 
individuals to have access to my records.  
 
 
4.  I agree to take part in the above study. 
 
 
5.   I agree to my GP being informed of my participation in this study.           
Name of the patient (capital letters) --------------------------------------- 
Signature of the patient          ---------------------------------------- Date: 
Name of investigator: ------------------------------------------------------------ 
Signature of investigator         --------------------------------------           Date:
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Appendix X: Standard Operating Procedure 
 
Body Composition changes and hydration status after stroke 
Anthropometrics: Skinfold measurement 
Triceps Skinfold (first choice) 
 
1. Use patient’s right arm 
2. Determine the midpoint between the top of the shoulder) to the bottom of the elbow.  
3. Once the midpoint is determined...... 
4. Pinch the skin, the skin fold has to be at 90° to the arm 
5. Place Calipers on the skinfold and record measurement 
6. Repeat three times 
 
 
 
 
Adopted from:  http://www.urmc.rochester.edu/physiology-exercise-lab/equipment/assessment.cfm 
Inter ratter reproducibility assessment:  
After the first investigator carries the Triceps Skinfold thickness measurement, another investigator 
must take same measurement at the same time repeating the exact same procedure.  Record TSF 
result on a separate data sheet.  
Anthropometrics:  Mid Upper Arm Circumference 
1. Use patient right arm (if patients suffers from hemiparesis try your best to take the 
measurement from the right arm unless you cannot, use the other arm however by 
indicating that you used the other arm; formula is validated for right arm however we can 
see the difference between MUAC measurement in both sides compared to FFM values 
from MF-MF-BIA) 
2. Identify the midpoint between the elbow and the shoulder (you can measure the upper arm 
length and determined the midpoint) 
3. Record the measurement  
4. Repeat three times 
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Adopted from: http://www.topendsports.com/testing/tests/girth-arm-relaxed.htm 
 
Inter ratter reproducibility assessment:  
After the first investigator carries the Mid Upper Arm Circumference measurement, another 
investigator must take same measurement at the same time repeating the exact same 
procedure.  Record your measurement on separate data sheet.   
Anthropometrics: Waist circumference 
 
1. As the patient to stand (if the patient cannot stand try measuring while sitting on bed, 
making sure his back is straight); if the patient cannot stand or sit do not make the 
measurement; note this.   
2. Locate the highest end of the hip bone (the iliac crest) 
3. Once located, place the measuring tape horizontally across the waist 
4. Record measurement 
5. Repeat three times 
 
 
 
Adopted from:  http://www.drsharma.ca/wp-content/uploads/sharma-obesity-waist-circumference.jpg 
Anthropometrics:  Hip circumference 
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1. Ask the patient to stand ( if the patient cannot stand try measuring while sitting on bed, 
making sure his back is straight ) 
2. Find the widest point on the buttock 
3. Once the point is located, place a tap horizontally around the buttocks and measure the hip 
circumference 
4. Repeat three times 
5. Round to the nearest 0.1 
 
 
 
Adopted from:   http://en.wikipedia.org/wiki/File:Waist-hip_ratio.png 
 
 
 Reproducibility assessment:  
After the first investigator carries the WC and HC measurement, another investigator must 
take same measurement at the same time repeating the exact same procedure.  Repeat the 
Waist and Hip circumference measurement each three times and record raw data.   
 
Hand grip strength 
 
1. Use patient’s unaffected arm 
2. Explain to the patients the measurement process 
3. Ask the patient to hold the dynamometer with the unaffected arm after setting it 
comfortably to suite the grip of each patient 
4. Make sure the dynamometer is set to Zero by pressing the on button and the number on the 
measuring meter is 0.0 
5. Ask the patient to squeeze press as hard as possible up to 15 seconds and record the 
measurement  
6. Repeat three times 
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Image adopted:  http://www.fitnessvenues.com/uk/fitness-testing-hand-grip-strength-test 
Physical Assessment of Hydration 
Tongue Furrows and Dryness 
1. Observe the patients tongue 
2. Record if Tongue furrows are present (tongue furrows are like small channels that looks 
somewhat white (due to peeling) present on the surface of the tongue indicating dryness)  
3. Classify as yes (furrows) or no (any furrows). 
4. Record if the tongue is dry or furred (if dry the tongue will have white dots, patches or will 
appear white in general due to surface peeling)   
5. Classify as furred (tongue furred), dry (tongue dry), both or no (not dry or furrowed) 
 
 Reliability assessment:  At the same time of this assessment another ratter must carry the same 
procedure again. Record your result on a separate data sheet. For comparison; carry out a Cohen 
Kappa test after a collection of several measurements 
Skin Turgor 
Definition: the ability of the skin to resume its normal form after being pinched or distorted.  
Delayed ability of the skin to obtain its natural form may indicate a sign of dehydration.   
 
1. Pinch the skin on the back of the hand of the unaffected side holding it for few seconds 
2. Release 
3. Observe how long the skin takes to return to its natural form (in seconds) 
4. Report in seconds 
 
 Reliability assessment:  At the same time of this assessment another ratter must carry the same 
procedure again. Record your result on a separate data sheet. For comparison; carry out a Cohen 
Kappa test after a collection of several measurements  
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Image adopted from: http://health.allrefer.com/health/dehydration-skin-turgor.html 
 
Capillary refill time 
Definition:  a test to assess circulation in the hand (usually thumb or any other finger).  It can 
signify dehydration with a host of other conditions.     
1. Pressure the nail bed of the middle (longest) finger of the unaffected side of the patient 
until the natural skin colour is gone (usually takes few seconds) 
2. Release the pressure and wait for the natural coloration to return 
3. Record the number of seconds taken for the natural colouration to return 
 
 Reliability assessment:  At the same time of this assessment another ratter must carry the same 
procedure again. Record your result on a separate data sheet. For comparison; carry out a Cohen 
Kappa test after a collection of several measurements.  
Blood sampling 
 
1. Investigate the presence of an obvious vein 
2. Make sure the arm was not used frequently before for blood sampling 
3. take a blood sample following hygienic procedure 
4. Use the venepuncture system (grey tube top for Glucose and Orange tube top for 
electrolytes/osmolality). 
5. Each tube can hold 5 ml, try to get at least one third full to have enough sample for analysis.   
6. If you are using a venepuncture system (use the electrolyte tube (orange colour first) then 
the glucose tube (grey colour) if you could not get the second sample of blood for glucose 
try the other arm. 
7. If it was difficult to take blood from patient, try first hand, then second...if you still can’t 
STOP and drop this step.   
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Appendix XI: National Institute of Health Stroke Severity Score
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Appendix XII: Malnutrition Universal Assessment Tool
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Appendix XIII: Short form Survey 36v2 (SF36v2) 
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Appendix XIV:  Stroke Impact Scare (SIS) 
 
Stroke Impact Scale 
 
The purpose of this questionnaire is to evaluate how stroke has affected your health and life. 
We want to know from YOUR POINT OF VIEW how stroke has affected you. We will ask 
you questions about impairments and disabilities caused by your stroke, as well as how stroke 
has affected your quality of life. Finally, we will ask you to rate how much you think you have 
recovered from your stroke. 
 
These questions are about the physical problems which may have occurred 
as a result of your stroke. 
 
 
1. In the past week, how 
would you rate the strength 
of you’re... 
A lot of 
strength 
Quite a bit of 
strength 
Some 
strength 
A little 
strength 
No 
strengt
h at all 
a. Arm that was most affected 
by your stroke? 5 4 3 2 1 
b. Grip of your hand that was 
most affected by your stroke? 5 4 3 2 1 
c. Leg that was most affected 
by your stroke? 5 4 3 2 1 
d. Foot/ankle that was most 
affected by your stroke? 5 4 3 2 1 
 
These questions are about your memory and thinking capacities. 
 
 
2. In the past week, how 
difficult was it to... 
Not difficult 
at all 
A little 
difficult 
Somewhat 
difficult 
Very 
difficult 
Extremely 
difficult 
a. Remember things that 
people had just told you? 5 4 3 2 1 
b. Remember things that 
happened the day before? 5 4 3 2 1 
C. Remember to do things 
(e.g. keep scheduled 5 4 3 2 1 
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appointments or take 
medication)?  
d. Remember the day of the 
week?  5 4 3 2 1 
e. Add and subtract 
numbers?  5 4 3 2 1 
f. Concentrate? 5 4 3 2 1 
g. Think quickly?  5 4 3 2 1 
h. Solve everyday 
problems?  5 4 3 2 1 
 
 
These questions are about how you feel, about changes in your mood 
and about your ability to control your emotions since your stroke. 
 
 
3. In the past week, how 
often did you… 
None of 
the time 
A little of 
the time 
Some of 
the time 
Most of 
the time 
All of the 
time 
a. Feel sad? 5 4 3  2 1 
b. Feel that there was 
nobody you were close to? 5 4 3 2 1 
c. Feel that you were a 
burden to others? 5 4 3 2 1 
d. Feel that you had 
nothing to look forward to? 5 4 3 2 1 
e. Blame yourself for 
mistakes or 
mishappenings? 
5 4 3 2 1 
f. Enjoy things as much as 
ever? 5 4 3 2 1 
g. Feel nervous? 5 4 3 2 1 
h. Feel that life would be 
worth living? 5 4 3 2 1 
i. Smile and laugh at least 
once a day? 5 4 3 2 1 
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The following questions are about your ability to communicate with other people, as well as 
your ability to understand what you read and what you hear in a conversation. 
 
 
4. In the past week, how 
difficult was it to... 
Not difficult 
at all 
A little 
difficult 
Somewhat 
difficult 
Very 
difficult 
Extremel
y difficult 
a. Say the name of 
someone who was in front 
of you? 
5 4 3 2 1 
b. Understand what was 
being said to you in a 
conversation? 
5 4 3 2 1 
c. Reply to questions? 5 4 3 2 1 
d. Correctly name 
objects? 5 4 3 2 1 
e. Participate in a 
conversation with a group 
of people? 
5 4 3 2 1 
f. Have a conversation on 
the telephone? 5 4 3 2 1 
g. Call another person on 
the telephone, including 
selecting the correct 
phone number and 
dialing? 
5 4 3 2 1 
 
The following questions ask about activities you might do 
during a typical day. 
 
 
5. In the past 2 weeks, 
how difficult was it to... 
Not difficult 
at all 
A little 
difficult 
Somewhat 
difficult 
Very 
difficult 
Cannot do 
at all 
a. Cut your food with a 
knife and fork? 5 4 3 2 1 
b. Dress the top part (from 
the waist up) of your 
body? 
5 4 3 2 1 
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c. Wash yourself (bath, 
shower…)?  5 4 3 2 1 
d. Clip your toenails? 5 4 3 2 1 
e. Get to the toilet 
quickly?  5 4 3 2 1 
f. Control your bladder 
(not have an accident)? 5 4 3 2 1 
g. Control your bowels 
(not have an accident)? 5 4 3 2 1 
h. Do light household 
tasks/chores?  5 4 3 2 1 
i. Go shopping? 5 4 3 2 1 
j. Handle money (e.g. 
count out money)? 5 4 3 2 1 
k. Manage finances (e.g. 
pay monthly bills, manage 
a bank account)? 
5 4 3 2 1 
l. Do heavy household 
tasks/chores? 5 4 3 2 1 
 
 
The following questions are about your ability to be mobile, 
at home and in the community. 
 
 
6. In the past 2 weeks, 
how difficult was it to...  
Not difficult 
at all 
A little 
difficult 
Somewhat 
difficult 
Very 
difficult 
Cannot 
do at 
all 
a. Stay sitting without 
losing your balance? 
5 4 3 2 1 
b. Stay standing without 
losing your balance? 
5 4 3 2 1 
c. Walk without losing 
your balance? 
5 4 3 2 1 
d. Move from a bed to a 
chair? 
5 4 3 2 1 
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e. Get out of a chair 
without using your hands 
for support? 
5 4 3 2 1 
f. Walk one hundred 
yards?  
5 4 3 2 1 
g. Walk fast?  5 4 3 2 1 
h. Climb one flight of 
stairs?  
5 4 3 2 1 
i. Climb several flights of 
stairs?  
5 4 3 2 1 
j. Get in and out of a car? 5 4 3 2 1 
 
 
The following questions are about your ability to use 
your hand that was MOST AFFECTED by your stroke. 
 
 
7. In the past 2 weeks, 
how difficult was it to use 
your hand that was most 
affected by your stroke 
to... 
Not 
difficult at 
all 
A little 
difficult 
Somewhat 
difficult 
Very 
difficult 
Cannot do 
at all 
a. Carry heavy objects? 5 4 3 2 1 
b. Turn a doorknob? 5 4 3 2 1 
c. Open a can or jar? 5 4 3 2 1 
d. Tie a shoe lace? 5 4 3 2 1 
e. Pick up a small coin? 5 4 3 2 1 
 
The following questions are about how stroke has affected your ability 
to participate in the activities that you usually do, things that 
are meaningful to you and help you to find purpose in life. 
 
 
 410 
 
8. During the past 4 
weeks, how much of the 
time have you been 
limited in... 
None of 
the time 
A little of 
the time 
Some of 
the time 
Most of 
the time 
All of the 
time 
a. Your work (paid, 
voluntary or other)? 
5 4 3 2 1 
b. Your social activities? 5 4 3 2 1 
c. Quiet recreation? 5 4 3 2 1 
d. Active recreation? 5 4 3 2 1 
e. Your role as a family 
member and/or friend? 
5  4 3 2 1 
f. Your participation in 
spiritual or religious 
activities? 
5 4 3 2 1 
g. Your ability to show 
your feelings to those 
close to you? 
5 4 3 2 1 
h. Your ability to control 
your life as you wish? 
5 4 3 2 1 
i. Your ability to help 
others? 
5 4 3 2 1 
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9. Stroke Recovery 
 
On a scale of 0 to 100, with 100 representing full recovery and 0 representing no recovery, how 
much have you recovered from your stroke? 
 
 
  
 100 Full Recovery 
  
  
 90 
  
  
 80 
  
  
 70 
  
  
 60 
  
  
 50 
  
  
 40 
  
  
 30 
  
  
 20 
  
  
 10 
  
   0 No Recovery 
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Appendix XV: Barthel Index Score 
 
THE BARTHEL INDEX  
 
Date: ___________________________ 
 
Activity Score 
 
FEEDING 
 
0 = unable 
 
5 = needs help cutting, spreading butter, etc., or requires modified diet 
 
10 = independent  
 
BATHING 
 
0 = dependent 
 
5 = independent (or in shower)  
 
GROOMING 
 
0 = needs to help with personal care 
 
5 = independent face/hair/teeth/shaving (implements provided)  
DRESSING 
0 = dependent 
 
5 = needs help but can do about half unaided 
 
10 = independent (including buttons, zips, laces, etc.)  
 
BOWELS 
 
0 = incontinent (or needs to be given enemas) 
 
5 = occasional accident 
 
10 = continent  
 
BLADDER 
 
0 = incontinent, or catheterized and unable to manage alone 
 
5 = occasional accident 
 
10 = continent  
 
TOILET USE 
 
0 = dependent 
 
5 = needs some help, but can do something alone 
 
10 = independent (on and off, dressing, wiping) 
  
 
 413 
 
TRANSFERS (BED TO CHAIR AND BACK) 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent ______ 
 
MOBILITY (ON LEVEL SURFACES) 
 
0 = immobile or < 50 yards 
 
5 = wheelchair independent, including corners, > 50 yards 
 
10 = walks with help of one person (verbal or physical) > 50 yards 
 
15 = independent (but may use any aid; for example, stick) > 50 yards  
STAIRS 
 
0 = unable 
 
5 = needs help (verbal, physical, carrying aid) 
 
10 = independent ______ 
 
TOTAL (0–100): ______ 
Provided by the Internet Stroke Center — www.strokecenter.org 
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Appendix XVI: Request for Hologic Discovery DXA assessment. 
Study name: Body Composition changes after acute stroke and long term outcomes  
 LREC number: 10/H0304/18 
Principal Investigator (requestor): Dr Phyo Myint 
Referrer: Professional healthcare 
 qualification/registration:  
(by signing referrer hereby confirms that subject meets inclusion criteria and that there is no 
possibility that female subject could be pregnant) 
Subject details: Verified by operator (initials) 
 Name: 
 Study number: 
 DoB: 
Address: 
Telephone: Email: 
For females, no possibility of pregnancy confirmed 
For all subjects, absence of metal implants etc confirmed 
DXA examination requested (please tick appropriate box): 
 Whole body  
Spine  
Hip  
Forearm 
Analyses required (in accordance with LREC): 
 Bone 
Body composition 
Segment/region  
  
 Specific/other details 
  
Operator: 
(by signing, operator hereby authorizes that the DXA assessment is appropriate) 
√ 
 
 
 
 
√ 
 
 
  
 
 
 
 
 
 
 
 415 
 
Appendix XVII:  Hologic Discovery dual energy X-ray absorptiometry 
(DXA) body composition and bone assessments: radiation exposure 
confirmation of directed dose and appropriate approvals checklist. 
 
(N.B. Radiation directed by the DXA procedure for each scan type is invariable and adherence to 
scans specified in the Local Research Ethics Committee (LREC) and its approval is mandatory.) 
 
Study details 
Study name: Body Composition changes after acute stroke and long term outcomes 
 
Sponsor: Res., Enterprise & Engagement Office for University of East Anglia 
 
Principal investigator and/or local lead: Dr P Myint / Mr M. Kafri 
 
R & D reference number: 2010MFE10S (116-08-10). 
 
LREC number: 10/H0304/18 
 
LREC approval date: 12-10-2010 
 
Confirmations 
  
Medical physics expert: Stuart Yates Approved signatory 
Clinical radiation expert: Andoni Toms Approved signatory 
DXA examination indicated on LREC approval: 
 
 Whole body  
 
 Spine  
 
 Hip  
 
 Forearm 
 
Radiation exposure appropriate as specified in LREC? 
 
Is the proposed DXA scan appropriate to address the particular research question? 
Body composition practitioner approval for study to go ahead in Clinical ResearchTrials 
Unit 
 
√ 
 
 
 
 
 
√ 
√ 
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Appendix XVIII:  Hologic Discovery (Wi) dual-energy X-ray 
absorptiometry (DEXA) operating procedure for whole body scan  
Preliminary DXA set up prior to patient/subject arrival 
 
1 Turn on DXA 
2 Run QC 
3 Run radiographic uniformity, if indicated 
 
Patient preparation 
 
1  Confirm that identity of patient/subject matches study identifiers and scan(s) required. 
2  Obtain and record patient/subject details, address hospital number etc. 
3  Patient/subject to undress and put on gown. 
4 Obtain and record patient/subject weight and height or ensure that the nurse has  
  measured these on the day. 
5 Use checklists to ensure patient/subject suitability and safety 
• Pregnancy for females 
• Metal objects for all subjects 
 
Whole body DXA scan procedure 
 
1  Click ‘Patients’ in the main window 
2 Click patient’s name or, if it their first scan, click ‘New patient’. 
3  Edit or create a patient record according to ‘Patient records’ as set out in the 
Discovery Operator’s Manual. 
4 Use checklists to confirm patient/subject suitability and safety 
• Pregnancy for females 
• Metal objects for all subjects 
5  Confirm that the subject is below the weight limit of 204 kg. 
6 Click ‘Perform scan’ and check all details 
7 Select ‘Scan type’ 
8 Select ‘Whole body’ 
9 Position patient (top of head located at end of midline marker on table, arms at side 
and toes pointed inwards as in Discovery Operator’s Manual) 
10 Start scan – runs for about 7 mins. 
11 Help patient from table and allow to dress. 
 
Warning: if control panel X-ray indicator fails to shut off within 10 secs of the end of the 
scan then press the red emergency stop button immediately. Call service engineer (Vertec 
Ltd) before resuming operation. 
 
12 Analyze scan as described in Discovery Operator’s Manual. 
13 Generate reports and record patient exposure 
14 Fully complete patient and scan record in log book.   
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Appendix XIX: Patient safety and DXA operational compliance: 
checklist questions 
For females: ask if there is there any chance that they might be pregnant? 
If so, postpone scan. 
For all subjects/patients: 
Ask if the patient/subject has had any medical procedure within the last 7 days involving: 
Contrast media? 
Arterial? 
Iodine? 
Barium? 
A nuclear medicine isotope study? If so, contact relevant practitioner/department to establish 
whether or not the DXA can/should be performed. 
Ask if the patient/subject is wearing any metal device or metal objects?  
Buttons, zips, belts etc?   
Jewellery?  
An ostomy device? 
Phones, money, in pockets etc? 
If so, remove them if at all possible.  
Ask if the patient has had any surgery that means they have metal somehow associated with their 
body? 
Pacemaker leads? 
Radioactive seeds? 
Metal implants? 
Hip replacements? 
Surgical staples? 
Foreign bodies, e.g. shrapnel? 
Radio-opaque catheters or tubes? 
Bullets? 
If so, it is not an issue for the patient but it is necessary to assess the extent that it might interfere 
with the scan. 
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Appendix XX: Consent form for adults and children over 16 years of age 
 
Dual energy X-ray absorptiometry (DXA) measurement for project  
entitled:  
 Please initial box 
1.  I confirm that I have read and understood the information  
 sheet dated …./…./20…. for the above study and have been  
 given the opportunity to ask questions.  
2.  I confirm that I understand that the study involves the direction  
 of a low level of X-ray radiation, exposing me to a level of  
 radiation which is equivalent to about 1 day of environmental  
 or background exposure. 
3. I understand that my participation in the DXA measurement  
 part of this study is voluntary and that I am free to withdraw  
 at any time and without giving a reason and without my  
 medical care or legal rights being affected. 
4.  I agree to my physician being notified of my participation and  
 also being given any findings that may require further  
 investigation. 
5.  I agree to take part in the DXA measurement as part of the  
 study entitled ' Body Composition changes after acute stroke and long term outcomes '. 
______________________ ______________ ______________________ 
Name of Participant: Date: Signature:  
Name of Researcher:  Date: Signature:  
Researcher:  
Supervisor:  
• Copy to participant  
• Copy to researcher 
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Glossary of Body Composition terms 
B 
Body cell mass (BCM):  mass of all the metabolically active cells in the body which 
constitute of muscles cell mass and organs cell mass (278) 
E 
Extracellular water (ECW): water volume in extracellular space only 
F 
Fat Free Mass: total mass of skeletal muscles, bones, body organs, and total body water  
Fat mass: mass of adipose tissue only 
I 
Intracellular water: total water available in intracellular space 
M 
Muscle mass:  skeletal muscle mass only 
P  
Protein mass:  total protein mass available in bones, skeletal muscles, and body organs 
T 
Total Body Water:  the sum of extracellular and intracellular water volume 
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